{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Row counts match. Proceeding with validation...\n"
     ]
    }
   ],
   "source": [
    "description_meta = pd.read_parquet(\n",
    "    \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description/description_meta.parquet\"\n",
    ")\n",
    "df_responses = pd.read_parquet(\n",
    "    \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description/chat_responses.parquet\"\n",
    ")\n",
    "\n",
    "# Check that the row counts match\n",
    "if len(description_meta) != len(df_responses):\n",
    "    print(\"Warning: The number of rows differ!\")\n",
    "else:\n",
    "    print(\"Row counts match. Proceeding with validation...\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "715"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_responses)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "CANCER_TYPE_NAME",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "527dc3f5-eed3-4b0c-9787-27a7ad5e263a",
       "rows": [
        [
         "0",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA-OR-A5KS, TCGA-OR-A5L2",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         null,
         "Adrenocortical carcinoma"
        ],
        [
         "1",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA-OR-A5K6, TCGA-OR-A5LO, TCGA-OR-A5JY, TCGA-OR-A5JV, TCGA-OR-A5K3, TCGA-OR-A5KO, TCGA-OR-A5K0, TCGA-OR-A5J6, TCGA-OR-A5LC, TCGA-OR-A5LA, TCGA-OR-A5LG, TCGA-OR-A5LB, TCGA-OR-A5JM, TCGA-OR-A5KQ, TCGA-OR-A5JD, TCGA-P6-A5OF, TCGA-PK-A5HA, TCGA-OR-A5KY, TCGA-OR-A5L4, TCGA-OR-A5J9, TCGA-OR-A5JS, TCGA-PK-A5H9, TCGA-OR-A5JJ, TCGA-OR-A5JI, TCGA-OR-A5JF, TCGA-OR-A5LF, TCGA-OR-A5JH, TCGA-OR-A5JU, TCGA-OR-A5JL, TCGA-OR-A5KP, TCGA-OR-A5JO, TCGA-OR-A5K8, TCGA-OR-A5LN, TCGA-OR-A5KX, TCGA-OR-A5KW, TCGA-OR-A5L8, TCGA-OR-A5JW, TCGA-OR-A5JK, TCGA-OR-A5LR, TCGA-OR-A5JZ, TCGA-OU-A5PI, TCGA-OR-A5LD, TCGA-OR-A5JE, TCGA-OR-A5LH, TCGA-OR-A5K5, TCGA-OR-A5LJ, TCGA-OR-A5LL, TCGA-OR-A5JX, TCGA-OR-A5JQ, TCGA-PA-A5YG, TCGA-PK-A5H8, TCGA-OR-A5J4, TCGA-OR-A5J2, TCGA-OR-A5JG, TCGA-OR-A5J5, TCGA-OR-A5JT, TCGA-OR-A5LK, TCGA-OR-A5JB, TCGA-OR-A5KT, TCGA-OR-A5J3, TCGA-OR-A5L6, TCGA-OR-A5LS, TCGA-OR-A5LP, TCGA-OR-A5K1, TCGA-OR-A5LI, TCGA-OR-A5L1, TCGA-OR-A5J7, TCGA-OR-A5LT, TCGA-OR-A5L5, TCGA-OR-A5JR, TCGA-OR-A5K2, TCGA-OR-A5K4, TCGA-OR-A5KZ, TCGA-OR-A5JC, TCGA-OR-A5L3, TCGA-OR-A5LE",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma"
        ],
        [
         "2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA-P6-A5OH, TCGA-OR-A5K9",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma"
        ],
        [
         "3",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA-FD-A6TE, TCGA-K4-A6MB, TCGA-BT-A2LD, TCGA-DK-AA6T, TCGA-FD-A3SS, TCGA-FD-A6TH, TCGA-FD-A5BV, TCGA-E7-A7DU, TCGA-FD-A3SN, TCGA-K4-A5RH, TCGA-DK-A6AW, TCGA-GC-A3RD, TCGA-KQ-A41P",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "4",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA-BT-A20R, TCGA-BT-A20Q",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "5",
         "BLCA",
         "C67.0",
         "8130/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-4Z-AA89, TCGA-FD-A3B3, TCGA-4Z-AA7R",
         "Trigone, bladder",
         "Trigone, bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "6",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A54R, TCGA-GC-A3BM, TCGA-DK-A3X1, TCGA-BT-A2LB, TCGA-BL-A0C8, TCGA-BL-A0C8, TCGA-DK-A6AV, TCGA-FD-A43P, TCGA-DK-AA74, TCGA-BL-A0C8, TCGA-4Z-AA86, TCGA-DK-A3WY, TCGA-DK-AA6L",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "7",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20X, TCGA-BT-A2LA",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "8",
         "BLCA",
         "C67.1",
         "8260/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-HQ-A2OF",
         "Dome, bladder",
         "Dome, bladder",
         "Papillary adenocarcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "9",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FD-A3SQ, TCGA-FD-A3B7, TCGA-4Z-AA7M, TCGA-DK-A3IK, TCGA-FD-A3SM, TCGA-ZF-A9RC, TCGA-UY-A9PA, TCGA-DK-AA6P, TCGA-DK-AA6R, TCGA-FD-A6TF, TCGA-FD-A62N, TCGA-DK-A3WX, TCGA-FD-A5BR, TCGA-GU-A763, TCGA-DK-A3IT, TCGA-FD-A43U, TCGA-DK-AA6X, TCGA-G2-A2EL, TCGA-2F-A9KP, TCGA-YF-AA3L, TCGA-R3-A69X, TCGA-FD-A3SJ, TCGA-DK-A6B0, TCGA-4Z-AA7W, TCGA-E7-A3X6, TCGA-UY-A9PB, TCGA-BT-A3PJ, TCGA-DK-AA71, TCGA-FD-A6TB, TCGA-GU-AATP, TCGA-DK-AA6S, TCGA-FD-A3B8, TCGA-DK-AA6W, TCGA-FD-A3B4, TCGA-PQ-A6FN, TCGA-ZF-AA54, TCGA-FJ-A871, TCGA-DK-A3IN, TCGA-DK-A3IL, TCGA-YF-AA3M, TCGA-FD-A6TG, TCGA-ZF-A9RG, TCGA-DK-A3IV, TCGA-DK-AA6U, TCGA-DK-A3X2, TCGA-E5-A2PC, TCGA-4Z-AA7N, TCGA-FD-A5BU, TCGA-FD-A3SO, TCGA-FD-A5BT, TCGA-DK-AA6M",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "10",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20W, TCGA-BT-A20O, TCGA-BT-A20V",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "11",
         "BLCA",
         "C67.2",
         "8130/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-XF-AAMQ, TCGA-BT-A42B, TCGA-UY-A9PF, TCGA-XF-AAML, TCGA-4Z-AA7Y, TCGA-FJ-A3Z9, TCGA-CF-A9FF, TCGA-4Z-AA7O, TCGA-FD-A6TA, TCGA-BT-A42C, TCGA-CF-A7I0",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "12",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-E7-A6ME, TCGA-FD-A43Y, TCGA-DK-AA75, TCGA-FD-A3N6, TCGA-UY-A9PD, TCGA-E7-A6MD, TCGA-KQ-A41Q, TCGA-FD-A6TK, TCGA-FD-A6TI, TCGA-GU-A764, TCGA-K4-AAQO, TCGA-DK-A6B1, TCGA-GV-A3QF, TCGA-FD-A5BZ, TCGA-FD-A6TD, TCGA-DK-AA76, TCGA-DK-A6B5",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "13",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20T, TCGA-G2-A2EO",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "14",
         "BLCA",
         "C67.3",
         "8130/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I4",
         null,
         null,
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "15",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A3IU, TCGA-DK-A3IQ, TCGA-FD-A62S, TCGA-FD-A3SP, TCGA-FD-A3SR, TCGA-FD-A3N5, TCGA-DK-AA77, TCGA-FD-A3NA, TCGA-FD-A3B5, TCGA-FD-A3SL, TCGA-K4-A6FZ, TCGA-BT-A3PK, TCGA-DK-A6B6, TCGA-BL-A5ZZ, TCGA-KQ-A41S, TCGA-ZF-AA56, TCGA-ZF-A9RD, TCGA-DK-A6B2, TCGA-ZF-AA5P, TCGA-DK-A3WW, TCGA-BL-A13J, TCGA-DK-AA6Q, TCGA-ZF-A9R0, TCGA-K4-A4AB, TCGA-FD-A5BY, TCGA-FD-A5BS, TCGA-GV-A3QG, TCGA-GV-A3QI, TCGA-SY-A9G0, TCGA-ZF-A9RN, TCGA-FD-A6TC, TCGA-FD-A5C0, TCGA-FD-A43N, TCGA-4Z-AA82, TCGA-FD-A5C1, TCGA-K4-A5RI, TCGA-BL-A13J, TCGA-BL-A13J, TCGA-FD-A5BX, TCGA-ZF-AA52, TCGA-FD-A43S, TCGA-FD-A62P, TCGA-XF-AAN8, TCGA-2F-A9KT",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "16",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KO, TCGA-BT-A20J",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "17",
         "BLCA",
         "C67.4",
         "8130/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A5RJ, TCGA-BT-A42E, TCGA-FD-A3B6, TCGA-FD-A43X, TCGA-4Z-AA81",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "18",
         "BLCA",
         "C67.5",
         "8120/3",
         "C67.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FT-A3EE",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "19",
         "BLCA",
         "C67.6",
         "8120/3",
         "C67.6",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-KQ-A41N",
         "Ureteric orifice",
         "Ureteric orifice",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "20",
         "BLCA",
         "C67.9",
         "8010/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-ZF-AA4N",
         "Bladder NOS",
         "Bladder NOS",
         "Carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "21",
         "BLCA",
         "C67.9",
         "8070/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A1HS",
         "Bladder NOS",
         "Bladder NOS",
         "Squamous cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "22",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-DK-A1A6",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "23",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-C4-A0EZ, TCGA-GV-A40G, TCGA-DK-A3IS, TCGA-GV-A40E, TCGA-DK-A2HX, TCGA-ZF-AA53, TCGA-HQ-A5ND, TCGA-E7-A7PW, TCGA-DK-A1A7, TCGA-GD-A3OQ, TCGA-C4-A0F0, TCGA-2F-A9KW, TCGA-UY-A78O, TCGA-4Z-AA87, TCGA-5N-A9KI, TCGA-C4-A0F6, TCGA-XF-A9SL, TCGA-XF-A9T3, TCGA-UY-A8OC, TCGA-GD-A76B, TCGA-YC-A9TC, TCGA-GC-A3I6, TCGA-SY-A9G5, TCGA-XF-AAMR, TCGA-XF-A9SY, TCGA-DK-A1AD, TCGA-XF-AAMJ, TCGA-5N-A9KM, TCGA-DK-A1A6, TCGA-CU-A3QU, TCGA-ZF-A9R3, TCGA-K4-A83P, TCGA-XF-A9T2, TCGA-E7-A97Q, TCGA-CU-A72E, TCGA-GC-A3RC, TCGA-UY-A9PH, TCGA-GU-AATO, TCGA-E7-A677, TCGA-ZF-A9R9, TCGA-XF-A8HD, TCGA-BL-A13I, TCGA-BL-A13I, TCGA-GU-A766, TCGA-XF-AAN0, TCGA-XF-A9SW, TCGA-DK-A1AB, TCGA-XF-AAMX, TCGA-ZF-A9RF, TCGA-ZF-A9RL, TCGA-K4-A4AC, TCGA-E7-A7XN, TCGA-LC-A66R, TCGA-CF-A8HX, TCGA-GC-A6I1, TCGA-XF-A9T0, TCGA-G2-A2EK, TCGA-ZF-AA4W, TCGA-GU-A762, TCGA-E7-A519, TCGA-XF-A9SP, TCGA-CU-A5W6, TCGA-FT-A61P, TCGA-XF-A8HF, TCGA-BT-A3PH, TCGA-YC-A89H, TCGA-KQ-A41O, TCGA-XF-A9SX, TCGA-GU-A42Q, TCGA-ZF-A9R5, TCGA-GU-AATQ, TCGA-XF-AAN4, TCGA-XF-AAMT, TCGA-ZF-AA4R, TCGA-GU-A767, TCGA-G2-AA3C, TCGA-XF-AAN5, TCGA-XF-A8HG, TCGA-E7-A85H, TCGA-H4-A2HQ, TCGA-LT-A5Z6, TCGA-ZF-A9R1, TCGA-DK-A1AF, TCGA-ZF-AA5N, TCGA-UY-A8OD, TCGA-4Z-AA7Q, TCGA-CU-A0YR, TCGA-C4-A0F7, TCGA-CU-A3KJ, TCGA-GU-A42P, TCGA-K4-A3WU, TCGA-DK-A1AA, TCGA-G2-A3IE, TCGA-GC-A3WC, TCGA-HQ-A2OE, TCGA-DK-A2I2, TCGA-E7-A678, TCGA-GC-A3OO, TCGA-XF-AAN3, TCGA-GV-A3JW, TCGA-G2-AA3B, TCGA-CF-A1HR, TCGA-DK-A1AE, TCGA-E7-A5KE, TCGA-E7-A5KF, TCGA-BT-A0S7, TCGA-FJ-A3Z7, TCGA-CF-A8HY, TCGA-XF-A8HE, TCGA-E7-A4XJ, TCGA-FJ-A3ZE, TCGA-GD-A6C6, TCGA-C4-A0F1, TCGA-GC-A4ZW, TCGA-GC-A6I3, TCGA-XF-A9SJ, TCGA-XF-A9SH, TCGA-G2-A2EJ, TCGA-XF-AAME, TCGA-DK-A1A3, TCGA-E5-A4TZ, TCGA-G2-AA3D, TCGA-KQ-A41R, TCGA-ZF-AA4X, TCGA-BL-A13I, TCGA-XF-A9T5, TCGA-E7-A3Y1, TCGA-UY-A9PE, TCGA-GV-A3QK, TCGA-GV-A3JV, TCGA-XF-AAMW, TCGA-ZF-AA51, TCGA-BT-A0YX, TCGA-ZF-AA4T, TCGA-XF-AAMH, TCGA-DK-A1AC, TCGA-4Z-AA84, TCGA-XF-A9SK, TCGA-DK-A1A5, TCGA-GC-A3RB, TCGA-PQ-A6FI, TCGA-XF-A8HH, TCGA-ZF-AA5H, TCGA-E7-A8O7, TCGA-ZF-AA58, TCGA-E7-A97P, TCGA-G2-A2EC, TCGA-GD-A3OP, TCGA-ZF-A9R4, TCGA-XF-AAMG, TCGA-XF-A9T8, TCGA-GC-A3YS, TCGA-K4-A3WS, TCGA-UY-A78M, TCGA-E5-A4U1, TCGA-G2-A2EF, TCGA-GD-A3OS, TCGA-ZF-A9RE, TCGA-DK-A3IM, TCGA-CF-A5U8, TCGA-UY-A78N, TCGA-ZF-AA4U, TCGA-GD-A2C5, TCGA-S5-A6DX, TCGA-ZF-A9RM, TCGA-XF-AAMF, TCGA-XF-AAN2, TCGA-G2-AA3F, TCGA-GV-A3JZ, TCGA-XF-AAN7, TCGA-G2-A3IB, TCGA-XF-A9SM, TCGA-CF-A5UA, TCGA-ZF-AA4V, TCGA-G2-A3VY, TCGA-ZF-A9R7, TCGA-GV-A3JX, TCGA-HQ-A5NE, TCGA-XF-A9SZ, TCGA-K4-A3WV, TCGA-XF-A9T4",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "24",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KQ, TCGA-UY-A78P, TCGA-UY-A8OB, TCGA-G2-A2ES, TCGA-BL-A3JM",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "25",
         "BLCA",
         "C67.9",
         "8130/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A47W, TCGA-XF-AAN1, TCGA-UY-A78K, TCGA-XF-A9T6, TCGA-LT-A8JT, TCGA-CF-A27C, TCGA-CF-A9FL, TCGA-XF-AAMY, TCGA-MV-A51V, TCGA-E7-A541, TCGA-2F-A9KR, TCGA-CF-A9FM, TCGA-CF-A3MF, TCGA-E7-A7DV, TCGA-CF-A3MG, TCGA-4Z-AA83, TCGA-CF-A9FH, TCGA-CF-A47X, TCGA-XF-A8HB, TCGA-S5-AA26, TCGA-XF-A9SV, TCGA-CF-A47S, TCGA-XF-AAMZ, TCGA-E7-A6MF, TCGA-E7-A4IJ, TCGA-H4-A2HO, TCGA-4Z-AA80, TCGA-CF-A47Y, TCGA-YC-A8S6, TCGA-ZF-A9R2, TCGA-CF-A3MH, TCGA-CF-A47V, TCGA-XF-A8HI, TCGA-4Z-AA7S, TCGA-CF-A3MI, TCGA-FJ-A3ZF, TCGA-CU-A0YO, TCGA-CU-A3YL, TCGA-CF-A47T, TCGA-UY-A78L, TCGA-DK-A2I1, TCGA-XF-A8HC, TCGA-XF-A9ST, TCGA-XF-A9SU, TCGA-XF-A9SI, TCGA-XF-A9SG, TCGA-GV-A6ZA",
         "Bladder NOS",
         "Bladder NOS",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "26",
         "BRCA",
         "C50.2",
         "8500/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18I",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "27",
         "BRCA",
         "C50.2",
         "8524/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-LD-A7W6",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating lobular mixed with other types of carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "28",
         "BRCA",
         "C50.3",
         "8500/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18M, TCGA-BH-A18P",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "29",
         "BRCA",
         "C50.3",
         "8523/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18S",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct mixed with other types of carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "30",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A18V",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "31",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18V, TCGA-BH-A18U",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "32",
         "BRCA",
         "C50.5",
         "8500/3",
         "C50.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18G",
         "Lower outer quadrant of breast",
         "Lower outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "33",
         "BRCA",
         "C50.8",
         "8022/3",
         "C50.8",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-Z7-A8R6",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Pleomorphic carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "34",
         "BRCA",
         "C50.8",
         "8500/3",
         "C50.8",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18Q",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "35",
         "BRCA",
         "C50.9",
         "8010/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A7-A5ZV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "36",
         "BRCA",
         "C50.9",
         "8013/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SK",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Large cell neuroendocrine carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "37",
         "BRCA",
         "C50.9",
         "8200/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SB",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Adenoid cystic carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "38",
         "BRCA",
         "C50.9",
         "8211/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73X",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Tubular adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "39",
         "BRCA",
         "C50.9",
         "8401/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A2-A04W",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Apocrine adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "40",
         "BRCA",
         "C50.9",
         "8480/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73W, TCGA-A2-A3KD, TCGA-C8-A12X, TCGA-D8-A27W, TCGA-D8-A1XV, TCGA-C8-A1HL, TCGA-C8-A8HQ, TCGA-D8-A1XC, TCGA-E9-A5UO, TCGA-OL-A66H, TCGA-AC-A8OR",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Mucinous adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "41",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-E2-A15A, TCGA-E2-A15E, TCGA-E2-A15K",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "42",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-AR-A24U, TCGA-AQ-A04J, TCGA-BH-A0HK, TCGA-A2-A04U, TCGA-BH-A202, TCGA-OL-A5RU, TCGA-E2-A154, TCGA-D8-A140, TCGA-AN-A0XV, TCGA-EW-A1OV, TCGA-OL-A66L, TCGA-D8-A1JU, TCGA-C8-A1HE, TCGA-A2-A04R, TCGA-AR-A0TP, TCGA-A7-A26I, TCGA-EW-A1PB, TCGA-C8-A26V, TCGA-AN-A0XR, TCGA-A8-A08X, TCGA-AR-A1AX, TCGA-BH-A0EB, TCGA-A7-A0DB, TCGA-BH-A0W7, TCGA-BH-A0B4, TCGA-EW-A1P8, TCGA-A2-A0CV, TCGA-A8-A083, TCGA-B6-A0WY, TCGA-AN-A0XP, TCGA-A8-A07R, TCGA-A2-A04Q, TCGA-EW-A1P6, TCGA-C8-A27B, TCGA-A8-A06R, TCGA-B6-A0RH, TCGA-A2-A0YG, TCGA-A2-A0SU, TCGA-BH-A0EE, TCGA-D8-A1JH, TCGA-E2-A152, TCGA-EW-A1IZ, TCGA-OL-A5D6, TCGA-A1-A0SD, TCGA-BH-A0DK, TCGA-E2-A156, TCGA-A7-A56D, TCGA-E9-A1ND, TCGA-AR-A1AR, TCGA-A2-A1G4, TCGA-AN-A0FN, TCGA-GM-A2DA, TCGA-AR-A0TX, TCGA-BH-A0BP, TCGA-D8-A27P, TCGA-BH-A0AW, TCGA-E9-A1RF, TCGA-E9-A1R0, TCGA-A7-A6VY, TCGA-A2-A0CX, TCGA-AR-A0TZ, TCGA-A2-A25F, TCGA-E2-A15D, TCGA-OL-A5D7, TCGA-AC-A5EH, TCGA-AR-A0TR, TCGA-AQ-A1H2, TCGA-GM-A2DL, TCGA-EW-A1PD, TCGA-AN-A0XN, TCGA-AO-A03P, TCGA-D8-A1XW, TCGA-A7-A26I, TCGA-D8-A1JL, TCGA-LL-A5YN, TCGA-S3-A6ZH, TCGA-EW-A1P1, TCGA-B6-A0WW, TCGA-AN-A03Y, TCGA-D8-A1X5, TCGA-AN-A0AR, TCGA-A8-A09I, TCGA-C8-A1HO, TCGA-AO-A0JI, TCGA-BH-A0BD, TCGA-C8-A274, TCGA-B6-A1KC, TCGA-E2-A1L7, TCGA-A8-A06Q, TCGA-E9-A1R4, TCGA-A2-A0D4, TCGA-AC-A62V, TCGA-AR-A24Q, TCGA-AC-A8OP, TCGA-B6-A0WV, TCGA-D8-A27R, TCGA-D8-A1XB, TCGA-A2-A259, TCGA-D8-A1XL, TCGA-E2-A1IO, TCGA-A8-A08B, TCGA-BH-A0W5, TCGA-AO-A0JD, TCGA-3C-AALJ, TCGA-AO-A03O, TCGA-A8-A07F, TCGA-A1-A0SH, TCGA-A7-A6VV, TCGA-A2-A3XW, TCGA-B6-A0WT, TCGA-D8-A1Y3, TCGA-AR-A255, TCGA-B6-A0RT, TCGA-C8-A278, TCGA-BH-A6R8, TCGA-D8-A27K, TCGA-EW-A1PH, TCGA-3C-AALK, TCGA-EW-A6S9, TCGA-C8-A12Q, TCGA-E2-A15I, TCGA-A8-A0A9, TCGA-A2-A04X, TCGA-PL-A8LY, TCGA-E9-A24A, TCGA-B6-A0RG, TCGA-A1-A0SO, TCGA-C8-A12W, TCGA-A7-A26J, TCGA-AO-A03L, TCGA-GM-A3XL, TCGA-BH-A0DX, TCGA-A8-A07Z, TCGA-B6-A0I6, TCGA-B6-A0I6, TCGA-GM-A2DB, TCGA-E9-A247, TCGA-A8-A07G, TCGA-AN-A0XW, TCGA-BH-A0B1, TCGA-D8-A143, TCGA-D8-A1XR, TCGA-E2-A155, TCGA-D8-A1JJ, TCGA-E2-A1IG, TCGA-BH-A0B0, TCGA-D8-A1JG, TCGA-B6-A0RM, TCGA-BH-A0BM, TCGA-E2-A14V, TCGA-A2-A0ET, TCGA-AN-A0FL, TCGA-A2-A0EO, TCGA-A2-A1G0, TCGA-BH-A5J0, TCGA-C8-A138, TCGA-E2-A1B1, TCGA-C8-A1HN, TCGA-E2-A1IN, TCGA-BH-A0HN, TCGA-LD-A9QF, TCGA-A8-A09B, TCGA-E2-A574, TCGA-BH-A0H9, TCGA-C8-A131, TCGA-AC-A62X, TCGA-AN-A046, TCGA-A7-A4SF, TCGA-E2-A1L6, TCGA-AR-A24S, TCGA-A2-A0YT, TCGA-E9-A1R5, TCGA-A8-A07J, TCGA-A2-A0EV, TCGA-A8-A06X, TCGA-E2-A14N, TCGA-AO-A12A, TCGA-E2-A10C, TCGA-AN-A04C, TCGA-LL-A5YP, TCGA-AN-A0AM, TCGA-E2-A1II, TCGA-AO-A0JC, TCGA-A8-A07W, TCGA-D8-A1XY, TCGA-BH-A0DQ, TCGA-AN-A0XT, TCGA-LL-A73Z, TCGA-B6-A0I8, TCGA-AQ-A0Y5, TCGA-C8-A1HI, TCGA-A7-A0CD, TCGA-A7-A0DA, TCGA-A8-A091, TCGA-D8-A1XU, TCGA-B6-A0IK, TCGA-AR-A0U0, TCGA-EW-A6SD, TCGA-OL-A5RY, TCGA-E9-A1R2, TCGA-AN-A0AK, TCGA-AR-A252, TCGA-BH-A0EI, TCGA-E9-A22A, TCGA-A2-A25B, TCGA-BH-A0BW, TCGA-C8-A12Y, TCGA-AR-A0U3, TCGA-A2-A0CQ, TCGA-AR-A24K, TCGA-BH-A0H0, TCGA-AR-A0U2, TCGA-GM-A2DK, TCGA-BH-A0GZ, TCGA-BH-A0BL, TCGA-LL-A740, TCGA-B6-A0RO, TCGA-A2-A0T2, TCGA-E2-A15S, TCGA-A2-A0T1, TCGA-D8-A1JC, TCGA-A2-A3XU, TCGA-EW-A1P7, TCGA-C8-A1HJ, TCGA-AN-A0XU, TCGA-BH-A5IZ, TCGA-AO-A0JB, TCGA-BH-A0W4, TCGA-AN-A0AT, TCGA-A8-A07I, TCGA-A2-A0YM, TCGA-C8-A134, TCGA-B6-A1KI, TCGA-A1-A0SN, TCGA-E2-A15R, TCGA-S3-AA11, TCGA-AO-A128, TCGA-E2-A15T, TCGA-A8-A095, TCGA-D8-A1Y2, TCGA-UL-AAZ6, TCGA-A2-A0CL, TCGA-A8-A08P, TCGA-C8-A12M, TCGA-AR-A1AS, TCGA-E9-A1QZ, TCGA-A7-A6VX, TCGA-A8-A081, TCGA-BH-A0BQ, TCGA-A8-A093, TCGA-C8-A26X, TCGA-A2-A0ER, TCGA-A2-A04Y, TCGA-A2-A0D2, TCGA-D8-A1JA, TCGA-A7-A0CE, TCGA-C8-A12K, TCGA-A7-A26J, TCGA-AN-A0FS, TCGA-OL-A5RW, TCGA-A2-A0YC, TCGA-D8-A1JM, TCGA-AN-A0AL, TCGA-LL-A7SZ, TCGA-A8-A06T, TCGA-A8-A06U, TCGA-BH-A0C0, TCGA-A2-A0SV, TCGA-E9-A22G, TCGA-AR-A0TS, TCGA-A8-A06P, TCGA-B6-A0X5, TCGA-D8-A1JP, TCGA-AN-A0FD, TCGA-GM-A2DF, TCGA-AR-A0TW, TCGA-AN-A0FZ, TCGA-AN-A0FF, TCGA-C8-A12V, TCGA-AC-A23E, TCGA-A1-A0SP, TCGA-A2-A0EQ, TCGA-A2-A1FW, TCGA-C8-A1HK, TCGA-D8-A1X6, TCGA-A2-A0EY, TCGA-A8-A09C, TCGA-EW-A6SB, TCGA-A8-A07U, TCGA-A8-A08G, TCGA-BH-A0BV, TCGA-C8-A12T, TCGA-E2-A1IF, TCGA-D8-A1XA, TCGA-E2-A15A, TCGA-E2-A1B0, TCGA-AR-A24W, TCGA-A7-A26J, TCGA-A8-A06O, TCGA-D8-A1JE, TCGA-V7-A7HQ, TCGA-C8-A1HF, TCGA-C8-A137, TCGA-E2-A15E, TCGA-A2-A0D1, TCGA-AR-A24Z, TCGA-E2-A15K, TCGA-E2-A14Y, TCGA-AN-A0XO, TCGA-LD-A7W5, TCGA-D8-A1J9, TCGA-E2-A15C, TCGA-C8-A26Z, TCGA-OL-A6VR, TCGA-D8-A27N, TCGA-A8-A08H, TCGA-A8-A097, TCGA-AO-A03V, TCGA-AR-A1AH, TCGA-A2-A1G6, TCGA-E2-A1IK, TCGA-BH-A0AV, TCGA-A2-A0YJ, TCGA-A7-A26H, TCGA-C8-A12L, TCGA-UU-A93S, TCGA-E2-A1L9, TCGA-A8-A08O, TCGA-E9-A1R3, TCGA-E2-A570, TCGA-A2-A04P, TCGA-A2-A0CS, TCGA-LL-A8F5, TCGA-BH-A0HI, TCGA-EW-A1OZ, TCGA-E2-A1B6, TCGA-BH-A0C7, TCGA-S3-AA14, TCGA-B6-A0RS, TCGA-A2-A0T0, TCGA-AN-A0G0, TCGA-OL-A66I, TCGA-A8-A09N, TCGA-C8-A135, TCGA-A2-A0CT, TCGA-AO-A0JE, TCGA-D8-A1Y1, TCGA-AO-A1KP, TCGA-A8-A092, TCGA-AR-A1AO, TCGA-D8-A27L, TCGA-BH-A0E1, TCGA-E2-A573, TCGA-AR-A0TV, TCGA-A2-A04N, TCGA-AR-A250, TCGA-BH-A0B8, TCGA-E9-A243, TCGA-BH-A0BJ, TCGA-E2-A159, TCGA-E2-A14Z, TCGA-BH-A0HB, TCGA-C8-A1HG, TCGA-E9-A1R7, TCGA-D8-A141, TCGA-AO-A0JM, TCGA-BH-A0GY, TCGA-GM-A2DN, TCGA-D8-A13Z, TCGA-A7-A13E, TCGA-AR-A251, TCGA-A8-A07P, TCGA-BH-A0B9, TCGA-D8-A1Y0, TCGA-BH-A0DH, TCGA-E9-A22D, TCGA-AR-A1AP, TCGA-D8-A1XK, TCGA-AQ-A54O, TCGA-A2-A0CU, TCGA-D8-A1X9, TCGA-A2-A0T5, TCGA-D8-A1XQ, TCGA-AR-A1AY, TCGA-A8-A09G, TCGA-OL-A6VO, TCGA-AR-A254, TCGA-A8-A09M, TCGA-A8-A08R, TCGA-E2-A14X, TCGA-E9-A1RH, TCGA-A2-A4S3, TCGA-BH-A0BR, TCGA-AN-A0FY, TCGA-B6-A0IB, TCGA-E2-A15J, TCGA-E2-A1IE, TCGA-A2-A3Y0, TCGA-D8-A1XG, TCGA-A2-A0T3, TCGA-A2-A0SX, TCGA-BH-A0B3, TCGA-A7-A0D9, TCGA-D8-A1JK, TCGA-BH-A0HF, TCGA-AC-A7VB, TCGA-EW-A1P5, TCGA-B6-A0RE, TCGA-D8-A13Y, TCGA-B6-A0I5, TCGA-AC-A6NO, TCGA-E2-A15H, TCGA-AR-A24P, TCGA-AO-A03T, TCGA-D8-A1JF, TCGA-OL-A5D8, TCGA-A2-A0YH, TCGA-BH-A0HW, TCGA-GM-A2DM, TCGA-A2-A0T7, TCGA-BH-A0DE, TCGA-GM-A2DH, TCGA-AN-A0AS, TCGA-OL-A5S0, TCGA-E2-A9RU, TCGA-E2-A56Z, TCGA-C8-A275, TCGA-BH-A0DZ, TCGA-S3-AA0Z, TCGA-E2-A1LA, TCGA-E9-A1R6, TCGA-E9-A229, TCGA-E2-A14T, TCGA-PL-A8LZ, TCGA-AN-A0FW, TCGA-LL-A6FQ, TCGA-BH-A0AY, TCGA-D8-A1XM, TCGA-AN-A0XS, TCGA-E9-A1RB, TCGA-AC-A5XU, TCGA-AR-A1AU, TCGA-A8-A09D, TCGA-E9-A1RD, TCGA-EW-A1IY, TCGA-D8-A1J8, TCGA-C8-A12Z, TCGA-AO-A03R, TCGA-C8-A12U, TCGA-A7-A13D, TCGA-BH-A18H, TCGA-B6-A0X4, TCGA-C8-A12N, TCGA-AC-A8OQ, TCGA-C8-A12P, TCGA-E9-A1N8, TCGA-BH-A0W3, TCGA-AR-A24V, TCGA-A8-A090, TCGA-BH-A0HQ, TCGA-BH-A0DS, TCGA-AO-A0J4, TCGA-AO-A0J6, TCGA-A8-A099, TCGA-A7-A0DB, TCGA-EW-A1PA, TCGA-AR-A1AQ, TCGA-C8-A132, TCGA-A7-A13D, TCGA-AN-A04A, TCGA-BH-A0RX, TCGA-A2-A1FZ, TCGA-BH-A201, TCGA-A8-A085, TCGA-GM-A2DD, TCGA-A8-A09A, TCGA-AO-A0JF, TCGA-EW-A6SA, TCGA-E2-A1AZ, TCGA-B6-A1KF, TCGA-S3-A6ZF, TCGA-AQ-A1H3, TCGA-AQ-A04H, TCGA-BH-A0HY, TCGA-AN-A049, TCGA-BH-A0BC, TCGA-A2-A0D0, TCGA-A2-A0CW, TCGA-AN-A04D, TCGA-E9-A1RA, TCGA-A1-A0SF, TCGA-BH-A0E2, TCGA-OL-A66P, TCGA-A2-A0EM, TCGA-AO-A12D, TCGA-E2-A14Q, TCGA-A8-A094, TCGA-A7-A13D, TCGA-E2-A14P, TCGA-AO-A1KR, TCGA-E9-A1RG, TCGA-BH-A0HX, TCGA-LL-A5YO, TCGA-C8-A27A, TCGA-WT-AB41, TCGA-D8-A27M, TCGA-BH-A0H6, TCGA-D8-A147, TCGA-E2-A14W, TCGA-A2-A0CP, TCGA-PL-A8LX, TCGA-C8-A26W, TCGA-B6-A0RI, TCGA-A2-A0EU, TCGA-S3-AA15, TCGA-E9-A245, TCGA-BH-A0HO, TCGA-E9-A228, TCGA-C8-A12O, TCGA-A2-A0YE, TCGA-B6-A0I2, TCGA-AN-A041, TCGA-A8-A079, TCGA-A8-A08T, TCGA-E2-A150, TCGA-S3-AA17, TCGA-A2-A0D3, TCGA-AC-A6IW, TCGA-C8-A1HM, TCGA-A8-A08L, TCGA-AN-A0FV, TCGA-AN-A0FK, TCGA-E9-A227, TCGA-A7-A6VW, TCGA-AR-A24N, TCGA-A2-A0SW, TCGA-AO-A0JA, TCGA-EW-A1J6, TCGA-A8-A07L, TCGA-AC-A23C, TCGA-A2-A0YF, TCGA-A2-A1FX, TCGA-A8-A07B, TCGA-A2-A04T, TCGA-AN-A03X, TCGA-E2-A14O, TCGA-LL-A73Y, TCGA-E2-A15O, TCGA-A2-A0CM, TCGA-EW-A1J1, TCGA-A7-A0DB, TCGA-E2-A158, TCGA-A8-A09Q, TCGA-AR-A24L, TCGA-BH-A0B7, TCGA-B6-A0RN, TCGA-E9-A22E, TCGA-E9-A1NG, TCGA-B6-A0WS, TCGA-A1-A0SQ, TCGA-3C-AALI, TCGA-B6-A0RL, TCGA-D8-A1XT, TCGA-A7-A4SE, TCGA-AR-A256, TCGA-A7-A0CJ, TCGA-AR-A1AV, TCGA-A8-A08Z, TCGA-A8-A096, TCGA-E9-A226, TCGA-E2-A153, TCGA-A2-A25E, TCGA-D8-A1JI, TCGA-A1-A0SM, TCGA-A8-A075, TCGA-C8-A273, TCGA-BH-A42V, TCGA-AR-A1AN, TCGA-OL-A5RX, TCGA-OL-A5RZ, TCGA-AR-A0TQ, TCGA-A8-A06Z, TCGA-S3-AA10, TCGA-A8-A076, TCGA-AR-A1AJ, TCGA-E9-A1RE, TCGA-A1-A0SJ, TCGA-OL-A66O, TCGA-E9-A244, TCGA-OL-A5RV, TCGA-BH-A0EA, TCGA-AO-A1KT, TCGA-E2-A14R, TCGA-A8-A06Y, TCGA-A7-A5ZW, TCGA-D8-A1JD, TCGA-B6-A409, TCGA-E9-A248, TCGA-A2-A0ST, TCGA-LL-A6FR, TCGA-AN-A0FX, TCGA-AR-A0TT, TCGA-D8-A1XZ, TCGA-E9-A22H, TCGA-A1-A0SI, TCGA-EW-A1P3, TCGA-BH-A0E0, TCGA-B6-A0X1, TCGA-EW-A1OY, TCGA-EW-A2FS, TCGA-E2-A15P, TCGA-BH-A0E7, TCGA-BH-A0HU, TCGA-AR-A0TY, TCGA-E2-A1B4, TCGA-GM-A2DC, TCGA-D8-A27H, TCGA-B6-A1KN, TCGA-E2-A1BD, TCGA-A8-A08C, TCGA-AN-A0FT, TCGA-A2-A25C, TCGA-B6-A0I9, TCGA-AQ-A54N, TCGA-A7-A13E, TCGA-A8-A082, TCGA-D8-A145, TCGA-D8-A27F, TCGA-B6-A0IJ, TCGA-A7-A13F, TCGA-BH-A0H7, TCGA-A2-A04V, TCGA-S3-AA12, TCGA-B6-A0WZ, TCGA-AR-A0U1, TCGA-C8-A130, TCGA-AN-A0FJ, TCGA-AR-A1AW, TCGA-LL-A7T0, TCGA-AO-A0J2, TCGA-AR-A24R, TCGA-BH-A0BO, TCGA-A2-A1G1, TCGA-C8-A26Y, TCGA-D8-A1JB, TCGA-E2-A10A, TCGA-D8-A1XF, TCGA-A7-A13E, TCGA-AO-A12F, TCGA-D8-A142, TCGA-A8-A07O, TCGA-AR-A0TU, TCGA-B6-A401",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "43",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A1FE",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "44",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A1F6, TCGA-BH-A1FU, TCGA-BH-A203, TCGA-BH-A1FJ, TCGA-BH-A1FD, TCGA-BH-A0BS, TCGA-BH-A1FE, TCGA-BH-A0BF, TCGA-BH-A0DT, TCGA-A7-A13G, TCGA-BH-A18L, TCGA-BH-A0HA, TCGA-BH-A1EN, TCGA-BH-A1F8, TCGA-BH-A18T, TCGA-BH-A1F5, TCGA-BH-A1EY, TCGA-BH-A0DI, TCGA-BH-A0BZ, TCGA-E2-A1IU, TCGA-BH-A204, TCGA-AC-A2BM, TCGA-BH-A1ES, TCGA-A7-A0CH, TCGA-BH-A1EW, TCGA-BH-A18N, TCGA-A7-A13G, TCGA-GI-A2C8, TCGA-E2-A1LB, TCGA-AC-A2BK, TCGA-GM-A2DI, TCGA-BH-A0H3, TCGA-GM-A2D9, TCGA-BH-A0DO, TCGA-BH-A0AU, TCGA-BH-A1EV, TCGA-BH-A1EU, TCGA-BH-A208, TCGA-BH-A1FM, TCGA-AC-A23H, TCGA-BH-A0DV, TCGA-E2-A1LS, TCGA-BH-A18J, TCGA-E9-A1NH, TCGA-BH-A18R, TCGA-BH-A18F, TCGA-BH-A1ET, TCGA-BH-A1FH, TCGA-E2-A1LH, TCGA-BH-A0DG, TCGA-BH-A1F0, TCGA-BH-A0BT, TCGA-E2-A1LK, TCGA-BH-A18K, TCGA-BH-A0AZ, TCGA-BH-A1FL, TCGA-E2-A1LL, TCGA-BH-A1FG, TCGA-BH-A1FN, TCGA-BH-A0DD, TCGA-BH-A1EX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "45",
         "BRCA",
         "C50.9",
         "8503/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-B6-A0IC, TCGA-EW-A2FW, TCGA-BH-A0HL, TCGA-D8-A1JS, TCGA-D8-A1X7",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Intraductal papillary adenocarcinoma with invasion",
         "Breast invasive carcinoma"
        ],
        [
         "46",
         "BRCA",
         "C50.9",
         "8507/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SG, TCGA-D8-A1XS, TCGA-EW-A1PE, TCGA-EW-A2FV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Invasive micropapillary carcinoma of breast",
         "Breast invasive carcinoma"
        ],
        [
         "47",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-PL-A8LV, TCGA-AR-A1AI, TCGA-EW-A1P4",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "48",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A209, TCGA-BH-A1FC",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "49",
         "BRCA",
         "C50.9",
         "8520/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-AC-A6IX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast invasive carcinoma"
        ]
       ],
       "shape": {
        "columns": 10,
        "rows": 715
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Case IDs</th>\n",
       "      <th>ICD_10_desc</th>\n",
       "      <th>ICD_O_3_SITE_desc</th>\n",
       "      <th>ICD_O_3_HISTOLOGY_desc</th>\n",
       "      <th>CANCER_TYPE_NAME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/1</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>None</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-N6-A4VF, TCGA-N6-A4VE, TCGA-N6-A4VC, TCGA...</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PI</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>712</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.2</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C54.2</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A59E</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>713</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PM</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>714</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C55</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C55.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...</td>\n",
       "      <td>None</td>\n",
       "      <td>Uterus NOS</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>715 rows Ã— 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE  \\\n",
       "0                   ACC  C74.0            8370/1        C74.0   \n",
       "1                   ACC  C74.0            8370/3        C74.0   \n",
       "2                   ACC  C74.0            8370/3        C74.0   \n",
       "3                  BLCA  C67.0            8120/3        C67.0   \n",
       "4                  BLCA  C67.0            8120/3        C67.0   \n",
       "..                  ...    ...               ...          ...   \n",
       "710                 UCS  C54.1            8950/3        C54.1   \n",
       "711                 UCS  C54.1            8980/3        C54.1   \n",
       "712                 UCS  C54.2            8950/3        C54.2   \n",
       "713                 UCS  C54.3            8980/3        C54.3   \n",
       "714                 UCS    C55            8950/3        C55.9   \n",
       "\n",
       "                  Normalized Sample Type  \\\n",
       "0    Blood Derived Normal, Primary Tumor   \n",
       "1    Blood Derived Normal, Primary Tumor   \n",
       "2     Primary Tumor, Solid Tissue Normal   \n",
       "3    Blood Derived Normal, Primary Tumor   \n",
       "4     Primary Tumor, Solid Tissue Normal   \n",
       "..                                   ...   \n",
       "710   Primary Tumor, Solid Tissue Normal   \n",
       "711  Blood Derived Normal, Primary Tumor   \n",
       "712  Blood Derived Normal, Primary Tumor   \n",
       "713  Blood Derived Normal, Primary Tumor   \n",
       "714  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                              Case IDs           ICD_10_desc  \\\n",
       "0    TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...  Adrenal gland cortex   \n",
       "1    TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...  Adrenal gland cortex   \n",
       "2    TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...  Adrenal gland cortex   \n",
       "3    TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...      Trigone, bladder   \n",
       "4    TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...      Trigone, bladder   \n",
       "..                                                 ...                   ...   \n",
       "710  TCGA-N6-A4VF, TCGA-N6-A4VE, TCGA-N6-A4VC, TCGA...           Endometrium   \n",
       "711                                       TCGA-N8-A4PI           Endometrium   \n",
       "712                                       TCGA-N5-A59E            Myometrium   \n",
       "713                                       TCGA-N8-A4PM          Fundus uteri   \n",
       "714  TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...                  None   \n",
       "\n",
       "        ICD_O_3_SITE_desc            ICD_O_3_HISTOLOGY_desc  \\\n",
       "0    Adrenal gland cortex                              None   \n",
       "1    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "2    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "3        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "4        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "..                    ...                               ...   \n",
       "710           Endometrium             Mullerian mixed tumor   \n",
       "711           Endometrium               Carcinosarcoma, NOS   \n",
       "712            Myometrium             Mullerian mixed tumor   \n",
       "713          Fundus uteri               Carcinosarcoma, NOS   \n",
       "714            Uterus NOS             Mullerian mixed tumor   \n",
       "\n",
       "                 CANCER_TYPE_NAME  \n",
       "0        Adrenocortical carcinoma  \n",
       "1        Adrenocortical carcinoma  \n",
       "2        Adrenocortical carcinoma  \n",
       "3    Bladder Urothelial Carcinoma  \n",
       "4    Bladder Urothelial Carcinoma  \n",
       "..                            ...  \n",
       "710        Uterine Carcinosarcoma  \n",
       "711        Uterine Carcinosarcoma  \n",
       "712        Uterine Carcinosarcoma  \n",
       "713        Uterine Carcinosarcoma  \n",
       "714        Uterine Carcinosarcoma  \n",
       "\n",
       "[715 rows x 10 columns]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "description_meta"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_details(prompt):\n",
    "    # Extract cancer type name, ICD-10 description, and tumor origin description\n",
    "    pattern = r\"Describe how (.*?) \\(per ICD-10: (.*?)\\) impacts survival, focusing on:\\n- Tumor Origin: How (.*?) influences\"\n",
    "    match = re.search(pattern, prompt, re.DOTALL)\n",
    "    if match:\n",
    "        cancer_type_name = match.group(1).strip()\n",
    "        icd10_desc = match.group(2).strip()\n",
    "        icd_o3_site_desc = match.group(3).strip()\n",
    "    else:\n",
    "        cancer_type_name, icd10_desc, icd_o3_site_desc = None, None, None\n",
    "\n",
    "    # Extract histology description\n",
    "    pattern_histology = r\"Histology: How (.*?) interacts with\"\n",
    "    match_histology = re.search(pattern_histology, prompt, re.DOTALL)\n",
    "    icd_o3_histology_desc = match_histology.group(1).strip() if match_histology else None\n",
    "\n",
    "    # Extract sampling bias (normalized sample type) details from the prompt\n",
    "    pattern_sample = r\"Sampling Bias: Limitations of (.*?) in genomic analysis\"\n",
    "    match_sample = re.search(pattern_sample, prompt, re.DOTALL)\n",
    "    normalized_sample_type = match_sample.group(1).strip() if match_sample else None\n",
    "\n",
    "    return {\n",
    "        \"CANCER_TYPE_NAME\": cancer_type_name,\n",
    "        \"ICD_10_desc\": icd10_desc,\n",
    "        \"ICD_O_3_SITE_desc\": icd_o3_site_desc,\n",
    "        \"ICD_O_3_HISTOLOGY_desc\": icd_o3_histology_desc,\n",
    "        \"Normalized_Sample_Type\": normalized_sample_type\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "response",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "2cead8bd-2bd5-4539-a012-65b30a996d05",
       "rows": [
        [
         "0",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Adrenocortical carcinoma (per ICD-10: Adrenal gland cortex) impacts survival, focusing on:\n- Tumor Origin: How Adrenal gland cortex influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How UNKOWN interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n**Influence on Survival:**\n1. **Metastatic Patterns and Patient Survival:**\n   - Adrenocortical carcinoma (ACC) originates in the adrenal cortex, which is a primary endocrine organ involved in hormone production. Its location and function influence its potential for substantial metastasis, often to the liver, lungs, and regional lymph nodes.\n   - **Impact on Survival:** The propensity for early metastatic spread significantly worsens the prognosis, often leading to decreased survival times.\n\n2. **Treatment Accessibility:**\n   - Surgical resection is often the most effective treatment, but ACC's capacity for metastasis can make complete surgical removal challenging, limiting treatment options primarily to systemic therapies such as mitotane, chemotherapy, or emerging targeted therapies.\n\n**Biological Rationale:**\n- The endocrine activity of the adrenal cortex, releasing hormones that can promote tumor growth and metastasis, directly correlates with aggressive disease progression.\n\n### Histology\n\n**Influence on Survival:**\n1. **Histological Characteristics:**\n   - While you mentioned \"UNKNOWN,\" I assume examining histological variants is essential. ACC typically lacks distinct histological subtypes but may vary significantly in cellular differentiation and necrosis.\n   - **Impact on Survival:** Poorly differentiated histological features often correlate with aggressive clinical behavior and worse outcomes.\n\n**Biological Rationale:**\n- The variability in cell differentiation affects the tumor's responsiveness to treatment and its intrinsic growth rate, impacting survival.\n\n### Sampling Bias\n\n**Influence on Survival:**\n1. **Limitations from Sampling:**\n   - Relying on blood-derived normals or primary tumors can obscure the heterogeneity inherent in ACC.\n   - **Impact on Survival:** This can result in incomplete genomic analyses, potentially missing key mutations or pathways active in metastatic sites.\n\n**Biological Rationale:**\n- Genomic comparisons using inadequate reference samples may not capture the full landscape of driver mutations or resistance mechanisms critical for patient-specific treatment plans.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **Survival-Associated Genes:**\n   - **TP53:** Mutations in TP53 can lead to evasion of apoptosis and unchecked cellular proliferation.\n   - **CTNNB1:** Alterations in the WNT/Î²-catenin signaling pathway can drive tumor growth and metastasis.\n   - **RB1:** Regulates the cell cycle; mutations can lead to loss of cell cycle control.\n   - **MEN1:** Involved in genomic stability; mutations disrupt endocrine pathways.\n   - **IGF2:** Overexpression can promote mitogenic and anti-apoptotic effects.\n   - **PRKAR1A:** Alterations can affect hormone signaling pathways, driving tumorigenesis.\n\n**Biological Mechanisms and Impact:**\n- Each gene alters cellular processes such as proliferation, apoptosis, and hormonal signaling, aggravating the aggressive nature of ACC and impacting overall survival negatively.\n\n### Conclusion Synthesis\n\n**Key Survival Risk Factors:**\n- *Origin and Metastasis:* The endocrine origin predisposes early metastatic spread, a crucial factor in poor prognosis.\n- *Histological Variability:* Lacking distinct subtypes but demonstrating varying differentiation impacts treatment responses.\n- *Genomic Insights and Sampling Biases:* Comprehensive genomic profiling is essential, yet limited significantly by current sampling practices.\n- *Genomic Targets:* Key mutations in genes such as TP53 and CTNNB1 exemplify crucial therapeutic targets but require individualized treatment strategies due to the tumor's complexity.\n\n**Clinically Relevant Insights:**\n- An integrated approach considering both the unique genetic and histological features of ACC, as well as the potential biases in current genomic interpretations, is essential for developing effective treatment strategies.\n- Enhanced genomic analysis and improved understanding of metastatic mechanisms can significantly alter treatment paradigms, potentially leading to tailored, effective interventions improving patient survival rates."
        ],
        [
         "1",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Adrenocortical carcinoma (per ICD-10: Adrenal gland cortex) impacts survival, focusing on:\n- Tumor Origin: How Adrenal gland cortex influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Adrenal cortical carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Adrenocortical Carcinoma\n\n#### Influence on Survival\n- **Positive/Negative Impact**: Adrenocortical carcinoma (ACC) originates from the adrenal cortex, which inherently possesses high hormonal activity and metabolic roles. This origin limits early detection due to deep anatomical positioning and contributes to an initially advanced stage upon diagnosis, negatively impacting survival. \n- **Biological Rationale**: The adrenal glands are involved in cortisol and aldosterone production. Tumorigenesis disrupts endocrine balance, often resulting in paraneoplastic syndromes, which complicates the clinical picture. This dysfunction supports aggressive tumor growth and facilitates metastatic potential, especially to the liver and lungs, worsening prognosis.\n- **Treatment Accessibility**: The location and function of the adrenal gland influence surgical resectability and sensitivity to systemic therapies, with mitotane being the mainstay. Advanced interventions are often required but are less accessible, particularly in metastatic phases.\n\n### Histology\n\n#### Influence on Survival\n- **Interaction with Mutation Profiles**: Histologically, ACCs exhibit heterogeneously aggressive features. High-grade tumors coupled with frequent mutations in genes such as TP53 lead to genomic instability.\n- **Biological Rationale**: Poor cellular differentiation and pleomorphic cells indicate rapid growth and high metastatic potential, facilitating immune evasion and resistance mechanisms.\n- **Negative Impact**: This histological aggressiveness correlates with poor response to conventional chemotherapies, contributing to lower survival rates.\n\n### Sampling Bias: Limitations of Genomic Analysis\n\n#### Blood Derived Normal vs. Primary Tumor\n- **Biological Rationale**: Using blood-derived normal samples as a control can miss somatic mutations occurring specifically in the tumor microenvironment, leading to an incomplete understanding of cancer genomics.\n- **Limitations**: Primary tumor samples might not capture the full extent of intratumoral heterogeneity. Sampling might miss subclonal populations, causing a bias in therapeutic target identification, and potentially skewing survival projections.\n\n### Key Genes and Survival\n\n#### Genes Involved\n1. **TP53**: Tumor suppressor often mutated in ACC. Loss of function leads to unchecked proliferation and genomic instability.\n2. **CTNNB1**: Aberrant activation of beta-catenin signaling fosters tumor growth and invasion.\n3. **IGF2**: Overexpression seen in ACC reinforces autocrine growth stimulation, promoting tumor development.\n4. **MDM2**: This oncogene amplifies further disruption of p53 pathways, accelerating tumor progression.\n5. **TERT**: Mutations in telomerase reverse transcriptase sustain cellular immortality, aiding metastasis.\n6. **RB1**: Disrupted function removes critical cell cycle checks, allowing unchecked division.\n7. **PRKAR1A**: Loss can deregulate cyclic AMP pathways, impacting cellular growth control mechanisms.\n8. **MEN1**: Mutated in some ACCs, impacting protein-protein interactions essential for cellular homeostasis and longevity.\n\n#### Influence on Survival\n- **Mechanisms**: These genes typically manage proliferation, apoptosis, and genomic integrity. When mutated, they create survival advantages for tumor cells, overwhelming host defenses and treatments.\n- **Negative Impact**: Their dysregulation not only drives malignancy but also creates formidable barriers to effective therapeutic intervention.\n\n### Conclusion: Key Survival Risk Factors\n\n#### Synthesis\n- **Key Insights**: The combination of aggressive tumor origin, deleterious mutations, sampling biases, and high-risk gene profiles create a multifaceted threat to survival. ACC often remains refractory to existing treatments owing to these complex biological interactions.\n- **Clinical Implications**: Incorporating a deeper understanding of ACCâ€™s genomic landscape could refine prognostic models and guide precision medicine applications. This would likely enhance personalized treatment plans and improve survival outcomes, emphasizing the necessity for vigilant genetic screenings and innovative therapeutic strategies.\n\nUltimately, advancements in capturing the comprehensive genetic signature of adrenocortical carcinoma are paramount in shifting survival curves favorably."
        ],
        [
         "2",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Adrenocortical carcinoma (per ICD-10: Adrenal gland cortex) impacts survival, focusing on:\n- Tumor Origin: How Adrenal gland cortex influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Adrenal cortical carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Adrenocortical Carcinoma (ACC) and Survival Impact: A Detailed Analysis**\n\n**1. Tumor Origin**\n- **Impact on Survival:** The adrenal gland cortex is crucial in producing steroid hormones, and tumors here are known for aggressive behavior and a high propensity for early metastasis, often to the liver, lungs, and retroperitoneum. This widespread metastatic pattern significantly reduces survival rates, often resulting in median survival being less than five years for advanced cases.\n- **Biological Rationale:** The adrenal gland's hormone secretion capability can drive tumor growth and dissemination. Tumors can produce excess cortisol, leading to Cushingâ€™s syndrome, which affects overall prognosis negatively by further complicating the systemic health.\n- **Bias in Interpretation:** Accessibility to the adrenal gland is challenging, which can limit surgical resection options. This can bias the understanding of tumor biology as fewer tissue samples from metastatic sites might be obtained for comprehensive genomic profiling.\n\n**2. Histology**\n- **Impact on Survival:** ACC histology shows variable differentiation, ranging from well-differentiated (better prognosis) to poorly differentiated (worse prognosis) tumors. The presence of necrosis, invasion into surrounding tissues, and vascular invasion in histological samples are bad prognostic indicators.\n- **Biological Rationale:** Poor differentiation correlates with higher proliferative indices and aggressive phenotypes. Histological analysis often aligns with genetic instability and aneuploidy, correlating with poorer outcomes.\n- **Potential Biases:** Histological analyses often depend on the quality and quantity of biopsy samples, which might miss heterogeneity within the tumor, leading to underestimation of aggressive subclones that drive poorer outcomes.\n\n**3. Sampling Bias**\n- **Influence on Survival Interpretation:** Sampling biases occur when genomic data is derived only from primary tumors or non-malignant tissue, potentially missing metastatic or more aggressive tumor subpopulations. This affects survival analysis as metastatic traits may not be fully represented.\n- **Biological Rationale:** Primary tumors may not exhibit the full spectrum of mutational changes present in metastatic lesions, which can lead to less informed treatment decisions impacting survival negatively.\n- **Bias in Genomic Interpretation:** Reliance on primary tumor biopsies risks missing key mutations and evolutionary adaptations present in metastatic sites. This underscores the need for comprehensive sampling to inform prognosis accurately.\n\n**4. Key Genes Associated with Survival**\n- **Impact on Survival:** The following genes are crucial in influencing ACC outcomes:\n\n  - **TP53:** Commonly mutated in ACC, leading to loss of tumor suppressor function and unchecked cellular proliferation.\n  - **CTNNB1:** Alterations in the Wnt/Î²-catenin pathway can lead to increased cellular proliferation and dedifferentiation.\n  - **MEN1:** Mutation of this gene is linked with endocrine tumors, influencing survival via altered cell cycle and proliferation.\n  - **IGF2:** Overexpression can activate pathways that promote tumor growth and survival, impacting overall prognosis negatively.\n  - **ZNRF3:** Its loss enhances Wnt signaling, augmenting tumor aggressiveness.\n  - **TERT:** Mutations often result in increased telomerase activity, permitting unlimited cellular replication.\n  - **RB1:** Loss of function in this gene affects cell cycle regulation, enhancing proliferation rates.\n  - **SF1:** Overexpression is associated with worse prognosis, as it drives steroidogenic dysregulation.\n\n- **Biological Mechanisms:** These genes are involved in crucial pathways such as apoptosis regulation, cell cycle control, and hormonal regulation, directly impacting tumor behavior and resistance to treatment.\n\n**Synthesis and Clinically Relevant Insights:**\nSurvival in ACC is heavily influenced by both innate biological features and treatment access hindered by anatomical location. Tumor genomics offer insights into aggressive behavior and potential therapeutic targets but require careful interpretation due to sampling biases. Understanding histological differentiation and integrating comprehensive genomic profiling are vital in tailoring management strategies to improve patient outcomes. Continued research in comprehensive, multi-site genetic analysis and more effective systemic therapies is crucial for enhancing survival rates in ACC patients."
        ],
        [
         "3",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Trigone, bladder) impacts survival, focusing on:\n- Tumor Origin: How Trigone, bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "To understand the survival impact of Bladder Urothelial Carcinoma, particularly originating in the trigone of the bladder, we need to systematically assess each relevant aspect.\n\n### Tumor Origin: Trigone, Bladder\n1. **Influence on Metastatic Patterns and Survival:**\n   - **Anatomical Considerations:** The bladder trigone's anatomical location, bordered by the ureters and urethral orifice, potentially facilitates early dissemination of cancer cells through the urinary system. This can lead to early metastasis to nearby lymph nodes and organs, negatively impacting survival.\n   - **Survival Impact:** Tumors in the trigone often present at a more advanced stage as early symptoms might be mistaken for benign conditions, delaying diagnosis and treatment.\n   - **Treatment Accessibility:** Surgical approaches can be more complex due to proximity to critical structures, sometimes limiting resection margins.\n\n2. **Biological Rationale:** The proximity to vascular and lymphatic channels can facilitate hematogenous and lymphatic spread, accounting for reduced survival.\n\n3. **Potential Biases:** Registry data might underreport trigone-specific outcomes, leading to underappreciation of its distinct survival challenges.\n\n### Histology: Transitional Cell Carcinoma, NOS\n1. **Mutation Profiles and Outcomes:**\n   - **Genetic Landscape:** Transitional cell carcinoma (TCC) frequently exhibits mutations in genes like TP53, FGFR3, and RB1. TP53 mutations disrupt apoptosis, allowing survival of damaged cells, while FGFR3 mutations can promote proliferation.\n   - **Survival Outcomes:** Generally, TP53 mutations are associated with high-grade, aggressive tumors and poorer survival, whereas FGFR3 mutations might indicate lower-grade tumors with better prognosis.\n\n2. **Biological Rationale:** Aberrant cell signaling due to these mutations contributes to unchecked cell proliferation and impaired cell death, crucial factors in disease progression.\n\n3. **Potential Biases:** Studies often underrepresent low-grade tumors, skewing understanding of mutation impact on survival.\n\n### Sampling Bias: Blood Derived Normal, Primary Tumor\n1. **Limitations:**\n   - **Genomic Analysis:** Blood-derived normal samples might not accurately represent tumor heterogeneity seen in the primary site, leading to possible misinterpretation of somatic mutations.\n   - **Detection of Circulating Tumor DNA (ctDNA):** While ctDNA can provide insights into mutational burden, it may not reflect entire mutational landscapes, particularly in early stages or low tumor burden situations.\n\n2. **Biological Rationale:** Differences in DNA extraction sites can have significant implications for understanding genomic alterations that drive cancer progression and treatment responses.\n\n3. **Potential Biases:** The reliance on blood samples for genomic analysis may exclude crucial information about clonal evolution that is only present in tissue biopsies.\n\n### Key Genes and Their Impact\n1. **Survival-Associated Genes:**\n   - **TP53:** Loss of tumor suppressor function leads to genomic instability and aggressive tumor behavior.\n   - **FGFR3:** Often associated with better survival due to its prevalence in low-grade disease.\n   - **RB1:** Loss of function affects cell cycle regulation, promoting unchecked proliferation.\n   - **PIK3CA:** Activating mutations enhance signaling pathways that drive growth and survival, often associated with more advanced disease.\n   - **ERBB2 (HER2):** Amplification or overexpression can lead to aggressive tumor growth, linked with poor outcomes but targetable therapeutically.\n   - **CDKN2A:** Deletions/mutations lead to dysregulation in cell cycle checkpoints, correlating with disease aggressiveness.\n   - **ARID1A:** Loss of ARID1A impairs chromatin remodeling and transcriptional control, associated with poor prognosis.\n   - **TSC1:** Mutations can lead to mTOR pathway activation, providing potential targets for therapeutic intervention.\n\n2. **Biological Mechanisms:** The roles of these genes in apoptosis regulation, cell proliferation, and immune evasion are pivotal for understanding their impact on survival.\n\n3. **Potential Biases:** Population-specific studies sometimes skew results regarding the frequency and impact of these mutations.\n\n### Synthesis of Key Survival Risk Factors\nThe survival of patients with bladder urothelial carcinoma depends on a complex interplay of tumor location, histological characteristics, genetic mutations, and sampling strategies. The trigone's unique anatomical challenges, coupled with specific mutational profiles like TP53 and FGFR3, significantly shape outcomes. Understanding sampling biases in genomic data interpretation is critical for accurate assessment and treatment personalization. These insights underscore the importance of comprehensive patient assessment to improve survival predictions and develop targeted therapeutics."
        ],
        [
         "4",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Trigone, bladder) impacts survival, focusing on:\n- Tumor Origin: How Trigone, bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Trigone of the Bladder\n\n1. **Influence on Survival:**\n   - Tumors originating in the trigone area of the bladder exhibit a tendency for a more aggressive clinical course compared to other bladder regions.\n   - Given its anatomical proximity to the ureters and urethra, there is a higher risk for early invasion and subsequent metastasis, potentially reducing overall survival.\n\n2. **Biological Rationale:**\n   - The trigone is a fixed region with rich vascular and nerve supply, contributing to rapid tumor growth and dissemination.\n   - This areaâ€™s involvement often complicates surgical interventions and may necessitate more aggressive treatment options which carry greater morbidity.\n\n3. **Metastatic Patterns and Treatment Accessibility:**\n   - Early lymphatic spread is common, especially to pelvic lymph nodes.\n   - The location may limit complete surgical resection, affecting prognostic outcomes.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n1. **Influence on Survival:**\n   - As the most common histological subtype, transitional cell carcinoma (TCC) exhibits varied outcomes based on genetic heterogeneity.\n   - Prognosis is often worse with high-grade, muscle-invasive TCC due to robust proliferative capacity and potential for deeper tissue invasion.\n\n2. **Mutation Profiles:**\n   - Frequent mutations in FGFR3, PIK3CA, TP53, and RB1 characterize TCC, influencing pathways pivotal in cell cycle regulation and apoptosis.\n\n3. **Biological Rationale:**\n   - FGFR3 mutations often correlate with non-invasive low-grade tumors, offering better prognosis, while TP53 and RB1 mutations align with aggressive, poor-survival phenotypes.\n\n### Sampling Bias: Limitations of Primary Tumor and Solid Tissue Normal Genomic Analysis\n\n1. **Influence on Interpretation:**\n   - Genomic data might reflect sampling bias when derived primarily from easily accessible or non-representative tumor regions.\n   - Subclonal diversity and heterogeneity might be underrepresented, skewing treatment response predictions and survival estimates.\n\n2. **Biological Rationale:**\n   - Tumor heterogeneity means a single biopsy may not encapsulate the full mutation spectrum, impacting targeted therapy approaches.\n\n3. **Potential Bias:**\n   - Normal tissues adjacent to tumors might display field cancerization effects, where seemingly normal cells possess early oncogenic mutations, complicating interpretation of â€˜normalâ€™ controls.\n\n### Key Survival-Associated Genes\n\n1. **FGFR3:**\n   - Typically mutated in low-grade tumors, facilitating tumor proliferation. Paradoxically, associated with better survival due to less aggressive phenotypes.\n\n2. **TP53:**\n   - Mutations lead to loss of apoptosis, promoting tumor survival and progression. High correlation with poor prognosis due to unchecked cellular proliferation.\n\n3. **RB1:**\n   - Loss of function results in deregulated cell cycle progression, linked to high-grade, muscle-invasive cancers, negatively impacting survival.\n\n4. **PIK3CA:**\n   - Activates downstream signaling pathways like AKT, supporting cell survival and growth. Plays dual roles, with implications in both tumorigenesis and potential therapeutic targeting.\n\n5. **ERCC2:**\n   - Involved in DNA repair pathways; mutations can indicate susceptibility to cisplatin-based therapies, highlighting personalized treatment approaches.\n\n6. **TSC1:**\n   - Its involvement relates to mTOR pathway regulation. Alterations may guide mTOR inhibitor therapies, influencing survival positively in contexts of targeted therapy.\n\n### Synthesis of Key Survival Risk Factors\n\n- The interplay of anatomical origin, histological characteristics, genomic mutations, and sampling biases fundamentally shapes survival outcomes in bladder urothelial carcinoma.\n- Clinically, understanding these factors aids in tailoring treatments, from invasive surgical interventions to targeted molecular therapies, emphasizing the importance of precision in genomic and clinical profiling.\n- Key insights illustrate the necessity for comprehensive approaches that integrate early diagnosis, accurate subtype characterization, and adaptive therapeutic strategies to improve patient survival rates.\n\nThis synthesis underscores the critical nature of a multidimensional understanding of bladder cancer, fostering better, individualized care paradigms that are grounded in extensive genetic and clinical explorations."
        ],
        [
         "5",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Trigone, bladder) impacts survival, focusing on:\n- Tumor Origin: How Trigone, bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Papillary transitional cell carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin: Trigone, Bladder\n\n### Influence on Survival\nThe trigone, a part of the urinary bladder located between the openings of the ureters and the urethra, is an area with unique anatomical considerations. Tumors originating in this area can potentially affect patient survival due to proximity to critical structures, influencing metastatic spread and treatment options.\n\n### Biological Rationale\n1. **Metastatic Patterns**: The rich lymphatic drainage around the trigone can facilitate early metastasis, particularly to pelvic lymph nodes. This propensity for early dissemination is often associated with poorer prognosis.\n2. **Treatment Accessibility**: Due to its anatomical position, complete surgical excision might be more challenging, leading to higher recurrence rates compared to tumors in other bladder locations. This complexity can limit effective surgical interventions, impacting survival negatively.\n\n### Potential Biases\nWhile location-specific data enhances understanding of survival disparities, many studies may not disaggregate outcomes by precise bladder tumor locations, potentially underestimating the distinct survival outcomes of trigone tumors.\n\n## Histology: Papillary Transitional Cell Carcinoma\n\n### Influence on Survival\nPapillary transitional cell carcinoma (PTCC), a common bladder cancer histology, interacts with mutation profiles that affect cell growth and apoptosis, directly influencing survival rates.\n\n### Biological Rationale\n1. **Interaction with Mutations**: PTCC often harbors mutations in genes like FGFR3, which may drive tumor growth but also make tumors susceptible to targeted therapies, potentially improving survival.\n2. **Prognostic Indicators**: The histological pattern offers insights into prognosis; non-muscle invasive papillary tumors usually have a better prognosis than muscle-invasive forms due to differences in mutation-driven aggressive behaviors.\n\n### Potential Biases\nHistological analysis can be subject to sampling bias if tumor heterogeneity is not adequately sampled, potentially skewing mutation association studies and subsequent survival predictions.\n\n## Sampling Bias: Blood Derived Normal, Primary Tumor\n\n### Influence on Survival Studies\nInaccuracies in genomic analyses, driven by sampling biases, can misinform survival-related findings.\n\n### Biological Rationale\n1. **Blood Derived Normals**: Using blood-derived controls may not suitably reflect the genetic background of urothelial cells, leading to erroneous assumptions about somatic mutations versus germline variations.\n2. **Primary Tumor Sampling**: Insufficient sampling of primary tumors can overlook intratumoral heterogeneity, failing to capture the full mutation spectrum affecting prognosis and therapy response.\n\n### Potential Biases\nInadequate representation of genomic variation due to these biases can obscure the true impact of certain mutations on survival, limiting effective clinical interventions based on genomic profiling.\n\n## Key Genes Affecting Survival\n\n### Genes and Mechanisms\n1. **TP53**: A critical tumor suppressor, mutations here can lead to loss of apoptosis control, resulting in poor responses to therapy and worsening survival.\n2. **RB1**: Dysfunction in this regulatory checkpoint gene is associated with uncontrolled cell proliferation; its mutations frequently correlate with aggressive tumor behavior.\n3. **FGFR3**: While mutations can drive oncogenesis, they also facilitate targeted treatments, potentially improving survival when accessible to targeted drugs.\n4. **PIK3CA**: Mutations in this pathway can activate survival and proliferation signals, with significant survival implications depending on pathway targeting.\n5. **CDKN2A**: Loss of function mutations here deregulate the cell cycle, correlating with aggressive cancer forms and challenging prognosis.\n6. **ERBB2 (HER2)**: Overexpression or mutation can activate oncogenic signaling, influencing survival negatively but also offering therapeutic targets.\n7. **EGFR**: Alterations in this receptor can drive tumor growth and relate to poorer survival, especially in its presence influencing metastasis and therapy resistance.\n\n### Biological Rationale\nThese genes impact survival through mechanisms like cell cycle dysregulation, promoting proliferation, evasion of apoptosis, and influencing immune interactions. Their expression and mutation status can serve as prognostic indicators and therapeutic targets.\n\n## Conclusion: Synthesis of Key Survival Risk Factors\n\n### Clinically Relevant Insights\nThe anatomical location, histological characteristics, genetic mutations, and sampling methods individually and collectively impact survival in Bladder Urothelial Carcinoma. Tumors in the trigone often have worse outcomes due to metastatic advantages. PTCC histology coupled with relevant mutations can define distinct prognostic pathways. Recognizing sampling biases is crucial for accurate genomic insights.\n\n### Impact on Patient Survival\nEfforts to improve survival should prioritize comprehensive molecular profiling, consider anatomical-specific therapeutic strategies, and exploit targeted treatments based on precise mutation profiles. Addressing these key risk factors can significantly refine prognostic models and therapeutic approaches, ultimately enhancing patient outcomes."
        ],
        [
         "6",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Dome, bladder) impacts survival, focusing on:\n- Tumor Origin: How Dome, bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Dome, Bladder\n\n**Influence on Survival:**\n- **Metastatic Patterns:** Tumors originating in the dome of the bladder can potentially invade adjacent structures like the peritoneum earlier due to anatomical proximity, contributing to quicker dissemination and metastasis.\n- **Patient Survival:** This can result in earlier stage IV diagnoses when the cancer is more widespread, negatively affecting survival rates.\n- **Treatment Accessibility:** The location might not significantly impede initial surgical interventions but could complicate complete resection if invasion is extensive at diagnosis, affecting long-term remission.\n\n**Biological Rationale:**\n- Anatomical position influences tumor grow-out patterns and access to lymphatic and vascular pathways crucial for metastasis.\n\n**Biases:**\n- Studies might underreport early metastatic potentials owing to sampling biases, particularly when peripheral parts of tumors are analyzed more often than their point of origin.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n**Influence on Survival:**\n- **Mutation Profiles:** The histological subtype interacts with certain mutations like TP53 or FGFR3 that have distinct prognostic implications, affecting survival strategies.\n- **Outcomes:** Tumors with FGFR3 mutations often present less aggressively, correlating with better outcomes, whereas TP53 mutations often correlate with poor responses and lower survival.\n\n**Biological Rationale:**\n- Transitional cell carcinomas exhibit particular chromosomal instabilities that enhance survival through driver mutations promoting uncontrolled proliferation.\n\n**Biases:**\n- Primary Tumor sampling might not capture heterogeneity, underestimating subclonal variations which contribute to treatment resistance.\n\n### Sampling Bias: Blood Derived Normal and Primary Tumor\n\n**Limitations:**\n- Blood-derived normal samples lack the clonal architecture of the primary tumor, potentially overlapping somatic mutation data interpretation.\n- Tumor biopsy heterogeneity can lead to skewing understanding of the mutational load and its prognostic interpretations.\n\n### Key Genes: Survival-Associated Genes\n\n1. **TP53:** Mutations in TP53 often lead to faulty DNA repair mechanisms, enabling rapid clonal expansions and resistance to therapy, correlating with poor survival.\n   \n2. **FGFR3:** Often mutated in less aggressive forms, affecting proliferation pathways that can be inhibited therapeutically, improving prognosis.\n\n3. **PIK3CA:** Alters cell growth and survival systems via PI3K/AKT signaling, often correlating with resistance to standard chemotherapies.\n\n4. **CDH1:** Mutations affect cellular adhesion, facilitating metastatic potential and correlating with aggressive phenotypes.\n\n5. **HRAS:** Involved in the MAPK pathway, these mutations enhance proliferative signaling contributing to tumor growth, impacting overall survival negatively.\n\n6. **PTEN:** Tumor suppressor gene mutation leads to unchecked PI3K/AKT signaling, facilitating survival and growth in malignant cells, reducing survival prospects.\n\n**Biological Mechanisms:**\n- These genes play diverse roles from regulating cell cycle checkpoints (TP53) to signaling cascades (FGFR3, PIK3CA) and maintaining cellular architecture (CDH1).\n\n### Conclusion: Key Survival Risk Factors\n\n- **Location Influences:** Bladder dome origin contributes to early dissemination risks.\n- **Genetic Context:** Genetic mutations within transitional cell carcinoma shape treatment response and prognosis.\n- **Sampling Considerations:** Overlooked heterogeneity can lead to unexpected treatment failures.\n- **Clinically Relevant Insights:** Personalized treatments targeting specific mutational profiles and careful surgical planning reflect necessary approaches to improve survival outcomes.\n\nIntegrating these genomic and anatomical insights is essential for precision medicine approaches to optimize therapeutic interventions and prognostic assessments in patients with Bladder Urothelial Carcinoma of the dome."
        ],
        [
         "7",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Dome, bladder) impacts survival, focusing on:\n- Tumor Origin: How Dome, bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Dome, Bladder\n\n1. **Impact on Metastatic Patterns and Survival:**\n   - **Apical Origin:** Tumors originating from the dome, which is the apex of the bladder, may have distinct metastatic behaviors. Their location can potentially facilitate early dissemination via rich lymphatic drainage paths leading to pelvic lymph nodes and beyond, impacting survival negatively by increasing the likelihood of advanced-stage detection.\n   - **Survival Impact:** This origination point might result in delayed detection due to symptoms manifesting later in disease progression, influencing overall survival negatively by presenting at an advanced stage with less curative options available.\n\n2. **Treatment Accessibility:**\n   - **Surgical Challenges:** The dome location might present technical challenges for surgical resection and could limit the applicability or success of bladder-preserving techniques, such as a partial cystectomy, further impacting survival.\n   \n### Histology: Transitional Cell Carcinoma (TCC), NOS\n\n1. **Mutation Profiles and Survival Impact:**\n   - **Histological Influence:** TCC, also known as urothelial carcinoma, is characterized by its tendency to harbor specific mutations in genes like FGFR3, PIK3CA, and TP53, each influencing survival differently. FGFR3 mutations typically correspond to lower-grade, potentially better prognosis cancers, while TP53 alterations are linked to high-grade tumors with a worse survival outlook.\n   - **Outcomes:** This interaction suggests that survival is highly contingent on the mutational landscape. A predominantly FGFR3-mutated profile could indicate a more indolent course, whereas the presence of TP53 mutations may suggest aggressive behavior and poorer survival.\n\n### Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal\n\n1. **Genomic Analysis Challenges:**\n   - **Selection Bias:** Genomic analyses using primary tumor without matched normal tissue may lack context on the individual patient's baseline genetic backdrop, leading to potential misinterpretation of what may be somatic versus germline variations.\n   - **Outcome Influence:** This bias could skew findings towards prevalent somatic mutations while under-appreciating germline contributions to survival, leading to potential misestimation of true mutational driver significance regarding patient prognosis.\n\n### Key Genes Associated with Survival\n\n1. **FGFR3:**\n   - **Mechanism:** Often associated with low-grade tumors, FGFR3 mutations are linked to increased cell proliferation but less aggressive behavior, potentially enhancing survival in contrast to mutations promoting high-grade pathology.\n   \n2. **TP53:**\n   - **Mechanism:** As a major tumor suppressor, alterations often herald aggressive disease, leading to increased proliferation and reduced apoptosis, thus worsening survival outcomes.\n   \n3. **ERBB2 (HER2):**\n   - **Mechanism:** Overexpression can lead to uncontrolled cell growth. While traditionally linked with aggressive behavior, targeted therapies might improve survival if HER2 overexpression is present.\n   \n4. **PIK3CA:**\n   - **Mechanism:** Activating mutations can lead to oncogenesis through cell proliferation pathways, possibly suggesting a nuanced survival impact depending on the mutation spectrum alongside the therapeutic landscape.\n   \n5. **CDKN2A:**\n   - **Mechanism:** Loss of CDKN2A function, a regulator of cell cycle, might lead to unchecked cell division, correlating with aggressive disease and poorer prognosis.\n   \n6. **KMT2D:**\n   - **Mechanism:** Alterations can affect chromatin remodeling, influencing tumor progression and potentially signaling a negative survival impact.\n\n7. **RB1:**\n   - **Mechanism:** Loss of tumor suppressive activity due to mutations suggests more aggressive cancer, affecting cellular proliferation, hence negatively impacting survival. \n\n### Conclusion: Key Survival Risk Factors\n\n1. **Synthesis:**\n   - **Locational Origin and Detection:** The dome location of bladder cancer impacts early detection and metastatic spread, possibly hindering early intervention strategies.\n   - **Histological and Genomic Interplay:** The survival outcome is significantly dictated by the histological subtype and accompanying genomic mutations, indicating the necessity of precise histogenomic profiling.\n   - **Biased Interpretation Risks:** Ensuring precise genomic interpretation through improved sampling strategies, like including normal tissues, is crucial in understanding survival impacts accurately and personalizing treatment pathways.\n\n2. **Clinical Relevance:**\n   - The integration of anatomical, histological, and genetic insights is critical in designing therapeutic approaches, impacting individual survival by tailoring the management plan based on predictive genomic indicators, thereby maximizing patient outcome potential."
        ],
        [
         "8",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Dome, bladder) impacts survival, focusing on:\n- Tumor Origin: How Dome, bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Papillary adenocarcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin and Impact on Survival\n\n**Step 1: Influence on Metastatic Patterns**\n- **Anatomical Consideration**: The dome of the bladder is a less common origin for bladder cancer compared to the trigone or lateral wall. However, its position can influence the direction of cancer spread. The dome being adjacent to the peritoneal surface poses an elevated risk for transperitoneal dissemination.\n- **Survival Impact**: Because of this increased risk of spreading to the peritoneum, patients might experience a more aggressive metastatic course, leading to a worse prognosis and potentially lower survival rates compared to tumors originating in other areas of the bladder.\n- **Treatment Accessibility**: Tumors at the dome may be less accessible for surgical interventions and diagnostic procedures like transurethral resections, potentially delaying definitive treatment and impacting survival negatively.\n\n### Histology and Molecular Interactions\n\n**Step 2: Papillary Adenocarcinoma and Mutation Profiles**\n- **Histological Features**: Papillary adenocarcinoma, NOS (not otherwise specified), is rare in bladder cancer and typically has a worse prognosis than conventional urothelial carcinoma. Its glandular structures hint at a different metastatic pattern and response to chemotherapy.\n- **Mutational Interactome**: This subtype often presents unique genetic mutations, such as alterations in ALK or NRG1 fusions, which can drive poor outcomes through unchecked cellular proliferation and metastatic capability. Understanding these mutations can tailor targeted therapies, which might improve survival outcomes if appropriately addressed.\n\n### Sampling Bias in Genomic Analysis\n\n**Step 3: Blood Derived Normal, Primary Tumor**\n- **Limitations**: Using blood-derived normal samples often misses tumor heterogeneity. Primary tumor samples provide richer insight into specific mutational burdens but might not reflect the full diversity of metastatic sites or subclones.\n- **Survival Impact**: These biases can lead to underestimation or overestimation of mutation frequencies, affecting prognostic estimates. Incomplete genetic profiling may overlook potential therapeutic targets, thereby limiting intervention strategies.\n- **Biological Rationale**: This impacts survival through potential oversight of particular aggressiveness in minor clones that are significant in metastasis, ultimately affecting treatment choices and outcomes.\n\n### Key Genes Impacting Survival\n\n**Step 4: Identification and Explanation**\n1. **TP53**: Mutations here disrupt apoptosis and the DNA damage response, leading to genetic instability. Their presence typically portends a poorer prognosis.\n2. **FGFR3**: Often mutated in non-muscle invasive bladder cancers, these changes can drive excessive proliferation via the MAPK and PI3K-Akt pathways. Targeted drugs against FGFR3 mutations can improve outcomes.\n3. **PIK3CA**: When mutated, promotes angiogenesis and survival through the PI3K/AKT/mTOR pathway, usually indicative of aggressive cancers.\n4. **CDKN2A**: Alterations result in loss of cell cycle regulation, leading to unchecked proliferation. Dysregulation here often correlates with advanced disease.\n5. **ERBB2 (HER2)**: Amplification can drive aggressive growth, similar to its effect in breast cancer, making it a target for HER2 inhibitors.\n6. **ARID1A**: Mutations may impair chromatin remodeling, influencing cellular differentiation and proliferation. This mutation is often associated with poor outcomes.\n7. **KDM6A**: Losses can lead to disrupted transcriptional regulation, correlated with higher-grade tumors and poor differentiation.\n8. **RB1**: Loss or mutation typically results in cell cycle deregulation. It acts as a hallmark indicator of aggressive and chemoresistant forms.\n\n### Synthesis of Key Survival Risk Factors\n\n**Concluding Synthesis**\nThe interplay between the tumor's anatomical origin, histological subtype, and specific genetic alterations frames the prognosis for bladder urothelial carcinoma, especially those originating from the dome. Genetic heterogeneity, driven by sampling biases and diversification of tumor cells, complicates accurate survival predictions and tailored interventions. Clinically, identifying significant genetic drivers like TP53 and FGFR3 mutations offers routes for targeted therapies, potentially improving survival stats. Nonetheless, intrinsic sampling limitations necessitate comprehensive analyses that integrate multiple data types to refine prognostication and appropriately address patient-specific treatment needs. Emphasizing molecular diagnostics aids in navigating the complex biological landscape of bladder cancer, guiding therapeutic strategies toward more personalized medicine, ultimately impacting survival positively by curtailing disease progression and recurrence."
        ],
        [
         "9",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Lateral wall bladder) impacts survival, focusing on:\n- Tumor Origin: How Lateral wall bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin and Influences on Survival\n\n1. **Lateral Wall Bladder and Metastasis Patterns:**\n   - **Influence on Survival:** The origin of the tumor on the lateral wall of the bladder influences metastatic routes, commonly involving lymphatic spread to pelvic lymph nodes which can increase metastasis and reduce survival rates.\n   - **Biological Rationale:** The lateral wall is richly innervated with vasculature allowing for efficient lymphatic transport. Tumor cells can thus access these pathways more readily, facilitating early dissemination.\n   - **Treatment Accessibility:** Tumors here might be more accessible for surgical resections, positively influencing outcomes if detected early.\n\n2. **Histology and Genetic Interplay:**\n   - **Transitional Cell Carcinoma, NOS Influence:** This is the most common histological subtype and has a well-documented relationship with mutations that affect cell proliferation and survival negatively.\n   - **Biological Rationale:** Histological characteristics of urothelial origin contribute to genetic mutations, primarily in genes regulating cell cycle and apoptosis, leading to aggressive growth.\n   - **Impact on Mutation Profiles:** It affects survivability as certain mutations, such as in the FGFR3 gene, are associated with a better prognosis due to potential targeted therapy options.\n\n### Limitations from Sampling Bias\n\n3. **Sampling Bias â€“ Blood Derived Normal vs. Primary Tumor:**\n   - **Influence on Survival Interpretation:** Using blood-derived normals (the unaffected tissue) as genomic controls can mask certain mutations prevalent in tumors but absent in blood, influencing survival predictions.\n   - **Biological Rationale:** The mismatch between primary tumor samples (which directly exhibit oncogenic mutations) and blood-derived normals might obscure critical genomic aberrations, skewing data on mutation frequencies.\n   - **Potential Bias:** This bias leads to underrepresentation of the tumor's genomic landscape, limiting understanding of heterogeneity and personalized treatment strategies.\n\n### Key Genes Impacting Survival\n\n4. **Survival-Associated Genes:**\n   - **TP53:** Involved in apoptotic regulation and cell cycle control, mutations here usually predict poor outcomes due to uncontrolled cell proliferation.\n   - **FGFR3:** Mutations are often associated with non-invasive tumors and a more favorable prognosis, providing targets for FGFR inhibitors.\n   - **PIK3CA:** Influences cell growth and survival pathways; mutations can indicate aggressive tumor behavior leading to poor survival.\n   - **RB1:** Affects cell cycle regulation. Loss-of-function mutations correlate with high-grade and muscle-invasive bladder cancer, indicative of poor survival scenarios.\n   - **TSC1:** Regulates mTOR pathway, affecting tumor growth potential. Its mutations might suggest sensitivity to mTOR inhibitors, potentially improving outcomes.\n   - **ERBB2:** Overexpression or mutation leads to aggressive phenotypes but presents an opportunity for targeted therapies.\n   - **CDKN2A:** Influences cell cycle arrest; deletion is linked to high-grade tumors and unfavorable outcomes.\n   - **E2F3:** Regulates DNA synthesis and mitosis; amplification is associated with aggressive tumor proliferation and reduced survival.\n\n### Conclusion and Synthesis\n\nIn conclusion, the survival of a patient with bladder urothelial carcinoma, particularly from the lateral wall, is intricately linked to the tumor's origin, genetic makeup, and associated histology. Tumor positioning affects metastatic potential, while the interplay between specific histologic and genetic characteristics dictates disease aggressiveness and therapy response. Sampling biases, particularly in genomic studies, pose significant challenges, necessitating meticulous interpretation of data to draw accurate clinical correlations.\n\nCritical survival risk factors: \n\n- Genetic mutations (e.g., TP53, FGFR3)\n- Tumor accessibility and histology\n- Sampling approaches and bias considerations\n\nThese insights are crucial in tailoring personalized therapies, impacting patient survival by optimizing intervention strategies and enhancing treatment precision. Understanding these dynamics offers pathways to improve prognostic accuracy and therapeutic responsiveness, ultimately aiming for better patient outcomes in bladder carcinoma management."
        ],
        [
         "10",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Lateral wall bladder) impacts survival, focusing on:\n- Tumor Origin: How Lateral wall bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Lateral Wall of Bladder\n\n1. **Influence on Metastatic Patterns:**  \n   The lateral wall of the bladder, due to its proximity to major blood vessels and lymphatic pathways, may facilitate earlier metastatic spread than tumors located elsewhere within the bladder. Cancers originating here are more likely to invade the surrounding pelvic wall, promoting metastatic dissemination.\n\n2. **Impact on Survival:**  \n   - **Negative Effect:** The proximity to vasculature not only aids in metastasis but also often results in a higher stage at diagnosisâ€”diminishing survival probabilities as systemic dissemination reduces treatment efficacy.\n   - **Treatment Accessibility:** Location-based challenges can limit surgical options. Access for removal may require more complex surgical techniques, potentially reducing complete resection likelihood.\n\n3. **Biological Rationale:**  \n   The understanding that anatomically strategic locations increase vascular access for metastatic cells aligns with known patterns of hematogenous spread in malignancies.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n1. **Interaction with Mutation Profiles:**  \n   Transitional cell carcinoma (TCC), particularly NOS (Not Otherwise Specified), frequently shows common mutations like FGFR3, TP53, and RB1. FGFR3 mutations are often associated with low-grade tumors, whereas TP53 and RB1 are linked to high-grade variants.\n\n2. **Impact on Outcomes:**\n   - **Variable Impact:** Mutational status heavily influences both the aggressiveness of the carcinoma and the responsiveness to treatments.\n   - **Biological Rationale:** Elevated FGFR3, prevalent in low-grade tumors, offers a more benign prognosis, whereas loss of function in TP53 or RB1 disrupts cell cycle control, enhancing malignancy.\n\n### Sampling Bias: Primary Tumor vs. Solid Tissue Normal\n\n1. **Genomic Analysis Limitations:**  \n   - **Bias Introduction:** Analysis exclusively of primary tumor and adjacent unaffected tissues might neglect the heterogeneous nature of metastatic lesions.\n   - **Impact on Interpretations:** This bias could skew the perceived mutational landscape, inadvertently masking driver mutations highly represented in metastatic settings.\n\n2. **Biological Consequences:**  \n   Understanding limitations in sampling can misguide therapeutic targeting and affect estimations of genomic instability, particularly when unfocused on potential heterogeneous subclones driving metastasis.\n\n### Key Genes and Their Mechanisms\n\n1. **TP53:** Essential for apoptosis and genomic stability, mutations in TP53 often predict poor survival due to higher grades and stages at presentation.\n2. **FGFR3:** Mutations correlate with enhanced survival in low-grade TCC cases but are linked to therapy resistance in advanced stages.\n3. **RB1:** Inactivation is common in aggressive TCC, correlating with poor prognosis due to its role in cell cycle regulation.\n4. **ERBB2 (HER2):** Overexpression predicts an aggressive clinical course, suggesting actionable target potential in personalized therapies.\n5. **PIK3CA:** Frequently mutated in bladder cancer, driving proliferation and linked to poor prognosis through activated downstream signaling pathways.\n6. **MDM2:** Amplified in some TCCs, inhibiting TP53 pathway; the implication is towards reduced apoptosis, contributing to tumorigenesis.\n7. **PD-L1:** Its expression modulates immune evasion, permitting unchecked tumor growth, denoting potentially poorer outcomes.\n8. **HRAS:** Mutations can drive oncogenic signals, associated with both tumor progression and potential responsiveness to MEK inhibitors.\n\n### Synthesis and Clinically Relevant Insights\n\nFrom understanding these facets, it's apparent that anatomical origin, histological subtype, and key genomic contributors punctuate the survival landscape in bladder urothelial carcinoma. Clinicians should consider:\n- Early metastatic potential and advanced staging associated with lateral wall tumors.\n- Mutational profiles to tailor therapy, where FGFR3 mutations might signal for conservative treatment, whereas TP53 or RB1 alterations suggest aggressive regimens.\n- Limitations in genomic data **should** incite the inclusion of metastatic deposit analyses to accurately reflect tumor heterogeneity.\n\nUltimately, leveraging these insights into comprehensive management plans can enhance survival through personalized medicine, incorporating genetic, anatomical, and histological nuances of each tumor scenario."
        ],
        [
         "11",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Lateral wall bladder) impacts survival, focusing on:\n- Tumor Origin: How Lateral wall bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Papillary transitional cell carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "To assess survival impacts in Bladder Urothelial Carcinoma (BUC), specifically originating from the lateral wall of the bladder, we must dissect multiple interrelated factors, each contributing to patient outcomes in distinctive ways.\n\n### Tumor Origin: Lateral Wall Bladder\n1. **Influence on Metastatic Patterns and Survival**:\n   - **Anatomical Considerations**: The lateral wall of the bladder allows for easier access to surrounding muscular and connective structures, potentially aiding in lymphatic spread at an earlier stage.\n   - **Survival Impact**: Early dissemination often correlates with poorer prognosis due to the high likelihood of nodal involvement, which complicates surgical resection considerations and may necessitate more aggressive systemic treatment.\n\n2. **Treatment Accessibility**:\n   - **Surgical Challenges**: The proximity to vital structures may reduce eligibility for certain bladder-preserving surgeries, impacting survival options negatively.\n   - **Biological Rationale**: The lateral wall's anatomical features can foster more complex invasive behavior, making complete excision with clean margins difficult.\n\n### Histology: Papillary Transitional Cell Carcinoma\n1. **Integration with Mutation Profiles**:\n   - **Morphological Traits**: Papillary structures often resemble finger-like projections, which might superficially limit invasive depth but carry other risks.\n   - **Mutation Interaction**: Common mutations in FGFR3 and TP53 within these carcinomas influence proliferative capacity and genomic stability, directly linking to how the tumor evolves under therapeutic pressure.\n\n2. **Survival Outcomes**:\n   - **Positive Influence**: FGFR3 mutations are frequently associated with less aggressive, low-grade tumors, possibly prolonging disease-specific survival.\n   - **Negative Influence**: TP53 mutations disrupt apoptotic processes, leading to chemoresistance and poorer survival rates.\n\n### Sampling Bias\n1. **Blood Derived Normal vs. Primary Tumor**:\n   - **Limitations**: Reliance on blood-derived samples may underestimate mutational load specific to the tumor, missing tumor-specific alterations due to normal cell DNA overshadowing the analysis.\n   - **Genomic Interpretation**: This bias can skew research results, impacting the perceived efficacy of targeted therapies that appear promising in vitro but do not translate to patient outcomes when blood samples drive genomic insights.\n  \n2. **Primary Tumor Sampling**:\n   - **Challenge**: Intratumor heterogeneity is not fully captured in singular biopsies leading to underrepresentation of aggressive subclonal populations in genomic profiling.\n   - **Impact on Survival**: Incomplete genomic profiling can lead to suboptimal therapeutic targeting, potentially compromising survival outcomes.\n\n### Key Survival-Associated Genes\n1. **TP53**: Integral in controlling apoptosis; mutations often lead to poor survival as they confer resistance to treatments.\n2. **FGFR3**: Mutations might indicate a less aggressive tumor phenotype and better prognosis in superficial tumor presentations.\n3. **RB1**: Its loss affects cell cycle regulation, fostering unchecked proliferation and is correlated with high-grade tumors and worse survival.\n4. **PIK3CA** and **PTEN**: These influence pathways related to cell growth and survival, with dysregulations linked to aggressive tumor behavior.\n5. **CDKN2A**: Alters cell cycle checkpoints, with deletions heavily linked to poor differentiation status and survival.\n6. **ERBB2 (HER2)**: Amplifications or mutations promote rapid cell division and potential treatment resistance, impacting survival negatively.\n7. **MIB1 (Ki-67)**: High expression signifies high proliferative index, often predicting aggressive disease and suboptimal survival.\n\n### Synthesis of Key Survival Risk Factors\n- **Summary**: Key survival risk factors in BUC include anatomic origin-driven dissemination patterns, specific mutational profiles such as TP53 and FGFR3, and challenges posed by sampling biases. Each factor intricately interplays, influencing tumor aggressiveness, therapy resistance, and ultimately, survival outcomes.\n- **Clinical Insights**: Understanding these factors allows for better prognostication and personalized treatment strategies, emphasizing genomic stress testing, and targeted therapies to improve patient outcomes. Clinically, this necessitates comprehensive tumor profiling through multi-regional biopsies and integration of multi-omic data to effectively outline patient-specific treatment plans."
        ],
        [
         "12",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: UNKOWN) impacts survival, focusing on:\n- Tumor Origin: How UNKOWN influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Bladder Urothelial Carcinoma Survival Analysis\n\n#### Tumor Origin\n1. **Influence on Metastatic Patterns**: Bladder urothelial carcinoma, particularly when classified under \"unknown\" status (UNKOWN), presents a variable metastatic pattern. This ambiguity often leads to challenges in predicting how the cancer might spread. It typically metastasizes to lymph nodes, liver, and lungs, but without defined primary site specifics, determining progression can be complex, affecting treatment decisions and survival rates.\n   \n2. **Impact on Patient Survival**: The unknown origin complicates staging and directly impacts prognosis. Without clear metastatic patterns, personalized treatment becomes challenging, leading to potentially delayed or suboptimal therapeutic interventions, thus negatively impacting survival.\n\n3. **Treatment Accessibility**: An unspecified origin may limit eligibility for site-specific clinical trials and therapies, often reducing available treatment options, thus adversely affecting overall survival outcomes. Treatment plans might become generalized rather than tailored, affecting efficacy.\n\n#### Histology\n1. **Transitional Cell Carcinoma (NOS)**: As the most prevalent histological type of bladder cancer, transitional cell carcinoma can significantly influence treatment response and prognosis. The \"not otherwise specified\" (NOS) category indicates lack of further sub-classification, often leading to generic treatment approaches.\n\n2. **Mutation Profiles and Outcomes**: Mutations common in transitional cell carcinoma, including FGFR3, PIK3CA, and TP53, can dictate tumor behavior. FGFR3 mutations, for example, are often associated with better prognoses in non-invasive cases, while TP53 mutations correlate with more aggressive cancer and poorer survival.\n\n3. **Biological Interaction**: These mutations affect cell proliferation and apoptosis regulation, influencing the tumorâ€™s biological behavior and patient outcomes. For example, FGFR3 affects pathways controlling cell division, and TP53 mutations lead to reduced apoptosis, driving aggressive tumor growth.\n\n#### Sampling Bias\n1. **Limitations in Genomic Analysis**: Using blood-derived normal samples against primary tumors for comparative genomic studies can introduce biases as blood-derived normal tissues may not accurately reflect mutation statuses relevant to the tumor microenvironment.\n\n2. **Impact on Interpretation**: Differences in mutation load and expression profiles between these samples may lead to an underestimation or misinterpretation of mutation prevalence, impacting precision medicine efforts.\n\n3. **Biological Rationale**: Discrepancies arise because blood-derived tissues might not capture localized tumor-specific processes, such as immune interactions or microenvironmental influences, leading to potentially skewed interpretations of tumor biology.\n\n#### Key Survival-Associated Genes\n1. **FGFR3**: Frequently mutated in non-muscle invasive bladder cancers, it often indicates a good prognosis when mutated in isolation due to its role in proliferation signaling pathways.\n\n2. **TP53**: Mutations here often confer aggressive characteristics to the cancer by disrupting apoptosis, correlating with poor survival outcomes.\n\n3. **PIK3CA**: Mutations activate the PI3K/AKT pathway, promoting survival and proliferation, impacting tumor aggressiveness and survival rates.\n\n4. **ERBB2 (HER2)**: Amplifications or overexpression can lead to enhanced tumor proliferation and poorer prognosis, though it may also open targeted therapy options.\n\n5. **CDKN2A**: Alterations affect cell cycle regulation, influencing proliferation and tumor suppression capacity, with deletions often leading to aggressive tumors.\n\n6. **TERT Promoter Mutations**: Common in bladder cancer, these lead to increased telomerase activity, promoting cell immortality and associated with a variable prognosis.\n\n#### Synthesis and Clinical Insights\n- Bladder urothelial carcinoma survival is significantly influenced by the interplay of tumor origin, histological characteristics, genetic mutations, and sampling biases.\n- Tumor origin ambiguity reduces treatment precision, potentially worsening survival.\n- Histological subtypes and mutation profiles offer actionable insights, impacting treatment strategies and survival forecasts.\n- Genomic interpretation biases must be carefully managed to accurately reflect tumor biology and inform decisions.\n- Clinically, emphasis on comprehensive genomic profiling alongside histological evaluation improves survival by facilitating targeted and personalized treatment strategies. \n\nUnderstanding these layers of complexity guides therapeutic decision-making and enhances prognostication, ultimately aiming to improve patient outcomes in bladder urothelial carcinoma."
        ],
        [
         "13",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: UNKOWN) impacts survival, focusing on:\n- Tumor Origin: How UNKOWN influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Bladder Urothelial Carcinoma: Impact on Survival**\n\n### Tumor Origin\n1. **Influence on Survival:**\n   - **Metastatic Patterns:** Bladder urothelial carcinoma often spreads locoregionally to pelvic and para-aortic lymph nodes and can metastasize to the liver, lungs, and bones. Metastatic patterns significantly reduce survival due to the essential organs involved.\n   - **Treatment Accessibility:** The unknown ICD-10 specification might hint at confusion during data categorization, potentially leading to discrepancies in treatment plans. Accurate staging and classification are crucial for guiding therapeutic interventions like radical cystectomy and intravesical chemotherapy, thereby impacting survival.\n\n2. **Biological Rationale:**\n   - Urothelial cells form the transitional epithelium, capable of expanding and contracting, providing a pathway for cancerous cells to infiltrate surrounding tissues easily.\n   - Late detection and high recurrence risk, characteristics of these cancers, negatively affect survival rates.\n\n3. **Potential Biases:**\n   - Misclassification or unknown primary sites can skew survival statistics and undermine the validity of treatment efficacy studies.\n\n### Histology: Transitional Cell Carcinoma, NOS\n1. **Influence on Survival:**\n   - **Interaction with Mutation Profiles:** Transitional cell carcinoma is prone to mutations in tumor suppressor genes (e.g., TP53) and those regulating cell cycle checkpoints (e.g., RB1). These mutations often correlate with higher-grade tumors that are more aggressive and less responsive to treatment, worsening survival prospects.\n\n2. **Biological Rationale:**\n   - This type involves a proliferation of cells that resemble the bladderâ€™s transitional epithelium, creating histological heterogeneity that complicates treatment planning and effectiveness.\n\n3. **Potential Biases:**\n   - Variability in tumor grading and classification could lead to inconsistencies in data interpretation and subsequent treatment strategies.\n\n### Sampling Bias\n1. **Influence on Survival:**\n   - **Primary Tumor & Solid Tissue Normal:** Analyses often compare tumor samples with nominally normal tissues, failing to account for field changes where adjacent 'normal' tissues might not be truly normal. This can lead to missed precancerous conditions.\n\n2. **Biological Rationale:**\n   - Sample heterogeneity, especially sampling at the tumor interface, risks capturing altered genomic landscapes that do not fully reflect genomic drivers of malignancy or resistance.\n\n3. **Potential Biases:**\n   - Misleading conclusions may arise due to overestimation of differential gene expression between normal and tumor samples.\n\n### Key Genes and Their Impact on Survival\n1. **TP53:** Tumor suppressor gene that regulates the cell cycle and apoptosis; mutations lead to unchecked cell division and survival of aberrant cells, worsening outcomes.\n2. **FGFR3:** Mutations in this gene might drive cancer growth and are associated with low-grade tumors, which surprisingly show better prognosis if treated early.\n3. **PIK3CA:** Often altered in bladder cancer, leading to activation of pathways involved in cellular growth; contributes to cancer progression.\n4. **CDKN2A (p16):** Typically deleted or hypermethylated, leading to disrupted cell cycle control and increased tumor aggressiveness.\n5. **ERBB2 (HER2):** Overexpression is linked to aggressive tumor subtypes and poorer survival outcomes; HER2-targeted therapies can be transformative.\n6. **RB1:** Its loss results in dysregulated cell cycle progression, contributing to aggressive tumor behavior.\n7. **EGFR:** Overactivation promotes proliferation and survival signals; targeting EGFR in therapy can improve outcomes.\n\n### Synthesis of Key Survival Risk Factors\n- Bladder urothelial carcinoma survival is a complex interplay of histological characteristics, genetic alterations, and tumor origin, complicated by potential biases in genomic interpretation due to sampling errors and classification imprecision.\n- Key factors like TP53 mutations profoundly impact apoptosis regulation, while FGFR3 and ERBB2 mutations affect cellular growth pathways. Understanding these relationships enables precise therapeutic targeting.\n- Clinically, accurate genotyping and molecular characterization can guide personalized treatment plans to mitigate aggressive disease trajectory and enhance treatment efficacy, underscoring the importance of comprehensive genomic profiling in improving patient survival."
        ],
        [
         "14",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: UNKOWN) impacts survival, focusing on:\n- Tumor Origin: How UNKOWN influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Papillary transitional cell carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n**Influence on Survival:**\nBladder Urothelial Carcinoma often originates in the urothelium lining of the bladder. This location facilitates early local spread and potential metastasis due to its anatomical closeness to lymphatics and blood vessels.\n\n**Biological Rationale:**\nThe urothelium's role is critical in normal urinary function, yet its cellular structure may promote early dissemination when malignant. Local infiltration into muscle layers or perivesical fat indicates a greater risk of metastatic spread, negatively influencing survival rates.\n\n**Potential Biases in Genomic Interpretation:**\nUncertain origin (UNKNOWN) coding in datasets can obscure the true metastatic potential, underestimating the apparent aggressiveness due to misclassification or unrecorded progression stages, impacting survival analysis.\n\n### Histology\n\n**Influence on Survival:**\nPapillary transitional cell carcinoma, a subtype of bladder cancer, shows unique mutation profiles, influencing patient outcomes positively if early-stage and low-grade but adversely if high-grade due to aggressive tendencies.\n\n**Biological Rationale:**\nThese tumors frequently feature mutations in FGFR3, promoting unchecked proliferation in low-grade forms associated with relatively better outcomes. Conversely, TP53 mutations in high-grade forms reduce apoptotic signals, leading to poor prognosis due to enhanced aggressiveness.\n\n**Potential Biases in Genomic Interpretation:**\nHistological sampling may preferentially capture superficial over invasive tumors, skewing mutation prevalence data and survival correlation analyses.\n\n### Sampling Bias\n\n**Limitations of Source Material:**\nRelying solely on blood-derived normals and primary tumors for genomic analyses can introduce biases; blood samples may not accurately reflect tumor heterogeneity or mutations exclusively present within the tumor, potentially leading to incomplete mutation profiling.\n\n**Impact on Survival Analysis:**\nBiological variation between circulating DNA and tumor DNA might result in misinterpretations of mutational significance, underestimating or overestimating genetic impact on survival rates.\n\n**Potential Biases in Genomic Interpretation:**\nThe absence of certain mutations in blood samples might mislead the perceived aggressiveness of the carcinoma, erroneously categorizing patient risk.\n\n### Key Genes Impacting Survival\n\n1. **FGFR3:**\n   - **Role:** Promotes cell proliferation.\n   - **Impact:** Often mutated in low-grade, less aggressive cancers, associated with better prognosis.\n\n2. **TP53:**\n   - **Role:** Regulates cell cycle and apoptosis.\n   - **Impact:** Commonly altered in high-grade cancers, leading to poor prognosis due to compromised cell cycle control.\n\n3. **PIK3CA:**\n   - **Role:** Influences the PI3K/AKT pathway.\n   - **Impact:** Activating mutations contribute to cell survival and proliferation, often linked with aggressive behavior.\n\n4. **ERBB2:**\n   - **Role:** Encodes HER2, promoting cell growth.\n   - **Impact:** Overexpression leads to increased tumor growth and poor survival odds.\n\n5. **CDKN2A:**\n   - **Role:** Cell cycle inhibitor.\n   - **Impact:** Loss of function mutations lead to unregulated proliferation, worsening outcomes.\n\n6. **TSC1:**\n   - **Role:** Tumor suppressor involved in mTOR signaling.\n   - **Impact:** Mutations can enhance tumor growth, negatively impacting survival when not functioning.\n\n7. **MLL/SETD2:**\n   - **Role:** Epigenetic regulators.\n   - **Impact:** Mutations affect chromatin remodeling, impacting differentiation and survival rates.\n\n### Synthesis of Key Survival Factors\n\n**Clinically Relevant Insights:**\n- Early detection and accurate staging, particularly regarding tumor origin and histological grading, are critical for improving survival outcomes.\n- Understanding specific mutation profiles in relation to histology can guide personalized therapeutic approaches, enhancing survival prospects.\n- Addressing genomic sampling biases through comprehensive tumor profiling, beyond just blood-derived and superficial tissue samples, will yield better survival predictions and tailored interventions.\n\n**Impact on Patient Survival:**\nIncorporating these genomic insights into routine diagnostics and considering potential biases are essential for optimizing treatment strategies and ultimately improving survival outcomes for bladder urothelial carcinoma patients."
        ],
        [
         "15",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Posterior wall bladder) impacts survival, focusing on:\n- Tumor Origin: How Posterior wall bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "To address the various factors that influence survival in patients with Bladder Urothelial Carcinoma (specifically, as it relates to the posterior wall) in a structured and precise manner, letâ€™s break down each component:\n\n### Tumor Origin: Posterior Wall Bladder Influence\n\n1. **Impact on Metastatic Patterns and Survival:**\n\n   - **Influence on Survival:**\n     - Tumors originating in the posterior wall of the bladder can have specific implications for metastatic spread due to their anatomical location, which is near the ureters and other pelvic organs.\n     - This may facilitate local invasion and rapid dissemination to nearby lymph nodes, potentially negatively affecting survival outcomes.\n\n   - **Biological Rationale:**\n     - The proximity to vascular and lymphatic structures can contribute to increased metastatic potential, making early detection challenging and often leading to a diagnosis at a more advanced stage.\n     - Anatomically, posterior wall involvement may impede treatment, as precise surgical resection is necessary to avoid damage to surrounding structures.\n\n   - **Treatment Accessibility:**\n     - Treatment options may be restricted due to anatomical limitations, necessitating more complex surgical approaches. This complexity might hinder the timely initiation of treatment, impacting overall survival.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n2. **Histology and Mutation Profiles:**\n\n   - **Influence on Survival:**\n     - Transitional cell carcinoma (TCC) is the most common histological type of bladder cancer, which is characterized by a high propensity for genetic mutations such as TP53, FGFR3, and PI3K pathway alterations.\n     - Mutation profiles directly influence tumor behavior, including growth rate, metastatic potential, and drug resistance, impacting patient outcomes.\n\n   - **Biological Rationale:**\n     - Alterations in TP53 can lead to unregulated cell cycle progression and defective apoptosis, contributing to tumorigenic potential.\n     - Mutations in FGFR3 are often associated with low-grade tumors, whereas TP53 mutations are more prevalent in high-grade, invasive tumors, influencing treatment response.\n\n   - **Outcome Impacts:**\n     - Understanding the mutation spectrum can help stratify patients by risk and influence therapeutic strategies, thus tailoring survival predictions and interventions.\n\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\n\n3. **Limitations in Genomic Analysis:**\n\n   - **Impact on Survival Analysis:**\n     - Genomic sampling, such as relying on blood-derived normal controls, introduces biases as it may not capture the full mutational landscape of the primary tumor, leading to misinterpretation of clonal heterogeneity and variant allele frequency.\n     - This can result in an underestimation of tumor genetic complexity, affecting prognostic evaluations and targeted therapy development.\n\n   - **Biological Rationale:**\n     - Primary tumor samples provide direct insight into somatic mutations and tumor microenvironment interactions, which are critical for accurate genomic profiling and therapeutic targeting.\n     - Blood-derived normals may overlook subclonal populations, crucial for predicting resistance emergence and metastasis.\n\n### Key Genes: Survival Association\n\n4. **Genes Influencing Survival (5-8):**\n\n   - **TP53:** \n     - Involved in DNA damage response and apoptosis; mutations lead to poor prognosis due to aggressive tumor behavior.\n     \n   - **FGFR3:**\n     - Associated with cell proliferation; mutations often indicate lower-grade tumors with better outcomes, but can be misleading in absence of other markers.\n     \n   - **PIK3CA:**\n     - Important for cell growth and survival; alterations can lead to enhanced proliferation and survival of cancer cells, impacting drug resistance.\n\n   - **ERBB2 (HER2):**\n     - Overexpression is associated with aggressive disease; targeted therapies can alter survival significantly.\n\n   - **MDM2:**\n     - Regulates p53 degradation; overexpression leads to poorer outcomes as it mimics TP53 loss-of-function effects.\n\n   - **CDKN2A:**\n     - Loss impairs cell cycle arrest, facilitating unchecked proliferation and thus, poorer prognosis.\n\n5. **Conclusion:**\n\n   Synthesizing these insights, the major survival risk factors in Bladder Urothelial Carcinoma include the anatomical origin of the tumor, genetic profile, histological characteristics, and potential biases in genomic interpretation due to sample inconsistencies. Clinically, recognizing the interplay between these factors allows for more targeted treatment strategies, personalized patient care, and improved prognostic accuracy. Comprehensive genomic profiling, alongside precise anatomical and histological assessment, forms the basis for optimizing therapeutic interventions and enhancing patient survival in this cohort."
        ],
        [
         "16",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Posterior wall bladder) impacts survival, focusing on:\n- Tumor Origin: How Posterior wall bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "Understanding the survival impact of Bladder Urothelial Carcinoma, specifically arising from the posterior wall of the bladder, necessitates a multifaceted examination of tumor origin, histology, genetic mutations, and sampling biases.\n\n1. **Tumor Origin: Posterior Wall Bladder**\n   - **Metastatic Patterns**: Tumors originating from the posterior wall have distinct implications due to their proximity to the trigone of the bladder, affecting the spread to pelvic lymph nodes and potentially facilitating earlier metastatic dissemination to common iliac and para-aortic nodes, impacting survival negatively.\n   - **Patient Survival and Treatment Accessibility**: Tumors in this location may present challenges in terms of resectability, given the vicinity to crucial anatomical structures like the ureters and seminal vesicles in males or the uterus in females. This can influence surgical margins and complicate complete local excision, often leading to poorer outcomes.\n   - **Survival Influence**: Overall, posterior wall origin can complicate treatment strategies, potentially reducing survival rates due to the difficulty in achieving clear surgical margins and increased likelihood of metastatic spread.\n\n2. **Histology: Transitional Cell Carcinoma, NOS**\n   - **Mutation Profiles and Outcomes**: Transitional cell carcinoma, representing more than 90% of bladder cancers, commonly exhibits mutations in genes like FGFR3, TP53, and PIK3CA. FGFR3 mutations often correlate with a less aggressive phenotype and better survival, whereas TP53 mutations are associated with more aggressive disease.\n   - **Survival Influence**: The variability in mutation profiles underscores differential prognostic outcomesâ€”distinct mutational landscapes can drive more aggressive behavior, influencing treatment resistance and thus affecting survival.\n   - **Rationale**: The histological type dictates the fundamental biological behavior of tumors, providing therapeutic targets which can modify survival outcomes through tailored treatment plans.\n\n3. **Sampling Bias in Genomic Analysis**\n   - **Primary Tumor vs. Solid Tissue Normal**: Genomic studies often compare primary tumor samples with adjacent normal tissues. However, \"normal\" tissue may already harbor premalignant changes, skewing results and potentially downplaying certain mutations or pathways that appear less significant.\n   - **Survival Influence**: This bias can lead to incomplete understanding of oncogenic drivers, affecting treatment decisions based on flawed genomic interpretations, ultimately influencing survival negatively.\n   - **Rationale**: Accurate sampling is crucial for precise mutation identification and subsequent treatment planning, emphasizing the need for careful interpretation of genomic data.\n\n4. **Key Genes Affecting Survival**\n   - **TP53**: Mutations lead to defective cell cycle control and apoptosis, typically signifying poorer prognosis.\n   - **FGFR3**: Mutations often result in better-prognosis superficial tumors due to less aggressive behavior.\n   - **PIK3CA**: Involved in cell proliferation; mutations here can indicate a role in more aggressive disease subsets.\n   - **TSC1**: Mutated in some cases, influences mTOR pathway, with implications on tumor growth and survival.\n   - **RB1**: Its inactivation is linked to tumor progression and resistance to therapy.\n   - **ERBB2 (HER2)**: Overexpression can lead to increased cell proliferation, often indicating a more aggressive clinical course.\n   - **KDM6A**: Tumor suppressor gene, whose loss is linked to poor differentiation and aggressive phenotypes.\n\n   - **Survival Mechanisms**: Mutations and alterations in these genes affect survival through mechanisms impacting proliferation, apoptosis, and interaction with treatment modalities.\n\n**Conclusion**\nIn synthesis, survival factors in bladder cancer with posterior wall origin are heavily influenced by the anatomical tumor origin, histological subtype-driven mutations, genetic alterations in specific oncogenes and tumor suppressors, and potential biases in genomic sampling. Clinically, these insights facilitate personalized therapies and prognostic assessments, aiding in stratifying patients for more aggressive monitoring or innovative treatment approaches, ultimately aiming to enhance survival outcomes."
        ],
        [
         "17",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Posterior wall bladder) impacts survival, focusing on:\n- Tumor Origin: How Posterior wall bladder influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Papillary transitional cell carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "To address the impact of Bladder Urothelial Carcinoma (specifically from the posterior wall of the bladder) on patient survival, we need to consider multiple intertwined factors: tumor origin, histology, sampling bias, and key genetic mutations.\n\n### Tumor Origin\n- **Influence on Metastatic Patterns:** Tumors originating from the posterior bladder wall often show distinct metastatic behavior due to their proximity to pelvic structures. This can facilitate local invasion or early metastasis to pelvic lymph nodes, negatively impacting survival rates. Moreover, posterior wall tumors may be less accessible surgically, complicating complete resection.\n- **Treatment Accessibility:** The location can affect treatment accessibility. Posterior wall tumors may require more complex surgical routes or may not be amenable to certain local therapies like intravesical chemotherapy, impacting therapeutic success and survival outcomes.\n\n### Histology\n- **Papillary Transitional Cell Carcinoma (PTCC):** This is the most common subtype of bladder cancer. PTCC typically presents with a better initial prognosis due to its papillary nature, allowing earlier detection and intervention. However, if it progresses, especially with high-grade features, it can have aggressive behaviors influenced by specific genetic mutations.\n- **Mutation Profiles:** Mutations in TP53, FGFR3, and PIK3CA are commonly associated with PTCC, each influencing survival differently. TP53 mutations are linked with aggressive disease and poorer outcomes due to impaired apoptosis and cell cycle regulation, whereas FGFR3 mutations often correlate with low-grade tumors and better prognosis due to their association with cell proliferation pathways.\n\n### Sampling Bias\n- **Blood Derived Normal vs. Primary Tumor:** Blood-derived samples may not accurately reflect the tumor's mutational landscape. This discrepancy can lead to biases in genomic analysis, such as underestimating tumor heterogeneity or missing mutations that confer aggressive phenotypes.\n- **Impact on Survival Analysis:** Reliance on non-tumor tissues can skew survival predictions by not accounting for specific tumor-exclusive genetic changes that drive behavior and treatment responses.\n\n### Key Genes Impacting Survival\n1. **TP53:** A tumor suppressor gene often mutated in aggressive bladder cancers, leading to loss of apoptosis and genomic instability, negatively affecting survival.\n2. **FGFR3:** Mutations are frequent in low-grade PTCC, driving cell proliferation via receptor tyrosine kinase pathways, typically associated with better outcomes if targeted therapeutically.\n3. **PIK3CA:** Involved in the PI3K/AKT pathway; mutations can promote tumor growth and survival, making it a potential therapeutic target to improve survival.\n4. **ERBB2 (HER2):** Amplification can contribute to aggressive tumor behavior through enhanced growth signaling pathways, posing a negative impact on survival if not targeted appropriately.\n5. **CDKN2A:** Deletions or mutations can disable regulation of the cell cycle, often correlating with more aggressive disease phenotypes and poor prognosis.\n6. **RB1:** Loss-of-function mutations contribute to unchecked cell cycle progression, increasing malignancy and reducing survival likelihood.\n7. **TSC1/TSC2:** Tumor suppressors implicated in low-grade forms but loss can switch phenotype to a more aggressive form, impacting survival.\n8. **ARID1A:** Its inactivation may confer resistance to certain therapies while driving mutations can degrade chromatin regulation, impacting patient prognosis adversely.\n\n### Synthesis\nIn conclusion, the posterior wall origin of bladder urothelial carcinoma directly influences metastatic potential and treatment challenges. Histological subtypes like papillary transitional cell carcinoma and its associated mutations play pivotal roles in determining patient outcomes. Sampling biases in genomic analysis need careful consideration to accurately depict the genomic underpinnings driving survival. Collectively, a thorough understanding and intervention targeted at these genetic and clinical factors can significantly influence survival trajectories, offering personalized treatment opportunities and improving patient outcomes."
        ],
        [
         "18",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: UNKOWN) impacts survival, focusing on:\n- Tumor Origin: How UNKOWN influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Unknown Influence on Metastatic Patterns, Patient Survival, and Treatment Accessibility\n\n1. **Tumor Origin**: Bladder Urothelial Carcinomas (BUC) typically originate from the urothelium, the layer of tissue lining the bladder. When the specific origin subtype is unknown or unclassified, there can be implications for clinical decision-making and anticipated metastatic patterns.\n\n2. **Influence on Metastasis and Survival**: Tumors of unknown origin may be less predictable in their metastatic pathways. This lack of specific site origin knowledge may hinder accurate risk stratification. Metastases typically proceed to pelvic lymph nodes, bone, liver, and lungs, but unknown origins could alter this expectation, affecting targeted surveillance and management strategies. Resultantly, survival could negatively impact if metastasis occurs unexpectedly or is under-monitored.\n\n3. **Treatment Accessibility**: Knowing the specific tumor origin can guide eligibility for targeted therapies or clinical trials, influencing therapeutic plans and potentially limiting access when the origin is uncertain. This may reduce survival rates as options are constricted.\n\n### Histology: Interaction of Transitional Cell Carcinoma, NOS and Mutation Profiles\n\n1. **Histology**: The predominant histological type for BUC is transitional cell carcinoma, Not Otherwise Specified (NOS). This classification lacks detailed subtype information that could guide personalized treatment.\n\n2. **Mutation Profiles and Survival**: The mutation profile in transitional cell carcinoma includes common aberrations like FGFR3, TP53, and RB1. These genetic alterations can vary survival outcomes:\n   - FGFR3 mutations often correlate with non-invasive tumors with relatively better prognoses.\n   - TP53 and RB1 mutations are linked to higher-grade, aggressive cancers, associated with poorer survival.\n\n3. **Biological Rationale**: FGFR3 mutations may enhance proliferation but remain susceptible to less aggressive treatment outcomes, while TP53 and RB1 deficiencies often derail cell cycle regulation and apoptosis, leading to aggressive tumor behavior and reduced survival.\n\n### Sampling Bias: Limitations of Blood Derived Normal and Primary Tumor in Genomic Analysis\n\n1. **Sampling Bias**: Using blood-derived normal and primary tumor samples can introduce biases. Blood-derived normals might not reflect true somatic mutation burdens due to clonal hematopoiesis. Primary tumors may not encompass the full genomic scope inclusive of metastases.\n\n2. **Influence on Genomic Interpretations**: Sampling limitations can lead to skewed mutational landscapes or oversight of subclonal populations contributing to treatment resistance, potentially misinforming survival estimations.\n\n### Key Genes: Survival-Associated Genes and Biological Mechanisms\n\n1. **TP53**: Mutations impair DNA repair and promote genomic instability, negatively influencing survival.\n\n2. **FGFR3**: Frequently mutated in low-grade, non-invasive tumors, possessing potentially protective effects on overall survival when not concurrent with other mutations.\n\n3. **RB1**: Loss of function leads to unregulated cell cycle progression, associated with negative survival due to facilitation of tumor progression.\n\n4. **PIK3CA**: Mutations activate PI3K/AKT signaling, promoting survival pathways and tumor growth, often leading to poorer outcomes when present with other aggressive mutations.\n\n5. **ERBB2 (HER2)**: Overexpression or amplification can drive uncontrolled proliferation, with implications for targeted HER2 therapies and mixed survival impacts.\n\n6. **CDKN2A**: Inactivation via deletion results in loss of cell cycle control, correlating with worse survival due to enhanced proliferative capacity.\n\n7. **ARID1A**: Loss-of-function mutations affect chromatin remodeling, often found co-mutated with PIK3CA, complicating prognosis due to therapy resistance arrangements.\n\n8. **TSC1/TSC2**: Mutations foster mTOR pathway activation and cellular proliferation, potentially mitigating responses to immune checkpoints.\n\n### Synthesis of Key Survival Risk Factors\n\n- **Clinically Relevant Insights**: The interplay of mutation profiles, histological classification, origin clarity, and sampling quality are critical in understanding BUC prognosis. FGFR3 mutations in isolation may denote favorable outcomes, whereas TP53, RB1, and complex mutational networks suggest advanced disease and poorer survival.\n\n- **Impact on Patient Survival**: Survival is worsened by aggressive genetic profiles, less specific histological categorization, and origin uncertainties. Precision in sampling and integration of genomic data are vital for prognosis estimation and therapeutic decision-making, highlighting a need for comprehensive profiling in clinical practice."
        ],
        [
         "19",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Ureteric orifice) impacts survival, focusing on:\n- Tumor Origin: How Ureteric orifice influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Ureteric Orifice\n\n**Influence on Survival:**\n- **Metastatic Patterns:** Tumors originating in the ureteric orifice can spread either upwards to the renal pelvis or downwards to the bladder, influencing survival negatively due to complex metastatic pathways and potential dissemination to distant sites.\n- **Treatment Accessibility:** Anatomical positioning may complicate surgical approaches, making local resection challenging, which can adversely affect survival rates by limiting effective removal of cancerous tissues.\n   \n**Biological Rationale:**\n- The ureteric orifice acts as a critical junction between the kidney and the bladder, allowing for diverse metastatic routes. This anatomical feature can lead to early metastasis due to vascular and lymphatic proximity, reducing survival prospects.\n  \n**Potential Biases:**\n- Sampling biases can occur when distinguishing localized vs. metastatic disease in the ureteric orifice, leading to misclassification that influences survival statistics.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n**Influence on Survival:**\n- The nonspecific nature of â€œNOSâ€ (not otherwise specified) may complicate prognostic predictions, generally resulting in moderate survival projections due to uncertainty and variability in aggressiveness.\n\n**Biological Rationale:**\n- **Mutation Profiles:** Transitional cell carcinoma (TCC) is prone to specific mutations in oncogenes or tumor suppressor genes (e.g., FGFR3, TP53), which drive variabilities in tumor growth rates and immune evasion abilities, influencing survival outcomes.\n  \n**Potential Biases:**\n- Histological analysis may overlook minor variants or hybrid forms of TCC, which could affect the accuracy of survival projections.\n\n### Sampling Bias: Blood Derived Normal, Primary Tumor in Genomic Analysis\n\n**Influence on Survival:**\n- **Accuracy of Genomic Insight:** The use of blood-derived normal samples can misrepresent mutational burdens, skewing survival-associated data by not accurately reflecting tumor-specific genetics.\n\n**Biological Rationale:**\n- Blood-derived reference assumptions may not capture tumor-specific somatic mutations accurately, potentially undermining tailored approaches to treatment that could enhance survival rates.\n\n**Potential Biases:**\n- Discrepancies in mutation profiles due to sampling sources (blood vs. primary tumor) may lead to inconsistent interpretations in survival studies, particularly in terms of targeted therapies.\n\n### Key Genes and Their Biological Mechanisms\n\n1. **TP53**  \n   - **Influence on Survival:** Mutations in TP53 are associated with poor prognosis due to disruptions in cell cycle regulation and apoptosis, leading to uncontrolled cell proliferation.\n   \n2. **FGFR3**  \n   - **Influence on Survival:** Generally linked to lower-grade, non-invasive tumors. Mutations can be predictive of relatively better outcomes unless they coexist with other high-risk mutations.\n   \n3. **PIK3CA**  \n   - **Influence on Survival:** Activation of this gene through mutations leads to cell survival and proliferation, impacting negatively on long-term survival due to enhanced oncogenic signaling.\n   \n4. **ERBB2 (HER2)**  \n   - **Influence on Survival:** Overexpression or amplification is associated with aggressive tumor behavior and reduced survival, due to its role in promoting tumor cell growth and survival.\n   \n5. **RB1**  \n   - **Influence on Survival:** Loss of function mutations correlate with poor prognosis due to disturbed cell cycle control and enhanced genomic instability.\n   \n6. **CDKN2A**  \n   - **Influence on Survival:** Deletions/mutations often result in poorer outcomes via impaired suppression of cellular growth signals.\n   \n7. **TERT**  \n   - **Influence on Survival:** TERT promoter mutations increase telomerase activity contributing to cellular immortality, negatively impacting survival by fostering sustained growth and division.\n\n**Biological Rationale:**\n- These genes, through diverse pathways such as cell cycle regulation, apoptosis, and cellular proliferation, dictate the pace at which tumors grow and spread.\n\n### Concluding Synthesis\n\n- **Key Survival Risk Factors:** Anatomical position (ureteric orifice) impacts metastasis, while TCCâ€™s histology and gene mutation profiles (TP53, FGFR3, etc.) define cellular behavior. Sampling biases often obscure true genetic landscapes, influencing clinical decision-making.\n- **Clinically Relevant Insights:** Accurate histopathological classification and genomic profiling, particularly using primary tumor samples, are vital for reliable prognostic assessments. Understanding site-specific dissemination patterns and mechanics at a molecular level enhances individualized patient care, thereby improving survival outcomes."
        ],
        [
         "20",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Bladder NOS) impacts survival, focusing on:\n- Tumor Origin: How Bladder NOS influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "Certainly! Let's approach the analysis of Bladder Urothelial Carcinoma (Bladder NOS) and its impact on patient survival by segmenting it into key components:\n\n### Tumor Origin\n\n**1. Influence on Survival:**\n- **Metastatic Patterns:** Bladder Urothelial Carcinoma (UC) often originates from the urothelial cells lining the bladder. These tumors have a predilection to metastasize to lymph nodes, bones, liver, and lungs, which can dramatically decrease survival rates.\n\n**2. Biological Rationale:**\n- **Tumor Plasticity:** The urothelial origin facilitates a diverse mutation spectrum, which includes transitional cell characteristics promoting spread and metastatic ability.\n\n**3. Potential Bias:**\n- **Clinical Presentation:** Misclassification in ICD codes can lead to varied recorded outcomes, affecting survival statistics if \"Bladder NOS\" is interchangeably used without histological clarification.\n\n### Histology\n\n**1. Influence on Survival:**\n- **Carcinoma, NOS Types:** Variants of urothelial carcinoma often display different mutation profiles, affecting therapeutic responsiveness. Histological grading (G1-G3) frequently correlates with prognosis, with high-grade tumors showing poorer outcomes.\n\n**2. Biological Rationale:**\n- **Mutation Influence:** Differences in histologic variants, especially presence of squamous and glandular differentiation, impact the tumorâ€™s aggressiveness and subsequent survival.\n\n**3. Potential Bias:**\n- **Sampling Biases:** Definitions of carcinoma NOS can lead to underrecognition of unique histological subtypes, skewing survival data if these arenâ€™t differentiated.\n\n### Sampling Bias\n\n**1. Influence on Survival:**\n- **Genomic Analysis Limitations:** Discrepancies between blood-derived normal and primary tumor sampling can lead to biased interpretations of somatic mutationsâ€™ oncogenic significance.\n\n**2. Biological Rationale:**\n- **Varying Mutational Landscape:** Tumor heterogeneity introduces distinct somatic mutations in different parts of the tumor, potentially overlooked in more homogeneous blood-derived samples.\n\n**3. Potential Bias:**\n- **Analysis Variability:** False negatives/positives in mutation analysis could underestimate or overestimate the genomic impact on survival.\n\n### Key Genes\n\nIn Bladder Urothelial Carcinoma, several key genes play a crucial role in survival, through various biological mechanisms:\n\n**1. FGFR3 (Fibroblast Growth Factor Receptor 3):**\n- **Mechanism:** Impacts cell proliferation and survival, commonly mutated in low-grade non-muscle invasive bladder cancers, often indicative of a favorable prognosis.\n\n**2. TP53 (Tumor Protein 53):**\n- **Mechanism:** Crucial in genome stability and apoptosis. Mutations suggest higher tumor aggression and poorer survival rates.\n\n**3. RB1 (Retinoblastoma 1):**\n- **Mechanism:** Governs cell cycle regulation. Loss-of-function mutations correlate with more aggressive tumor behavior and lower survival.\n\n**4. PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha):**\n- **Mechanism:** Modulates PI3K/AKT signaling pathway, driving growth. Its mutations might signal a more aggressive course.\n\n**5. TERT (Telomerase Reverse Transcriptase):**\n- **Mechanism:** Lengthens telomeres, promoting immortality in cancer cells. Common mutations associate with invasive tumors and poor prognosis.\n\n### Synthesizing Key Survival Risk Factors\n\nIn conclusion, survival in Bladder Urothelial Carcinoma centers around a complex interplay of tumor origin, histology, sampling biases, and genetic underpinnings. Histological differentiation, presence and type of mutations (e.g., in TP53, FGFR3, RB1), and the precise genomic landscape revealed by unbiased sampling are critical. Clinically, focusing on early detection of high-risk histological and genetic markers can optimize therapeutic strategies, potentially improving patient outcomes significantly. Understanding and addressing these facets in patient management could enhance predictive accuracy for survival and guide personalized therapeutic approaches."
        ],
        [
         "21",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Bladder NOS) impacts survival, focusing on:\n- Tumor Origin: How Bladder NOS influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Squamous cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Bladder Urothelial Carcinoma (Bladder NOS) and Survival Impact**\n\n**1. Tumor Origin and Its Influence on Survival**\n\n- **Influence on Survival:**\n  - Bladder Urothelial Carcinoma generally arises from the epithelial lining of the urinary bladder and is often classified as Bladder NOS when further specification is not available. The location in the urinary system allows for ease of regional spread and potential metastasis to distant sites such as the lungs, bones, and liver. Patients with advanced disease often experience poorer survival outcomes due to these metastatic patterns.\n\n- **Biological Rationale:**\n  - The urothelium is a transitional epithelium, which means it undergoes regular cycles of stretching and contracting. This cellular plasticity can contribute to genetic instability, promoting tumorigenic mutations. \n\n- **Potential Bias:**\n  - Studies focusing solely on primary bladder tumors might underestimate the genomic alterations involved in metastasis, obscuring a full understanding of survival implications.\n\n**2. Histology Interacting with Mutation Profiles**\n\n- **Influence on Survival:**\n  - Squamous cell carcinoma within the bladder, while less common than transitional cell carcinoma, tends to be associated with more aggressive behavior and worse survival outcomes due to its invasive nature.\n\n- **Biological Rationale:**\n  - Histologically, these tumors are characterized by dysregulated squamous differentiation often driven by chronic irritation or infection. Genetic studies suggest that these are frequently accompanied by mutations in genes relevant to cell cycle regulation and apoptosis, such as TP53 and PIK3CA, contributing to aggressive growth.\n\n- **Potential Bias:**\n  - Because squamous differentiation is rare, limited sample size can skew genomic data interpretation, underrepresenting its impact on broader bladder cancer survival statistics.\n\n**3. Sampling Bias in Genomic Analysis**\n\n- **Influence on Survival:**\n  - Using blood-derived normal samples as controls in genomic studies can introduce biases. Primary tumor samples might not capture the full landscape of genetic alterations present.\n\n- **Biological Rationale:**\n  - Blood-derived samples may reflect only systemic mutations and fail to reveal local genomic changes critical to cancerous behavior. Consequently, mutation studies may overemphasize systemic mutations while neglecting tumor-specific alterations.\n\n- **Potential Bias:**\n  - This may lead to an incomplete understanding of gene mutations that impact survival, particularly those involved in local invasion and metastasis.\n\n**4. Key Genes Affecting Survival**\n\n- **Influence on Survival (with mechanisms):**\n  - **TP53:** Loss of function here is linked to impaired apoptosis, contributing to tumor progression.\n  - **FGFR3:** Mutations often lead to uninterrupted cellular signaling promoting unchecked proliferation.\n  - **PIK3CA:** Alters cell growth and survival pathways, facilitating increasing malignancy.\n  - **ERBB2 (HER2):** Overexpression encourages rapid cell division and is associated with poor prognosis.\n  - **CDKN2A:** Loss of this tumor suppressor disrupts the cell cycle checkpoints.\n  - **ARID1A:** Mutations here affect chromatin remodeling, gene expression regulation, potentially altering cancer susceptibility.\n\n- **Potential Bias:**\n  - Relying on datasets that exclude or underrepresent mutations from advanced metastatic sites fails to fully elucidate their roles in survival, thereby potentially misguiding therapeutic targets.\n\n**Synthesis and Clinical Insights**\n\nBladder Urothelial Carcinoma impacts survival significantly through a combination of anatomical, histological, and genetic factors. From origin-driven metastasis patterns to specific mutational profiles that disrupt growth and apoptosis regulation, each factor contributes uniquely to patient outcomes. Recognizing the limitations of present sampling strategies and understanding key survival-related genetic alterations, clinicians can refine prognostic assessments and tailor therapeutic interventions more precisely. As such, advancing our grasp of these survival determinants can critically enhance targeted treatment, ultimately improving patient survival rates."
        ],
        [
         "22",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Bladder NOS) impacts survival, focusing on:\n- Tumor Origin: How Bladder NOS influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Metastatic in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin\n\n### Influence on Survival\nBladder Urothelial Carcinoma (BUC), coded as Bladder NOS under ICD-10, originates in the epithelial lining of the bladder. This origin significantly influences the pattern of metastasis, often spreading to regional lymph nodes, lungs, liver, and bones. The extent and pattern of metastatic spread have a direct negative impact on survival rates.\n\n### Biological Rationale\nThe urothelial origin means the carcinoma primarily affects transitional epithelium, which allows it to invade surrounding tissue easily due to inherent flexibility and less rigid cellular adhesion. This biological trait enables early local invasion and facilitates further systemic dissemination.\n\n### Treatment Accessibility\nBladder NOS might limit treatment options due to challenges in acquiring a precise histopathological diagnosis. Without definitive subclassification, patients may not receive the most tailored therapeutics, negatively affecting survival.\n\n## Histology\n\n### Influence on Survival\nThe predominant histological type, Transitional Cell Carcinoma (NOS), often correlates with specific mutation profiles that impact prognosis and therapeutic outcomes. The presence and pattern of mutations can significantly affect cellular behavior such as growth and invasion, thereby influencing survival.\n\n### Biological Rationale\nThis specific histology often exhibits mutations in genes like TP53, FGFR3, and RB1. These mutations can lead to uncontrolled cell proliferation, disruptions in apoptosis, and increased invasive potential, directly affecting tumor aggressiveness and patient survival negatively.\n\n## Sampling Bias\n\n### Influence on Genomic Analysis\nThe use of blood-derived normals or metastatic tissue for genomic analyses introduces potential biases. These sampling methods might not fully represent the tumorâ€™s genomic landscape, missing crucial mutations present in the primary tumor.\n\n### Biological Rationale\nBlood samples generally reflect germline DNA and may not capture somatic mutations. Additionally, analyzing metastatic lesions may emphasize evolutionarily late mutations, missing early drivers crucial for understanding primary tumorigenesis.\n\n## Key Genes\n\n### Influence on Survival\n1. **TP53**: Often mutated, leading to loss of cell cycle control and increased genomic instability. Negative influence due to its role in unchecked growth and progression.\n2. **FGFR3**: Mutations can lead to continuous cell proliferation signaling, influencing early-stage tumor growth negatively.\n3. **PIK3CA**: Alters pathways involved in growth and survival, contributing to chemotherapy resistance when mutated, lowering survival.\n4. **RB1**: Loss of function results in disturbed G1 to S phase cell cycle transition, leading to aggressive tumor behavior.\n5. **TP63**: Regulative functions in cell proliferation and apoptosis, with negative impacts tied to its alterations.\n6. **ERBB2**: Amplifications lead to enhanced signaling for growth and survival, potentially increasing metastatic potential.\n7. **MAML1**: Involved in NOTCH signaling, mutations can disrupt cell differentiation, affecting invasive potential.\n\n### Biological Rationale\nEach geneâ€™s alteration disrupts vital cellular functions, affecting tumor growth (e.g., cell cycle regulation by TP53 and RB1), invasion, and resistance to apoptosis, which cumulatively drive poor survival.\n\n## Synthesis and Conclusion\n\n### Key Survival Risk Factors\nThe survival impact in Bladder Urothelial Carcinoma is multifaceted, involving tumor origin, histology-related mutation profiles, and biases in sample selection impacting genomic insights. Clinically, identifying and understanding the intricate interactions of key genes like TP53 and FGFR3 aid in tailoring therapeutic strategies to improve survival outcomes.\n\n### Clinical Insights\nAddressing these factors involves refining diagnostic precision, employing comprehensive genomic profiling that accurately reflects the tumorâ€™s evolutionary state, and designing therapies that target specific genetic alterations. Enhanced diagnostic accuracy and personalized therapeutic approaches represent the most significant opportunities to improve survival rates and manage Bladder Urothelial Carcinoma more effectively."
        ],
        [
         "23",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Bladder NOS) impacts survival, focusing on:\n- Tumor Origin: How Bladder NOS influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Bladder NOS\n\n1. **Metastatic Patterns & Survival**: Bladder urothelial carcinoma (UC), when classified as Bladder NOS, lacks specific sub-group identification but generally follows recognized metastatic routes typical for urothelial tumors. These include nodal spread and distant metastasis, often to the bones, liver, and lungs. The general prognosis is poorer for advanced metastatic cases.\n\n2. **Treatment Accessibility**: Bladder NOS categories can sometimes lead to non-specific treatment routing if critical histological details are omitted. This may result in non-optimal therapeutic strategies, impacting survival negatively.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n1. **Mutation Profiles & Outcomes**: Transitional cell carcinoma (TCC), a subtype of bladder UC, often presents alterations in genes like TP53, FGFR3, and RB1. Mutations in TP53 correlate with more aggressive disease, whereas FGFR3 mutations, often associated with low-grade tumors, can have less impact on survival if appropriately targeted.\n\n2. **Prognostic Implications**: The histological grade and stage are critical determinants of survival, with higher grade and stage linked to aggressive disease and poorer outcomes. Understanding these interactions can guide interventions.\n\n### Sampling Bias in Genomic Analysis\n\n1. **Blood-Derived Normal vs. Primary Tumor Samples**: Utilizing blood-derived normal samples for comparative analyses can introduce biases, particularly in detecting tumor-specific mutations. Differences in clonal populations between blood and primary tumor samples can misrepresent mutation burdens or lead to oversight of certain oncogenic drivers.\n\n2. **Impact on Genomic Interpretation**: Reliance on a single type of tissue can result in skewed data, which may impact treatment decisions, such as the use of targeted therapies. It can also obscure understanding of tumor heterogeneity, affecting prognostic assessments.\n\n### Key Genes Associated with Survival\n\n1. **TP53**: This tumor suppressor gene, frequently mutated in high-grade UC, is involved in cell cycle control. Mutations result in loss of apoptotic regulation, leading to unchecked proliferationâ€”negatively impacting survival.\n\n2. **FGFR3**: Mutations here are common in lower-grade tumors and may suggest a more favorable prognosis if targeted therapies are utilized.\n\n3. **RB1**: Loss of function in this gene disrupts cell cycle regulation, correlating with poorer outcomes due to aggressive tumor growth.\n\n4. **PIK3CA**: Activating mutations impact PI3K signaling pathways, promoting growth and survival. Its presence suggests potential therapeutic targeting but generally indicates worse prognosis.\n\n5. **ERBB2 (HER2)**: Overexpression or amplification can drive tumor proliferation. While negative for prognosis, it opens avenues for targeted therapies, potentially mitigating survival declines.\n\n6. **MDM2**: Amplification or overactivity leads to p53 inhibition, impacting cell cycle arrest and apoptosis, driving poor survival outcomes.\n\n7. **TERT**: Mutations in the promoter region can lead to increased telomerase activity, contributing to immortality of cancer cells and aggressive disease.\n\n### Conclusion\n\nBladder Urothelial Carcinoma, under the NOS classification, highlights critical survival determinants driven by tumor origin, histological insights, genetic aberrations, and potential sampling biases. The interplay of histology, precise gene mutations, and the resultant signaling pathways substantially influences patient prognosis. Correct characterization and understanding of these factors enable optimal therapeutic strategies aimed at improving survival outcomes. Clinicians should strive for accurate histological classification and comprehensive genomic profiling to leverage targeted treatments effectively and address survival disparities within this patient population."
        ],
        [
         "24",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Bladder NOS) impacts survival, focusing on:\n- Tumor Origin: How Bladder NOS influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Transitional cell carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin\n\n### Influence on Survival\nBladder Urothelial Carcinoma (Bladder NOS) originates in the urothelial cells lining the bladder. This localization predetermines its metastatic pathway, frequently extending to adjacent pelvic organs, lymph nodes, and distant sites such as the liver and lungs. Its unchecked dissemination adversely impacts survival rates.\n\n### Biological Rationale\nThe urothelial origin contributes to carcinoma's ability to exploit the rich blood supply and lymphatic network of the bladder, facilitating early and effective metastatic spread. The anatomical structure makes early detection difficult, leading to advanced disease at diagnosis.\n\n### Treatment Accessibility\nThe classification of \"Bladder NOS\" complicates treatment pathways, as it may lack specificity regarding tumor grade or variant, thus impacting treatment precision and accessibility, potentially affecting survival outcomes negatively.\n\n### Sampling Bias\nBladder NOS encompasses a broad category that might introduce heterogeneity into study samples, complicating genetic and survival analyses due to variability in tumor grading and staging.\n\n## Histology: Transitional Cell Carcinoma, NOS\n\n### Influence on Survival\nTransitional cell carcinoma represents the predominant histological subtype, characterized by papillary and solid growth patterns that dictate recurrence and progression risks, thus influencing survival significantly.\n\n### Mutation Profiles\nCommon mutations include FGFR3, TP53, and RB1, impacting survival by driving various pathways related to cell cycle regulation, apoptosis, and cellular proliferation.\n\n### Interaction\nTransitional cell carcinoma's interaction with mutation profiles like TP53 (associated with aggressive growth) often necessitates aggressive treatment, which might not always improve survival due to therapy-resistant mutations.\n\n### Sampling Bias\nHistological diversity in samples (due to intra-tumor heterogeneity) can blur associations between genetic mutations and outcomes, potentially skewing survival data.\n\n## Key Genes and Biological Mechanisms\n\n### Influence on Survival\n\n1. **TP53**: Mutations often result in loss of apoptotic control, enhancing cell survival and proliferation. This negatively impacts survival by contributing to high-grade tumor aggressiveness and resistance to chemotherapy.\n\n2. **FGFR3**: Frequently mutated in low-grade tumors, promoting proliferation. While mutated FGFR3 is associated with non-aggressive tumors, it suggests a paradoxical positive influence on the survival of low-grade carcinoma patients.\n\n3. **RB1**: Loss of RB1 function disrupts cell cycle regulation, promoting uncontrolled cell division and aggressive tumor behavior, negatively influencing survival.\n\n4. **PIK3CA**: Mutations activate survival pathways, promoting resistance. While beneficial for cellular growth, clinically, they can signal therapeutic challenges, impacting survival negatively.\n\n5. **ERBB2**: Overexpression or mutation leads to enhanced cellular proliferation and survival, contributing to aggressive tumor phenotypes with poorer prognosis.\n\n6. **CDKN2A**: Loss of function mutations in CDKN2A negatively impact cell cycle regulation, promoting tumorigenesis and reducing survival.\n\n7. **MRE11A**: Involved in DNA repair; its mutation or loss implies defective repair mechanisms, resulting in genomic instability and potentially poorer survival outcomes.\n\n### Biological Rationale\nThese genetic alterations interact collectively to modulate pathways of cell cycle control, repair mechanisms, and survival strategies within tumors, exerting direct influence on clinical aggressiveness and the overall survival landscape.\n\n## Sampling Bias: Limitations of Genomic Analysis\n\nIn genomic studies, bladder tumor samples often classify as primary tumors or solid tissue normal. This selection method may omit divergent molecular characteristics present in residual or small metastatic deposits.\n\n- **Primary Tumor Sampling**: May not represent the full genomic landscape because of intra-tumoral heterogeneity, affecting clarity in survival correlation studies.\n- **Solid Tissue Normal**: Utilized as a baseline often lacks precision due to potential pre-cancerous changes being unnoticed, skewing comparative genomic data and interpretations.\n\n## Synthesis of Key Survival Risk Factors\n\n### Summary\nThe interplay of tumor origin, histological subtype, and specific genetic profiles fundamentally determines the survival prognosis of bladder urothelial carcinoma. Common biases in genomic sampling, in addition to the tumor's intrinsic properties, contribute to variable treatment outcomes.\n\n### Clinically Relevant Insights\nA multifaceted understanding of these factors is essential:\n\n- **Precision Medicine**: Knowing specific genetic mutations and their biological impacts fosters tailored therapies.\n- **Risk Stratification**: Recognizing high-risk mutations such as TP53 and RB1 allows for stratified patient management, improving survival outcomes through targeted therapy.\n- **Screening and Detection**: Enhanced detection of histological characteristics and genetic profiling can aid in earlier intervention and more effective treatment planning.\n\nOverall, the integration of genomic, histological, and biological insights drives the path toward improved patient survival, underscoring the necessity for continual advancement in both detection methodologies and therapeutic strategies."
        ],
        [
         "25",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Bladder Urothelial Carcinoma (per ICD-10: Bladder NOS) impacts survival, focusing on:\n- Tumor Origin: How Bladder NOS influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Papillary transitional cell carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Tumor Origin**\n\n1. **Influence on Survival:**\n   - Bladder Urothelial Carcinoma (BUC) inherently arises from the urothelium, the transitional epithelium lining the bladder. Its origin influences metastatic patterns since BUC is prone to local invasion and distant metastasis. The survival impact is predominantly negative, as the propensity for metastasis correlates with poorer prognosis.\n   \n2. **Biological Rationale:**\n   - The urothelial origin allows these tumors to develop strategies for cellular adhesion and invasion, facilitated by the loss of cell-to-cell adhesion molecules, like E-cadherin, promoting metastatic dissemination.\n\n3. **Impact on Treatment Accessibility:**\n   - Bladder NOS classification can obscure specific histological subtypes, potentially delaying appropriate subtype-specific treatment that could improve outcomes.\n\n**Histology**\n\n1. **Influence on Survival:**\n   - Papillary transitional cell carcinoma, a common histological subtype, often exhibits a more favorable prognosis compared to non-papillary variants due to its growth pattern, which is generally exophytic rather than invasive.\n\n2. **Mutation Profiles:**\n   - These tumors frequently harbor FGFR3 mutations, which are associated with low-grade tumors and better outcomes, whereas high-grade tumors might present with TP53 or RB1 mutations, indicating aggressive behavior.\n\n3. **Biological Rationale:**\n   - FGFR3 mutations lead to constitutive activation of growth factor signaling, which in a papillary context, tends to result in slower progression as opposed to TP53 mutation-driven cell cycle dysregulation that enhances tumor aggressiveness.\n\n**Sampling Bias**\n\n1. **Limitations:**\n   - Genomic data often exhibit biases due to reliance on Blood Derived Normals, which may not reflect tumor-specific mutational burdens. Similarly, reliance solely on Primary Tumor samples may miss heterogeneity and metastatic features crucial for comprehensive landscape assessment.\n\n2. **Influence on Survival Interpretation:**\n   - Sampling bias can lead to inaccurate assessment of clonality and tumor evolution, affecting survival predictions if pre-metastatic alterations are undetected.\n\n**Key Genes**\n\n1. **Associated Genes and Mechanisms:**\n   - **TP53:** Regulates apoptosis and genomic stability; mutations often lead to unchecked cell growth and poor prognosis.\n   - **FGFR3:** Associated with cell proliferation; mutations often indicate tumors with a less aggressive course.\n   - **RB1:** Involved in cell cycle regulation; loss is associated with more aggressive cancer far progression and worse survival.\n   - **PIK3CA:** Mutations activate the PI3K/AKT pathway, promoting cell survival and tumor development, impacting treatment response.\n   - **TSC1:** Integral to the mTOR pathway, its mutation can lead to advanced tumor growth and worse outcomes.\n   - **KDM6A:** Involved in chromatin modification; mutations can lead to transcriptional dysregulation.\n   - **ERBB2 (HER2):** Overexpression associated with aggressive disease but suggests potential for targeted therapy.\n\n2. **Biological Mechanism:**\n   - These genes are involved in critical pathways like cell cycle regulation, DNA repair, growth factor signaling, and immune evasion, integral to cancer progression and treatment response variances.\n\n**Conclusion: Synthesis of Survival Risk Factors**\n\n- Survival in Bladder Urothelial Carcinoma hinges on the interplay between tumor origin, histologic subtypes, and mutation profiles, with significant biases derived from inadequate genomic sampling. Clinically, identifying aggressive genetic alterations (e.g., TP53, RB1) alongside histology guides treatment strategies, while recognizing sampling bias can refine prognostic assessments. Ultimately, targeted therapies tailored to genetic landscapes promise to improve survival, underscoring the importance of precise genomic profiling in tailoring patient management."
        ],
        [
         "26",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Upper inner quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Upper inner quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Upper Inner Quadrant of Breast\n\n1. **Survival Impact**: Tumors located in the upper inner quadrant of the breast typically have a slightly different clinical presentation compared to other quadrants. This can influence survival as these tumors often have less access to the axillary lymph nodes, potentially resulting in different metastatic patterns and prognostic outcomes.\n\n2. **Biological Rationale**: The anatomical location affects lymphatic drainage pathways. The upper inner quadrant often directs drainage towards internal mammary nodes rather than axillary nodes, which may sometimes lead to later detection of metastases, altering staging and treatment planning.\n\n3. **Therapeutic Accessibility**: While tumor location can sometimes complicate surgical access, it doesnâ€™t inherently limit the feasibility of chemotherapy or radiation, preserving treatment effectiveness.\n\n### Histology: Infiltrating Duct Carcinoma, NOS (IDC)\n\n1. **Survival Impact**: Infiltrating Duct Carcinoma represents the most common form of breast cancer and is known for its heterogeneous nature, influencing prognosis variably depending on the grade and molecular subtype.\n\n2. **Biological Rationale**: Histologically, IDCs exhibit diverse morphological features and genetic alterations influencing tumor behavior and patient outcomes. Its progression and outcomes are often driven by prevalent somatic mutations in key oncogenes and tumor suppressor genes such as PIK3CA and TP53, respectively.\n\n3. **Mutation Interaction**: The interplay of genetic mutations within IDC contributes to diverse responses to treatment, refractory cases, and differential prognostic outcomes. Mutation-driven aggressiveness or resistance strongly correlates with histological findings.\n\n### Sampling Bias: Genomic Analysis\n\n1. **Survival Impact**: Sampling biases related to using Blood Derived Normal vs. Primary Tumor samples for genomic characterizations can influence apparent mutation frequencies and, consequently, inferred cancer prognosis and treatment paths.\n\n2. **Biological Rationale**: Primary tumor sampling may underrepresent heterogeneity, missing subclonal populations driving aggressive phenotypes, while blood-derived samples might not accurately reflect somatic mutations restricted to the tumor cells.\n\n3. **Biases**: Biases occur when mutations present in circulating tumor DNA may suggest high prevalence for resistant clones, potentially misrepresenting the tumorâ€™s bulk genomic profile.\n\n### Key Genes Associated with Survival\n\n1. **TP53**: Mutation in TP53 is associated with loss of apoptotic regulation and increased genomic instability, correlating with poorer survival outcomes.\n\n2. **PIK3CA**: Activating mutations in PIK3CA result in increased proliferative signals, often associated with more aggressive disease but targetable therapeutically.\n\n3. **HER2 (ERBB2)**: Overexpression or amplification leads to aggressive growth and has been linked with poorer outcomes but does benefit from targeted therapies like trastuzumab, which can improve survival.\n\n4. **BRCA1/2**: Germline mutations predispose individuals to higher risks of breast cancer with implications for treatment strategies and targeted therapies improving survival in mutation carriers.\n\n5. **ESR1**: Encodes the estrogen receptor; mutations or altered expression levels affect hormone therapy responsiveness and relate to varying survival outcomes.\n\n6. **CDH1**: Associated with cell adhesion; its loss or mutation contributes to increased tumor cell migration and metastasis, worsening prognosis.\n\n7. **PTEN**: Tumor suppressor gene whose loss can activate the PI3K/AKT pathway, enhancing cell survival and proliferation, leading to poorer outcomes.\n\n8. **KMT2C**: Known for regulating genes associated with DNA repair and cell cycle, mutations here can result in genomic alterations contributing to aggressive tumors.\n\n### Conclusion\n\nThe survival outcomes in breast invasive carcinoma are intricately linked to a convergence of anatomical, histological, and genetic factors. Upper inner quadrant tumors present unique challenges due to distinct metastatic pathways and detection difficulties, impacting survival potential. Histological variations in IDC, coupled with complex mutational landscapes, drive differential prognoses. Genomic sampling biases can either cloud or clarify therapeutic strategies depending on the source material. Understanding the contribution of key genetic alterations helps integrate molecular targeted therapy into treatment regimens, improving survival probabilities, and exemplifying precision oncologyâ€™s role in patient-centric care.\n\nThis synthesis underscores that improved prognostic assessments and personalized treatments rely on a comprehensive grasp of multi-dimensional interactions between tumor biology and treatment paths, thereby significantly impacting patient survival."
        ],
        [
         "27",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Upper inner quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Upper inner quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating lobular mixed with other types of carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Upper Inner Quadrant of the Breast\n\n1. **Influence on Metastatic Patterns**:\n   - **Survival Impact**: Tumors originating in the upper inner quadrant of the breast may have a somewhat different pattern of lymphatic drainage, leading to distinct metastatic sites. Typically, these tumors might metastasize laterally to supraclavicular nodes due to the anatomy.\n   - **Biological Rationale**: The unique lymphatic drainage of the breast quadrants can influence the route of metastatic spread. While upper outer quadrant tumors more commonly spread axillary, upper inner quadrant ones might have varied paths, potentially affecting treatment strategies.\n   - **Treatment Accessibility**: Tumors in the inner quadrants may necessitate more complex surgical resections due to proximity to critical structures, potentially impacting resection completeness and thus survival.\n\n2. **Histology: Infiltrating Lobular Carcinoma Mixed with Other Types**\n\n   - **Survival Impact**: Infiltrating lobular carcinomas (ILCs) have a distinctive growth pattern, typically presenting as diffuse and less well-circumscribed tumors, which can affect detection and treatment response, often correlating with poorer prognoses compared to ductal carcinomas.\n   - **Biological Rationale**: ILCs often result from loss of E-cadherin, leading to their characteristic discohesive growth. Mixed histologies can involve different mutation profiles, complicating prediction of treatment response.\n   - **Interactions**: Mixed histology with other carcinomas can complicate genetic and histological assessments, impacting therapeutic decisions and highlighting the biological heterogeneity that affects survival outcomes.\n\n3. **Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in Genomic Analysis**\n\n   - **Survival Impact**: Relying solely on primary tumor samples and comparing them with blood-derived normal can overlook microenvironmental factors and tumoral heterogeneity, leading to misinterpretations of oncogenic drivers.\n   - **Biological Rationale**: Tumor genomic signatures are influenced by the microenvironment and evolutionary pressures, which primary versus metastatic or multi-site sampling might not capture.\n   - **Bias**: Limited sampling sites can result in a skewed understanding of the cancerâ€™s mutational landscape, overlooking potential metastatic or subclone dynamics, potentially misleading survival assessments.\n\n4. **Key Genes Impacting Survival**\n\n   - **BRCA1/2**: These genes, critical in DNA repair, when mutated, lead to homologous recombination deficiencies, common in breast carcinoma, making them targets for specific treatments (e.g., PARP inhibitors), positively influencing targeted therapy outcomes.\n   - **PIK3CA**: Mutations in this gene activate the PI3K/AKT pathway, promoting cell growth and survival, contributing to therapeutic resistance and poorer outcomes.\n   - **TP53**: Alterations in this gene, a major tumor suppressor, often correlate with more aggressive phenotypes and resistance to treatment.\n   - **GATA3**: Mutations here can influence differentiation and hormonal response, impacting endocrine therapy outcomes.\n   - **HER2 (ERBB2)**: Amplified or overexpressed in some breast cancers, directs the use of HER2-targeted therapies, which have drastically improved survival in affected patients.\n   - **CDH1**: Loss of function (as seen in lobular carcinoma) disrupts cellular adhesion, fostering invasiveness and complicating effective treatment.\n   - **PTEN**: Loss or mutation in PTEN, a tumor suppressor that inhibits PI3K signaling, can lead to unchecked cell growth and survival, complicating treatment response.\n\n### Synthesis of Key Survival Risk Factors\n\nClinically, the survival of breast carcinoma patients in the upper inner quadrant with infiltrating lobular carcinoma mixed with other types depends heavily on tumor biology, genetic profiles, and surgical accessibility. Understanding the impact of key genes on treatment resistance or sensitivity is crucial to patient-specific therapy decisions. Limitations in genomic analysis underscore the importance of comprehensive sample collection to avoid biases that could misguide treatment strategies.\n\nThese insights affirm the value of integrating tumor biology with genomic data for prognostication and emphasize precision medicine's role in improving survival through tailored therapies. Consistent monitoring and refined sampling methodologies are essential to reflect true oncologic complexity, thereby supporting optimal clinical interventions and enhancing patient outcomes."
        ],
        [
         "28",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Lower inner quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Lower inner quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n#### Influence on Survival\n- **Lower Inner Quadrant and Metastatic Patterns**: Tumors originating in the lower inner quadrant of the breast have distinct lymphatic drainage patterns. This quadrant is close to the internal mammary nodes, potentially leading to atypical metastatic spread.\n- **Patient Survival**: Tumors in this region often show poorer survival due to the relatively late detection and complex lymphatic spread, as they might bypass the more common axillary node involvement.\n- **Treatment Accessibility**: Surgical accessibility can be more challenging due to proximity to the chest wall, potentially complicating surgical margins and increasing local recurrence risks.\n\n#### Biological Rationale\n- **Lymphatic Spread**: The unique lymphatic pathway can facilitate early metastatic dissemination beyond typical axillary nodes, complicating early detection and standard treatment protocols.\n\n### Histology\n\n#### Influence on Survival\n- **Infiltrating Duct Carcinoma, NOS**: This histological type is the most common and is associated with a broad spectrum of genetic mutations. Its variability in genetic profile can contribute to divergent survival outcomes.\n\n#### Biological Rationale\n- **Mutation Profiles**: Key mutations in genes such as TP53 or PIK3CA are prevalent and impact tumor aggressiveness, propensity for metastasis, and resistance to therapies, thereby influencing patient survival outcomes.\n\n### Sampling Bias\n\n#### Limitations in Genomic Analysis\n- **Primary Tumor vs. Solid Tissue Normal**: Genomic analyses often compare cancer tissue with adjacent normal tissue. However, 'normal' tissue in cancer patients may have precancerous changes or field effects, leading to potential biases.\n- **Survival Implication**: These biases may result in underestimating actual mutation burden and potential driver mutations, skewing data towards non-representative profiles.\n\n### Key Genes\n\n1. **TP53**\n   - **Role**: Tumor suppressor gene involved in DNA repair and apoptosis.\n   - **Impact**: Mutations lead to impaired apoptosis and increased survival of malignant cells, worsening prognosis.\n\n2. **PIK3CA**\n   - **Role**: Part of the PI3K/AKT signaling pathway regulating cell growth and survival.\n   - **Impact**: Mutations are linked to enhanced tumor cell proliferation and treatment resistance, negatively impacting survival.\n\n3. **BRCA1/BRCA2**\n   - **Role**: DNA repair through homologous recombination.\n   - **Impact**: Lack of functional copies increases genomic instability, but paradoxically, may enhance responsiveness to certain chemotherapies, impacting survival variably.\n\n4. **HER2**\n   - **Role**: Promotes cell growth and differentiation.\n   - **Impact**: Overexpression leads to aggressive tumor phenotypes but also allows for targeted therapies (e.g., trastuzumab), which can improve survival.\n\n5. **ESR1**\n   - **Role**: Encodes estrogen receptor critical for hormone-responsive tumors.\n   - **Impact**: Mutations might predict resistance to hormonal therapies, negatively affecting hormone-receptor-positive breast cancer outcomes.\n\n6. **PTEN**\n   - **Role**: Tumor suppressor that negatively regulates the PI3K/AKT pathway.\n   - **Impact**: Loss of PTEN activity results in uncontrolled cell proliferation, correlating with poorer outcomes.\n\n### Conclusion\n\nThe survival impact of breast invasive carcinoma, particularly in the lower inner quadrant, is multifaceted. It involves an interplay between anatomical origin, histological subtype, and genetic makeup, compounded by challenges in accurate genomic sampling. Clinically, effective management requires a tailored approach that considers these factors. Addressing key genetic mutations with targeted treatments can optimize survival, emphasizing the importance of personalized medicine in managing breast cancer. Understanding these elements collectively improves prognostic accuracy and therapeutic strategies, directly influencing patient survival outcomes."
        ],
        [
         "29",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Lower inner quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Lower inner quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct mixed with other types of carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "Certainly, let's delve into the specifics of breast invasive carcinoma originating from the lower inner quadrant of the breast and its implications on patient survival, integrating aspects of tumor origin, histology, sampling biases, and pivotal genetic factors.\n\n### Tumor Origin\n1. **Influences on Survival:**\n   - **Metastatic Patterns:** Tumors originating in the lower inner quadrant may have different lymphatic drainage patterns compared to those in other quadrants, potentially influencing sentinel node involvement and distant metastasis. These variations can affect prognosis and survival depending on how effectively metastasis occurs.\n   - **Patient Survival Impact:** Studies suggest that lesions in the inner quadrants may be less accessible for lumpectomy, complicating surgical interventions. Additionally, these regions might have a different proximity to vital structures, influencing surgical resection completeness and consequently survival.\n   - **Treatment Accessibility:** Access for imaging and biopsy might be more challenging, potentially delaying diagnosis and treatment initiation, impacting survival adversely.\n\n2. **Biological Rationale:**\n   - The anatomical location impacts the lymphatic network involved, which in turn affects the likelihood of local versus distant dissemination.\n\n3. **Potential Biases:**\n   - Variability in detection rates due to anatomical challenges may lead to underestimation of tumor burden in early detectable stages.\n\n### Histology\n1. **Influence on Survival:**\n   - Carcinomas that are infiltrating ductal mixed with other types often have heterogeneous behaviors and treatment responses, potentially leading to less predictable outcomes.\n   \n2. **Biological Rationale:**\n   - Mixed histological types suggest varied cellular origins or differentiation statuses, affecting mutation profiles and response to targeted therapies (e.g., mixed ductal and lobular elements).\n\n3. **Potential Biases:**\n   - Histological heterogeneity poses challenges in accurate grading and staging, sometimes leading to misrepresentation of aggressiveness based on sampling site.\n\n### Sampling Bias\n1. **Limitations Impacting Genomic Analysis:**\n   - Use of primary tumor and solid tissue normals in genomic studies can introduce biases, as these samples often reflect only a segment of the tumor's heterogeneity or the host tissue's baseline genomics.\n\n2. **Biological Rationale:**\n   - Genomic interpretation might overlook subclonal variations present only in metastatic sites or later emerging tumor provinces.\n\n3. **Potential Biases:**\n   - Analyses based solely on primary specimens may not capture the entirety of genomic drift and clonal evolution that occurs during metastasis.\n\n### Key Genes\n1. **Common Survival-Associated Genes:**\n   - **TP53:** Tumor suppressor whose mutation can lead to uncontrolled proliferation and resistance to apoptosis, negatively impacting survival.\n   - **PIK3CA:** Implicated in cell growth regulation and survival; mutations can lead to activated pathways supporting tumor aggressiveness.\n   - **BRCA1/2:** Associated with DNA repair mechanisms; mutations increase genomic instability, influencing survival outcomes negatively.\n   - **HER2:** Overexpression or amplification is associated with increased proliferation; targeted therapies improve survival in HER2-positive breast cancers.\n   - **ER/PR:** Hormone receptor status provides therapeutic avenues; ER/PR positive cancers often have better outcomes with hormonal therapies.\n   - **PTEN:** Loss of function mutations may activate AKT pathway, promoting cell survival and resistance to apoptosis.\n   - **CDH1 (E-cadherin):** Loss of this cell adhesion molecule is associated with increased metastatic potential and worse survival.\n\n2. **Biological Mechanisms:**\n   - These genes are pivotal in controlling key cellular processes such as cell cycle regulation, apoptosis, and cellular adhesion, all of which significantly influence cancer progression and therapeutic responses.\n\n### Synthesis of Key Survival Risk Factors\n- **Location-Specific Challenges:** Inner quadrant origination can subtly influence patterns of metastasis and treatment accessibility, impacting overall survival rates.\n- **Histological Complexity:** Mixed histology underscores the importance of personalized treatment approaches due to varied tumorigenic pathways and responses.\n- **Genomic Insights and Biases:** Recognizing limitations in sampling is crucial for accurate prognostication and therapeutic strategy formulation.\n- **Genetic Profile Utilization:** A deep understanding of genetic landscapes facilitates the targeting of therapy and impacts survival outcomes positively through precision medicine.\n\nIn summary, a multi-faceted approach integrating anatomical, histological, sampling, and genetic perspectives is essential to understand and address the survival nuances of lower inner quadrant breast carcinomas effectively. This strategy enhances the precision of treatment modalities and ultimately aims to improve patient outcomes."
        ],
        [
         "30",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Upper outer quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Upper outer quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Metastatic, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Tumor Origin: Impact on Survival**\n\n1. **Influence on Metastatic Patterns**: \n   - The upper outer quadrant of the breast is known for a higher density of lymphatics, leading to a propensity for lymphatic spread. This often results in earlier nodal involvement, which is a significant prognostic factor.\n   - **Survival Impact**: Negative. Quick dissemination to lymph nodes often correlates with worse prognosis due to higher chances of systemic metastasis.\n\n2. **Patient Survival and Treatment Accessibility**:\n   - Tumors in the upper outer quadrant may be detected earlier in mammographic screenings because of their location, potentially improving outcomes.\n   - **Accessibility**: Positive. Early detection generally increases treatment options and improves survival rates.\n\n**Histology: Interactions with Mutation Profiles**\n\n1. **Infiltrating Duct Carcinoma, NOS**:\n   - This is the most common histological subtype and exhibits a wide range of mutation profiles.\n   - Prominent mutations often include those in the TP53, PIK3CA, and GATA3 genes, which can dictate aggressive behavior and response to therapy.\n\n2. **Survival Outcome**:\n   - **TP53 mutations**: Often lead to chemoresistance and have a negative impact on survival due to loss of apoptosis regulation.\n   - **PIK3CA mutations**: May confer sensitivity to targeted therapies, potentially improving outcomes.\n   - **Biological Rationale**: Tumor suppressors and oncogenes interact to influence tumor growth, apoptosis, and, consequently, survival.\n\n**Sampling Bias: Limitations in Genomic Analysis**\n\n1. **Metastatic Versus Solid Tissue Normal**:\n   - Samples from metastatic sites may not reflect the primary tumorâ€™s genomic landscape, leading to biases.\n   - **Survival Impact**: Misrepresented mutation burden and clonality can misguide therapeutic decisions, negatively impacting survival.\n\n2. **Potential Biases**:\n   - Normal tissue samples may contain fewer mutations, providing a non-representative baseline.\n   - **Interpretation**: Analysts may overlook clonal heterogeneity and evolution under therapeutic pressure.\n\n**Key Genes Influencing Survival**\n\n1. **TP53**: \n   - Regulates cell cycle and apoptosis.\n   - **Impact**: Frequent mutations characterize poor prognostic subtypes due to unchecked cell proliferation.\n\n2. **PIK3CA**:\n   - Part of the PI3K/AKT pathway.\n   - **Impact**: Mutations can promote survival through growth factor signaling but also offer therapeutic targets.\n\n3. **BRCA1/2**:\n   - Involved in DNA repair.\n   - **Impact**: Mutations, while increasing risk, can lead to better responses to DNA-damaging treatments.\n\n4. **HER2**:\n   - Growth factor receptor.\n   - **Impact**: Overexpression linked to aggressiveness, but targeted therapies improve survival significantly.\n\n5. **GATA3**:\n   - Transcription factor related to luminal subtype.\n   - **Impact**: Mutations are associated with favorable outcomes due to its role in maintaining differentiated epithelial characteristics.\n\n6. **MYC**:\n   - Affects transcription and cell cycle regulation.\n   - **Impact**: Amplification often correlates with aggressive cancer phenotypes and poor survival.\n\n**Concluding Synthesis**\n\nUnderstanding survival in breast invasive carcinoma requires a confluence of factors from tumor origin to molecular genetics. The upper outer quadrantâ€™s implications on metastasis emphasize the importance of early detection. Histological and genetic variances outline potential therapeutic paths and their likely effectiveness, underscoring the need for personalized medicine. Lastly, genomic analyses must account for sampling biases to avoid skewed interpretations. Collectively, these insights illuminate the pathways through which clinicians can strategize optimal individualized treatments, ultimately enhancing patient survival outcomes."
        ],
        [
         "31",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Upper outer quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Upper outer quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin: Upper Outer Quadrant of Breast\n\n1. **Influence on Metastatic Patterns and Survival:**\n   - The upper outer quadrant (UOQ) of the breast is the most common site for breast cancer. Its proximity to axillary lymph nodes can facilitate lymphatic spread, impacting metastatic patterns and subsequent survival.\n   - **Positive Survival Impact:** Cancers originating in the UOQ often have better access to surgical excision with clear margins and sentinel lymph node biopsy, which is a crucial step in staging and treatment planning.\n\n2. **Treatment Accessibility:**\n   - **Neutral/Positive Impact:** The anatomical location often allows for easier surgical access and complete resection, which can positively influence treatment outcomes and survival. Radiation therapy can be adequately targeted due to its location.\n\n3. **Biological Rationale:**\n   - Proximity to significant lymphatic channels increases potential for early detection but also potential for early metastasis through lymphatic spread.\n\n### Histology: Infiltrating Duct Carcinoma, NOS\n\n1. **Mutation Interaction and Outcomes:**\n   - Infiltrating duct carcinoma (IDC), NOS is the most common histological subtype, characterized by various genetic mutations impacting cell cycle regulation and apoptosis.\n   - **Negative Survival Impact:** High-grade IDCs are often associated with more aggressive behavior and poorer prognosis.\n\n2. **Biological Rationale:**\n   - Mutations, particularly in TP53 or PIK3CA, contribute to unregulated growth and resistance to apoptosis, complicating treatment and negatively influencing survival.\n\n3. **Genomic Interpretation Bias:**\n   - Overrepresentation of certain mutations in genomic databases can lead to bias in interpreting typical profiles for IDCs, potentially misinforming treatment strategies.\n\n### Sampling Bias in Genomic Analysis\n\n1. **Limitations:**\n   - Biopsies from primary tumors may not capture the full genetic diversity of metastatic sites, leading to sampling bias. This can impact survival assessment due to incomplete representation of the tumorâ€™s genomic landscape.\n\n2. **Biological Rationale:**\n   - Tumor heterogeneity means that genomic analysis based solely on primary tumor samples may not account for divergent subclones driving metastasis and resistance.\n\n### Key Genes Impacting Survival\n\n1. **BRCA1/BRCA2:**\n   - **Function:** DNA repair via homologous recombination.\n   - **Impact:** Mutations lead to genomic instability, associated with aggressive cancers and poor survival.\n\n2. **TP53:**\n   - **Function:** Regulates cell cycle and apoptosis.\n   - **Impact:** Mutations result in uncontrolled proliferation and resistance to standard therapies, leading to poorer survival.\n\n3. **PIK3CA:**\n   - **Function:** Part of the PI3K/AKT pathway, regulating cell growth and survival.\n   - **Impact:** Common mutations can drive oncogenesis, impacting treatment efficiency.\n\n4. **HER2/ERBB2:**\n   - **Function:** Growth factor receptor involved in cell proliferation.\n   - **Impact:** Amplification or overexpression is a targetable factor, with survival impact depending on response to targeted therapies.\n\n5. **ESR1:**\n   - **Function:** Codes for estrogen receptor, influencing cell growth.\n   - **Impact:** Hormone receptor positivity typically predicts better survival due to responsiveness to endocrine therapies.\n\n6. **PTEN:**\n   - **Function:** Tumor suppressor gene involved in PI3K/AKT signaling.\n   - **Impact:** Loss of function can lead to enhanced growth signaling and poorer prognosis.\n\n### Synthesis of Key Survival Risk Factors\n\n1. **Tumor Origin and Metastasis:**\n   - Location influences lymphatic spread and treatment planning.\n\n2. **Histological and Genetic Factors:**\n   - Mutation profiles in IDC significantly alter prognosis and treatment outcomes.\n\n3. **Biological and Genomic Complexity:**\n   - Perception of risk and effective treatment planning necessitates comprehensive genomic sampling and analysis.\n\n4. **Clinically Relevant Insights:**\n   - Understanding the interaction of tumor location, histology, and mutation profiles with survival is crucial for personalized treatment strategies. Advances in targeted therapies and genetically informed models can significantly refine prognosis and therapeutic approaches, ultimately improving patient survival outcomes."
        ],
        [
         "32",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Lower outer quadrant of breast) impacts survival, focusing on:\n- Tumor Origin: How Lower outer quadrant of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "To analyze how breast invasive carcinoma, specifically originating in the lower outer quadrant, impacts patient survival, we'll examine several factors: tumor origin, histology, sampling biases, and key genetic mutations.\n\n### Tumor Origin: Lower Outer Quadrant Effects\n\n1. **Influence on Metastatic Patterns and Survival**\n   - **Anatomic Consideration**: Tumors originating in the lower outer quadrant often tend to metastasize to axillary lymph nodes earlier due to their proximity. This can lead to earlier detection compared to other quadrants, potentially improving survival rates.\n   - **Patient Survival**: Early lymphatic involvement might initially suggest poorer outcomes. However, earlier detection through routine imaging and surgical interventions in this accessible area may offset these risks, often translating into better overall survival compared to the medial quadrants.\n   - **Treatment Accessibility**: The lower outer quadrantâ€™s accessibility facilitates surgical interventions like lumpectomy or mastectomy, boosting survival by enabling complete tumor resection.\n\n2. **Biological Rationale**: The anatomical positioning and lymphatic network around the lower outer quadrant help in directing diagnostic and treatment efforts, often leading to earlier intervention and potentially improved survival rates.\n\n### Histology: Infiltrating Duct Carcinoma, NOS\n\n1. **Interaction with Genetic Mutations**\n   - **Common Mutations**: Often characterized by mutations like PIK3CA, TP53, and BRCA1/2. These mutations can drive progression through unchecked proliferation (PIK3CA), impaired apoptosis (TP53), and defective DNA repair (BRCA1/2).\n   - **Survival Impacts**: PIK3CA mutations are generally associated with a better prognosis due to responsiveness to targeted therapies, while TP53 mutations often correlate with poorer outcomes due to aggressive tumor behavior and resistance to chemotherapy.\n\n2. **Biological Rationale**: The infiltrating nature of ductal carcinoma with these mutations facilitates both the aggressive and indolent growth patterns, impacting different survival outcomes based on the mutation burden and therapy responsiveness.\n\n### Sampling Bias: Blood Derived Normal, Primary Tumor\n\n1. **Genomic Analysis Limitations**\n   - **Blood Derived Normal**: This control can miss somatic mutations present uniquely in the tumor due to its reliance on non-tumor DNA, potentially skewing results toward germline variations.\n   - **Primary Tumor**: Sampling only the primary tumor might overlook heterogeneity within metastatic sites, leading to incomplete mutation profiles.\n\n2. **Survival Influence**: These biases could either overestimate or underestimate the aggressiveness of the tumor, influencing treatment choices and subsequent survival probabilities if certain aggressive mutations are undetected.\n\n### Key Survival-Associated Genes\n\n1. **PIK3CA**: \n   - **Mechanism**: Activates PI3K/AKT/mTOR pathway, leading to cell growth and survival.\n   - **Survival Impact**: Offers targets for specific inhibitors that improve outcomes in mutated cases.\n\n2. **TP53**: \n   - **Mechanism**: Acts as a tumor suppressor gene by regulating apoptosis and DNA repair.\n   - **Survival Impact**: Mutations often correlate with poor prognosis due to resistance to therapy.\n\n3. **BRCA1/2**: \n   - **Mechanism**: Essential for DNA repair through homologous recombination.\n   - **Survival Impact**: Mutations increase cancer risk but might respond to PARP inhibitors, altering survival positively in targeted therapies.\n\n4. **HER2**: \n   - **Mechanism**: Receptor tyrosine kinase involved in cell growth.\n   - **Survival Impact**: Amplification correlates with aggressive disease but is targetable with therapies like trastuzumab, improving survival outcomes.\n\n5. **ESR1**: \n   - **Mechanism**: Encodes estrogen receptor, critical in hormone-driven cancers.\n   - **Survival Impact**: Expression links to prognosis, modifiable by hormone therapies.\n\n### Synthesis of Key Survival Risk Factors\n\nOverall, survival outcomes in breast carcinoma involving the lower outer quadrant are influenced by a strategic interplay of anatomic positioning, characteristic histological behavior, and mutation patterns. Despite potential sampling biases, targeted therapies aligned with genetic insights pave the way for improved prognosis. Emphasizing routine imaging and comprehensive mutation profiling can refine therapeutic strategies, presenting clinical teams with vital pathways to prolong and enhance patient survival."
        ],
        [
         "33",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Overlapping lesion of breast) impacts survival, focusing on:\n- Tumor Origin: How Overlapping lesion of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Pleomorphic carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Tumor Origin: Breast invasive carcinoma with overlapping lesions**\n\n1. **Influence on Survival and Metastatic Patterns**:\n   - **Survival Impact**: Overlapping lesions in breast carcinoma complicate the understanding of tumor boundaries, potentially allowing for more aggressive invasion into adjacent tissues. This can hasten metastatic spread, typically reducing overall survival.\n   - **Metastatic Patterns**: Given their diffuse nature, these lesions might spread through lymphatic and vascular systems more readily, leading to metastasis in common sites such as bones, liver, lungs, and brain.\n   - **Treatment Accessibility**: Complex overlapping lesions might require multimodal treatment approaches but can evade some localized treatment options such as surgery, impacting survival negatively.\n\n2. **Histology: Role of Pleomorphic Carcinoma**\n\n   - **Survival Influence**: Histologically, pleomorphic carcinoma, a subtype characterized by high-grade cellular atypia, is aggressive, often correlating with poorer survival rates.\n   - **Mutation Profiles**: These tumors frequently harbor diverse mutations, including those in TP53 and HER2. Such mutations promote unchecked proliferation and resistance to treatments, driving poor outcomes.\n   - **Outcomes**: Because of these mutations, therapeutic options targeting specific pathways (e.g., HER2-targeted therapies) may be more effective but only if identified and treated early.\n\n3. **Sampling Bias: Limitations in Genomic Analysis**\n\n   - **Blood vs. Tumor Derived Samples**: Blood-derived normal tissue samples often miss tumor heterogeneity, reducing the accuracy of genomic profiling. This can lead to biased conclusions about genetic alterations influencing survival.\n   - **Primary Tumor Samples**: While closer reflections of the tumorâ€™s genetic makeup, they may not capture the genomic variability present within metastatic sites, again skewing survival predictions.\n\n4. **Key Survival-Associated Genes**\n\n   - **TP53**: Mutations lead to loss of apoptosis regulation, contributing to both tumor survival and chemoresistance.\n   - **BRCA1/BRCA2**: Essential in DNA repair mechanisms; mutations heighten genomic instability and increase the risk of aggressive breast cancers.\n   - **HER2**: Overexpression drives proliferation. Targeted therapies improve outcomes if identified.\n   - **PIK3CA**: Mutations can activate downstream signaling (AKT/mTOR pathways), promoting growth and survival.\n   - **ESR1**: Estrogen receptor mutations affect hormone therapy effectiveness, impacting treatment outcomes.\n   - **CDH1**: E-cadherin mutations are linked with weakened cell adhesion and increased metastasis potential.\n   - **PTEN**: Loss of this tumor suppressor gene leads to increased cell survival pathways via PI3K/AKT.\n\n**Synthesis of Key Survival Risk Factors**\n\nOverall survival in breast invasive carcinoma with overlapping lesions is governed by complex interplays of tumor origin, histology, and genomic makeup. Specifically, the invasion-prone, heterogeneous nature of overlapping lesions fosters aggressive phenotypes. Histological factors such as pleomorphic characteristics further heighten aggressiveness due to distinctive mutation profiles promoting resistance against conventional therapies. Recognizing and mitigating sampling biases, especially in genomic analysis, is critical to accurately identify and target survival-associated genetic drivers such as TP53, BRCA1/2, and HER2. Clinically, early detection and personalized treatments based on comprehensive genomic profiling are essential to improving outcomes. Understanding these dynamics paves the way for developing refined, patient-specific therapeutic strategies to optimize survival."
        ],
        [
         "34",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Overlapping lesion of breast) impacts survival, focusing on:\n- Tumor Origin: How Overlapping lesion of breast influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\nThe breast invasive carcinoma classified under ICD-10 as \"Overlapping lesions of breast\" refers to tumors located at the convergence of anatomic sub-regions of the breast, often complicating clear surgical demarcation. This positional complexity can influence metastatic patterns as these tumors are predisposed to involving multiple ductal networks, thereby facilitating regional lymphatic spread and potentially distant metastasis earlier than tumors confined to a single quadrant. \n\n- **Survival Impact**: Negative, due to increased metastatic potential.\n- **Biological Rationale**: Tumors at the ductal intersections are facilitated by rich vascular networks, increasing the likelihood of hematogenous or lymphatic dissemination.\n- **Treatment Accessibility**: The overlap in anatomical regions might complicate localized surgical interventions, potentially necessitating more aggressive systemic treatments.\n\n### Histology\n\nBreast invasive carcinoma most commonly presents as Infiltrating Duct Carcinoma, Not Otherwise Specified (NOS). This histological subtype is characterized by variability in differentiation and a broad spectrum of genetic mutations, influencing clinical outcomes.\n\n- **Influence on Survival**: Variable, largely contingent on mutation profiles present.\n- **Biological Rationale**: Infiltrating duct carcinoma, NOS often shows heterogeneity in HER2, ER, and PR receptor status, which guides targeted therapies. The mutation landscapes can include BRCA, TP53, and PIK3CA among others, driving tumor behavior.\n- **Outcomes Impact**: Certain mutations like TP53 and BRCA might confer poorer prognoses due to aggressive phenotypes, while hormone receptor positivity typically predicts responsiveness to hormonal therapies.\n\n### Sampling Bias\n\nIn genomic studies, sampling biases are prominent when profiles focus on the primary tumor without adequately representing the complex tumor microenvironment or metastatic sites.\n\n- **Survival Association**: Biases could lead to overrepresentation of specific mutations that do not fully account for metastatic capacity or recurrence.\n- **Biological Rationale**: Primary tumor and solid tissue normal samples often miss the spatial genetic heterogeneity of tumors, thereby underestimating subpopulations responsible for treatment resistance.\n- **Interpretation Limitations**: Focusing solely on primary sites can mislead therapeutic strategies by omitting data on emergent clones resistant to commonly used drugs.\n\n### Key Genes\n\n1. **TP53**: Critical in DNA repair and apoptosis. Mutations often result in loss of function, leading to unchecked cell proliferation and poor prognosis.\n2. **BRCA1/2**: Implicated in homologous recombination repair; mutations notoriously lead to genomic instability and enhanced metastatic potential.\n3. **PIK3CA**: Part of the PI3K/AKT pathway, mutations lead to proliferation and survival advantages, affecting treatment resistance.\n4. **HER2**: Overexpression typically indicates aggressive growth but is also a target for specific monoclonal antibody therapies that improve outcomes.\n5. **ER/PR**: Hormone receptor positivity generally correlates with better survival due to effective engagement with hormone-blocking therapies.\n6. **PTEN**: Tumor suppressor involved in cell cycle regulation; loss or mutation correlates with poor prognosis and therapy resistance.\n7. **CDH1**: Involved in cell adhesion; mutations often relate to increased invasiveness and metastatic potential.\n\n### Conclusion\n\nIn synthesizing these factors, the complexity of breast invasive carcinoma survival trends demands a multi-faceted approach. The anatomical origin influences metastasis and surgical strategies, while histological profiles guided by genetic mutations dictate responsiveness to targeted therapies. Sampling biases in genomic studies highlight the necessity for comprehensive profiling to inform effective treatment. Clinically, key survival risk factors include mutational status of critical genes like TP53 and BRCA, which establish prospective targeting opportunities while demanding vigilant monitoring for resistance. Insightful integration of these elements is essential for optimizing patient management and improving survival outcomes."
        ],
        [
         "35",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin: Breast NOS (Excludes Skin of Breast C44.5)\n\n### Influence on Survival\n\n1. **Metastatic Patterns**: Breast invasive carcinoma typically originates in the epithelial cells of the ducts or lobules. Excluding skin of breast implications, the primary concern is the propensity for these tumors to metastasize to bones, liver, lungs, and brain, significantly impacting survival negatively.\n\n2. **Survival Predictions**: Early detection of metastases often improves survival, but the location of metastasis can drastically affect survival times, with brain metastases associated with poorer prognosis.\n\n3. **Treatment Accessibility**: Variability in histological subtypes (e.g., ER, PR, HER2) dictates available treatments, impacting patient outcomes. For instance, HER2-positive cases benefit from targeted therapies improving survival, unlike certain triple-negative types which lack such options.\n\n### Biological Rationale\n\n- Breast carcinomas acquire genetic changes that enable dissemination from the primary site, guided by receptor status affecting treatment pathways.\n\n### Genomic Interpretation Bias\n\n- Variations in subtypes and heterogeneity can skew survival analysis, as generalized treatment efficacy may not account for molecular diversity.\n\n## Histology: Carcinoma, NOS\n\n### Influence on Survival\n\n1. **Outcome Drivers**: Carcinoma, NOS (not otherwise specified) describes tumors without specific histological differentiation, requiring detailed genetic profiling to dictate therapy.\n\n2. **Mutation Profiles**: Variability in common mutations (e.g., TP53, BRCA1/2) affects tumor behavior and therapeutic responsiveness, influencing outcomes. Mutations like TP53 correlate with poor prognosis due to aggressive tumor nature.\n\n### Biological Rationale\n\n- Histological ambiguity can reflect greater tumor plasticity and resilience, complicating treatment.\n\n### Genomic Interpretation Bias\n\n- Bias arises during tumor sampling since less differentiated tumors may represent a skewed genetic landscape compared to more typical invasive breast cancers.\n\n## Sampling Bias: Limitations of Blood Derived Normal and Primary Tumor\n\n### Influence on Survival\n\n1. **Complexity in Genomic Profiles**: Blood-derived normals may not accurately reflect tumor-specific mutations, potentially overlooking actionable targets.\n\n2. **Primary Tumor Sampling**: Spatial heterogeneity within tumors can result in sampling bias affecting mutation detection and subsequent therapy decisions.\n\n### Biological Rationale\n\n- Tumor clonal diversity must be matched in profile to treatment strategy. Sampling may miss subclonal mutations critical for tailored therapies.\n\n### Genomic Interpretation Bias\n\n- Analysis may under- or over-estimate mutation prevalence, risking ineffective treatment allocations based on incomplete mutation landscapes.\n\n## Key Genes Impacting Survival\n\n### Five to Eight Critical Genes\n\n1. **TP53**: Encodes tumor suppressor; mutations lead to unchecked cell division, correlating with poorer outcomes.\n   \n2. **BRCA1/2**: Critical in DNA repair; loss-of-function mutations increase cancer risk and guide PARP inhibitor therapy.\n\n3. **PIK3CA**: Involved in growth signaling; mutations often indicate poor prognosis but guide PI3K inhibitor use.\n\n4. **HER2 (ERBB2)**: Overexpression results in aggressive growth phenotype; targeted by trastuzumab, significantly improving survival.\n\n5. **ESR1**: Encodes ER, mutations post-therapy associate with endocrine resistance, necessitating alternative therapeutic strategies.\n\n6. **GATA3**: Implicated in differentiation; associated mutations may indicate treatment resistance.\n\n7. **CDH1**: E-cadherin mutations signify lobular subtype, often linked to survival differences due to distinct growth patterns.\n\n### Biological Mechanisms\n\n- These genes regulate proliferation, apoptosis, DNA repair, and signal transduction, essential for stratifying therapies and improving survival.\n\n### Genomic Interpretation Bias\n\n- Focusing only on these genes could overshadow polygenic interactions and epigenetic factors critical in survival predictions.\n\n## Synthesis of Key Survival Risk Factors\n\n### Clinically Relevant Insights\n\n- **Early Detection & Receptor Status**: Must be prioritized for better prognoses.\n- **Genetic Profiling Precision**: Essential for selecting effective treatments.\n- **Subtype-Specific Treatments**: Key in tapping into molecular drivers of survival.\n\n### Impact on Patient Survival\n\nClinically, understanding diverse genomic and histological landscapes enhances tailored treatment strategies, ultimately improving survival rates and quality of life for breast cancer patients. Actionable insights into these factors guide therapeutic precision, reducing overtreatment and optimizing long-term outcomes."
        ],
        [
         "36",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Large cell neuroendocrine carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin\n\n### Influence on Survival\nBreast invasive carcinoma, particularly Breast NOS (excluding skin of breast C44.5), originates within the glandular tissue of the breast, impacting metastatic patterns and patient survival. Given its origin, this type of carcinoma is predisposed to spread via lymphatic and hematogenous routes to common sites such as bone, liver, lung, and brain.\n\n### Biological Rationale\nThe glandular origin encourages early access to lymphatic channels, facilitating systemic dissemination. This metastatic propensity generally worsens survival outcomes, as distant metastases are a chief determinant of prognosis.\n\n### Treatment Accessibility\nOrigin impacts treatment accessibility due to variability in receptor status (ER, PR, HER2), dictating eligibility for targeted therapies that significantly influence outcomes (e.g., HER2-targeted therapies in HER2-positive tumors improving survival).\n\n## Histology\n\n### Influence on Survival\nLarge cell neuroendocrine carcinoma of the breast, while rare, is characterized by aggressive behavior and poor prognosis due to its high-grade histologic features and rapid proliferative index.\n\n### Biological Interaction with Mutations\nThis carcinoma type often harbors complex mutation profiles involving TP53, RB1, and others that drive oncogenesis through dysregulated cell cycle control, leading to rapid tumor growth and dissemination.\n\n### Outcomes\nThe aggressive histology and mutation synergy lead to reduced survival, emphasizing the need for early detection and novel therapeutic approaches. Traditional therapies may not be as effective, necessitating consideration of histotype-specific interventions.\n\n## Sampling Bias\n\n### Limitations\nUsing blood-derived normal samples or only primary tumors for genomic analyses poses challenges. Blood-derived samples might not accurately represent tumor heterogeneity, while primary tumors may not reflect metastatic sites' genomic landscape.\n\n### Influence on Survival Interpretation\nThis sampling bias can lead to an incomplete understanding of tumor biology, potentially overlooking subclonal variations that contribute to therapy resistance and metastatic competence, skewing survival predictions.\n\n## Key Genes\n\n### Influence on Survival\n1. **TP53**: Mutations lead to loss of normal p53 tumor suppressor function, allowing unchecked cell cycle progression and resistance to apoptosis. Frequently associated with poor survival.\n2. **BRCA1/BRCA2**: Germline mutations compromise DNA repair, fostering genomic instability. Olaparib and other PARP inhibitors improve survival in mutation carriers by exploiting DNA repair deficiencies.\n3. **ERBB2 (HER2)**: Amplification drives aggressive tumor behavior due to amplified growth signaling. Survival is improved with targeted therapies such as trastuzumab.\n4. **ESR1**: Alterations leading to hormone-independent activation of estrogen receptor pathways can contribute to endocrine therapy resistance.\n5. **PIK3CA**: Activating mutations in the PI3K pathway can lead to enhanced cell growth and survival, potential targets for PI3K inhibitors.\n6. **CDH1**: Loss of E-cadherin impairs cell-cell adhesion, promoting invasion and metastasis. Associated with worse survival in lobular carcinoma.\n\n### Biological Mechanisms\nThese genes play critical roles in cellular proliferation (PIK3CA, ERBB2), apoptosis regulation (TP53), immune response modulation, and hormonal pathways (ESR1), directly affecting clinical outcomes and therapeutic approaches.\n\n## Synthesis\n\n### Key Survival Risk Factors\n1. **Metastatic Patterns**: Early lymphovascular metastasis associated with breast origin types.\n2. **Histologic Aggressiveness**: Poor prognosis linked to high-grade carcinomas like large cell neuroendocrine.\n3. **Mutation Burden**: Specific mutations (TP53, BRCA1/BRCA2, ERBB2) markedly influence treatment decision-making and survival probabilities.\n4. **Sampling Bias**: Recognition of genomic sampling limitations is crucial for accurate survival estimations and personalized treatment planning.\n\n### Clinically Relevant Insights\nUnderstanding these factors enables more precise stratification of patients for targeted therapies, improved surveillance strategies, and interventions tailored to the underlying biology of each tumor subtype, ultimately enhancing patient survival outcomes."
        ],
        [
         "37",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Adenoid cystic carcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin\n\n### Influence on Survival:\n1. **Metastatic Patterns and Survival Impact:**\n   - **Breast Invasive Carcinoma (Breast NOS):** Unlike localized breast cancers, this entity often involves deeper tissues, which may facilitate early lymphatic and hematogenous dissemination.\n   - **Metastatic Sites:** Common distal metastasis includes bones, lungs, and liver, adversely affecting survival due to complications like organ failure.\n   - **Treatment Challenges:** Some metastases may be less accessible to therapies designed initially for local breast cancer settings, diminishing treatment efficacy.\n\n2. **Biological Rationale:**\n   - **Growth Dynamics:** Tumors originating from the breast's epithelial components often have structural pathways amenable to rapid growth and spread.\n   - **Microenvironment Influence:** This tissue origin allows tumors to evade local immune responses effectively, promoting unchecked proliferation.\n\n3. **Potential Biases:**\n   - **Diagnostic Variability:** Classifying all non-specific breast cancers under NOS might overlook nuances in oncogenesis or response to certain treatments, impacting survival evaluations.\n\n## Histology\n\n### Influence on Survival:\n1. **Adenoid Cystic Carcinoma (ACC) Specifics:**\n   - **Prognostic Differences:** While rare, ACC generally has a slower progression but may possess resistance to conventional chemotherapy, influencing long-term survival.\n   - **Mutation Interactions:** Often presents with MYB-NFIB gene fusions, affecting cell cycle regulation and apoptosis.\n\n2. **Biological Rationale:**\n   - **Genetic Mutations:** These mutations conduct chromosomal rearrangements pivotal for tumor sustenance and chemoresistance.\n   - **Histologic Features:** ACC's characteristic infiltration into nerve tissues can contribute substantially to local recurrence and pain, affecting quality of life and survival.\n\n3. **Potential Biases:**\n   - **Sampling Bias in Histological Studies:** Certain less prevalent histologic types might be underrepresented in genomic databases, skewing insights into treatment and survival.\n\n## Sampling Bias\n\n### Limitations in Genomic Analysis:\n1. **Blood-Derived Normal Samples:**\n   - **Storage and Handling:** Potential contamination issues may skew normal baseline adjustments, affecting downstream genomic interpretations.\n   - **Genetic Reflectance:** Peripheral blood might not accurately represent somatic mutations present in the primary tumor.\n\n2. **Primary Tumor Variability:**\n   - **Heterogeneity Issues:** Tumors are often sampled from easily accessible areas, missing deeper or heterogenous regions potentially harboring aggressive clones.\n   - **Impact on Survival Analysis:** Genomic analyses based on limited sampling could inadequately predict survival outcomes due to incomplete mutational insight.\n\n## Key Genes and Their Survival Association\n\n### Genes Involved:\n1. **TP53:** Commonly mutated, leading to defective apoptosis, increased survival of malignant cells.\n2. **PIK3CA:** Drives proliferative pathways, commonly associated with aggressive cancers.\n3. **BRCA1/2:** Involved in DNA repair mechanisms; mutations lead to genomic instability.\n4. **HER2:** Overexpression triggers proliferation and survival pathways, directly impacting treatment routes.\n5. **ESR1:** Estrogen receptor essential for growth and survival; mutations can lead to endocrine therapy resistance.\n6. **EGFR:** Augments proliferation; often a target for specific therapeutic interventions.\n7. **AR:** Androgen receptor pathways implicated in certain subclass tumors influencing therapy approaches.\n\n### Biological Mechanisms:\n- **Proliferation:** PIK3CA and HER2 activate pathways leading to rapid tumor cell multiplication.\n- **Apoptosis:** TP53 mutations hinder typical cell death, conferring survival advantage.\n- **DNA Repair:** BRCA1/2 mutations lead to faulty repair and subsequent mutagenesis.\n\n### Potential Biases:\n- **Underrepresentation and Sequencing Depths:** Low-frequency mutations in smaller subpopulations might be overlooked, skewing correlations with survival outcomes.\n\n## Conclusion\n\n### Key Survival Risk Factors\n- **Prognostic factors like histology (e.g., ACC) and tumor genetic background are critical in determining patient survival trajectories.\n- **Genomic biases:** Adequate caution must be exercised regarding sampling methods, considering comprehensive tissue profiling to encompass inherent variability.\n- **Clinically Relevant Insights:** Understanding the core genetic drivers and mutations pivotal to critical pathways (e.g., TP53, BRCA1/2) forms the basis of accurate prognosis and personalized treatment planning.\n\n### Clinical Translation:\nEmphasizing specific genomic and histologic characteristics can guide therapeutic decisions, particularly tailoring interventions to individual molecular profiles, thus potentially enhancing survival rates and minimizing overtreatment."
        ],
        [
         "38",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Tubular adenocarcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n**Breast NOS (not otherwise specified)** refers to malignant neoplasms originating from breast tissue but is categorically distinct from skin lesions on the breast. This differentiation is vital because it influences the metastatic potential and patterns, which subsequently impacts survival outcomes and treatment strategies. \n\n1. **Survival Influence**: Breast NOS primarily metastasizes to the axillary lymph nodes, lung, liver, bones, and occasionally the brain. Metastasis to vital organs can significantly reduce survival rates as it complicates treatment and management.\n   \n2. **Biological Rationale**: Given its origin, Breast NOS tumors possess intrinsic traits favoring dissemination, such as enhanced cell motility and protease activity that facilitate tissue invasion and circulation entry.\n\n3. **Treatment Accessibility**: Early detection is crucial, but geographical and socioeconomic factors can limit timely access to suitable therapies, such as surgery, chemotherapy, and targeted treatments, thereby affecting survival.\n\n### Histology\n**Tubular adenocarcinoma** represents a specific histological subtype characterized by well-differentiated glandular structures.\n\n1. **Survival Influence**: Generally, tubular adenocarcinomas are associated with a more favorable prognosis compared to other subtypes, owing to their indolent growth and limited metastatic potential.\n\n2. **Biological Rationale**: This histotype often has lower-grade genetic mutations and a decreased proliferation index, which minimize aggressive behavior and thereby extend patient survival.\n\n3. **Mutation Profiles**: The mutation landscape in tubular adenocarcinoma typically lacks high-risk oncogenes associated with worse outcomes, positioning this subtype in a category with enhanced survival prognosis.\n\n### Sampling Bias\nGenomic analyses often employ **Blood Derived Normal** and **Primary Tumor** samples. However, biases can be introduced:\n\n1. **Survival Influence**: These biases might skew the understanding of tumor evolution and treatment response, inadvertently impacting prognostic models.\n\n2. **Biological Rationale**: Blood-derived DNA might not capture all somatic mutations present in primary tumors. Conversely, primary tumor samples might over-represent more abundant, but less metastatic clones, missing aggressive subclones.\n\n3. **Interpretative Limitations**: Failure to capture tumor heterogeneity can lead to underestimating potential resistive pathways that manifest under treatment pressure, affecting survival prediction and therapeutic decisions.\n\n### Key Genes\nThe genetic landscape is fundamental in shaping survival outcomes in breast carcinoma. Key genes include:\n\n1. **TP53**: Often mutated, impacting genomic stability and apoptosis, typically correlating with poorer outcomes.\n   \n2. **BRCA1/BRCA2**: Involved in DNA repair. Germline mutations in these genes can compromise DNA repair mechanisms, increasing risk but also guiding targeted therapy (e.g., PARP inhibitors).\n\n3. **HER2 (ERBB2)**: Overexpression/amplification is seen in a subset of breast cancers, requiring targeted therapy, which significantly alters survival rates when appropriately treated.\n\n4. **PIK3CA**: Common mutations here can activate major growth pathways. Presence often indicates susceptibility to PI3K inhibitors, influencing treatment and survival.\n\n5. **ESR1 (Estrogen Receptor 1)** and **PGR (Progesterone Receptor)**: Positivity indicates potential responsiveness to hormonal therapy, linked with improved survival in ER-positive cancers.\n\n6. **CDH1 (E-cadherin)**: Mutations or loss can lead to increased invasion and metastasis, typically associated with worse survival in lobular carcinomas.\n\n### Synthesis of Key Survival Risk Factors\nThe integration of tumor origin, histological subtype, genetic alterations, and sampling biases collectively shapes survival. Breast invasive carcinoma prognosis hinges on early detection and precise phenotypic and genotypic characterizations, guiding therapeutic choices. Clinically, the prompt identification of aggressive phenotypes (via genomic profiling) alongside adaptive treatment strategies is pivotal. Personalized medicine, based on robust genomic insights and available therapeutics, emerges as the cornerstone for improving patient survival outcomes amidst these complex, intertwined factors."
        ],
        [
         "39",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Apocrine adenocarcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin and Survival Impact\n\n1. **Influence on Metastatic Patterns and Survival:**\n   - **Tumor Origin:** Breast invasive carcinoma classified as Breast NOS (excludes Skin of breast C44.5) primarily involves glandular tissue. This origin typically allows metastasis primarily via lymphatic spread initially to axillary lymph nodes, and potentially to distant sites such as lungs, bones, liver, and brain.\n   - **Patient Survival Influence:** The potential for early lymphatic spread affects survival negatively. Rapid dissemination may lead to a higher stage at diagnosis, correlating with decreased survival outcomes.\n   - **Treatment Accessibility:** Treatment strategies often involve a combination of surgery, radiation, and systemic therapies (e.g., chemotherapy, hormonal, and targeted therapies). However, localized diagnosis without metastasis facilitates more curative treatment approaches, improving survival rates.\n\n2. **Rationale and Bias Considerations:**\n   - **Biological Rationale:** Lymphatic spread is facilitated by the close anatomical proximity of lymphatics in the breast tissue, posing a challenge for early detection before nodal involvement.\n   - **Sampling Bias:** Biopsies typically emphasize primary tumor analysis, potentially overlooking micro-metastatic exploration which can underestimate metastatic potential and alter survival estimates in genomic profiling.\n\n### Histology: Apocrine Adenocarcinoma\n\n1. **Outcome Impact via Mutation Profiles:**\n   - **Histological Influence:** Apocrine adenocarcinoma, a rare subtype, displays distinct molecular characteristics and an androgen receptor-positive status, often resistant to typical endocrine therapies.\n   - **Mutation Profiles:** Common mutations include PIK3CA, TP53, and AR. Such mutations can lead to aggressive behavior impacting patient survival negatively if not appropriately targeted.\n\n2. **Biological Rationale and Interpretation Limitations:**\n   - **Rationale:** Mutation profiles signify aberrant cell growth pathways and potential endocrine therapy resistance, complicating treatment and reducing the survival prospects.\n   - **Bias in Genomic Analysis:** Lack of comprehensive histological diversity in tumor genomic databases might skew data interpretation, masking specific survival-affecting mutations related to distinct sub-histologies.\n\n### Sampling Bias in Genomic Analysis\n\n1. **Impact of Blood Derived Normal Versus Primary Tumor:**\n   - **Bias Implications:** Using blood-derived normals for comparative genomic analysis might miss tumor-specific genomic alterations, leading to inaccurate somatic mutation profiles.\n   - **Survival Impact:** Mischaracterization of mutation load or specific genomic aberrations can influence perceived aggressiveness and treatment efficacy projections, affecting survival indirectly.\n\n2. **Rationale for Genomic Underestimations:**\n   - **Biological Understanding:** Blood-derived samples lack tumor-specific mutational context, increasing false negative rates and omitting key survival-related mutations.\n\n### Key Survival-Associated Genes\n\n1. **Identified Genes and Mechanisms:**\n   - **TP53:** Pro-apoptotic gene; mutation often leads to unchecked cellular proliferation and reduced survival.\n   - **BRCA1/2:** DNA repair genes; alterations cause genome instability, mandating aggressive treatment strategies.\n   - **PIK3CA:** Alters PI3K/AKT pathway; promotes proliferation and survival, linked to aggressive disease phenotype.\n   - **ERBB2 (HER2):** Gene amplification leads to enhanced growth signaling; targeted therapeutics significantly improve survival.\n   - **ESR1 (Estrogen Receptor):** Hormonal pathway driver; pivotal for therapy selection, impacting long-term survival.\n   - **GATA3:** Influences differentiation; loss impacts cellular maturation and growth control mechanisms.\n   - **CDH1:** E-cadherin loss impacts adhesion; drives invasion and metastasis, adversely affecting survival.\n\n2. **Biological Underpinnings and Analysis Challenges:**\n   - **Functional Insights:** Each gene described plays a critical role in pathway dysregulation, directly impacting cell cycle control, apoptosis, or metastatic potential.\n   - **Bias Considerations:** Genetic heterogeneity within tumor samples and across populations can lead to erroneous survival predictions if broad conclusions are drawn from limited data sets.\n\n### Conclusion and Synthesis\n\n- **Key Survival Risk Factors:** A comprehensive understanding that incorporates tumor origin, detailed histological analysis, mutation burden, and precise genomic profiling, reveals a multifactorial survival landscape.\n- **Clinical Insights:** Identifying critical genes and pathways offers therapeutic targeting opportunities, influencing patient management choices. Genomic biases should be mitigated by diverse and representative sampling to ensure precision oncology truly reflects individualized patient prognoses and survival projections.\n- **Overall Impact:** Focusing on personalized medicine, correct genotypic and phenotypic characterizations can direct optimal treatment strategies, significantly improving survival for breast invasive carcinoma patients."
        ],
        [
         "40",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Mucinous adenocarcinoma interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "**Tumor Origin: Breast Invasive Carcinoma**\n\n1. **Influence on Metastatic Patterns**: \n   Breast NOS (Not Otherwise Specified) carcinomas, excluding the skin of the breast, have distinct metastatic patterns primarily targeting bones, lungs, liver, and brain. The lack of precise subtyping can lead to less targeted early interventions, impacting overall survival.\n\n2. **Impact on Patient Survival**: \n   The broad categorization as Breast NOS means these tumors may initially be managed with generalized treatments, possibly delaying more effective targeted therapies, which affects survival adversely.\n\n3. **Treatment Accessibility**: \n   While initial treatments are standardized, complexities arise in accessing next-line therapies that are subtler to specific molecular subtypes. For instance, HER2-positive or ER-positive tumors have specific targeted therapies that, if delayed in treatment consideration, can negatively influence outcomes.\n\n**Histology: Mucinous Adenocarcinoma**\n\n1. **Influence on Outcomes**:\n   Mucinous adenocarcinoma of the breast often has a better prognosis due to its lower aggressiveness; however, its response to chemotherapy can vary significantly with its mutation profile.\n\n2. **Interaction with Mutation Profiles**:\n   This subtype commonly exhibits mutations in genes like PIK3CA, which are implicated in cell survival and proliferation pathways. When mutations lead to active signaling pathways such as PI3K/AKT, the tumor may resist certain therapies, influencing survival.\n\n**Sampling Bias: Blood-Derived Normal vs. Primary Tumor**\n\n1. **Limitations in Genomic Analysis**:\n   Blood-derived normal samples as controls may not capture intratumoral heterogeneity present in primary tumors. This can bias genomic analyses towards more common mutations, potentially overlooking rarer, significant driver mutations.\n\n2. **Impact on Survival Evaluation**:\n   Biopsying primary tumors provides more accurate mutation profiles relevant for targeted therapy. However, inadequate sampling might miss important subclonal populations, underestimating tumor aggressiveness and misrepresenting the survival outlook.\n\n**Key Genes and Survival Associations**\n\n1. **TP53**:\n   Often mutated in breast carcinoma, TP53 mutations lead to loss of apoptotic control and enhance genomic instability, worsening prognosis.\n\n2. **BRCA1/2**:\n   BRCA mutations, especially BRCA1, are associated with DNA repair deficiencies, increasing tumor aggression and affecting survival negatively. However, they open therapeutic opportunities with PARP inhibitors.\n\n3. **PIK3CA**:\n   Activation of the PI3K/AKT pathway through PIK3CA mutations generally promotes survival via enhanced cell growth, forming a common target for novel inhibitors in clinical trials.\n\n4. **HER2/ERBB2**:\n   HER2 amplification results in increased cell proliferation. While traditionally linked to poor prognosis, HER2-targeted therapies significantly improve survival outcomes.\n\n5. **ESR1**:\n   Mutations in estrogen receptor gene (ESR1) can lead to endocrine resistance. These mutations neutralize the survival advantage conferred by hormonal therapies in ER-positive cancers.\n\n6. **CDH1**:\n   Associated with E-cadherin, mutations in CDH1 can lead to loss of cell-cell adhesion, facilitating metastasis predominantly to the lobular subtype, affecting survival variably.\n\n**Conclusion: Synthesis of Key Survival Risk Factors**\n\n- *Survival in breast invasive carcinoma is intricately linked to the biological behavior dictated by tumor origin, histological variability, and the mutational landscape.*\n- *Early targeted intervention, driven by precise genomic profiling, can significantly alter survival outcomes, emphasizing the necessity of overcoming sampling biases to achieve accurate tumor characterization.*\n- *Transformative therapeutic strategies, aligned with genetic insights, substantially modulate prognosis, underscoring their critical role in improving patient-centered outcomes in breast cancer survival.*"
        ],
        [
         "41",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Metastatic in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n1. **Influence on Survival:**\n   - Breast invasive carcinoma, classified as Breast NOS (Not Otherwise Specified), is a primary tumor that originates within the breast tissue, excluding the skin of the breast (unlike C44.5). Survival is largely influenced by the tumor's potential to metastasize to common sites such as bone, liver, lung, and brain. The ability to metastasize is correlated with lower survival rates.\n\n2. **Biological Rationale:**\n   - The origin of the tumor in breast tissue means it interacts directly with nearby lymphatic and vascular systems, facilitating the spread of cancer cells. These pathways enable metastasis, impacting overall survival negatively.\n\n3. **Potential Biases:**\n   - In research, breast cancer patient data may preferentially include non-metastatic cases or those with easily treatable tumors, skewing survival statistics. Studies may not fully account for the heterogeneity in metastatic potential based on original tumor location.\n\n### Histology\n\n1. **Influence on Survival:**\n   - Infiltrating duct carcinoma, NOS, the most prevalent histological subtype, displays variability in outcomes based on genetic mutations. Aggressive subtypes often have poorer survival due to increased potential for early metastasis.\n\n2. **Biological Rationale:**\n   - This carcinoma type is characterized by its origin in the epithelial cells of the milk ducts. The genetic mutations within these cells can drive tumor aggressiveness and treatment resistance, influencing patient prognosis.\n\n3. **Potential Biases:**\n   - Histological evaluation may overlook nuanced prestages of invasive growth, leading to underestimation of the progression risk. Moreover, reliance on biopsy-alone data presents a limited view if the sample doesn't represent tumor heterogeneity.\n\n### Sampling Bias\n\n1. **Limitations:**\n   - Genomic analyses using blood-derived normal samples can miss tumor-specific mutations present only in the tumor tissue itself, leading to incomplete mutation profiling. Sampling metastatic rather than primary tumor sites may also not reflect the full mutation burden of the initial tumor.\n\n2. **Impact on Interpretation:**\n   - This bias can distort assessments of mutation-driven prognosis factors and affect therapeutic targeting, leading to less effective treatment strategies and poorer survival outcomes.\n\n### Key Genes\n\n1. **Influence on Survival:**\n   - Some genes known to affect survival in breast invasive carcinoma include TP53, BRCA1/2, PIK3CA, HER2, ESR1, PTEN, CDH1, and GATA3.\n\n2. **Biological Mechanisms:**\n   - **TP53**: Tumor suppressor involved in DNA repair and apoptosis. Mutations often lead to unchecked cell division.\n   - **BRCA1/2**: DNA repair proteins. Mutations increase risk of breast cancer and impact survival through inherited syndromes.\n   - **PIK3CA**: Involved in cell growth signaling pathways. Mutations result in unregulated cell proliferation.\n   - **HER2**: Growth factor receptor. Overexpression leads to rapid tumor growth.\n   - **ESR1**: Estrogen receptor that, when mutated, can lead to hormone therapy resistance.\n   - **PTEN**: Tumor suppressor gene that regulates cell cycle. Loss of function results in increased cell survival.\n   - **CDH1**: Encodes for E-cadherin, affecting cell adhesion. Loss leads to increased invasiveness.\n   - **GATA3**: Transcription factor playing role in cell differentiation. Aberrations impact cancer cell proliferation and immune interaction.\n\n3. **Potential Biases:**\n   - Variability in sample collection can result in differential expression data, impacting the perceived influence of these genes on survival. Studies might not reflect the broader genomic landscape if based on selected patient cohorts.\n\n### Synthesis of Key Survival Risk Factors\n\nClinically, survival in breast invasive carcinoma depends on a multifactorial interplay of tumor origin, histological subtype, genetic mutations, and sampling techniques. Metastatic behavior and mutation profiles primarily drive prognosis, influenced by biological factors like cell proliferation, invasion capabilities, and immune response. A nuanced understanding of these elements aids in more accurate risk stratification and treatment planning. It is crucial to recognize sampling biases in genomic studies to ensure effective translation into personalized medicine approaches. Continuous efforts toward comprehensive patient genomics integration will optimize survivorship outcomes."
        ],
        [
         "42",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n**Influence on Survival:**\n1. **Metastatic Patterns:** Breast invasive carcinoma, defined here as Breast NOS (excludes Skin of breast C44.5), primarily originates in breast tissue, making it more prone to metastasize via lymphatic or hematogenous routes to bone, lungs, liver, and brain. These metastases significantly worsen prognosis.\n2. **Treatment Accessibility:** Originating within breast tissue generally allows for earlier detection through screening methods like mammography, improving survival. However, the stage at diagnosis remains critical, with earlier stages (I-II) having better prognoses compared to more advanced stages (III-IV).\n\n**Biological Rationale:**\n- The rich vascular supply and lymphatic drainage of breast tissue facilitate both the local invasion and distant spread of carcinomas, influencing metastatic patterns crucial for survival.\n\n### Histology\n\n**Influence on Survival:**\n1. **Infiltrating Duct Carcinoma, NOS:** This subtype accounts for a majority of breast cancers. It often presents with a more aggressive clinical course compared to other subtypes like lobular carcinoma.\n2. **Mutation Profiles:** Common mutations in genes like TP53, PIK3CA, and HER2 influence this carcinoma's behavior, affecting proliferation, survival, and therapeutic responses.\n\n**Biological Rationale:**\n- Specific histological subtypes possess distinct molecular characteristics. For example, HER2 overexpression seen in some ductal carcinomas leads to enhanced growth signaling. Targeted therapies such as trastuzumab substantially improve outcomes for HER2-positive tumors.\n\n### Sampling Bias\n\n**Influence on Survival:**\n1. **Blood Derived Normal Samples:** These control samples help distinguish somatic mutations from germline variants but may miss tumor microenvironment interactions.\n2. **Primary Tumor Samples:** Biopsies can provide heterogenous data, potentially missing subclonal populations relevant to resistance and progression.\n\n**Biological Rationale:**\n- Genomic analysis reliant on primary tumor samples may not fully capture clonal evolution or the presence of hypoxic regions, which drive treatment resistance and alter survival predictions.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **TP53:** Mutations lead to loss of apoptotic control, allowing for unchecked proliferation. Predicts poorer survival.\n2. **BRCA1/BRCA2:** Germinal mutations predispose individuals to breast cancer. Their impact on DNA repair mechanisms informs survival, with implications for targeted therapies like PARP inhibitors.\n3. **HER2:** Overexpression predicts aggressive behavior but also guides therapy, improving survival with effective targeting.\n4. **PIK3CA:** Commonly mutated; influences PI3K/AKT signaling, affecting cell growth and survival. Its impact varies depending on mutation context.\n5. **ESR1:** Critical for hormone receptor-positive tumors. Its modulation through therapeutics can extend survival while resistance patterns present limitations.\n6. **PTEN:** Loss of function impacts growth pathways, with its status often correlating with prognosis and treatment outcomes.\n\n**Biological Rationale:**\n- Alterations in these genes drive oncogenesis and therapeutic responses. Understanding functional roles and interactions within pathways allows precision in predicting and improving survival outcomes.\n\n### Conclusion\n\n**Synthesis of Key Survival Risk Factors:**\n- **Stage at Diagnosis:** Determines the baseline survival metric, underscoring the importance of early detection.\n- **Histological Subtype and Mutation Profile:** Dictate tumor aggressiveness and potential for targeted treatments, directly influencing survival.\n- **Genomic Insights:** While profound, are subject to sampling biases impacting interpretation, underscoring the need for comprehensive analyses including liquid biopsies to capture dynamic tumor landscapes.\n\n**Clinically Relevant Insights:**\n- Emphasizing early detection and tailored treatment approaches guided by genetic profiling holds promise for improved survival.\n- Awareness of sampling and interpretative biases in genomic data can steer research and clinical practice towards more nuanced and accurate survival prognostications.\n"
        ],
        [
         "43",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Metastatic, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "To address the complexity of Breast Invasive Carcinoma, I'll systematically break down the relevant factors affecting survival, including tumor origin, histology, genetic mutations, and sampling biases, while integrating potential biases in genomic interpretations.\n\n### Tumor Origin:\n1. **Influence on Survival and Metastatic Patterns:**\n   - **Breast NOS (excludes Skin of breast C44.5):** Refers broadly to breast tumors, excluding skin tumors, which means the focus is on the traditional breast tissue origin, impacting the routes of metastasis.\n   - **Impact on Metastatic Patterns:** Tumors originating from breast tissue often metastasize to axillary lymph nodes, lung, liver, bone, and brain. These sites reflect both the spread and severity, influencing survival negatively due to complications and organ failure.\n   - **Patient Survival and Treatment Accessibility:** Survival is affected by early detection and treatment access. Tumors caught in early stages have better outcomes due to interventions like surgery, chemotherapy, and radiation.\n\n2. **Biological Rationale:** The specific tissue origin affects disease progression, as breast-specific factors such as hormonal influences play a role in tumor aggression and treatment responsiveness. Hormone receptor status (e.g., estrogen, progesterone) significantly influences survival, as hormone-responsive tumors often have better prognoses due to effective hormonal therapies.\n\n### Histology:\n1. **Infiltrating Duct Carcinoma, NOS:**\n   - **Influence on Survival:** This subtype is the most common and is characterized by forming duct-like structures; it has variable survival outcomes depending on staging and grading.\n   - **Interaction with Mutation Profiles:** Common mutations include p53, HER2, and BRCA1/2. HER2 amplification often predicts poor survival but can be mitigated by targeted therapies like trastuzumab.\n\n2. **Biological Rationale:** Ductal carcinoma's histological features interact with genetic mutations, affecting cellular proliferation and apoptosis. Aberrant pathways involving these mutations lead to aggressive tumor behavior and potential resistance to therapies without specific targeting agents.\n\n### Sampling Bias:\n1. **Limitations in Genomic Analysis Using Metastatic, Solid Tissue Normal:**\n   - **Bias in Comparisons:** Often, comparisons are drawn between metastatic tissues and tissue considered \"normal\" from a nearby site, which may not accurately represent genetic baselines due to field cancerization where surrounding tissues are genetically altered.\n   - **Impact on Genomic Interpretation:** This can lead to overestimation or underestimation of mutation significance, affecting perceived survival impacts. Attributes such as tumor mutation burden and neoantigenic loads might be misrepresented without contextual baseline corrections.\n\n### Key Genes:\n1. **Survival-Associated Genes:**\n   - **TP53:** Mutations are linked to poor prognosis due to loss of function in genes regulating cell cycle and apoptosis.\n   - **BRCA1/2:** Germline mutations elevate risk and influence survival based on DNA repair inefficiencies, often necessitating specialized treatment approaches.\n   - **HER2 (ERBB2):** Overexpression associates with aggressive disease but provides a tractable target for therapy, altering survival trajectories positively with treatment.\n   - **PIK3CA:** Implicated in survival due to its role in cell growth and survival pathways; inhibitors can positively influence outcomes.\n   - **ESR1 (estrogen receptor 1):** Mutations or expression levels affect hormonal therapy responsiveness, influencing survival outcomes based on hormonal manipulations.\n   - **CDH1:** Affects cell adhesion properties, with mutations leading to invasiveness and metastasis, negatively affecting survival if unchecked by intervention.\n   - **GATA3:** Mutations are related to differentiation and proliferation, influencing survival via interactions with hormonal pathways.\n\n2. **Biological Mechanism Impacts:**\n   - **Proliferation and Growth:** Genes like PIK3CA drive proliferation through growth signaling pathways.\n   - **Immune Response:** Alterations can create immune-evasive environments, leading to decreased survival if unchecked.\n   - **Apoptosis Regulation:** Loss of regulation from TP53 mutations results in unchecked cell survival and tumor growth.\n\n### Conclusion:\nThe survival of patients with breast invasive carcinoma is multifactorial, encompassing the tumor origin, histological characteristics, genetic mutation profiles, and inherent sampling biases in genomic analyses. Clinically, these factors guide personalized treatment interventions, underscoring the importance of early detection and targeted therapies in enhancing survival. The emergence of gene-specific therapies continues to transform the landscape, offering increased survival rates when genetic aberrations are precisely targeted. Understanding these dimensions provides a robust framework for prognostication and tailoring treatment to improve patient outcomes significantly."
        ],
        [
         "44",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Infiltrating duct carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n1. **Influence on Survival:**\n   - Breast NOS, specifically excluding the skin of the breast (ICD-10: Breast NOS), pertains to cancers arising from the breast tissue proper without cutaneous involvement. These tumors often follow a well-defined metastatic pattern, primarily disseminating to lymph nodes, bones, liver, and lungs. The survival rate is impacted by early metastasis, particularly when it involves vital organs like the liver and lungs.\n\n2. **Biological Rationale:**\n   - The propensity of these tumors to metastasize is partly due to the presence of lymphatic and vascular channels in breast tissue that facilitate dissemination. Additionally, tumor cell-microenvironment interactions, including those involving the extracellular matrix and growth factors, can enhance metastatic potential.\n\n3. **Treatment Accessibility:**\n   - Breast NOS cancers, especially at stages where spread is more localized, often benefit from targeted therapies (e.g., HER2 inhibitors in HER2-positive cancers), which has a significant positive impact on survival outcomes.\n\n### Histology\n\n1. **Influence on Survival:**\n   - Infiltrating duct carcinoma, NOS, the most common form of breast cancer histologically, carries variable prognostics based on its molecular subtype (e.g., luminal A, luminal B, HER2-positive, or triple-negative).\n\n2. **Biological Rationale:**\n   - Different subtypes exhibit distinct mutation profiles. For instance, luminal types often harbor hormone receptor mutations conducive to hormone therapy use, while triple-negative cancers lack these targets and thus have poorer outcomes and fewer treatment options.\n\n### Sampling Bias\n\n1. **Limitations:**\n   - Genomic analyses often focus on primary tumor samples or adjacent normal tissue. This can skew findings as metastatic lesions or microenvironmental influences (e.g., immune cell infiltration) crucial for understanding progression and treatment resistance might be missed.\n\n2. **Impact on Survival Studies:**\n   - This bias can lead to an incomplete picture, particularly in understanding the genetic evolution from primary to metastatic disease, which is vital for assessing treatment efficacy and developing new therapies.\n\n### Key Genes\n\n1. **Influence on Survival:**\n   - **TP53:** Tumor suppressor; mutations often lead to unchecked proliferation, contributing to poorer prognosis.\n   - **PIK3CA:** Alters proliferation and survival pathways; mutations are common and involved in treatment resistance.\n   - **BRCA1/2:** DNA repair genes; mutations result in high breast cancer risk but predict response to PARP inhibitors, influencing survival positively when treated appropriately.\n   - **HER2 (ERBB2):** Overexpression leads to aggressive disease but good response to targeted therapies like trastuzumab, enhancing survival rates.\n   - **ESR1:** Estrogen receptor gene; mutations confer hormone therapy resistance, affecting treatment outcomes.\n   - **PTEN:** Tumor suppressor involved in apoptosis; loss correlates with aggressive phenotypes and poorer survival.\n\n2. **Biological Mechanisms:**\n   - These genes impact cell cycle regulation, DNA damage repair, growth factor signaling, and apoptotic pathways. Their interactions shape tumor behavior, response to therapy, and ultimately, patient survival.\n\n### Conclusion\n\nBreast invasive carcinomas, particularly those categorized as Breast NOS, exhibit survival outcomes influenced by their metastatic behavior, histological subtype, and genetic landscape. Their prognosis is predominantly dictated by specific genetic aberrations and histological subtyping, which guide personalized treatment strategies. Sampling bias remains a challenge, often limiting the understanding of tumor evolution and resistance in heterogenous cancer presentations. Recognizing genes that drive proliferation, survival, and therapy response leads to refined therapeutic approaches, translating into improved patient survival, especially when these molecular insights inform evidence-based clinical decisions."
        ],
        [
         "45",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Intraductal papillary adenocarcinoma with invasion interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "## Tumor Origin: Breast NOS (Excludes Skin of breast C44.5)\n\n### Influence on Survival\n- **Positive/Negative:** The origin of the breast invasive carcinoma from breast tissue excluding the skin significantly affects survival based on its ability to metastasize to distant organs such as bone, liver, lungs, and brain. In general, breast cancers that metastasize beyond regional lymph nodes have poorer survival outcomes.\n- **Biological Rationale:** Breast NOS, classified under invasive ductal carcinoma, typically originates in the milk ducts, allowing for relatively straightforward access to lymphatic and vascular channels, promoting metastasis. This invasive nature can lead to more extensive disease with a higher likelihood of spreading, thus negatively impacting survival.\n- **Potential Biases:** Regional variations in healthcare accessibility and differences in the application of biopsy and imaging protocols can result in delayed diagnosis and treatment, further influencing survival rates across populations.\n\n## Histology: Intraductal Papillary Adenocarcinoma with Invasion\n\n### Influence on Survival\n- **Positive/Negative:** The histological classification of intraductal papillary adenocarcinoma with invasive components suggests an aggressive cancer phenotype associated with worse survival compared to non-invasive forms. However, responsiveness to targeted therapies dependent on specific mutation profiles can alter outcomes positively.\n- **Biological Rationale:** This histology features a mixture of papillary structures and invasive carcinoma, which can lead to heterogeneity in growth behavior and prognosis. Invasive growth denotes a more advanced disease stage, potentially resulting in poorer survival unless managed with effective treatment strategies.\n- **Potential Biases:** Misclassification or sampling errors can occur if pre-invasive elements dominate the sample, thus skewing pathological assessments and prognostications.\n\n## Sampling Bias: Blood Derived Normal, Primary Tumor\n\n### Influence on Survival\n- **Potential Impact:** Sampling biases can lead to incomplete genomic profiling, particularly if blood-derived normals are not representative of tumor-specific genetics or if primary tumor samples are inadequately resected.\n- **Biological Rationale:** In cancer genomic studies, utilizing blood-derived DNA as a normal comparator might not fully account for germline variations, leading to false assumptions about somatic mutations within the tumor tissue. Biopsies might not capture intratumoral heterogeneity, missing crucial mutations driving cancer progression.\n- **Potential Biases:** Limited tumor sampling can result in partial characterization of the genetic landscape, potentially missing actionable mutations which could inform targeted therapies, thereby negatively impacting survival outcomes.\n\n## Key Genes: Survival-Associated\n\n### Influence on Survival\n- **Genes Identified:**\n  1. **TP53:** This tumor suppressor gene, when mutated, loses its apoptosis regulation ability, resulting in unchecked cell proliferation and tumor progression, negatively impacting survival.\n  2. **PIK3CA:** Mutations here drive proliferation through the PI3K/AKT signaling pathway. While potentially negative due to resistance in traditional therapies, specific inhibitors can provide positive survival outcomes.\n  3. **BRCA1/2:** Critical in DNA repair; mutations here lead to genomic instability but are also targets for PARP inhibitors, improving survival in targeted patient subsets.\n  4. **HER2 (ERBB2):** Overexpression leads to aggressive growth; however, HER2-targeted therapies have significantly improved survival.\n  5. **CDH1:** Loss of this gene impacts cell adhesion, facilitating metastasis, negatively influencing survival.\n  6. **GATA3:** Mutations can impact differentiation and growth, with varying effects on prognosis depending on the broader mutation context.\n  7. **ESR1:** Estrogen receptor mutations affect hormone therapy susceptibility, directly influencing treatment efficacy and survival.\n  8. **CHEK2:** Involved in DNA damage response; mutations might increase susceptibility to cancer but can also be leveraged for therapeutic targeting.\n\n## Conclusion\n\nIn summary, survival in breast invasive carcinoma (ICD-10: Breast NOS, excluding skin) is heavily influenced by the original site of tumor development and its histological properties, impacting the metastatic capacity and treatment options available. Intratumoral heterogeneity and specific genetic profiles dictate potential therapy responsiveness, with precision medicine offering a pathway to improved survival outcomes. Identifying genetic mutations in key genes such as TP53, BRCA1/2, and HER2 provides critical insights into tumor behavior and potential therapeutic intervention points. Understanding these factors, while accounting for biases in genomic sampling and interpretation, is essential for optimizing clinical interventions and ultimately improving patient survival outcomes."
        ],
        [
         "46",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Invasive micropapillary carcinoma of breast interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin and Survival\n\n**Breast NOS Impact on Metastatic Patterns and Survival:**\n1. **Influence on Metastasis:**\n   - Breast NOS cancers, excluding skin-origin tumors, predominantly originate from ductal cells. These tumors tend to metastasize to lymph nodes, lungs, bones, liver, and brain.\n   - *Survival Impact:* Metastasis generally indicates advanced disease stages, resulting in lower survival rates. The patterns of metastasis directly affect prognosis.\n\n2. **Treatment Accessibility:**\n   - Diagnosis of Breast NOS includes a broad spectrum of subtypes, influencing treatment plans and approaches. Lack of specificity might delay tailored treatments.\n   - *Survival Impact:* Access to subtype-specific treatments, like HER2-targeted therapies, is crucial for improved survival â€” untreated or delayed treatment reduces prognosis.\n\n### Histology and Mutation Profiles\n\n**Invasive Micropapillary Carcinoma (IMPC) Interaction:**\n1. **Histological Traits:**\n   - IMPC is characterized by small clusters of cancer cells surrounded by fluid spaces, highly prone to lymphovascular invasion.\n   - *Survival Impact:* This histology often correlates with a higher rate of lymph node metastasis, leading to reduced overall survival.\n\n2. **Mutation Profiles:**\n   - Common mutations associated with IMPC include PIK3CA, TP53, and GATA3. These mutations influence cell proliferation and survival.\n   - *Survival Impact:* Alteration of pathways regulating apoptosis and cell cycle control leads to aggressive tumor behavior and impacts targeted therapeutic responses, affecting survival.\n\n### Sampling Bias in Genomic Analysis\n\n**Limitations of Blood Derived Normal, Primary Tumor:**\n1. **Bias in Normal Sample Usage:**\n   - Blood-derived normal samples might not effectively represent the genetic backgrounds of breast tissues.\n   - *Impact on Survival Predictions:* Could lead to misinterpretation of somatic vs. germline mutations, skewing risk profiles and therapeutic decisions.\n\n2. **Tumor Sample Representation:**\n   - Primary tumor samples may not encompass the heterogeneity seen in metastases.\n   - *Impact on Survival Predictions:* Fails to capture full genomic landscape, affecting treatment strategies and survival estimations.\n\n### Key Genes Influencing Survival\n\n1. **TP53:** Mutations lead to impaired DNA repair and apoptosis, fostering tumor progression.\n   - *Survival Impact:* Generally negative, as loss of function correlates with aggressive disease.\n\n2. **BRCA1/2:** Involvement in DNA damage repair.\n   - *Survival Impact:* Mutations associate with increased risk but targeted PARP inhibitors can improve outcomes.\n\n3. **PIK3CA:** Affects cellular growth pathways.\n   - *Survival Impact:* Mutations suggest targeted therapy opportunities, potentially improving outcomes.\n\n4. **HER2:** Involves cell growth and differentiation.\n   - *Survival Impact:* Overexpression correlates with poor prognosis but responsive to targeted therapies (e.g., trastuzumab).\n\n5. **GATA3:** Impacts differentiation and development of luminal cells.\n   - *Survival Impact:* Mutations could disrupt differentiation, but generally linked to better prognoses in luminal breast cancers.\n\n6. **CDH1:** Encodes E-cadherin, crucial for cell adhesion.\n   - *Survival Impact:* Loss can facilitate invasion and metastasis, negatively influencing survival.\n\n7. **MYC:** Regulator of growth and apoptosis.\n   - *Survival Impact:* Amplification leads to unchecked growth, often associated with worse outcomes.\n\n### Synthesis of Key Survival Risk Factors\n\nThe major survival determinants in breast invasive carcinoma encompass tumor origin specificity, histological subtype, genetic mutation profiles, and sampling biases impacting genomic interpretation. Tumor-specific treatments, understanding of histological aggressiveness, and accurate genetic profiling are pivotal. Clinically, ensuring precise diagnosis and tailored therapies based on genomic insights, while considering sample limitations, can markedly affect survival, underscoring the need for precision oncology in improving patient outcomes."
        ],
        [
         "47",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Medullary carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n**Influence on Survival**:  \nBreast invasive carcinoma, classified under Breast NOS (not otherwise specified), does not cover specific histological subtypes like skin-originated tumors. This makes its metastatic pattern crucial as it commonly metastasizes to the bone, liver, and brain, affecting survival negatively. Early detection and treatment accessibility vary significantly based on geographical, socioeconomic, and healthcare factors.\n\n**Biological Rationale**:  \nThe breast microenvironment supports cancer cell dissemination through complex interactions among stromal and epithelial components, leading to the establishment of secondary tumors in targeted organs.\n\n**Potential Biases**:  \nThis broad classification may overlook subtype-specific management strategies, thereby potentially underestimating survival variability across different histological subtypes.\n\n### Histology\n\n**Influence on Survival**:  \nMedullary carcinoma, NOS, typically exhibits a better prognosis than other subtypes due to its association with a prominent lymphocytic infiltration, indicative of a robust immune response.\n\n**Biological Rationale**:  \nTumors characterized as medullary in nature often show specific genetic profiles, such as overexpression of BRCA mutations, which while typically being aggressive, in the medullary context, seem to elicit a stronger immune-mediated elimination of cancer cells.\n\n**Potential Biases**:  \nHistological classification can miss nuances in individual mutational landscapes, failing to capture heterogeneity. Medullary carcinoma cases in real-world settings may be misclassified due to overlapping characteristics with other subtypes.\n\n### Sampling Bias\n\n**Influence on Genomic Analysis**:  \nThe reliance on Blood Derived Normal, Primary Tumor samples introduces biases as it may not accurately represent the mutational landscape of metastases or recurrence, which are critical to survival outcomes.\n\n**Biological Rationale**:  \nBlood-derived samples predominantly capture germline mutations or highly prevalent hematological markers, missing tumor-specific mutations that occur post-diagnosis or during metastasis. This can obscure the detection of key dynamic changes in tumor biology.\n\n**Potential Biases**:  \nGenomic analyses may overlook intra-tumor heterogeneity and temporal changes in mutation profiles, reducing the precision of survival predictions and targeted therapies.\n\n### Key Genes\n\n1. **TP53**: Mutation prevalence leads to poor survival due to loss of its role in DNA repair and apoptosis.\n2. **BRCA1/2**: Germline mutations affect DNA repair mechanisms; however, therapeutic options like PARP inhibitors provide targeted treatment, improving survival in some contexts.\n3. **PIK3CA**: Frequently mutated, contributing to oncogenic signaling pathways enhancing proliferation; inhibitors can mitigate negative impacts on survival.\n4. **ERBB2 (HER2)**: Overexpression is associated with aggressive disease; however, targeted therapies like trastuzumab improve outcomes.\n5. **PTEN**: Loss of function impacts growth regulation; its status helps in therapeutic stratification.\n6. **CDH1**: Mutation inactivates cell adhesion, promoting metastasis, negatively influencing survival.\n7. **PD-L1**: Overexpression leads to immune escape; immune checkpoint inhibitors can reverse this, offering better survival.\n\n### Synthesis of Key Survival Risk Factors\n\nThe interplay between tumor origin, histology, genetic mutations, and sampling strategies crucially determines survival outcomes in breast invasive carcinoma. Histological characterization combined with precise genetic profiling can guide targeted therapies, improving patient prognoses. However, sampling biases in genomic interpretations must be diligently addressed to ensure accurate survival predictions. Advancements in genomic technologies and personalized medicine approaches are pivotal in refining these assessments, translating into more effective, individualized patient care strategies. Increasing accessibility to innovative treatments and acknowledging tumor heterogeneity remain central to optimizing survival across patient populations."
        ],
        [
         "48",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Medullary carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n1. **Breast NOS (excludes Skin of breast C44.5) and Metastatic Patterns**: \n   - **Influence on Survival**: The origin of the breast tumor significantly impacts metastatic patterns, influencing patient survival. Breast NOS typically refers to invasive ductal carcinoma, which is prone to metastasizing to the bones, lungs, liver, and brain.\n   - **Biological Rationale**: The high propensity of ductal carcinoma cells to infiltrate surrounding tissue and enter systemic circulation facilitates distant metastases, thereby reducing survival rates. This is attributed to their ability to evade local tissue barriers and migrate, a process often enhanced by epithelial-to-mesenchymal transition (EMT).\n   - **Treatment Accessibility**: Early-stage detection improves access to curative treatments, including surgery, chemotherapy, and radiation. However, metastasis complicates treatment, often requiring systemic therapies with more limited efficacy.\n\n2. **Histology: Medullary Carcinoma, NOS and Mutation Profiles**:\n   - **Influence on Survival**: Medullary carcinoma is associated with a more favorable prognosis compared to other invasive types, often attributed to its unique histological features and immune cell presence.\n   - **Biological Rationale**: These tumors demonstrate a syncytial growth pattern with high lymphocytic infiltration, suggesting robust immune surveillance. This histology is frequently associated with BRCA1 mutations, which predict better response to DNA-damaging chemotherapies.\n   - **Interaction with Mutation Profiles**: The mutation profile of medullary carcinoma, often marked by a high mutation burden, may enhance neoantigen presentation, improving immune response and survival outcomes.\n\n### Sampling Bias\n\n- **Limitations of Primary Tumor vs. Solid Tissue Normal**:\n  - **Influence on Genomic Interpretation**: Sampling biases can skew our understanding of the tumor's genomic landscape. Primary tumors and solid tissue normals may not capture intratumor heterogeneity or subclonal populations that drive metastasis and treatment resistance.\n  - **Biological Rationale**: Genomic analyses often miss rare cell populations within the tumor that could be critical for metastasis or treatment resistance. Solid tissue normal samples may not accurately reflect the tumor microenvironment or immune contexture.\n  - **Bias Implication**: This can lead to an underestimation of the aggressive or stem-like cell populations within the tumor, which can impact prognosis and treatment strategies.\n\n### Key Genes\n\n1. **TP53**: Often mutated in breast cancer, contributing to genomic instability and resistance to apoptosis, negatively impacting survival.\n2. **BRCA1/2**: Germline mutations in these genes lead to defective DNA repair mechanisms. While they are associated with an increased predisposition to cancer, they can also predict better responses to platinum-based therapies and PARP inhibitors, potentially prolonging survival.\n3. **PIK3CA**: Mutations in this gene promote oncogenic signaling through the PI3K/AKT/mTOR pathway, affecting cell proliferation. Targeted therapies can improve outcomes in affected patients.\n4. **HER2**: Amplification leads to aggressive tumor growth, but targeted therapies (e.g., trastuzumab) have significantly improved survival outcomes.\n5. **ER (Estrogen Receptor)**: ER-positive tumors tend to have a better prognosis with hormone therapy becoming a mainstay treatment, enhancing survival.\n6. **CDH1 (E-cadherin)**: Mutations can lead to loss of cell adhesion and increased invasiveness, reducing survival; however, these mutations are less common in ductal cancers compared to lobular variants.\n7. **PD-L1**: Expression is associated with immune evasion but can also identify patients eligible for immune checkpoint inhibitors, potentially improving survival.\n8. **GATA3**: This transcription factor is involved in maintaining the differentiated state of luminal cells and is often mutated in ER-positive cancers, influencing response to endocrine therapies.\n\n### Conclusion\n\nKey determinants of survival in breast cancer include the tumor's origin, histological subtype, and specific genetic mutations. Tumor origin influences metastatic spread and treatment options, with histology impacting immune response and predictive treatment profiles. Genetic mutations, particularly in genes like TP53, BRCA1/2, and HER2, significantly impact prognosis and therapeutic strategies.\n\nAn understanding of these factors helps tailor treatment to individual tumor biology, potentially improving outcomes. However, sampling biases must be accounted for in genomic studies to ensure comprehensive and accurate representation of tumor biology. Clinical insights derived from integrating these factors emphasize personalized treatment approaches to improve survival in breast cancer patients."
        ],
        [
         "49",
         "\nresponse = client.chat.completions.create(\n  model=\"gpt-4o\",\n  messages=[\n    {\n      \"role\": \"system\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n        }\n      ]\n    },\n    {\n      \"role\": \"user\",\n      \"content\": [\n        {\n          \"type\": \"text\",\n          \"text\": \"Describe how Breast invasive carcinoma (per ICD-10: Breast NOS (excludes Skin of breast C44.5)) impacts survival, focusing on:\n- Tumor Origin: How Breast NOS (excludes Skin of breast C44.5) influences metastatic patterns, patient survival, and treatment accessibility.\n- Histology: How Lobular carcinoma, NOS interacts with mutation profiles to drive outcomes.\n- Sampling Bias: Limitations of Blood Derived Normal, Metastatic in genomic analysis.\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n\nFor each aspect, explain step by step:\n- How it influences survival (positive/negative)\n- Biological rationale without excessive jargon\n- Potential biases in genomic interpretation\n\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n        }\n      ]\n    }\n  ],\n  response_format={ \"type\": \"text\" },\n  temperature=1,\n  max_completion_tokens=2048,\n  top_p=1,\n  frequency_penalty=0,\n  presence_penalty=0\n)\n",
         "### Tumor Origin\n\n**Influence on Survival:**\n- Breast invasive carcinoma, specifically Breast NOS (excluding skin of breast C44.5), can metastasize to lymph nodes, bone, liver, and lungs. These patterns are critical as they determine the stage at diagnosis and dictate treatment complexity, directly impacting survival rates negatively if metastasis is extensive.\n\n**Biological Rationale:**\n- The tumor originates from the epithelial cells of the breast ducts or lobules, characterized by invasive behavior due to disruptions in cell adhesion molecules like E-cadherin. This disruption allows tumor cells to detach and invade surrounding tissues, contributing to their metastatic potential.\n\n**Genomic Interpretation Bias:**\n- When assessing genomic data, tumors categorized under Breast NOS might mask specific histological subtypes, resulting in potential overgeneralization in survival estimations.\n\n### Histology - Lobular Carcinoma, NOS\n\n**Influence on Survival:**\n- Lobular carcinoma is often distinctive in its growth patterns, exhibiting a \"single-file\" invasion mechanism. This complicates early detection and often leads to a later stage diagnosis, potentially reducing survival time.\n\n**Interaction with Mutation Profiles:**\n- Common mutations found in lobular carcinoma include CDH1 (E-cadherin) mutations which reduce cell-cell adhesion, and alterations in genes like PIK3CA, driving oncogenic signaling pathways. These genetic mutations influence responsiveness to certain therapies, affecting outcomes markedly.\n\n**Genomic Interpretation Bias:**\n- Lack of clear subtype classification might lead to underrepresentation of lobular carcinoma in data cohorts, skewing specific survival-related prognostic insights.\n\n### Sampling Bias - Blood Derived Normal, Metastatic\n\n**Limitations in Analysis:**\n- Utilizing blood-derived normal samples versus tumor tissue can lead to misinterpretation, as peripheral blood lacks the tumor-specific mutational landscape. Furthermore, metastatic site sampling may not represent the heterogeneity of the primary tumor.\n\n**Influence on Survival Prediction:**\n- Biases might skew mutation frequency data, leading to erroneous risk stratification models, ultimately affecting clinical management strategies.\n\n### Key Genes Associated with Survival\n\n1. **TP53**: Mutations lead to loss of cell cycle control and apoptotic pathways, worsening prognosis.\n   \n2. **BRCA1/BRCA2**: Alterations in these genes hinder DNA repair, fostering genomic instability and aggressive tumor phenotypes.\n\n3. **PIK3CA**: Involved in the PI3K/AKT pathway, driving cell proliferation; mutations may predict resistance to hormone therapies, impacting survival negatively.\n\n4. **HER2/ERBB2**: Amplification results in aggressive tumor growth but also indicates responsiveness to targeted therapies like trastuzumab, which can improve survival.\n\n5. **PTEN**: Loss or mutation in PTEN leads to unchecked PI3K pathway activation, contributing to tumor aggressiveness and poor survival.\n\n6. **AKT1**: Oncogenic mutations promote survival signals, enhancing resistance to apoptosis and potentially unfavorable survival outcomes.\n\n7. **CDH1**: Mutations disrupt cell adhesion, aiding metastasis particularly in lobular carcinoma, reducing survival rates.\n\n**Biological Mechanisms:**\n- These genes contribute to survival through pathways influencing cellular proliferation, apoptosis, repair fidelity, and metastatic capability, each modulated by specific alterations in their function or expression level.\n\n### Synthesis of Key Survival Risk Factors\n\nIn conclusion, survival in breast invasive carcinoma is intricately linked to the tumor's origin, histological type, and molecular characteristics. Understanding the tumor's histological subtype such as lobular carcinoma can inform targeted therapeutic approaches. Recognizing genomic biases, such as those associated with sampling methods, is crucial for accurate risk stratification. Identifying survival-associated genes and their pathways can help customize patient care, offering therapeutic targets and prognostic indicators crucial for improving patient outcomes. The clinical integration of these insights, underpinned by a precision oncology approach, holds the potential to markedly enhance survival prospects by tailoring interventions to individual genetic landscapes."
        ]
       ],
       "shape": {
        "columns": 2,
        "rows": 715
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>prompt</th>\n",
       "      <th>response</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>### Tumor Origin: Adrenocortical Carcinoma\\n\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>**Adrenocortical Carcinoma (ACC) and Survival ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>To understand the survival impact of Bladder U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>### Tumor Origin: Trigone of the Bladder\\n\\n1....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>1. **Tumor Origin:**\\n   - **Influences on Sur...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>### Tumor Origin: Endometrium\\n\\n**Influence o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>712</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>### Uterine Carcinosarcoma and Survival Impact...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>713</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>### Tumor Origin: Influence of Fundus Uteri on...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>714</th>\n",
       "      <td>\\nresponse = client.chat.completions.create(\\n...</td>\n",
       "      <td>## Tumor Origin: Uterus NOS and Its Influence ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>715 rows Ã— 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                prompt  \\\n",
       "0    \\nresponse = client.chat.completions.create(\\n...   \n",
       "1    \\nresponse = client.chat.completions.create(\\n...   \n",
       "2    \\nresponse = client.chat.completions.create(\\n...   \n",
       "3    \\nresponse = client.chat.completions.create(\\n...   \n",
       "4    \\nresponse = client.chat.completions.create(\\n...   \n",
       "..                                                 ...   \n",
       "710  \\nresponse = client.chat.completions.create(\\n...   \n",
       "711  \\nresponse = client.chat.completions.create(\\n...   \n",
       "712  \\nresponse = client.chat.completions.create(\\n...   \n",
       "713  \\nresponse = client.chat.completions.create(\\n...   \n",
       "714  \\nresponse = client.chat.completions.create(\\n...   \n",
       "\n",
       "                                              response  \n",
       "0    ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "1    ### Tumor Origin: Adrenocortical Carcinoma\\n\\n...  \n",
       "2    **Adrenocortical Carcinoma (ACC) and Survival ...  \n",
       "3    To understand the survival impact of Bladder U...  \n",
       "4    ### Tumor Origin: Trigone of the Bladder\\n\\n1....  \n",
       "..                                                 ...  \n",
       "710  1. **Tumor Origin:**\\n   - **Influences on Sur...  \n",
       "711  ### Tumor Origin: Endometrium\\n\\n**Influence o...  \n",
       "712  ### Uterine Carcinosarcoma and Survival Impact...  \n",
       "713  ### Tumor Origin: Influence of Fundus Uteri on...  \n",
       "714  ## Tumor Origin: Uterus NOS and Its Influence ...  \n",
       "\n",
       "[715 rows x 2 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Added 'Normalized_Sample_Type' column to description_meta.\n"
     ]
    }
   ],
   "source": [
    "if \"Normalized_Sample_Type\" not in description_meta.columns:\n",
    "    normalized_values = []\n",
    "    for idx, row in df_responses.iterrows():\n",
    "        details = extract_details(row[\"prompt\"])\n",
    "        normalized_values.append(details[\"Normalized_Sample_Type\"])\n",
    "    description_meta[\"Normalized_Sample_Type\"] = normalized_values\n",
    "    print(\"Added 'Normalized_Sample_Type' column to description_meta.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Row 0:\n",
      "  CANCER_TYPE_NAME matches.\n",
      "  ICD_10_desc matches.\n",
      "  ICD_O_3_SITE_desc matches.\n",
      "  MISMATCH in ICD_O_3_HISTOLOGY_desc: dataframe has 'None' vs prompt extracted 'UNKOWN'\n",
      "  Normalized_Sample_Type matches.\n",
      "----------------------------------------\n",
      "Row 1:\n",
      "  CANCER_TYPE_NAME matches.\n",
      "  ICD_10_desc matches.\n",
      "  ICD_O_3_SITE_desc matches.\n",
      "  ICD_O_3_HISTOLOGY_desc matches.\n",
      "  Normalized_Sample_Type matches.\n",
      "----------------------------------------\n",
      "Row 2:\n",
      "  CANCER_TYPE_NAME matches.\n",
      "  ICD_10_desc matches.\n",
      "  ICD_O_3_SITE_desc matches.\n",
      "  ICD_O_3_HISTOLOGY_desc matches.\n",
      "  Normalized_Sample_Type matches.\n",
      "----------------------------------------\n"
     ]
    }
   ],
   "source": [
    "n_check = min(3, len(df_responses))\n",
    "for i in range(n_check):\n",
    "    prompt = df_responses.loc[i, \"prompt\"]\n",
    "    extracted = extract_details(prompt)\n",
    "    original_row = description_meta.iloc[i]\n",
    "    print(f\"Row {i}:\")\n",
    "    for key, val in extracted.items():\n",
    "        if key in description_meta.columns:\n",
    "            original_val = str(original_row[key]).strip()\n",
    "            if original_val != val:\n",
    "                print(f\"  MISMATCH in {key}: dataframe has '{original_val}' vs prompt extracted '{val}'\")\n",
    "            else:\n",
    "                print(f\"  {key} matches.\")\n",
    "        else:\n",
    "            print(f\"  Column '{key}' not found in description_meta!\")\n",
    "    print(\"-\" * 40)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Updated description_meta saved successfully.\n"
     ]
    }
   ],
   "source": [
    "description_meta[\"generated_description\"] = df_responses[\"response\"].values\n",
    "\n",
    "# Save the updated dataframe back to the parquet file\n",
    "description_meta.to_parquet(\n",
    "    \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description/description_meta_with_answers.parquet\",\n",
    "    index=False\n",
    ")\n",
    "description_meta.to_parquet(\n",
    "    \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description/description_meta.parquet\",\n",
    "    index=False\n",
    ")\n",
    "print(\"Updated description_meta saved successfully.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "CANCER_TYPE_NAME",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized_Sample_Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "generated_description",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "9465f003-4da6-4612-8996-6c0b7facbcd3",
       "rows": [
        [
         "0",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA-OR-A5KS, TCGA-OR-A5L2",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         null,
         "Adrenocortical carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin\n\n**Influence on Survival:**\n1. **Metastatic Patterns and Patient Survival:**\n   - Adrenocortical carcinoma (ACC) originates in the adrenal cortex, which is a primary endocrine organ involved in hormone production. Its location and function influence its potential for substantial metastasis, often to the liver, lungs, and regional lymph nodes.\n   - **Impact on Survival:** The propensity for early metastatic spread significantly worsens the prognosis, often leading to decreased survival times.\n\n2. **Treatment Accessibility:**\n   - Surgical resection is often the most effective treatment, but ACC's capacity for metastasis can make complete surgical removal challenging, limiting treatment options primarily to systemic therapies such as mitotane, chemotherapy, or emerging targeted therapies.\n\n**Biological Rationale:**\n- The endocrine activity of the adrenal cortex, releasing hormones that can promote tumor growth and metastasis, directly correlates with aggressive disease progression.\n\n### Histology\n\n**Influence on Survival:**\n1. **Histological Characteristics:**\n   - While you mentioned \"UNKNOWN,\" I assume examining histological variants is essential. ACC typically lacks distinct histological subtypes but may vary significantly in cellular differentiation and necrosis.\n   - **Impact on Survival:** Poorly differentiated histological features often correlate with aggressive clinical behavior and worse outcomes.\n\n**Biological Rationale:**\n- The variability in cell differentiation affects the tumor's responsiveness to treatment and its intrinsic growth rate, impacting survival.\n\n### Sampling Bias\n\n**Influence on Survival:**\n1. **Limitations from Sampling:**\n   - Relying on blood-derived normals or primary tumors can obscure the heterogeneity inherent in ACC.\n   - **Impact on Survival:** This can result in incomplete genomic analyses, potentially missing key mutations or pathways active in metastatic sites.\n\n**Biological Rationale:**\n- Genomic comparisons using inadequate reference samples may not capture the full landscape of driver mutations or resistance mechanisms critical for patient-specific treatment plans.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **Survival-Associated Genes:**\n   - **TP53:** Mutations in TP53 can lead to evasion of apoptosis and unchecked cellular proliferation.\n   - **CTNNB1:** Alterations in the WNT/Î²-catenin signaling pathway can drive tumor growth and metastasis.\n   - **RB1:** Regulates the cell cycle; mutations can lead to loss of cell cycle control.\n   - **MEN1:** Involved in genomic stability; mutations disrupt endocrine pathways.\n   - **IGF2:** Overexpression can promote mitogenic and anti-apoptotic effects.\n   - **PRKAR1A:** Alterations can affect hormone signaling pathways, driving tumorigenesis.\n\n**Biological Mechanisms and Impact:**\n- Each gene alters cellular processes such as proliferation, apoptosis, and hormonal signaling, aggravating the aggressive nature of ACC and impacting overall survival negatively.\n\n### Conclusion Synthesis\n\n**Key Survival Risk Factors:**\n- *Origin and Metastasis:* The endocrine origin predisposes early metastatic spread, a crucial factor in poor prognosis.\n- *Histological Variability:* Lacking distinct subtypes but demonstrating varying differentiation impacts treatment responses.\n- *Genomic Insights and Sampling Biases:* Comprehensive genomic profiling is essential, yet limited significantly by current sampling practices.\n- *Genomic Targets:* Key mutations in genes such as TP53 and CTNNB1 exemplify crucial therapeutic targets but require individualized treatment strategies due to the tumor's complexity.\n\n**Clinically Relevant Insights:**\n- An integrated approach considering both the unique genetic and histological features of ACC, as well as the potential biases in current genomic interpretations, is essential for developing effective treatment strategies.\n- Enhanced genomic analysis and improved understanding of metastatic mechanisms can significantly alter treatment paradigms, potentially leading to tailored, effective interventions improving patient survival rates."
        ],
        [
         "1",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA-OR-A5K6, TCGA-OR-A5LO, TCGA-OR-A5JY, TCGA-OR-A5JV, TCGA-OR-A5K3, TCGA-OR-A5KO, TCGA-OR-A5K0, TCGA-OR-A5J6, TCGA-OR-A5LC, TCGA-OR-A5LA, TCGA-OR-A5LG, TCGA-OR-A5LB, TCGA-OR-A5JM, TCGA-OR-A5KQ, TCGA-OR-A5JD, TCGA-P6-A5OF, TCGA-PK-A5HA, TCGA-OR-A5KY, TCGA-OR-A5L4, TCGA-OR-A5J9, TCGA-OR-A5JS, TCGA-PK-A5H9, TCGA-OR-A5JJ, TCGA-OR-A5JI, TCGA-OR-A5JF, TCGA-OR-A5LF, TCGA-OR-A5JH, TCGA-OR-A5JU, TCGA-OR-A5JL, TCGA-OR-A5KP, TCGA-OR-A5JO, TCGA-OR-A5K8, TCGA-OR-A5LN, TCGA-OR-A5KX, TCGA-OR-A5KW, TCGA-OR-A5L8, TCGA-OR-A5JW, TCGA-OR-A5JK, TCGA-OR-A5LR, TCGA-OR-A5JZ, TCGA-OU-A5PI, TCGA-OR-A5LD, TCGA-OR-A5JE, TCGA-OR-A5LH, TCGA-OR-A5K5, TCGA-OR-A5LJ, TCGA-OR-A5LL, TCGA-OR-A5JX, TCGA-OR-A5JQ, TCGA-PA-A5YG, TCGA-PK-A5H8, TCGA-OR-A5J4, TCGA-OR-A5J2, TCGA-OR-A5JG, TCGA-OR-A5J5, TCGA-OR-A5JT, TCGA-OR-A5LK, TCGA-OR-A5JB, TCGA-OR-A5KT, TCGA-OR-A5J3, TCGA-OR-A5L6, TCGA-OR-A5LS, TCGA-OR-A5LP, TCGA-OR-A5K1, TCGA-OR-A5LI, TCGA-OR-A5L1, TCGA-OR-A5J7, TCGA-OR-A5LT, TCGA-OR-A5L5, TCGA-OR-A5JR, TCGA-OR-A5K2, TCGA-OR-A5K4, TCGA-OR-A5KZ, TCGA-OR-A5JC, TCGA-OR-A5L3, TCGA-OR-A5LE",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Adrenocortical Carcinoma\n\n#### Influence on Survival\n- **Positive/Negative Impact**: Adrenocortical carcinoma (ACC) originates from the adrenal cortex, which inherently possesses high hormonal activity and metabolic roles. This origin limits early detection due to deep anatomical positioning and contributes to an initially advanced stage upon diagnosis, negatively impacting survival. \n- **Biological Rationale**: The adrenal glands are involved in cortisol and aldosterone production. Tumorigenesis disrupts endocrine balance, often resulting in paraneoplastic syndromes, which complicates the clinical picture. This dysfunction supports aggressive tumor growth and facilitates metastatic potential, especially to the liver and lungs, worsening prognosis.\n- **Treatment Accessibility**: The location and function of the adrenal gland influence surgical resectability and sensitivity to systemic therapies, with mitotane being the mainstay. Advanced interventions are often required but are less accessible, particularly in metastatic phases.\n\n### Histology\n\n#### Influence on Survival\n- **Interaction with Mutation Profiles**: Histologically, ACCs exhibit heterogeneously aggressive features. High-grade tumors coupled with frequent mutations in genes such as TP53 lead to genomic instability.\n- **Biological Rationale**: Poor cellular differentiation and pleomorphic cells indicate rapid growth and high metastatic potential, facilitating immune evasion and resistance mechanisms.\n- **Negative Impact**: This histological aggressiveness correlates with poor response to conventional chemotherapies, contributing to lower survival rates.\n\n### Sampling Bias: Limitations of Genomic Analysis\n\n#### Blood Derived Normal vs. Primary Tumor\n- **Biological Rationale**: Using blood-derived normal samples as a control can miss somatic mutations occurring specifically in the tumor microenvironment, leading to an incomplete understanding of cancer genomics.\n- **Limitations**: Primary tumor samples might not capture the full extent of intratumoral heterogeneity. Sampling might miss subclonal populations, causing a bias in therapeutic target identification, and potentially skewing survival projections.\n\n### Key Genes and Survival\n\n#### Genes Involved\n1. **TP53**: Tumor suppressor often mutated in ACC. Loss of function leads to unchecked proliferation and genomic instability.\n2. **CTNNB1**: Aberrant activation of beta-catenin signaling fosters tumor growth and invasion.\n3. **IGF2**: Overexpression seen in ACC reinforces autocrine growth stimulation, promoting tumor development.\n4. **MDM2**: This oncogene amplifies further disruption of p53 pathways, accelerating tumor progression.\n5. **TERT**: Mutations in telomerase reverse transcriptase sustain cellular immortality, aiding metastasis.\n6. **RB1**: Disrupted function removes critical cell cycle checks, allowing unchecked division.\n7. **PRKAR1A**: Loss can deregulate cyclic AMP pathways, impacting cellular growth control mechanisms.\n8. **MEN1**: Mutated in some ACCs, impacting protein-protein interactions essential for cellular homeostasis and longevity.\n\n#### Influence on Survival\n- **Mechanisms**: These genes typically manage proliferation, apoptosis, and genomic integrity. When mutated, they create survival advantages for tumor cells, overwhelming host defenses and treatments.\n- **Negative Impact**: Their dysregulation not only drives malignancy but also creates formidable barriers to effective therapeutic intervention.\n\n### Conclusion: Key Survival Risk Factors\n\n#### Synthesis\n- **Key Insights**: The combination of aggressive tumor origin, deleterious mutations, sampling biases, and high-risk gene profiles create a multifaceted threat to survival. ACC often remains refractory to existing treatments owing to these complex biological interactions.\n- **Clinical Implications**: Incorporating a deeper understanding of ACCâ€™s genomic landscape could refine prognostic models and guide precision medicine applications. This would likely enhance personalized treatment plans and improve survival outcomes, emphasizing the necessity for vigilant genetic screenings and innovative therapeutic strategies.\n\nUltimately, advancements in capturing the comprehensive genetic signature of adrenocortical carcinoma are paramount in shifting survival curves favorably."
        ],
        [
         "2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA-P6-A5OH, TCGA-OR-A5K9",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "**Adrenocortical Carcinoma (ACC) and Survival Impact: A Detailed Analysis**\n\n**1. Tumor Origin**\n- **Impact on Survival:** The adrenal gland cortex is crucial in producing steroid hormones, and tumors here are known for aggressive behavior and a high propensity for early metastasis, often to the liver, lungs, and retroperitoneum. This widespread metastatic pattern significantly reduces survival rates, often resulting in median survival being less than five years for advanced cases.\n- **Biological Rationale:** The adrenal gland's hormone secretion capability can drive tumor growth and dissemination. Tumors can produce excess cortisol, leading to Cushingâ€™s syndrome, which affects overall prognosis negatively by further complicating the systemic health.\n- **Bias in Interpretation:** Accessibility to the adrenal gland is challenging, which can limit surgical resection options. This can bias the understanding of tumor biology as fewer tissue samples from metastatic sites might be obtained for comprehensive genomic profiling.\n\n**2. Histology**\n- **Impact on Survival:** ACC histology shows variable differentiation, ranging from well-differentiated (better prognosis) to poorly differentiated (worse prognosis) tumors. The presence of necrosis, invasion into surrounding tissues, and vascular invasion in histological samples are bad prognostic indicators.\n- **Biological Rationale:** Poor differentiation correlates with higher proliferative indices and aggressive phenotypes. Histological analysis often aligns with genetic instability and aneuploidy, correlating with poorer outcomes.\n- **Potential Biases:** Histological analyses often depend on the quality and quantity of biopsy samples, which might miss heterogeneity within the tumor, leading to underestimation of aggressive subclones that drive poorer outcomes.\n\n**3. Sampling Bias**\n- **Influence on Survival Interpretation:** Sampling biases occur when genomic data is derived only from primary tumors or non-malignant tissue, potentially missing metastatic or more aggressive tumor subpopulations. This affects survival analysis as metastatic traits may not be fully represented.\n- **Biological Rationale:** Primary tumors may not exhibit the full spectrum of mutational changes present in metastatic lesions, which can lead to less informed treatment decisions impacting survival negatively.\n- **Bias in Genomic Interpretation:** Reliance on primary tumor biopsies risks missing key mutations and evolutionary adaptations present in metastatic sites. This underscores the need for comprehensive sampling to inform prognosis accurately.\n\n**4. Key Genes Associated with Survival**\n- **Impact on Survival:** The following genes are crucial in influencing ACC outcomes:\n\n  - **TP53:** Commonly mutated in ACC, leading to loss of tumor suppressor function and unchecked cellular proliferation.\n  - **CTNNB1:** Alterations in the Wnt/Î²-catenin pathway can lead to increased cellular proliferation and dedifferentiation.\n  - **MEN1:** Mutation of this gene is linked with endocrine tumors, influencing survival via altered cell cycle and proliferation.\n  - **IGF2:** Overexpression can activate pathways that promote tumor growth and survival, impacting overall prognosis negatively.\n  - **ZNRF3:** Its loss enhances Wnt signaling, augmenting tumor aggressiveness.\n  - **TERT:** Mutations often result in increased telomerase activity, permitting unlimited cellular replication.\n  - **RB1:** Loss of function in this gene affects cell cycle regulation, enhancing proliferation rates.\n  - **SF1:** Overexpression is associated with worse prognosis, as it drives steroidogenic dysregulation.\n\n- **Biological Mechanisms:** These genes are involved in crucial pathways such as apoptosis regulation, cell cycle control, and hormonal regulation, directly impacting tumor behavior and resistance to treatment.\n\n**Synthesis and Clinically Relevant Insights:**\nSurvival in ACC is heavily influenced by both innate biological features and treatment access hindered by anatomical location. Tumor genomics offer insights into aggressive behavior and potential therapeutic targets but require careful interpretation due to sampling biases. Understanding histological differentiation and integrating comprehensive genomic profiling are vital in tailoring management strategies to improve patient outcomes. Continued research in comprehensive, multi-site genetic analysis and more effective systemic therapies is crucial for enhancing survival rates in ACC patients."
        ],
        [
         "3",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA-FD-A6TE, TCGA-K4-A6MB, TCGA-BT-A2LD, TCGA-DK-AA6T, TCGA-FD-A3SS, TCGA-FD-A6TH, TCGA-FD-A5BV, TCGA-E7-A7DU, TCGA-FD-A3SN, TCGA-K4-A5RH, TCGA-DK-A6AW, TCGA-GC-A3RD, TCGA-KQ-A41P",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "To understand the survival impact of Bladder Urothelial Carcinoma, particularly originating in the trigone of the bladder, we need to systematically assess each relevant aspect.\n\n### Tumor Origin: Trigone, Bladder\n1. **Influence on Metastatic Patterns and Survival:**\n   - **Anatomical Considerations:** The bladder trigone's anatomical location, bordered by the ureters and urethral orifice, potentially facilitates early dissemination of cancer cells through the urinary system. This can lead to early metastasis to nearby lymph nodes and organs, negatively impacting survival.\n   - **Survival Impact:** Tumors in the trigone often present at a more advanced stage as early symptoms might be mistaken for benign conditions, delaying diagnosis and treatment.\n   - **Treatment Accessibility:** Surgical approaches can be more complex due to proximity to critical structures, sometimes limiting resection margins.\n\n2. **Biological Rationale:** The proximity to vascular and lymphatic channels can facilitate hematogenous and lymphatic spread, accounting for reduced survival.\n\n3. **Potential Biases:** Registry data might underreport trigone-specific outcomes, leading to underappreciation of its distinct survival challenges.\n\n### Histology: Transitional Cell Carcinoma, NOS\n1. **Mutation Profiles and Outcomes:**\n   - **Genetic Landscape:** Transitional cell carcinoma (TCC) frequently exhibits mutations in genes like TP53, FGFR3, and RB1. TP53 mutations disrupt apoptosis, allowing survival of damaged cells, while FGFR3 mutations can promote proliferation.\n   - **Survival Outcomes:** Generally, TP53 mutations are associated with high-grade, aggressive tumors and poorer survival, whereas FGFR3 mutations might indicate lower-grade tumors with better prognosis.\n\n2. **Biological Rationale:** Aberrant cell signaling due to these mutations contributes to unchecked cell proliferation and impaired cell death, crucial factors in disease progression.\n\n3. **Potential Biases:** Studies often underrepresent low-grade tumors, skewing understanding of mutation impact on survival.\n\n### Sampling Bias: Blood Derived Normal, Primary Tumor\n1. **Limitations:**\n   - **Genomic Analysis:** Blood-derived normal samples might not accurately represent tumor heterogeneity seen in the primary site, leading to possible misinterpretation of somatic mutations.\n   - **Detection of Circulating Tumor DNA (ctDNA):** While ctDNA can provide insights into mutational burden, it may not reflect entire mutational landscapes, particularly in early stages or low tumor burden situations.\n\n2. **Biological Rationale:** Differences in DNA extraction sites can have significant implications for understanding genomic alterations that drive cancer progression and treatment responses.\n\n3. **Potential Biases:** The reliance on blood samples for genomic analysis may exclude crucial information about clonal evolution that is only present in tissue biopsies.\n\n### Key Genes and Their Impact\n1. **Survival-Associated Genes:**\n   - **TP53:** Loss of tumor suppressor function leads to genomic instability and aggressive tumor behavior.\n   - **FGFR3:** Often associated with better survival due to its prevalence in low-grade disease.\n   - **RB1:** Loss of function affects cell cycle regulation, promoting unchecked proliferation.\n   - **PIK3CA:** Activating mutations enhance signaling pathways that drive growth and survival, often associated with more advanced disease.\n   - **ERBB2 (HER2):** Amplification or overexpression can lead to aggressive tumor growth, linked with poor outcomes but targetable therapeutically.\n   - **CDKN2A:** Deletions/mutations lead to dysregulation in cell cycle checkpoints, correlating with disease aggressiveness.\n   - **ARID1A:** Loss of ARID1A impairs chromatin remodeling and transcriptional control, associated with poor prognosis.\n   - **TSC1:** Mutations can lead to mTOR pathway activation, providing potential targets for therapeutic intervention.\n\n2. **Biological Mechanisms:** The roles of these genes in apoptosis regulation, cell proliferation, and immune evasion are pivotal for understanding their impact on survival.\n\n3. **Potential Biases:** Population-specific studies sometimes skew results regarding the frequency and impact of these mutations.\n\n### Synthesis of Key Survival Risk Factors\nThe survival of patients with bladder urothelial carcinoma depends on a complex interplay of tumor location, histological characteristics, genetic mutations, and sampling strategies. The trigone's unique anatomical challenges, coupled with specific mutational profiles like TP53 and FGFR3, significantly shape outcomes. Understanding sampling biases in genomic data interpretation is critical for accurate assessment and treatment personalization. These insights underscore the importance of comprehensive patient assessment to improve survival predictions and develop targeted therapeutics."
        ],
        [
         "4",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA-BT-A20R, TCGA-BT-A20Q",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin: Trigone of the Bladder\n\n1. **Influence on Survival:**\n   - Tumors originating in the trigone area of the bladder exhibit a tendency for a more aggressive clinical course compared to other bladder regions.\n   - Given its anatomical proximity to the ureters and urethra, there is a higher risk for early invasion and subsequent metastasis, potentially reducing overall survival.\n\n2. **Biological Rationale:**\n   - The trigone is a fixed region with rich vascular and nerve supply, contributing to rapid tumor growth and dissemination.\n   - This areaâ€™s involvement often complicates surgical interventions and may necessitate more aggressive treatment options which carry greater morbidity.\n\n3. **Metastatic Patterns and Treatment Accessibility:**\n   - Early lymphatic spread is common, especially to pelvic lymph nodes.\n   - The location may limit complete surgical resection, affecting prognostic outcomes.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n1. **Influence on Survival:**\n   - As the most common histological subtype, transitional cell carcinoma (TCC) exhibits varied outcomes based on genetic heterogeneity.\n   - Prognosis is often worse with high-grade, muscle-invasive TCC due to robust proliferative capacity and potential for deeper tissue invasion.\n\n2. **Mutation Profiles:**\n   - Frequent mutations in FGFR3, PIK3CA, TP53, and RB1 characterize TCC, influencing pathways pivotal in cell cycle regulation and apoptosis.\n\n3. **Biological Rationale:**\n   - FGFR3 mutations often correlate with non-invasive low-grade tumors, offering better prognosis, while TP53 and RB1 mutations align with aggressive, poor-survival phenotypes.\n\n### Sampling Bias: Limitations of Primary Tumor and Solid Tissue Normal Genomic Analysis\n\n1. **Influence on Interpretation:**\n   - Genomic data might reflect sampling bias when derived primarily from easily accessible or non-representative tumor regions.\n   - Subclonal diversity and heterogeneity might be underrepresented, skewing treatment response predictions and survival estimates.\n\n2. **Biological Rationale:**\n   - Tumor heterogeneity means a single biopsy may not encapsulate the full mutation spectrum, impacting targeted therapy approaches.\n\n3. **Potential Bias:**\n   - Normal tissues adjacent to tumors might display field cancerization effects, where seemingly normal cells possess early oncogenic mutations, complicating interpretation of â€˜normalâ€™ controls.\n\n### Key Survival-Associated Genes\n\n1. **FGFR3:**\n   - Typically mutated in low-grade tumors, facilitating tumor proliferation. Paradoxically, associated with better survival due to less aggressive phenotypes.\n\n2. **TP53:**\n   - Mutations lead to loss of apoptosis, promoting tumor survival and progression. High correlation with poor prognosis due to unchecked cellular proliferation.\n\n3. **RB1:**\n   - Loss of function results in deregulated cell cycle progression, linked to high-grade, muscle-invasive cancers, negatively impacting survival.\n\n4. **PIK3CA:**\n   - Activates downstream signaling pathways like AKT, supporting cell survival and growth. Plays dual roles, with implications in both tumorigenesis and potential therapeutic targeting.\n\n5. **ERCC2:**\n   - Involved in DNA repair pathways; mutations can indicate susceptibility to cisplatin-based therapies, highlighting personalized treatment approaches.\n\n6. **TSC1:**\n   - Its involvement relates to mTOR pathway regulation. Alterations may guide mTOR inhibitor therapies, influencing survival positively in contexts of targeted therapy.\n\n### Synthesis of Key Survival Risk Factors\n\n- The interplay of anatomical origin, histological characteristics, genomic mutations, and sampling biases fundamentally shapes survival outcomes in bladder urothelial carcinoma.\n- Clinically, understanding these factors aids in tailoring treatments, from invasive surgical interventions to targeted molecular therapies, emphasizing the importance of precision in genomic and clinical profiling.\n- Key insights illustrate the necessity for comprehensive approaches that integrate early diagnosis, accurate subtype characterization, and adaptive therapeutic strategies to improve patient survival rates.\n\nThis synthesis underscores the critical nature of a multidimensional understanding of bladder cancer, fostering better, individualized care paradigms that are grounded in extensive genetic and clinical explorations."
        ],
        [
         "5",
         "BLCA",
         "C67.0",
         "8130/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-4Z-AA89, TCGA-FD-A3B3, TCGA-4Z-AA7R",
         "Trigone, bladder",
         "Trigone, bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "## Tumor Origin: Trigone, Bladder\n\n### Influence on Survival\nThe trigone, a part of the urinary bladder located between the openings of the ureters and the urethra, is an area with unique anatomical considerations. Tumors originating in this area can potentially affect patient survival due to proximity to critical structures, influencing metastatic spread and treatment options.\n\n### Biological Rationale\n1. **Metastatic Patterns**: The rich lymphatic drainage around the trigone can facilitate early metastasis, particularly to pelvic lymph nodes. This propensity for early dissemination is often associated with poorer prognosis.\n2. **Treatment Accessibility**: Due to its anatomical position, complete surgical excision might be more challenging, leading to higher recurrence rates compared to tumors in other bladder locations. This complexity can limit effective surgical interventions, impacting survival negatively.\n\n### Potential Biases\nWhile location-specific data enhances understanding of survival disparities, many studies may not disaggregate outcomes by precise bladder tumor locations, potentially underestimating the distinct survival outcomes of trigone tumors.\n\n## Histology: Papillary Transitional Cell Carcinoma\n\n### Influence on Survival\nPapillary transitional cell carcinoma (PTCC), a common bladder cancer histology, interacts with mutation profiles that affect cell growth and apoptosis, directly influencing survival rates.\n\n### Biological Rationale\n1. **Interaction with Mutations**: PTCC often harbors mutations in genes like FGFR3, which may drive tumor growth but also make tumors susceptible to targeted therapies, potentially improving survival.\n2. **Prognostic Indicators**: The histological pattern offers insights into prognosis; non-muscle invasive papillary tumors usually have a better prognosis than muscle-invasive forms due to differences in mutation-driven aggressive behaviors.\n\n### Potential Biases\nHistological analysis can be subject to sampling bias if tumor heterogeneity is not adequately sampled, potentially skewing mutation association studies and subsequent survival predictions.\n\n## Sampling Bias: Blood Derived Normal, Primary Tumor\n\n### Influence on Survival Studies\nInaccuracies in genomic analyses, driven by sampling biases, can misinform survival-related findings.\n\n### Biological Rationale\n1. **Blood Derived Normals**: Using blood-derived controls may not suitably reflect the genetic background of urothelial cells, leading to erroneous assumptions about somatic mutations versus germline variations.\n2. **Primary Tumor Sampling**: Insufficient sampling of primary tumors can overlook intratumoral heterogeneity, failing to capture the full mutation spectrum affecting prognosis and therapy response.\n\n### Potential Biases\nInadequate representation of genomic variation due to these biases can obscure the true impact of certain mutations on survival, limiting effective clinical interventions based on genomic profiling.\n\n## Key Genes Affecting Survival\n\n### Genes and Mechanisms\n1. **TP53**: A critical tumor suppressor, mutations here can lead to loss of apoptosis control, resulting in poor responses to therapy and worsening survival.\n2. **RB1**: Dysfunction in this regulatory checkpoint gene is associated with uncontrolled cell proliferation; its mutations frequently correlate with aggressive tumor behavior.\n3. **FGFR3**: While mutations can drive oncogenesis, they also facilitate targeted treatments, potentially improving survival when accessible to targeted drugs.\n4. **PIK3CA**: Mutations in this pathway can activate survival and proliferation signals, with significant survival implications depending on pathway targeting.\n5. **CDKN2A**: Loss of function mutations here deregulate the cell cycle, correlating with aggressive cancer forms and challenging prognosis.\n6. **ERBB2 (HER2)**: Overexpression or mutation can activate oncogenic signaling, influencing survival negatively but also offering therapeutic targets.\n7. **EGFR**: Alterations in this receptor can drive tumor growth and relate to poorer survival, especially in its presence influencing metastasis and therapy resistance.\n\n### Biological Rationale\nThese genes impact survival through mechanisms like cell cycle dysregulation, promoting proliferation, evasion of apoptosis, and influencing immune interactions. Their expression and mutation status can serve as prognostic indicators and therapeutic targets.\n\n## Conclusion: Synthesis of Key Survival Risk Factors\n\n### Clinically Relevant Insights\nThe anatomical location, histological characteristics, genetic mutations, and sampling methods individually and collectively impact survival in Bladder Urothelial Carcinoma. Tumors in the trigone often have worse outcomes due to metastatic advantages. PTCC histology coupled with relevant mutations can define distinct prognostic pathways. Recognizing sampling biases is crucial for accurate genomic insights.\n\n### Impact on Patient Survival\nEfforts to improve survival should prioritize comprehensive molecular profiling, consider anatomical-specific therapeutic strategies, and exploit targeted treatments based on precise mutation profiles. Addressing these key risk factors can significantly refine prognostic models and therapeutic approaches, ultimately enhancing patient outcomes."
        ],
        [
         "6",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A54R, TCGA-GC-A3BM, TCGA-DK-A3X1, TCGA-BT-A2LB, TCGA-BL-A0C8, TCGA-BL-A0C8, TCGA-DK-A6AV, TCGA-FD-A43P, TCGA-DK-AA74, TCGA-BL-A0C8, TCGA-4Z-AA86, TCGA-DK-A3WY, TCGA-DK-AA6L",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Dome, Bladder\n\n**Influence on Survival:**\n- **Metastatic Patterns:** Tumors originating in the dome of the bladder can potentially invade adjacent structures like the peritoneum earlier due to anatomical proximity, contributing to quicker dissemination and metastasis.\n- **Patient Survival:** This can result in earlier stage IV diagnoses when the cancer is more widespread, negatively affecting survival rates.\n- **Treatment Accessibility:** The location might not significantly impede initial surgical interventions but could complicate complete resection if invasion is extensive at diagnosis, affecting long-term remission.\n\n**Biological Rationale:**\n- Anatomical position influences tumor grow-out patterns and access to lymphatic and vascular pathways crucial for metastasis.\n\n**Biases:**\n- Studies might underreport early metastatic potentials owing to sampling biases, particularly when peripheral parts of tumors are analyzed more often than their point of origin.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n**Influence on Survival:**\n- **Mutation Profiles:** The histological subtype interacts with certain mutations like TP53 or FGFR3 that have distinct prognostic implications, affecting survival strategies.\n- **Outcomes:** Tumors with FGFR3 mutations often present less aggressively, correlating with better outcomes, whereas TP53 mutations often correlate with poor responses and lower survival.\n\n**Biological Rationale:**\n- Transitional cell carcinomas exhibit particular chromosomal instabilities that enhance survival through driver mutations promoting uncontrolled proliferation.\n\n**Biases:**\n- Primary Tumor sampling might not capture heterogeneity, underestimating subclonal variations which contribute to treatment resistance.\n\n### Sampling Bias: Blood Derived Normal and Primary Tumor\n\n**Limitations:**\n- Blood-derived normal samples lack the clonal architecture of the primary tumor, potentially overlapping somatic mutation data interpretation.\n- Tumor biopsy heterogeneity can lead to skewing understanding of the mutational load and its prognostic interpretations.\n\n### Key Genes: Survival-Associated Genes\n\n1. **TP53:** Mutations in TP53 often lead to faulty DNA repair mechanisms, enabling rapid clonal expansions and resistance to therapy, correlating with poor survival.\n   \n2. **FGFR3:** Often mutated in less aggressive forms, affecting proliferation pathways that can be inhibited therapeutically, improving prognosis.\n\n3. **PIK3CA:** Alters cell growth and survival systems via PI3K/AKT signaling, often correlating with resistance to standard chemotherapies.\n\n4. **CDH1:** Mutations affect cellular adhesion, facilitating metastatic potential and correlating with aggressive phenotypes.\n\n5. **HRAS:** Involved in the MAPK pathway, these mutations enhance proliferative signaling contributing to tumor growth, impacting overall survival negatively.\n\n6. **PTEN:** Tumor suppressor gene mutation leads to unchecked PI3K/AKT signaling, facilitating survival and growth in malignant cells, reducing survival prospects.\n\n**Biological Mechanisms:**\n- These genes play diverse roles from regulating cell cycle checkpoints (TP53) to signaling cascades (FGFR3, PIK3CA) and maintaining cellular architecture (CDH1).\n\n### Conclusion: Key Survival Risk Factors\n\n- **Location Influences:** Bladder dome origin contributes to early dissemination risks.\n- **Genetic Context:** Genetic mutations within transitional cell carcinoma shape treatment response and prognosis.\n- **Sampling Considerations:** Overlooked heterogeneity can lead to unexpected treatment failures.\n- **Clinically Relevant Insights:** Personalized treatments targeting specific mutational profiles and careful surgical planning reflect necessary approaches to improve survival outcomes.\n\nIntegrating these genomic and anatomical insights is essential for precision medicine approaches to optimize therapeutic interventions and prognostic assessments in patients with Bladder Urothelial Carcinoma of the dome."
        ],
        [
         "7",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20X, TCGA-BT-A2LA",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin: Dome, Bladder\n\n1. **Impact on Metastatic Patterns and Survival:**\n   - **Apical Origin:** Tumors originating from the dome, which is the apex of the bladder, may have distinct metastatic behaviors. Their location can potentially facilitate early dissemination via rich lymphatic drainage paths leading to pelvic lymph nodes and beyond, impacting survival negatively by increasing the likelihood of advanced-stage detection.\n   - **Survival Impact:** This origination point might result in delayed detection due to symptoms manifesting later in disease progression, influencing overall survival negatively by presenting at an advanced stage with less curative options available.\n\n2. **Treatment Accessibility:**\n   - **Surgical Challenges:** The dome location might present technical challenges for surgical resection and could limit the applicability or success of bladder-preserving techniques, such as a partial cystectomy, further impacting survival.\n   \n### Histology: Transitional Cell Carcinoma (TCC), NOS\n\n1. **Mutation Profiles and Survival Impact:**\n   - **Histological Influence:** TCC, also known as urothelial carcinoma, is characterized by its tendency to harbor specific mutations in genes like FGFR3, PIK3CA, and TP53, each influencing survival differently. FGFR3 mutations typically correspond to lower-grade, potentially better prognosis cancers, while TP53 alterations are linked to high-grade tumors with a worse survival outlook.\n   - **Outcomes:** This interaction suggests that survival is highly contingent on the mutational landscape. A predominantly FGFR3-mutated profile could indicate a more indolent course, whereas the presence of TP53 mutations may suggest aggressive behavior and poorer survival.\n\n### Sampling Bias: Limitations of Primary Tumor, Solid Tissue Normal\n\n1. **Genomic Analysis Challenges:**\n   - **Selection Bias:** Genomic analyses using primary tumor without matched normal tissue may lack context on the individual patient's baseline genetic backdrop, leading to potential misinterpretation of what may be somatic versus germline variations.\n   - **Outcome Influence:** This bias could skew findings towards prevalent somatic mutations while under-appreciating germline contributions to survival, leading to potential misestimation of true mutational driver significance regarding patient prognosis.\n\n### Key Genes Associated with Survival\n\n1. **FGFR3:**\n   - **Mechanism:** Often associated with low-grade tumors, FGFR3 mutations are linked to increased cell proliferation but less aggressive behavior, potentially enhancing survival in contrast to mutations promoting high-grade pathology.\n   \n2. **TP53:**\n   - **Mechanism:** As a major tumor suppressor, alterations often herald aggressive disease, leading to increased proliferation and reduced apoptosis, thus worsening survival outcomes.\n   \n3. **ERBB2 (HER2):**\n   - **Mechanism:** Overexpression can lead to uncontrolled cell growth. While traditionally linked with aggressive behavior, targeted therapies might improve survival if HER2 overexpression is present.\n   \n4. **PIK3CA:**\n   - **Mechanism:** Activating mutations can lead to oncogenesis through cell proliferation pathways, possibly suggesting a nuanced survival impact depending on the mutation spectrum alongside the therapeutic landscape.\n   \n5. **CDKN2A:**\n   - **Mechanism:** Loss of CDKN2A function, a regulator of cell cycle, might lead to unchecked cell division, correlating with aggressive disease and poorer prognosis.\n   \n6. **KMT2D:**\n   - **Mechanism:** Alterations can affect chromatin remodeling, influencing tumor progression and potentially signaling a negative survival impact.\n\n7. **RB1:**\n   - **Mechanism:** Loss of tumor suppressive activity due to mutations suggests more aggressive cancer, affecting cellular proliferation, hence negatively impacting survival. \n\n### Conclusion: Key Survival Risk Factors\n\n1. **Synthesis:**\n   - **Locational Origin and Detection:** The dome location of bladder cancer impacts early detection and metastatic spread, possibly hindering early intervention strategies.\n   - **Histological and Genomic Interplay:** The survival outcome is significantly dictated by the histological subtype and accompanying genomic mutations, indicating the necessity of precise histogenomic profiling.\n   - **Biased Interpretation Risks:** Ensuring precise genomic interpretation through improved sampling strategies, like including normal tissues, is crucial in understanding survival impacts accurately and personalizing treatment pathways.\n\n2. **Clinical Relevance:**\n   - The integration of anatomical, histological, and genetic insights is critical in designing therapeutic approaches, impacting individual survival by tailoring the management plan based on predictive genomic indicators, thereby maximizing patient outcome potential."
        ],
        [
         "8",
         "BLCA",
         "C67.1",
         "8260/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-HQ-A2OF",
         "Dome, bladder",
         "Dome, bladder",
         "Papillary adenocarcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin and Impact on Survival\n\n**Step 1: Influence on Metastatic Patterns**\n- **Anatomical Consideration**: The dome of the bladder is a less common origin for bladder cancer compared to the trigone or lateral wall. However, its position can influence the direction of cancer spread. The dome being adjacent to the peritoneal surface poses an elevated risk for transperitoneal dissemination.\n- **Survival Impact**: Because of this increased risk of spreading to the peritoneum, patients might experience a more aggressive metastatic course, leading to a worse prognosis and potentially lower survival rates compared to tumors originating in other areas of the bladder.\n- **Treatment Accessibility**: Tumors at the dome may be less accessible for surgical interventions and diagnostic procedures like transurethral resections, potentially delaying definitive treatment and impacting survival negatively.\n\n### Histology and Molecular Interactions\n\n**Step 2: Papillary Adenocarcinoma and Mutation Profiles**\n- **Histological Features**: Papillary adenocarcinoma, NOS (not otherwise specified), is rare in bladder cancer and typically has a worse prognosis than conventional urothelial carcinoma. Its glandular structures hint at a different metastatic pattern and response to chemotherapy.\n- **Mutational Interactome**: This subtype often presents unique genetic mutations, such as alterations in ALK or NRG1 fusions, which can drive poor outcomes through unchecked cellular proliferation and metastatic capability. Understanding these mutations can tailor targeted therapies, which might improve survival outcomes if appropriately addressed.\n\n### Sampling Bias in Genomic Analysis\n\n**Step 3: Blood Derived Normal, Primary Tumor**\n- **Limitations**: Using blood-derived normal samples often misses tumor heterogeneity. Primary tumor samples provide richer insight into specific mutational burdens but might not reflect the full diversity of metastatic sites or subclones.\n- **Survival Impact**: These biases can lead to underestimation or overestimation of mutation frequencies, affecting prognostic estimates. Incomplete genetic profiling may overlook potential therapeutic targets, thereby limiting intervention strategies.\n- **Biological Rationale**: This impacts survival through potential oversight of particular aggressiveness in minor clones that are significant in metastasis, ultimately affecting treatment choices and outcomes.\n\n### Key Genes Impacting Survival\n\n**Step 4: Identification and Explanation**\n1. **TP53**: Mutations here disrupt apoptosis and the DNA damage response, leading to genetic instability. Their presence typically portends a poorer prognosis.\n2. **FGFR3**: Often mutated in non-muscle invasive bladder cancers, these changes can drive excessive proliferation via the MAPK and PI3K-Akt pathways. Targeted drugs against FGFR3 mutations can improve outcomes.\n3. **PIK3CA**: When mutated, promotes angiogenesis and survival through the PI3K/AKT/mTOR pathway, usually indicative of aggressive cancers.\n4. **CDKN2A**: Alterations result in loss of cell cycle regulation, leading to unchecked proliferation. Dysregulation here often correlates with advanced disease.\n5. **ERBB2 (HER2)**: Amplification can drive aggressive growth, similar to its effect in breast cancer, making it a target for HER2 inhibitors.\n6. **ARID1A**: Mutations may impair chromatin remodeling, influencing cellular differentiation and proliferation. This mutation is often associated with poor outcomes.\n7. **KDM6A**: Losses can lead to disrupted transcriptional regulation, correlated with higher-grade tumors and poor differentiation.\n8. **RB1**: Loss or mutation typically results in cell cycle deregulation. It acts as a hallmark indicator of aggressive and chemoresistant forms.\n\n### Synthesis of Key Survival Risk Factors\n\n**Concluding Synthesis**\nThe interplay between the tumor's anatomical origin, histological subtype, and specific genetic alterations frames the prognosis for bladder urothelial carcinoma, especially those originating from the dome. Genetic heterogeneity, driven by sampling biases and diversification of tumor cells, complicates accurate survival predictions and tailored interventions. Clinically, identifying significant genetic drivers like TP53 and FGFR3 mutations offers routes for targeted therapies, potentially improving survival stats. Nonetheless, intrinsic sampling limitations necessitate comprehensive analyses that integrate multiple data types to refine prognostication and appropriately address patient-specific treatment needs. Emphasizing molecular diagnostics aids in navigating the complex biological landscape of bladder cancer, guiding therapeutic strategies toward more personalized medicine, ultimately impacting survival positively by curtailing disease progression and recurrence."
        ],
        [
         "9",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FD-A3SQ, TCGA-FD-A3B7, TCGA-4Z-AA7M, TCGA-DK-A3IK, TCGA-FD-A3SM, TCGA-ZF-A9RC, TCGA-UY-A9PA, TCGA-DK-AA6P, TCGA-DK-AA6R, TCGA-FD-A6TF, TCGA-FD-A62N, TCGA-DK-A3WX, TCGA-FD-A5BR, TCGA-GU-A763, TCGA-DK-A3IT, TCGA-FD-A43U, TCGA-DK-AA6X, TCGA-G2-A2EL, TCGA-2F-A9KP, TCGA-YF-AA3L, TCGA-R3-A69X, TCGA-FD-A3SJ, TCGA-DK-A6B0, TCGA-4Z-AA7W, TCGA-E7-A3X6, TCGA-UY-A9PB, TCGA-BT-A3PJ, TCGA-DK-AA71, TCGA-FD-A6TB, TCGA-GU-AATP, TCGA-DK-AA6S, TCGA-FD-A3B8, TCGA-DK-AA6W, TCGA-FD-A3B4, TCGA-PQ-A6FN, TCGA-ZF-AA54, TCGA-FJ-A871, TCGA-DK-A3IN, TCGA-DK-A3IL, TCGA-YF-AA3M, TCGA-FD-A6TG, TCGA-ZF-A9RG, TCGA-DK-A3IV, TCGA-DK-AA6U, TCGA-DK-A3X2, TCGA-E5-A2PC, TCGA-4Z-AA7N, TCGA-FD-A5BU, TCGA-FD-A3SO, TCGA-FD-A5BT, TCGA-DK-AA6M",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin and Influences on Survival\n\n1. **Lateral Wall Bladder and Metastasis Patterns:**\n   - **Influence on Survival:** The origin of the tumor on the lateral wall of the bladder influences metastatic routes, commonly involving lymphatic spread to pelvic lymph nodes which can increase metastasis and reduce survival rates.\n   - **Biological Rationale:** The lateral wall is richly innervated with vasculature allowing for efficient lymphatic transport. Tumor cells can thus access these pathways more readily, facilitating early dissemination.\n   - **Treatment Accessibility:** Tumors here might be more accessible for surgical resections, positively influencing outcomes if detected early.\n\n2. **Histology and Genetic Interplay:**\n   - **Transitional Cell Carcinoma, NOS Influence:** This is the most common histological subtype and has a well-documented relationship with mutations that affect cell proliferation and survival negatively.\n   - **Biological Rationale:** Histological characteristics of urothelial origin contribute to genetic mutations, primarily in genes regulating cell cycle and apoptosis, leading to aggressive growth.\n   - **Impact on Mutation Profiles:** It affects survivability as certain mutations, such as in the FGFR3 gene, are associated with a better prognosis due to potential targeted therapy options.\n\n### Limitations from Sampling Bias\n\n3. **Sampling Bias â€“ Blood Derived Normal vs. Primary Tumor:**\n   - **Influence on Survival Interpretation:** Using blood-derived normals (the unaffected tissue) as genomic controls can mask certain mutations prevalent in tumors but absent in blood, influencing survival predictions.\n   - **Biological Rationale:** The mismatch between primary tumor samples (which directly exhibit oncogenic mutations) and blood-derived normals might obscure critical genomic aberrations, skewing data on mutation frequencies.\n   - **Potential Bias:** This bias leads to underrepresentation of the tumor's genomic landscape, limiting understanding of heterogeneity and personalized treatment strategies.\n\n### Key Genes Impacting Survival\n\n4. **Survival-Associated Genes:**\n   - **TP53:** Involved in apoptotic regulation and cell cycle control, mutations here usually predict poor outcomes due to uncontrolled cell proliferation.\n   - **FGFR3:** Mutations are often associated with non-invasive tumors and a more favorable prognosis, providing targets for FGFR inhibitors.\n   - **PIK3CA:** Influences cell growth and survival pathways; mutations can indicate aggressive tumor behavior leading to poor survival.\n   - **RB1:** Affects cell cycle regulation. Loss-of-function mutations correlate with high-grade and muscle-invasive bladder cancer, indicative of poor survival scenarios.\n   - **TSC1:** Regulates mTOR pathway, affecting tumor growth potential. Its mutations might suggest sensitivity to mTOR inhibitors, potentially improving outcomes.\n   - **ERBB2:** Overexpression or mutation leads to aggressive phenotypes but presents an opportunity for targeted therapies.\n   - **CDKN2A:** Influences cell cycle arrest; deletion is linked to high-grade tumors and unfavorable outcomes.\n   - **E2F3:** Regulates DNA synthesis and mitosis; amplification is associated with aggressive tumor proliferation and reduced survival.\n\n### Conclusion and Synthesis\n\nIn conclusion, the survival of a patient with bladder urothelial carcinoma, particularly from the lateral wall, is intricately linked to the tumor's origin, genetic makeup, and associated histology. Tumor positioning affects metastatic potential, while the interplay between specific histologic and genetic characteristics dictates disease aggressiveness and therapy response. Sampling biases, particularly in genomic studies, pose significant challenges, necessitating meticulous interpretation of data to draw accurate clinical correlations.\n\nCritical survival risk factors: \n\n- Genetic mutations (e.g., TP53, FGFR3)\n- Tumor accessibility and histology\n- Sampling approaches and bias considerations\n\nThese insights are crucial in tailoring personalized therapies, impacting patient survival by optimizing intervention strategies and enhancing treatment precision. Understanding these dynamics offers pathways to improve prognostic accuracy and therapeutic responsiveness, ultimately aiming for better patient outcomes in bladder carcinoma management."
        ],
        [
         "10",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20W, TCGA-BT-A20O, TCGA-BT-A20V",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin: Lateral Wall of Bladder\n\n1. **Influence on Metastatic Patterns:**  \n   The lateral wall of the bladder, due to its proximity to major blood vessels and lymphatic pathways, may facilitate earlier metastatic spread than tumors located elsewhere within the bladder. Cancers originating here are more likely to invade the surrounding pelvic wall, promoting metastatic dissemination.\n\n2. **Impact on Survival:**  \n   - **Negative Effect:** The proximity to vasculature not only aids in metastasis but also often results in a higher stage at diagnosisâ€”diminishing survival probabilities as systemic dissemination reduces treatment efficacy.\n   - **Treatment Accessibility:** Location-based challenges can limit surgical options. Access for removal may require more complex surgical techniques, potentially reducing complete resection likelihood.\n\n3. **Biological Rationale:**  \n   The understanding that anatomically strategic locations increase vascular access for metastatic cells aligns with known patterns of hematogenous spread in malignancies.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n1. **Interaction with Mutation Profiles:**  \n   Transitional cell carcinoma (TCC), particularly NOS (Not Otherwise Specified), frequently shows common mutations like FGFR3, TP53, and RB1. FGFR3 mutations are often associated with low-grade tumors, whereas TP53 and RB1 are linked to high-grade variants.\n\n2. **Impact on Outcomes:**\n   - **Variable Impact:** Mutational status heavily influences both the aggressiveness of the carcinoma and the responsiveness to treatments.\n   - **Biological Rationale:** Elevated FGFR3, prevalent in low-grade tumors, offers a more benign prognosis, whereas loss of function in TP53 or RB1 disrupts cell cycle control, enhancing malignancy.\n\n### Sampling Bias: Primary Tumor vs. Solid Tissue Normal\n\n1. **Genomic Analysis Limitations:**  \n   - **Bias Introduction:** Analysis exclusively of primary tumor and adjacent unaffected tissues might neglect the heterogeneous nature of metastatic lesions.\n   - **Impact on Interpretations:** This bias could skew the perceived mutational landscape, inadvertently masking driver mutations highly represented in metastatic settings.\n\n2. **Biological Consequences:**  \n   Understanding limitations in sampling can misguide therapeutic targeting and affect estimations of genomic instability, particularly when unfocused on potential heterogeneous subclones driving metastasis.\n\n### Key Genes and Their Mechanisms\n\n1. **TP53:** Essential for apoptosis and genomic stability, mutations in TP53 often predict poor survival due to higher grades and stages at presentation.\n2. **FGFR3:** Mutations correlate with enhanced survival in low-grade TCC cases but are linked to therapy resistance in advanced stages.\n3. **RB1:** Inactivation is common in aggressive TCC, correlating with poor prognosis due to its role in cell cycle regulation.\n4. **ERBB2 (HER2):** Overexpression predicts an aggressive clinical course, suggesting actionable target potential in personalized therapies.\n5. **PIK3CA:** Frequently mutated in bladder cancer, driving proliferation and linked to poor prognosis through activated downstream signaling pathways.\n6. **MDM2:** Amplified in some TCCs, inhibiting TP53 pathway; the implication is towards reduced apoptosis, contributing to tumorigenesis.\n7. **PD-L1:** Its expression modulates immune evasion, permitting unchecked tumor growth, denoting potentially poorer outcomes.\n8. **HRAS:** Mutations can drive oncogenic signals, associated with both tumor progression and potential responsiveness to MEK inhibitors.\n\n### Synthesis and Clinically Relevant Insights\n\nFrom understanding these facets, it's apparent that anatomical origin, histological subtype, and key genomic contributors punctuate the survival landscape in bladder urothelial carcinoma. Clinicians should consider:\n- Early metastatic potential and advanced staging associated with lateral wall tumors.\n- Mutational profiles to tailor therapy, where FGFR3 mutations might signal for conservative treatment, whereas TP53 or RB1 alterations suggest aggressive regimens.\n- Limitations in genomic data **should** incite the inclusion of metastatic deposit analyses to accurately reflect tumor heterogeneity.\n\nUltimately, leveraging these insights into comprehensive management plans can enhance survival through personalized medicine, incorporating genetic, anatomical, and histological nuances of each tumor scenario."
        ],
        [
         "11",
         "BLCA",
         "C67.2",
         "8130/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-XF-AAMQ, TCGA-BT-A42B, TCGA-UY-A9PF, TCGA-XF-AAML, TCGA-4Z-AA7Y, TCGA-FJ-A3Z9, TCGA-CF-A9FF, TCGA-4Z-AA7O, TCGA-FD-A6TA, TCGA-BT-A42C, TCGA-CF-A7I0",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "To assess survival impacts in Bladder Urothelial Carcinoma (BUC), specifically originating from the lateral wall of the bladder, we must dissect multiple interrelated factors, each contributing to patient outcomes in distinctive ways.\n\n### Tumor Origin: Lateral Wall Bladder\n1. **Influence on Metastatic Patterns and Survival**:\n   - **Anatomical Considerations**: The lateral wall of the bladder allows for easier access to surrounding muscular and connective structures, potentially aiding in lymphatic spread at an earlier stage.\n   - **Survival Impact**: Early dissemination often correlates with poorer prognosis due to the high likelihood of nodal involvement, which complicates surgical resection considerations and may necessitate more aggressive systemic treatment.\n\n2. **Treatment Accessibility**:\n   - **Surgical Challenges**: The proximity to vital structures may reduce eligibility for certain bladder-preserving surgeries, impacting survival options negatively.\n   - **Biological Rationale**: The lateral wall's anatomical features can foster more complex invasive behavior, making complete excision with clean margins difficult.\n\n### Histology: Papillary Transitional Cell Carcinoma\n1. **Integration with Mutation Profiles**:\n   - **Morphological Traits**: Papillary structures often resemble finger-like projections, which might superficially limit invasive depth but carry other risks.\n   - **Mutation Interaction**: Common mutations in FGFR3 and TP53 within these carcinomas influence proliferative capacity and genomic stability, directly linking to how the tumor evolves under therapeutic pressure.\n\n2. **Survival Outcomes**:\n   - **Positive Influence**: FGFR3 mutations are frequently associated with less aggressive, low-grade tumors, possibly prolonging disease-specific survival.\n   - **Negative Influence**: TP53 mutations disrupt apoptotic processes, leading to chemoresistance and poorer survival rates.\n\n### Sampling Bias\n1. **Blood Derived Normal vs. Primary Tumor**:\n   - **Limitations**: Reliance on blood-derived samples may underestimate mutational load specific to the tumor, missing tumor-specific alterations due to normal cell DNA overshadowing the analysis.\n   - **Genomic Interpretation**: This bias can skew research results, impacting the perceived efficacy of targeted therapies that appear promising in vitro but do not translate to patient outcomes when blood samples drive genomic insights.\n  \n2. **Primary Tumor Sampling**:\n   - **Challenge**: Intratumor heterogeneity is not fully captured in singular biopsies leading to underrepresentation of aggressive subclonal populations in genomic profiling.\n   - **Impact on Survival**: Incomplete genomic profiling can lead to suboptimal therapeutic targeting, potentially compromising survival outcomes.\n\n### Key Survival-Associated Genes\n1. **TP53**: Integral in controlling apoptosis; mutations often lead to poor survival as they confer resistance to treatments.\n2. **FGFR3**: Mutations might indicate a less aggressive tumor phenotype and better prognosis in superficial tumor presentations.\n3. **RB1**: Its loss affects cell cycle regulation, fostering unchecked proliferation and is correlated with high-grade tumors and worse survival.\n4. **PIK3CA** and **PTEN**: These influence pathways related to cell growth and survival, with dysregulations linked to aggressive tumor behavior.\n5. **CDKN2A**: Alters cell cycle checkpoints, with deletions heavily linked to poor differentiation status and survival.\n6. **ERBB2 (HER2)**: Amplifications or mutations promote rapid cell division and potential treatment resistance, impacting survival negatively.\n7. **MIB1 (Ki-67)**: High expression signifies high proliferative index, often predicting aggressive disease and suboptimal survival.\n\n### Synthesis of Key Survival Risk Factors\n- **Summary**: Key survival risk factors in BUC include anatomic origin-driven dissemination patterns, specific mutational profiles such as TP53 and FGFR3, and challenges posed by sampling biases. Each factor intricately interplays, influencing tumor aggressiveness, therapy resistance, and ultimately, survival outcomes.\n- **Clinical Insights**: Understanding these factors allows for better prognostication and personalized treatment strategies, emphasizing genomic stress testing, and targeted therapies to improve patient outcomes. Clinically, this necessitates comprehensive tumor profiling through multi-regional biopsies and integration of multi-omic data to effectively outline patient-specific treatment plans."
        ],
        [
         "12",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-E7-A6ME, TCGA-FD-A43Y, TCGA-DK-AA75, TCGA-FD-A3N6, TCGA-UY-A9PD, TCGA-E7-A6MD, TCGA-KQ-A41Q, TCGA-FD-A6TK, TCGA-FD-A6TI, TCGA-GU-A764, TCGA-K4-AAQO, TCGA-DK-A6B1, TCGA-GV-A3QF, TCGA-FD-A5BZ, TCGA-FD-A6TD, TCGA-DK-AA76, TCGA-DK-A6B5",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Bladder Urothelial Carcinoma Survival Analysis\n\n#### Tumor Origin\n1. **Influence on Metastatic Patterns**: Bladder urothelial carcinoma, particularly when classified under \"unknown\" status (UNKOWN), presents a variable metastatic pattern. This ambiguity often leads to challenges in predicting how the cancer might spread. It typically metastasizes to lymph nodes, liver, and lungs, but without defined primary site specifics, determining progression can be complex, affecting treatment decisions and survival rates.\n   \n2. **Impact on Patient Survival**: The unknown origin complicates staging and directly impacts prognosis. Without clear metastatic patterns, personalized treatment becomes challenging, leading to potentially delayed or suboptimal therapeutic interventions, thus negatively impacting survival.\n\n3. **Treatment Accessibility**: An unspecified origin may limit eligibility for site-specific clinical trials and therapies, often reducing available treatment options, thus adversely affecting overall survival outcomes. Treatment plans might become generalized rather than tailored, affecting efficacy.\n\n#### Histology\n1. **Transitional Cell Carcinoma (NOS)**: As the most prevalent histological type of bladder cancer, transitional cell carcinoma can significantly influence treatment response and prognosis. The \"not otherwise specified\" (NOS) category indicates lack of further sub-classification, often leading to generic treatment approaches.\n\n2. **Mutation Profiles and Outcomes**: Mutations common in transitional cell carcinoma, including FGFR3, PIK3CA, and TP53, can dictate tumor behavior. FGFR3 mutations, for example, are often associated with better prognoses in non-invasive cases, while TP53 mutations correlate with more aggressive cancer and poorer survival.\n\n3. **Biological Interaction**: These mutations affect cell proliferation and apoptosis regulation, influencing the tumorâ€™s biological behavior and patient outcomes. For example, FGFR3 affects pathways controlling cell division, and TP53 mutations lead to reduced apoptosis, driving aggressive tumor growth.\n\n#### Sampling Bias\n1. **Limitations in Genomic Analysis**: Using blood-derived normal samples against primary tumors for comparative genomic studies can introduce biases as blood-derived normal tissues may not accurately reflect mutation statuses relevant to the tumor microenvironment.\n\n2. **Impact on Interpretation**: Differences in mutation load and expression profiles between these samples may lead to an underestimation or misinterpretation of mutation prevalence, impacting precision medicine efforts.\n\n3. **Biological Rationale**: Discrepancies arise because blood-derived tissues might not capture localized tumor-specific processes, such as immune interactions or microenvironmental influences, leading to potentially skewed interpretations of tumor biology.\n\n#### Key Survival-Associated Genes\n1. **FGFR3**: Frequently mutated in non-muscle invasive bladder cancers, it often indicates a good prognosis when mutated in isolation due to its role in proliferation signaling pathways.\n\n2. **TP53**: Mutations here often confer aggressive characteristics to the cancer by disrupting apoptosis, correlating with poor survival outcomes.\n\n3. **PIK3CA**: Mutations activate the PI3K/AKT pathway, promoting survival and proliferation, impacting tumor aggressiveness and survival rates.\n\n4. **ERBB2 (HER2)**: Amplifications or overexpression can lead to enhanced tumor proliferation and poorer prognosis, though it may also open targeted therapy options.\n\n5. **CDKN2A**: Alterations affect cell cycle regulation, influencing proliferation and tumor suppression capacity, with deletions often leading to aggressive tumors.\n\n6. **TERT Promoter Mutations**: Common in bladder cancer, these lead to increased telomerase activity, promoting cell immortality and associated with a variable prognosis.\n\n#### Synthesis and Clinical Insights\n- Bladder urothelial carcinoma survival is significantly influenced by the interplay of tumor origin, histological characteristics, genetic mutations, and sampling biases.\n- Tumor origin ambiguity reduces treatment precision, potentially worsening survival.\n- Histological subtypes and mutation profiles offer actionable insights, impacting treatment strategies and survival forecasts.\n- Genomic interpretation biases must be carefully managed to accurately reflect tumor biology and inform decisions.\n- Clinically, emphasis on comprehensive genomic profiling alongside histological evaluation improves survival by facilitating targeted and personalized treatment strategies. \n\nUnderstanding these layers of complexity guides therapeutic decision-making and enhances prognostication, ultimately aiming to improve patient outcomes in bladder urothelial carcinoma."
        ],
        [
         "13",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20T, TCGA-G2-A2EO",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "**Bladder Urothelial Carcinoma: Impact on Survival**\n\n### Tumor Origin\n1. **Influence on Survival:**\n   - **Metastatic Patterns:** Bladder urothelial carcinoma often spreads locoregionally to pelvic and para-aortic lymph nodes and can metastasize to the liver, lungs, and bones. Metastatic patterns significantly reduce survival due to the essential organs involved.\n   - **Treatment Accessibility:** The unknown ICD-10 specification might hint at confusion during data categorization, potentially leading to discrepancies in treatment plans. Accurate staging and classification are crucial for guiding therapeutic interventions like radical cystectomy and intravesical chemotherapy, thereby impacting survival.\n\n2. **Biological Rationale:**\n   - Urothelial cells form the transitional epithelium, capable of expanding and contracting, providing a pathway for cancerous cells to infiltrate surrounding tissues easily.\n   - Late detection and high recurrence risk, characteristics of these cancers, negatively affect survival rates.\n\n3. **Potential Biases:**\n   - Misclassification or unknown primary sites can skew survival statistics and undermine the validity of treatment efficacy studies.\n\n### Histology: Transitional Cell Carcinoma, NOS\n1. **Influence on Survival:**\n   - **Interaction with Mutation Profiles:** Transitional cell carcinoma is prone to mutations in tumor suppressor genes (e.g., TP53) and those regulating cell cycle checkpoints (e.g., RB1). These mutations often correlate with higher-grade tumors that are more aggressive and less responsive to treatment, worsening survival prospects.\n\n2. **Biological Rationale:**\n   - This type involves a proliferation of cells that resemble the bladderâ€™s transitional epithelium, creating histological heterogeneity that complicates treatment planning and effectiveness.\n\n3. **Potential Biases:**\n   - Variability in tumor grading and classification could lead to inconsistencies in data interpretation and subsequent treatment strategies.\n\n### Sampling Bias\n1. **Influence on Survival:**\n   - **Primary Tumor & Solid Tissue Normal:** Analyses often compare tumor samples with nominally normal tissues, failing to account for field changes where adjacent 'normal' tissues might not be truly normal. This can lead to missed precancerous conditions.\n\n2. **Biological Rationale:**\n   - Sample heterogeneity, especially sampling at the tumor interface, risks capturing altered genomic landscapes that do not fully reflect genomic drivers of malignancy or resistance.\n\n3. **Potential Biases:**\n   - Misleading conclusions may arise due to overestimation of differential gene expression between normal and tumor samples.\n\n### Key Genes and Their Impact on Survival\n1. **TP53:** Tumor suppressor gene that regulates the cell cycle and apoptosis; mutations lead to unchecked cell division and survival of aberrant cells, worsening outcomes.\n2. **FGFR3:** Mutations in this gene might drive cancer growth and are associated with low-grade tumors, which surprisingly show better prognosis if treated early.\n3. **PIK3CA:** Often altered in bladder cancer, leading to activation of pathways involved in cellular growth; contributes to cancer progression.\n4. **CDKN2A (p16):** Typically deleted or hypermethylated, leading to disrupted cell cycle control and increased tumor aggressiveness.\n5. **ERBB2 (HER2):** Overexpression is linked to aggressive tumor subtypes and poorer survival outcomes; HER2-targeted therapies can be transformative.\n6. **RB1:** Its loss results in dysregulated cell cycle progression, contributing to aggressive tumor behavior.\n7. **EGFR:** Overactivation promotes proliferation and survival signals; targeting EGFR in therapy can improve outcomes.\n\n### Synthesis of Key Survival Risk Factors\n- Bladder urothelial carcinoma survival is a complex interplay of histological characteristics, genetic alterations, and tumor origin, complicated by potential biases in genomic interpretation due to sampling errors and classification imprecision.\n- Key factors like TP53 mutations profoundly impact apoptosis regulation, while FGFR3 and ERBB2 mutations affect cellular growth pathways. Understanding these relationships enables precise therapeutic targeting.\n- Clinically, accurate genotyping and molecular characterization can guide personalized treatment plans to mitigate aggressive disease trajectory and enhance treatment efficacy, underscoring the importance of comprehensive genomic profiling in improving patient survival."
        ],
        [
         "14",
         "BLCA",
         "C67.3",
         "8130/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I4",
         null,
         null,
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin\n\n**Influence on Survival:**\nBladder Urothelial Carcinoma often originates in the urothelium lining of the bladder. This location facilitates early local spread and potential metastasis due to its anatomical closeness to lymphatics and blood vessels.\n\n**Biological Rationale:**\nThe urothelium's role is critical in normal urinary function, yet its cellular structure may promote early dissemination when malignant. Local infiltration into muscle layers or perivesical fat indicates a greater risk of metastatic spread, negatively influencing survival rates.\n\n**Potential Biases in Genomic Interpretation:**\nUncertain origin (UNKNOWN) coding in datasets can obscure the true metastatic potential, underestimating the apparent aggressiveness due to misclassification or unrecorded progression stages, impacting survival analysis.\n\n### Histology\n\n**Influence on Survival:**\nPapillary transitional cell carcinoma, a subtype of bladder cancer, shows unique mutation profiles, influencing patient outcomes positively if early-stage and low-grade but adversely if high-grade due to aggressive tendencies.\n\n**Biological Rationale:**\nThese tumors frequently feature mutations in FGFR3, promoting unchecked proliferation in low-grade forms associated with relatively better outcomes. Conversely, TP53 mutations in high-grade forms reduce apoptotic signals, leading to poor prognosis due to enhanced aggressiveness.\n\n**Potential Biases in Genomic Interpretation:**\nHistological sampling may preferentially capture superficial over invasive tumors, skewing mutation prevalence data and survival correlation analyses.\n\n### Sampling Bias\n\n**Limitations of Source Material:**\nRelying solely on blood-derived normals and primary tumors for genomic analyses can introduce biases; blood samples may not accurately reflect tumor heterogeneity or mutations exclusively present within the tumor, potentially leading to incomplete mutation profiling.\n\n**Impact on Survival Analysis:**\nBiological variation between circulating DNA and tumor DNA might result in misinterpretations of mutational significance, underestimating or overestimating genetic impact on survival rates.\n\n**Potential Biases in Genomic Interpretation:**\nThe absence of certain mutations in blood samples might mislead the perceived aggressiveness of the carcinoma, erroneously categorizing patient risk.\n\n### Key Genes Impacting Survival\n\n1. **FGFR3:**\n   - **Role:** Promotes cell proliferation.\n   - **Impact:** Often mutated in low-grade, less aggressive cancers, associated with better prognosis.\n\n2. **TP53:**\n   - **Role:** Regulates cell cycle and apoptosis.\n   - **Impact:** Commonly altered in high-grade cancers, leading to poor prognosis due to compromised cell cycle control.\n\n3. **PIK3CA:**\n   - **Role:** Influences the PI3K/AKT pathway.\n   - **Impact:** Activating mutations contribute to cell survival and proliferation, often linked with aggressive behavior.\n\n4. **ERBB2:**\n   - **Role:** Encodes HER2, promoting cell growth.\n   - **Impact:** Overexpression leads to increased tumor growth and poor survival odds.\n\n5. **CDKN2A:**\n   - **Role:** Cell cycle inhibitor.\n   - **Impact:** Loss of function mutations lead to unregulated proliferation, worsening outcomes.\n\n6. **TSC1:**\n   - **Role:** Tumor suppressor involved in mTOR signaling.\n   - **Impact:** Mutations can enhance tumor growth, negatively impacting survival when not functioning.\n\n7. **MLL/SETD2:**\n   - **Role:** Epigenetic regulators.\n   - **Impact:** Mutations affect chromatin remodeling, impacting differentiation and survival rates.\n\n### Synthesis of Key Survival Factors\n\n**Clinically Relevant Insights:**\n- Early detection and accurate staging, particularly regarding tumor origin and histological grading, are critical for improving survival outcomes.\n- Understanding specific mutation profiles in relation to histology can guide personalized therapeutic approaches, enhancing survival prospects.\n- Addressing genomic sampling biases through comprehensive tumor profiling, beyond just blood-derived and superficial tissue samples, will yield better survival predictions and tailored interventions.\n\n**Impact on Patient Survival:**\nIncorporating these genomic insights into routine diagnostics and considering potential biases are essential for optimizing treatment strategies and ultimately improving survival outcomes for bladder urothelial carcinoma patients."
        ],
        [
         "15",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A3IU, TCGA-DK-A3IQ, TCGA-FD-A62S, TCGA-FD-A3SP, TCGA-FD-A3SR, TCGA-FD-A3N5, TCGA-DK-AA77, TCGA-FD-A3NA, TCGA-FD-A3B5, TCGA-FD-A3SL, TCGA-K4-A6FZ, TCGA-BT-A3PK, TCGA-DK-A6B6, TCGA-BL-A5ZZ, TCGA-KQ-A41S, TCGA-ZF-AA56, TCGA-ZF-A9RD, TCGA-DK-A6B2, TCGA-ZF-AA5P, TCGA-DK-A3WW, TCGA-BL-A13J, TCGA-DK-AA6Q, TCGA-ZF-A9R0, TCGA-K4-A4AB, TCGA-FD-A5BY, TCGA-FD-A5BS, TCGA-GV-A3QG, TCGA-GV-A3QI, TCGA-SY-A9G0, TCGA-ZF-A9RN, TCGA-FD-A6TC, TCGA-FD-A5C0, TCGA-FD-A43N, TCGA-4Z-AA82, TCGA-FD-A5C1, TCGA-K4-A5RI, TCGA-BL-A13J, TCGA-BL-A13J, TCGA-FD-A5BX, TCGA-ZF-AA52, TCGA-FD-A43S, TCGA-FD-A62P, TCGA-XF-AAN8, TCGA-2F-A9KT",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "To address the various factors that influence survival in patients with Bladder Urothelial Carcinoma (specifically, as it relates to the posterior wall) in a structured and precise manner, letâ€™s break down each component:\n\n### Tumor Origin: Posterior Wall Bladder Influence\n\n1. **Impact on Metastatic Patterns and Survival:**\n\n   - **Influence on Survival:**\n     - Tumors originating in the posterior wall of the bladder can have specific implications for metastatic spread due to their anatomical location, which is near the ureters and other pelvic organs.\n     - This may facilitate local invasion and rapid dissemination to nearby lymph nodes, potentially negatively affecting survival outcomes.\n\n   - **Biological Rationale:**\n     - The proximity to vascular and lymphatic structures can contribute to increased metastatic potential, making early detection challenging and often leading to a diagnosis at a more advanced stage.\n     - Anatomically, posterior wall involvement may impede treatment, as precise surgical resection is necessary to avoid damage to surrounding structures.\n\n   - **Treatment Accessibility:**\n     - Treatment options may be restricted due to anatomical limitations, necessitating more complex surgical approaches. This complexity might hinder the timely initiation of treatment, impacting overall survival.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n2. **Histology and Mutation Profiles:**\n\n   - **Influence on Survival:**\n     - Transitional cell carcinoma (TCC) is the most common histological type of bladder cancer, which is characterized by a high propensity for genetic mutations such as TP53, FGFR3, and PI3K pathway alterations.\n     - Mutation profiles directly influence tumor behavior, including growth rate, metastatic potential, and drug resistance, impacting patient outcomes.\n\n   - **Biological Rationale:**\n     - Alterations in TP53 can lead to unregulated cell cycle progression and defective apoptosis, contributing to tumorigenic potential.\n     - Mutations in FGFR3 are often associated with low-grade tumors, whereas TP53 mutations are more prevalent in high-grade, invasive tumors, influencing treatment response.\n\n   - **Outcome Impacts:**\n     - Understanding the mutation spectrum can help stratify patients by risk and influence therapeutic strategies, thus tailoring survival predictions and interventions.\n\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\n\n3. **Limitations in Genomic Analysis:**\n\n   - **Impact on Survival Analysis:**\n     - Genomic sampling, such as relying on blood-derived normal controls, introduces biases as it may not capture the full mutational landscape of the primary tumor, leading to misinterpretation of clonal heterogeneity and variant allele frequency.\n     - This can result in an underestimation of tumor genetic complexity, affecting prognostic evaluations and targeted therapy development.\n\n   - **Biological Rationale:**\n     - Primary tumor samples provide direct insight into somatic mutations and tumor microenvironment interactions, which are critical for accurate genomic profiling and therapeutic targeting.\n     - Blood-derived normals may overlook subclonal populations, crucial for predicting resistance emergence and metastasis.\n\n### Key Genes: Survival Association\n\n4. **Genes Influencing Survival (5-8):**\n\n   - **TP53:** \n     - Involved in DNA damage response and apoptosis; mutations lead to poor prognosis due to aggressive tumor behavior.\n     \n   - **FGFR3:**\n     - Associated with cell proliferation; mutations often indicate lower-grade tumors with better outcomes, but can be misleading in absence of other markers.\n     \n   - **PIK3CA:**\n     - Important for cell growth and survival; alterations can lead to enhanced proliferation and survival of cancer cells, impacting drug resistance.\n\n   - **ERBB2 (HER2):**\n     - Overexpression is associated with aggressive disease; targeted therapies can alter survival significantly.\n\n   - **MDM2:**\n     - Regulates p53 degradation; overexpression leads to poorer outcomes as it mimics TP53 loss-of-function effects.\n\n   - **CDKN2A:**\n     - Loss impairs cell cycle arrest, facilitating unchecked proliferation and thus, poorer prognosis.\n\n5. **Conclusion:**\n\n   Synthesizing these insights, the major survival risk factors in Bladder Urothelial Carcinoma include the anatomical origin of the tumor, genetic profile, histological characteristics, and potential biases in genomic interpretation due to sample inconsistencies. Clinically, recognizing the interplay between these factors allows for more targeted treatment strategies, personalized patient care, and improved prognostic accuracy. Comprehensive genomic profiling, alongside precise anatomical and histological assessment, forms the basis for optimizing therapeutic interventions and enhancing patient survival in this cohort."
        ],
        [
         "16",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KO, TCGA-BT-A20J",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "Understanding the survival impact of Bladder Urothelial Carcinoma, specifically arising from the posterior wall of the bladder, necessitates a multifaceted examination of tumor origin, histology, genetic mutations, and sampling biases.\n\n1. **Tumor Origin: Posterior Wall Bladder**\n   - **Metastatic Patterns**: Tumors originating from the posterior wall have distinct implications due to their proximity to the trigone of the bladder, affecting the spread to pelvic lymph nodes and potentially facilitating earlier metastatic dissemination to common iliac and para-aortic nodes, impacting survival negatively.\n   - **Patient Survival and Treatment Accessibility**: Tumors in this location may present challenges in terms of resectability, given the vicinity to crucial anatomical structures like the ureters and seminal vesicles in males or the uterus in females. This can influence surgical margins and complicate complete local excision, often leading to poorer outcomes.\n   - **Survival Influence**: Overall, posterior wall origin can complicate treatment strategies, potentially reducing survival rates due to the difficulty in achieving clear surgical margins and increased likelihood of metastatic spread.\n\n2. **Histology: Transitional Cell Carcinoma, NOS**\n   - **Mutation Profiles and Outcomes**: Transitional cell carcinoma, representing more than 90% of bladder cancers, commonly exhibits mutations in genes like FGFR3, TP53, and PIK3CA. FGFR3 mutations often correlate with a less aggressive phenotype and better survival, whereas TP53 mutations are associated with more aggressive disease.\n   - **Survival Influence**: The variability in mutation profiles underscores differential prognostic outcomesâ€”distinct mutational landscapes can drive more aggressive behavior, influencing treatment resistance and thus affecting survival.\n   - **Rationale**: The histological type dictates the fundamental biological behavior of tumors, providing therapeutic targets which can modify survival outcomes through tailored treatment plans.\n\n3. **Sampling Bias in Genomic Analysis**\n   - **Primary Tumor vs. Solid Tissue Normal**: Genomic studies often compare primary tumor samples with adjacent normal tissues. However, \"normal\" tissue may already harbor premalignant changes, skewing results and potentially downplaying certain mutations or pathways that appear less significant.\n   - **Survival Influence**: This bias can lead to incomplete understanding of oncogenic drivers, affecting treatment decisions based on flawed genomic interpretations, ultimately influencing survival negatively.\n   - **Rationale**: Accurate sampling is crucial for precise mutation identification and subsequent treatment planning, emphasizing the need for careful interpretation of genomic data.\n\n4. **Key Genes Affecting Survival**\n   - **TP53**: Mutations lead to defective cell cycle control and apoptosis, typically signifying poorer prognosis.\n   - **FGFR3**: Mutations often result in better-prognosis superficial tumors due to less aggressive behavior.\n   - **PIK3CA**: Involved in cell proliferation; mutations here can indicate a role in more aggressive disease subsets.\n   - **TSC1**: Mutated in some cases, influences mTOR pathway, with implications on tumor growth and survival.\n   - **RB1**: Its inactivation is linked to tumor progression and resistance to therapy.\n   - **ERBB2 (HER2)**: Overexpression can lead to increased cell proliferation, often indicating a more aggressive clinical course.\n   - **KDM6A**: Tumor suppressor gene, whose loss is linked to poor differentiation and aggressive phenotypes.\n\n   - **Survival Mechanisms**: Mutations and alterations in these genes affect survival through mechanisms impacting proliferation, apoptosis, and interaction with treatment modalities.\n\n**Conclusion**\nIn synthesis, survival factors in bladder cancer with posterior wall origin are heavily influenced by the anatomical tumor origin, histological subtype-driven mutations, genetic alterations in specific oncogenes and tumor suppressors, and potential biases in genomic sampling. Clinically, these insights facilitate personalized therapies and prognostic assessments, aiding in stratifying patients for more aggressive monitoring or innovative treatment approaches, ultimately aiming to enhance survival outcomes."
        ],
        [
         "17",
         "BLCA",
         "C67.4",
         "8130/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A5RJ, TCGA-BT-A42E, TCGA-FD-A3B6, TCGA-FD-A43X, TCGA-4Z-AA81",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "To address the impact of Bladder Urothelial Carcinoma (specifically from the posterior wall of the bladder) on patient survival, we need to consider multiple intertwined factors: tumor origin, histology, sampling bias, and key genetic mutations.\n\n### Tumor Origin\n- **Influence on Metastatic Patterns:** Tumors originating from the posterior bladder wall often show distinct metastatic behavior due to their proximity to pelvic structures. This can facilitate local invasion or early metastasis to pelvic lymph nodes, negatively impacting survival rates. Moreover, posterior wall tumors may be less accessible surgically, complicating complete resection.\n- **Treatment Accessibility:** The location can affect treatment accessibility. Posterior wall tumors may require more complex surgical routes or may not be amenable to certain local therapies like intravesical chemotherapy, impacting therapeutic success and survival outcomes.\n\n### Histology\n- **Papillary Transitional Cell Carcinoma (PTCC):** This is the most common subtype of bladder cancer. PTCC typically presents with a better initial prognosis due to its papillary nature, allowing earlier detection and intervention. However, if it progresses, especially with high-grade features, it can have aggressive behaviors influenced by specific genetic mutations.\n- **Mutation Profiles:** Mutations in TP53, FGFR3, and PIK3CA are commonly associated with PTCC, each influencing survival differently. TP53 mutations are linked with aggressive disease and poorer outcomes due to impaired apoptosis and cell cycle regulation, whereas FGFR3 mutations often correlate with low-grade tumors and better prognosis due to their association with cell proliferation pathways.\n\n### Sampling Bias\n- **Blood Derived Normal vs. Primary Tumor:** Blood-derived samples may not accurately reflect the tumor's mutational landscape. This discrepancy can lead to biases in genomic analysis, such as underestimating tumor heterogeneity or missing mutations that confer aggressive phenotypes.\n- **Impact on Survival Analysis:** Reliance on non-tumor tissues can skew survival predictions by not accounting for specific tumor-exclusive genetic changes that drive behavior and treatment responses.\n\n### Key Genes Impacting Survival\n1. **TP53:** A tumor suppressor gene often mutated in aggressive bladder cancers, leading to loss of apoptosis and genomic instability, negatively affecting survival.\n2. **FGFR3:** Mutations are frequent in low-grade PTCC, driving cell proliferation via receptor tyrosine kinase pathways, typically associated with better outcomes if targeted therapeutically.\n3. **PIK3CA:** Involved in the PI3K/AKT pathway; mutations can promote tumor growth and survival, making it a potential therapeutic target to improve survival.\n4. **ERBB2 (HER2):** Amplification can contribute to aggressive tumor behavior through enhanced growth signaling pathways, posing a negative impact on survival if not targeted appropriately.\n5. **CDKN2A:** Deletions or mutations can disable regulation of the cell cycle, often correlating with more aggressive disease phenotypes and poor prognosis.\n6. **RB1:** Loss-of-function mutations contribute to unchecked cell cycle progression, increasing malignancy and reducing survival likelihood.\n7. **TSC1/TSC2:** Tumor suppressors implicated in low-grade forms but loss can switch phenotype to a more aggressive form, impacting survival.\n8. **ARID1A:** Its inactivation may confer resistance to certain therapies while driving mutations can degrade chromatin regulation, impacting patient prognosis adversely.\n\n### Synthesis\nIn conclusion, the posterior wall origin of bladder urothelial carcinoma directly influences metastatic potential and treatment challenges. Histological subtypes like papillary transitional cell carcinoma and its associated mutations play pivotal roles in determining patient outcomes. Sampling biases in genomic analysis need careful consideration to accurately depict the genomic underpinnings driving survival. Collectively, a thorough understanding and intervention targeted at these genetic and clinical factors can significantly influence survival trajectories, offering personalized treatment opportunities and improving patient outcomes."
        ],
        [
         "18",
         "BLCA",
         "C67.5",
         "8120/3",
         "C67.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FT-A3EE",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Unknown Influence on Metastatic Patterns, Patient Survival, and Treatment Accessibility\n\n1. **Tumor Origin**: Bladder Urothelial Carcinomas (BUC) typically originate from the urothelium, the layer of tissue lining the bladder. When the specific origin subtype is unknown or unclassified, there can be implications for clinical decision-making and anticipated metastatic patterns.\n\n2. **Influence on Metastasis and Survival**: Tumors of unknown origin may be less predictable in their metastatic pathways. This lack of specific site origin knowledge may hinder accurate risk stratification. Metastases typically proceed to pelvic lymph nodes, bone, liver, and lungs, but unknown origins could alter this expectation, affecting targeted surveillance and management strategies. Resultantly, survival could negatively impact if metastasis occurs unexpectedly or is under-monitored.\n\n3. **Treatment Accessibility**: Knowing the specific tumor origin can guide eligibility for targeted therapies or clinical trials, influencing therapeutic plans and potentially limiting access when the origin is uncertain. This may reduce survival rates as options are constricted.\n\n### Histology: Interaction of Transitional Cell Carcinoma, NOS and Mutation Profiles\n\n1. **Histology**: The predominant histological type for BUC is transitional cell carcinoma, Not Otherwise Specified (NOS). This classification lacks detailed subtype information that could guide personalized treatment.\n\n2. **Mutation Profiles and Survival**: The mutation profile in transitional cell carcinoma includes common aberrations like FGFR3, TP53, and RB1. These genetic alterations can vary survival outcomes:\n   - FGFR3 mutations often correlate with non-invasive tumors with relatively better prognoses.\n   - TP53 and RB1 mutations are linked to higher-grade, aggressive cancers, associated with poorer survival.\n\n3. **Biological Rationale**: FGFR3 mutations may enhance proliferation but remain susceptible to less aggressive treatment outcomes, while TP53 and RB1 deficiencies often derail cell cycle regulation and apoptosis, leading to aggressive tumor behavior and reduced survival.\n\n### Sampling Bias: Limitations of Blood Derived Normal and Primary Tumor in Genomic Analysis\n\n1. **Sampling Bias**: Using blood-derived normal and primary tumor samples can introduce biases. Blood-derived normals might not reflect true somatic mutation burdens due to clonal hematopoiesis. Primary tumors may not encompass the full genomic scope inclusive of metastases.\n\n2. **Influence on Genomic Interpretations**: Sampling limitations can lead to skewed mutational landscapes or oversight of subclonal populations contributing to treatment resistance, potentially misinforming survival estimations.\n\n### Key Genes: Survival-Associated Genes and Biological Mechanisms\n\n1. **TP53**: Mutations impair DNA repair and promote genomic instability, negatively influencing survival.\n\n2. **FGFR3**: Frequently mutated in low-grade, non-invasive tumors, possessing potentially protective effects on overall survival when not concurrent with other mutations.\n\n3. **RB1**: Loss of function leads to unregulated cell cycle progression, associated with negative survival due to facilitation of tumor progression.\n\n4. **PIK3CA**: Mutations activate PI3K/AKT signaling, promoting survival pathways and tumor growth, often leading to poorer outcomes when present with other aggressive mutations.\n\n5. **ERBB2 (HER2)**: Overexpression or amplification can drive uncontrolled proliferation, with implications for targeted HER2 therapies and mixed survival impacts.\n\n6. **CDKN2A**: Inactivation via deletion results in loss of cell cycle control, correlating with worse survival due to enhanced proliferative capacity.\n\n7. **ARID1A**: Loss-of-function mutations affect chromatin remodeling, often found co-mutated with PIK3CA, complicating prognosis due to therapy resistance arrangements.\n\n8. **TSC1/TSC2**: Mutations foster mTOR pathway activation and cellular proliferation, potentially mitigating responses to immune checkpoints.\n\n### Synthesis of Key Survival Risk Factors\n\n- **Clinically Relevant Insights**: The interplay of mutation profiles, histological classification, origin clarity, and sampling quality are critical in understanding BUC prognosis. FGFR3 mutations in isolation may denote favorable outcomes, whereas TP53, RB1, and complex mutational networks suggest advanced disease and poorer survival.\n\n- **Impact on Patient Survival**: Survival is worsened by aggressive genetic profiles, less specific histological categorization, and origin uncertainties. Precision in sampling and integration of genomic data are vital for prognosis estimation and therapeutic decision-making, highlighting a need for comprehensive profiling in clinical practice."
        ],
        [
         "19",
         "BLCA",
         "C67.6",
         "8120/3",
         "C67.6",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-KQ-A41N",
         "Ureteric orifice",
         "Ureteric orifice",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Ureteric Orifice\n\n**Influence on Survival:**\n- **Metastatic Patterns:** Tumors originating in the ureteric orifice can spread either upwards to the renal pelvis or downwards to the bladder, influencing survival negatively due to complex metastatic pathways and potential dissemination to distant sites.\n- **Treatment Accessibility:** Anatomical positioning may complicate surgical approaches, making local resection challenging, which can adversely affect survival rates by limiting effective removal of cancerous tissues.\n   \n**Biological Rationale:**\n- The ureteric orifice acts as a critical junction between the kidney and the bladder, allowing for diverse metastatic routes. This anatomical feature can lead to early metastasis due to vascular and lymphatic proximity, reducing survival prospects.\n  \n**Potential Biases:**\n- Sampling biases can occur when distinguishing localized vs. metastatic disease in the ureteric orifice, leading to misclassification that influences survival statistics.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n**Influence on Survival:**\n- The nonspecific nature of â€œNOSâ€ (not otherwise specified) may complicate prognostic predictions, generally resulting in moderate survival projections due to uncertainty and variability in aggressiveness.\n\n**Biological Rationale:**\n- **Mutation Profiles:** Transitional cell carcinoma (TCC) is prone to specific mutations in oncogenes or tumor suppressor genes (e.g., FGFR3, TP53), which drive variabilities in tumor growth rates and immune evasion abilities, influencing survival outcomes.\n  \n**Potential Biases:**\n- Histological analysis may overlook minor variants or hybrid forms of TCC, which could affect the accuracy of survival projections.\n\n### Sampling Bias: Blood Derived Normal, Primary Tumor in Genomic Analysis\n\n**Influence on Survival:**\n- **Accuracy of Genomic Insight:** The use of blood-derived normal samples can misrepresent mutational burdens, skewing survival-associated data by not accurately reflecting tumor-specific genetics.\n\n**Biological Rationale:**\n- Blood-derived reference assumptions may not capture tumor-specific somatic mutations accurately, potentially undermining tailored approaches to treatment that could enhance survival rates.\n\n**Potential Biases:**\n- Discrepancies in mutation profiles due to sampling sources (blood vs. primary tumor) may lead to inconsistent interpretations in survival studies, particularly in terms of targeted therapies.\n\n### Key Genes and Their Biological Mechanisms\n\n1. **TP53**  \n   - **Influence on Survival:** Mutations in TP53 are associated with poor prognosis due to disruptions in cell cycle regulation and apoptosis, leading to uncontrolled cell proliferation.\n   \n2. **FGFR3**  \n   - **Influence on Survival:** Generally linked to lower-grade, non-invasive tumors. Mutations can be predictive of relatively better outcomes unless they coexist with other high-risk mutations.\n   \n3. **PIK3CA**  \n   - **Influence on Survival:** Activation of this gene through mutations leads to cell survival and proliferation, impacting negatively on long-term survival due to enhanced oncogenic signaling.\n   \n4. **ERBB2 (HER2)**  \n   - **Influence on Survival:** Overexpression or amplification is associated with aggressive tumor behavior and reduced survival, due to its role in promoting tumor cell growth and survival.\n   \n5. **RB1**  \n   - **Influence on Survival:** Loss of function mutations correlate with poor prognosis due to disturbed cell cycle control and enhanced genomic instability.\n   \n6. **CDKN2A**  \n   - **Influence on Survival:** Deletions/mutations often result in poorer outcomes via impaired suppression of cellular growth signals.\n   \n7. **TERT**  \n   - **Influence on Survival:** TERT promoter mutations increase telomerase activity contributing to cellular immortality, negatively impacting survival by fostering sustained growth and division.\n\n**Biological Rationale:**\n- These genes, through diverse pathways such as cell cycle regulation, apoptosis, and cellular proliferation, dictate the pace at which tumors grow and spread.\n\n### Concluding Synthesis\n\n- **Key Survival Risk Factors:** Anatomical position (ureteric orifice) impacts metastasis, while TCCâ€™s histology and gene mutation profiles (TP53, FGFR3, etc.) define cellular behavior. Sampling biases often obscure true genetic landscapes, influencing clinical decision-making.\n- **Clinically Relevant Insights:** Accurate histopathological classification and genomic profiling, particularly using primary tumor samples, are vital for reliable prognostic assessments. Understanding site-specific dissemination patterns and mechanics at a molecular level enhances individualized patient care, thereby improving survival outcomes."
        ],
        [
         "20",
         "BLCA",
         "C67.9",
         "8010/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-ZF-AA4N",
         "Bladder NOS",
         "Bladder NOS",
         "Carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "Certainly! Let's approach the analysis of Bladder Urothelial Carcinoma (Bladder NOS) and its impact on patient survival by segmenting it into key components:\n\n### Tumor Origin\n\n**1. Influence on Survival:**\n- **Metastatic Patterns:** Bladder Urothelial Carcinoma (UC) often originates from the urothelial cells lining the bladder. These tumors have a predilection to metastasize to lymph nodes, bones, liver, and lungs, which can dramatically decrease survival rates.\n\n**2. Biological Rationale:**\n- **Tumor Plasticity:** The urothelial origin facilitates a diverse mutation spectrum, which includes transitional cell characteristics promoting spread and metastatic ability.\n\n**3. Potential Bias:**\n- **Clinical Presentation:** Misclassification in ICD codes can lead to varied recorded outcomes, affecting survival statistics if \"Bladder NOS\" is interchangeably used without histological clarification.\n\n### Histology\n\n**1. Influence on Survival:**\n- **Carcinoma, NOS Types:** Variants of urothelial carcinoma often display different mutation profiles, affecting therapeutic responsiveness. Histological grading (G1-G3) frequently correlates with prognosis, with high-grade tumors showing poorer outcomes.\n\n**2. Biological Rationale:**\n- **Mutation Influence:** Differences in histologic variants, especially presence of squamous and glandular differentiation, impact the tumorâ€™s aggressiveness and subsequent survival.\n\n**3. Potential Bias:**\n- **Sampling Biases:** Definitions of carcinoma NOS can lead to underrecognition of unique histological subtypes, skewing survival data if these arenâ€™t differentiated.\n\n### Sampling Bias\n\n**1. Influence on Survival:**\n- **Genomic Analysis Limitations:** Discrepancies between blood-derived normal and primary tumor sampling can lead to biased interpretations of somatic mutationsâ€™ oncogenic significance.\n\n**2. Biological Rationale:**\n- **Varying Mutational Landscape:** Tumor heterogeneity introduces distinct somatic mutations in different parts of the tumor, potentially overlooked in more homogeneous blood-derived samples.\n\n**3. Potential Bias:**\n- **Analysis Variability:** False negatives/positives in mutation analysis could underestimate or overestimate the genomic impact on survival.\n\n### Key Genes\n\nIn Bladder Urothelial Carcinoma, several key genes play a crucial role in survival, through various biological mechanisms:\n\n**1. FGFR3 (Fibroblast Growth Factor Receptor 3):**\n- **Mechanism:** Impacts cell proliferation and survival, commonly mutated in low-grade non-muscle invasive bladder cancers, often indicative of a favorable prognosis.\n\n**2. TP53 (Tumor Protein 53):**\n- **Mechanism:** Crucial in genome stability and apoptosis. Mutations suggest higher tumor aggression and poorer survival rates.\n\n**3. RB1 (Retinoblastoma 1):**\n- **Mechanism:** Governs cell cycle regulation. Loss-of-function mutations correlate with more aggressive tumor behavior and lower survival.\n\n**4. PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha):**\n- **Mechanism:** Modulates PI3K/AKT signaling pathway, driving growth. Its mutations might signal a more aggressive course.\n\n**5. TERT (Telomerase Reverse Transcriptase):**\n- **Mechanism:** Lengthens telomeres, promoting immortality in cancer cells. Common mutations associate with invasive tumors and poor prognosis.\n\n### Synthesizing Key Survival Risk Factors\n\nIn conclusion, survival in Bladder Urothelial Carcinoma centers around a complex interplay of tumor origin, histology, sampling biases, and genetic underpinnings. Histological differentiation, presence and type of mutations (e.g., in TP53, FGFR3, RB1), and the precise genomic landscape revealed by unbiased sampling are critical. Clinically, focusing on early detection of high-risk histological and genetic markers can optimize therapeutic strategies, potentially improving patient outcomes significantly. Understanding and addressing these facets in patient management could enhance predictive accuracy for survival and guide personalized therapeutic approaches."
        ],
        [
         "21",
         "BLCA",
         "C67.9",
         "8070/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A1HS",
         "Bladder NOS",
         "Bladder NOS",
         "Squamous cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "**Bladder Urothelial Carcinoma (Bladder NOS) and Survival Impact**\n\n**1. Tumor Origin and Its Influence on Survival**\n\n- **Influence on Survival:**\n  - Bladder Urothelial Carcinoma generally arises from the epithelial lining of the urinary bladder and is often classified as Bladder NOS when further specification is not available. The location in the urinary system allows for ease of regional spread and potential metastasis to distant sites such as the lungs, bones, and liver. Patients with advanced disease often experience poorer survival outcomes due to these metastatic patterns.\n\n- **Biological Rationale:**\n  - The urothelium is a transitional epithelium, which means it undergoes regular cycles of stretching and contracting. This cellular plasticity can contribute to genetic instability, promoting tumorigenic mutations. \n\n- **Potential Bias:**\n  - Studies focusing solely on primary bladder tumors might underestimate the genomic alterations involved in metastasis, obscuring a full understanding of survival implications.\n\n**2. Histology Interacting with Mutation Profiles**\n\n- **Influence on Survival:**\n  - Squamous cell carcinoma within the bladder, while less common than transitional cell carcinoma, tends to be associated with more aggressive behavior and worse survival outcomes due to its invasive nature.\n\n- **Biological Rationale:**\n  - Histologically, these tumors are characterized by dysregulated squamous differentiation often driven by chronic irritation or infection. Genetic studies suggest that these are frequently accompanied by mutations in genes relevant to cell cycle regulation and apoptosis, such as TP53 and PIK3CA, contributing to aggressive growth.\n\n- **Potential Bias:**\n  - Because squamous differentiation is rare, limited sample size can skew genomic data interpretation, underrepresenting its impact on broader bladder cancer survival statistics.\n\n**3. Sampling Bias in Genomic Analysis**\n\n- **Influence on Survival:**\n  - Using blood-derived normal samples as controls in genomic studies can introduce biases. Primary tumor samples might not capture the full landscape of genetic alterations present.\n\n- **Biological Rationale:**\n  - Blood-derived samples may reflect only systemic mutations and fail to reveal local genomic changes critical to cancerous behavior. Consequently, mutation studies may overemphasize systemic mutations while neglecting tumor-specific alterations.\n\n- **Potential Bias:**\n  - This may lead to an incomplete understanding of gene mutations that impact survival, particularly those involved in local invasion and metastasis.\n\n**4. Key Genes Affecting Survival**\n\n- **Influence on Survival (with mechanisms):**\n  - **TP53:** Loss of function here is linked to impaired apoptosis, contributing to tumor progression.\n  - **FGFR3:** Mutations often lead to uninterrupted cellular signaling promoting unchecked proliferation.\n  - **PIK3CA:** Alters cell growth and survival pathways, facilitating increasing malignancy.\n  - **ERBB2 (HER2):** Overexpression encourages rapid cell division and is associated with poor prognosis.\n  - **CDKN2A:** Loss of this tumor suppressor disrupts the cell cycle checkpoints.\n  - **ARID1A:** Mutations here affect chromatin remodeling, gene expression regulation, potentially altering cancer susceptibility.\n\n- **Potential Bias:**\n  - Relying on datasets that exclude or underrepresent mutations from advanced metastatic sites fails to fully elucidate their roles in survival, thereby potentially misguiding therapeutic targets.\n\n**Synthesis and Clinical Insights**\n\nBladder Urothelial Carcinoma impacts survival significantly through a combination of anatomical, histological, and genetic factors. From origin-driven metastasis patterns to specific mutational profiles that disrupt growth and apoptosis regulation, each factor contributes uniquely to patient outcomes. Recognizing the limitations of present sampling strategies and understanding key survival-related genetic alterations, clinicians can refine prognostic assessments and tailor therapeutic interventions more precisely. As such, advancing our grasp of these survival determinants can critically enhance targeted treatment, ultimately improving patient survival rates."
        ],
        [
         "22",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-DK-A1A6",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Metastatic",
         "## Tumor Origin\n\n### Influence on Survival\nBladder Urothelial Carcinoma (BUC), coded as Bladder NOS under ICD-10, originates in the epithelial lining of the bladder. This origin significantly influences the pattern of metastasis, often spreading to regional lymph nodes, lungs, liver, and bones. The extent and pattern of metastatic spread have a direct negative impact on survival rates.\n\n### Biological Rationale\nThe urothelial origin means the carcinoma primarily affects transitional epithelium, which allows it to invade surrounding tissue easily due to inherent flexibility and less rigid cellular adhesion. This biological trait enables early local invasion and facilitates further systemic dissemination.\n\n### Treatment Accessibility\nBladder NOS might limit treatment options due to challenges in acquiring a precise histopathological diagnosis. Without definitive subclassification, patients may not receive the most tailored therapeutics, negatively affecting survival.\n\n## Histology\n\n### Influence on Survival\nThe predominant histological type, Transitional Cell Carcinoma (NOS), often correlates with specific mutation profiles that impact prognosis and therapeutic outcomes. The presence and pattern of mutations can significantly affect cellular behavior such as growth and invasion, thereby influencing survival.\n\n### Biological Rationale\nThis specific histology often exhibits mutations in genes like TP53, FGFR3, and RB1. These mutations can lead to uncontrolled cell proliferation, disruptions in apoptosis, and increased invasive potential, directly affecting tumor aggressiveness and patient survival negatively.\n\n## Sampling Bias\n\n### Influence on Genomic Analysis\nThe use of blood-derived normals or metastatic tissue for genomic analyses introduces potential biases. These sampling methods might not fully represent the tumorâ€™s genomic landscape, missing crucial mutations present in the primary tumor.\n\n### Biological Rationale\nBlood samples generally reflect germline DNA and may not capture somatic mutations. Additionally, analyzing metastatic lesions may emphasize evolutionarily late mutations, missing early drivers crucial for understanding primary tumorigenesis.\n\n## Key Genes\n\n### Influence on Survival\n1. **TP53**: Often mutated, leading to loss of cell cycle control and increased genomic instability. Negative influence due to its role in unchecked growth and progression.\n2. **FGFR3**: Mutations can lead to continuous cell proliferation signaling, influencing early-stage tumor growth negatively.\n3. **PIK3CA**: Alters pathways involved in growth and survival, contributing to chemotherapy resistance when mutated, lowering survival.\n4. **RB1**: Loss of function results in disturbed G1 to S phase cell cycle transition, leading to aggressive tumor behavior.\n5. **TP63**: Regulative functions in cell proliferation and apoptosis, with negative impacts tied to its alterations.\n6. **ERBB2**: Amplifications lead to enhanced signaling for growth and survival, potentially increasing metastatic potential.\n7. **MAML1**: Involved in NOTCH signaling, mutations can disrupt cell differentiation, affecting invasive potential.\n\n### Biological Rationale\nEach geneâ€™s alteration disrupts vital cellular functions, affecting tumor growth (e.g., cell cycle regulation by TP53 and RB1), invasion, and resistance to apoptosis, which cumulatively drive poor survival.\n\n## Synthesis and Conclusion\n\n### Key Survival Risk Factors\nThe survival impact in Bladder Urothelial Carcinoma is multifaceted, involving tumor origin, histology-related mutation profiles, and biases in sample selection impacting genomic insights. Clinically, identifying and understanding the intricate interactions of key genes like TP53 and FGFR3 aid in tailoring therapeutic strategies to improve survival outcomes.\n\n### Clinical Insights\nAddressing these factors involves refining diagnostic precision, employing comprehensive genomic profiling that accurately reflects the tumorâ€™s evolutionary state, and designing therapies that target specific genetic alterations. Enhanced diagnostic accuracy and personalized therapeutic approaches represent the most significant opportunities to improve survival rates and manage Bladder Urothelial Carcinoma more effectively."
        ],
        [
         "23",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-C4-A0EZ, TCGA-GV-A40G, TCGA-DK-A3IS, TCGA-GV-A40E, TCGA-DK-A2HX, TCGA-ZF-AA53, TCGA-HQ-A5ND, TCGA-E7-A7PW, TCGA-DK-A1A7, TCGA-GD-A3OQ, TCGA-C4-A0F0, TCGA-2F-A9KW, TCGA-UY-A78O, TCGA-4Z-AA87, TCGA-5N-A9KI, TCGA-C4-A0F6, TCGA-XF-A9SL, TCGA-XF-A9T3, TCGA-UY-A8OC, TCGA-GD-A76B, TCGA-YC-A9TC, TCGA-GC-A3I6, TCGA-SY-A9G5, TCGA-XF-AAMR, TCGA-XF-A9SY, TCGA-DK-A1AD, TCGA-XF-AAMJ, TCGA-5N-A9KM, TCGA-DK-A1A6, TCGA-CU-A3QU, TCGA-ZF-A9R3, TCGA-K4-A83P, TCGA-XF-A9T2, TCGA-E7-A97Q, TCGA-CU-A72E, TCGA-GC-A3RC, TCGA-UY-A9PH, TCGA-GU-AATO, TCGA-E7-A677, TCGA-ZF-A9R9, TCGA-XF-A8HD, TCGA-BL-A13I, TCGA-BL-A13I, TCGA-GU-A766, TCGA-XF-AAN0, TCGA-XF-A9SW, TCGA-DK-A1AB, TCGA-XF-AAMX, TCGA-ZF-A9RF, TCGA-ZF-A9RL, TCGA-K4-A4AC, TCGA-E7-A7XN, TCGA-LC-A66R, TCGA-CF-A8HX, TCGA-GC-A6I1, TCGA-XF-A9T0, TCGA-G2-A2EK, TCGA-ZF-AA4W, TCGA-GU-A762, TCGA-E7-A519, TCGA-XF-A9SP, TCGA-CU-A5W6, TCGA-FT-A61P, TCGA-XF-A8HF, TCGA-BT-A3PH, TCGA-YC-A89H, TCGA-KQ-A41O, TCGA-XF-A9SX, TCGA-GU-A42Q, TCGA-ZF-A9R5, TCGA-GU-AATQ, TCGA-XF-AAN4, TCGA-XF-AAMT, TCGA-ZF-AA4R, TCGA-GU-A767, TCGA-G2-AA3C, TCGA-XF-AAN5, TCGA-XF-A8HG, TCGA-E7-A85H, TCGA-H4-A2HQ, TCGA-LT-A5Z6, TCGA-ZF-A9R1, TCGA-DK-A1AF, TCGA-ZF-AA5N, TCGA-UY-A8OD, TCGA-4Z-AA7Q, TCGA-CU-A0YR, TCGA-C4-A0F7, TCGA-CU-A3KJ, TCGA-GU-A42P, TCGA-K4-A3WU, TCGA-DK-A1AA, TCGA-G2-A3IE, TCGA-GC-A3WC, TCGA-HQ-A2OE, TCGA-DK-A2I2, TCGA-E7-A678, TCGA-GC-A3OO, TCGA-XF-AAN3, TCGA-GV-A3JW, TCGA-G2-AA3B, TCGA-CF-A1HR, TCGA-DK-A1AE, TCGA-E7-A5KE, TCGA-E7-A5KF, TCGA-BT-A0S7, TCGA-FJ-A3Z7, TCGA-CF-A8HY, TCGA-XF-A8HE, TCGA-E7-A4XJ, TCGA-FJ-A3ZE, TCGA-GD-A6C6, TCGA-C4-A0F1, TCGA-GC-A4ZW, TCGA-GC-A6I3, TCGA-XF-A9SJ, TCGA-XF-A9SH, TCGA-G2-A2EJ, TCGA-XF-AAME, TCGA-DK-A1A3, TCGA-E5-A4TZ, TCGA-G2-AA3D, TCGA-KQ-A41R, TCGA-ZF-AA4X, TCGA-BL-A13I, TCGA-XF-A9T5, TCGA-E7-A3Y1, TCGA-UY-A9PE, TCGA-GV-A3QK, TCGA-GV-A3JV, TCGA-XF-AAMW, TCGA-ZF-AA51, TCGA-BT-A0YX, TCGA-ZF-AA4T, TCGA-XF-AAMH, TCGA-DK-A1AC, TCGA-4Z-AA84, TCGA-XF-A9SK, TCGA-DK-A1A5, TCGA-GC-A3RB, TCGA-PQ-A6FI, TCGA-XF-A8HH, TCGA-ZF-AA5H, TCGA-E7-A8O7, TCGA-ZF-AA58, TCGA-E7-A97P, TCGA-G2-A2EC, TCGA-GD-A3OP, TCGA-ZF-A9R4, TCGA-XF-AAMG, TCGA-XF-A9T8, TCGA-GC-A3YS, TCGA-K4-A3WS, TCGA-UY-A78M, TCGA-E5-A4U1, TCGA-G2-A2EF, TCGA-GD-A3OS, TCGA-ZF-A9RE, TCGA-DK-A3IM, TCGA-CF-A5U8, TCGA-UY-A78N, TCGA-ZF-AA4U, TCGA-GD-A2C5, TCGA-S5-A6DX, TCGA-ZF-A9RM, TCGA-XF-AAMF, TCGA-XF-AAN2, TCGA-G2-AA3F, TCGA-GV-A3JZ, TCGA-XF-AAN7, TCGA-G2-A3IB, TCGA-XF-A9SM, TCGA-CF-A5UA, TCGA-ZF-AA4V, TCGA-G2-A3VY, TCGA-ZF-A9R7, TCGA-GV-A3JX, TCGA-HQ-A5NE, TCGA-XF-A9SZ, TCGA-K4-A3WV, TCGA-XF-A9T4",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Bladder NOS\n\n1. **Metastatic Patterns & Survival**: Bladder urothelial carcinoma (UC), when classified as Bladder NOS, lacks specific sub-group identification but generally follows recognized metastatic routes typical for urothelial tumors. These include nodal spread and distant metastasis, often to the bones, liver, and lungs. The general prognosis is poorer for advanced metastatic cases.\n\n2. **Treatment Accessibility**: Bladder NOS categories can sometimes lead to non-specific treatment routing if critical histological details are omitted. This may result in non-optimal therapeutic strategies, impacting survival negatively.\n\n### Histology: Transitional Cell Carcinoma, NOS\n\n1. **Mutation Profiles & Outcomes**: Transitional cell carcinoma (TCC), a subtype of bladder UC, often presents alterations in genes like TP53, FGFR3, and RB1. Mutations in TP53 correlate with more aggressive disease, whereas FGFR3 mutations, often associated with low-grade tumors, can have less impact on survival if appropriately targeted.\n\n2. **Prognostic Implications**: The histological grade and stage are critical determinants of survival, with higher grade and stage linked to aggressive disease and poorer outcomes. Understanding these interactions can guide interventions.\n\n### Sampling Bias in Genomic Analysis\n\n1. **Blood-Derived Normal vs. Primary Tumor Samples**: Utilizing blood-derived normal samples for comparative analyses can introduce biases, particularly in detecting tumor-specific mutations. Differences in clonal populations between blood and primary tumor samples can misrepresent mutation burdens or lead to oversight of certain oncogenic drivers.\n\n2. **Impact on Genomic Interpretation**: Reliance on a single type of tissue can result in skewed data, which may impact treatment decisions, such as the use of targeted therapies. It can also obscure understanding of tumor heterogeneity, affecting prognostic assessments.\n\n### Key Genes Associated with Survival\n\n1. **TP53**: This tumor suppressor gene, frequently mutated in high-grade UC, is involved in cell cycle control. Mutations result in loss of apoptotic regulation, leading to unchecked proliferationâ€”negatively impacting survival.\n\n2. **FGFR3**: Mutations here are common in lower-grade tumors and may suggest a more favorable prognosis if targeted therapies are utilized.\n\n3. **RB1**: Loss of function in this gene disrupts cell cycle regulation, correlating with poorer outcomes due to aggressive tumor growth.\n\n4. **PIK3CA**: Activating mutations impact PI3K signaling pathways, promoting growth and survival. Its presence suggests potential therapeutic targeting but generally indicates worse prognosis.\n\n5. **ERBB2 (HER2)**: Overexpression or amplification can drive tumor proliferation. While negative for prognosis, it opens avenues for targeted therapies, potentially mitigating survival declines.\n\n6. **MDM2**: Amplification or overactivity leads to p53 inhibition, impacting cell cycle arrest and apoptosis, driving poor survival outcomes.\n\n7. **TERT**: Mutations in the promoter region can lead to increased telomerase activity, contributing to immortality of cancer cells and aggressive disease.\n\n### Conclusion\n\nBladder Urothelial Carcinoma, under the NOS classification, highlights critical survival determinants driven by tumor origin, histological insights, genetic aberrations, and potential sampling biases. The interplay of histology, precise gene mutations, and the resultant signaling pathways substantially influences patient prognosis. Correct characterization and understanding of these factors enable optimal therapeutic strategies aimed at improving survival outcomes. Clinicians should strive for accurate histological classification and comprehensive genomic profiling to leverage targeted treatments effectively and address survival disparities within this patient population."
        ],
        [
         "24",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KQ, TCGA-UY-A78P, TCGA-UY-A8OB, TCGA-G2-A2ES, TCGA-BL-A3JM",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "## Tumor Origin\n\n### Influence on Survival\nBladder Urothelial Carcinoma (Bladder NOS) originates in the urothelial cells lining the bladder. This localization predetermines its metastatic pathway, frequently extending to adjacent pelvic organs, lymph nodes, and distant sites such as the liver and lungs. Its unchecked dissemination adversely impacts survival rates.\n\n### Biological Rationale\nThe urothelial origin contributes to carcinoma's ability to exploit the rich blood supply and lymphatic network of the bladder, facilitating early and effective metastatic spread. The anatomical structure makes early detection difficult, leading to advanced disease at diagnosis.\n\n### Treatment Accessibility\nThe classification of \"Bladder NOS\" complicates treatment pathways, as it may lack specificity regarding tumor grade or variant, thus impacting treatment precision and accessibility, potentially affecting survival outcomes negatively.\n\n### Sampling Bias\nBladder NOS encompasses a broad category that might introduce heterogeneity into study samples, complicating genetic and survival analyses due to variability in tumor grading and staging.\n\n## Histology: Transitional Cell Carcinoma, NOS\n\n### Influence on Survival\nTransitional cell carcinoma represents the predominant histological subtype, characterized by papillary and solid growth patterns that dictate recurrence and progression risks, thus influencing survival significantly.\n\n### Mutation Profiles\nCommon mutations include FGFR3, TP53, and RB1, impacting survival by driving various pathways related to cell cycle regulation, apoptosis, and cellular proliferation.\n\n### Interaction\nTransitional cell carcinoma's interaction with mutation profiles like TP53 (associated with aggressive growth) often necessitates aggressive treatment, which might not always improve survival due to therapy-resistant mutations.\n\n### Sampling Bias\nHistological diversity in samples (due to intra-tumor heterogeneity) can blur associations between genetic mutations and outcomes, potentially skewing survival data.\n\n## Key Genes and Biological Mechanisms\n\n### Influence on Survival\n\n1. **TP53**: Mutations often result in loss of apoptotic control, enhancing cell survival and proliferation. This negatively impacts survival by contributing to high-grade tumor aggressiveness and resistance to chemotherapy.\n\n2. **FGFR3**: Frequently mutated in low-grade tumors, promoting proliferation. While mutated FGFR3 is associated with non-aggressive tumors, it suggests a paradoxical positive influence on the survival of low-grade carcinoma patients.\n\n3. **RB1**: Loss of RB1 function disrupts cell cycle regulation, promoting uncontrolled cell division and aggressive tumor behavior, negatively influencing survival.\n\n4. **PIK3CA**: Mutations activate survival pathways, promoting resistance. While beneficial for cellular growth, clinically, they can signal therapeutic challenges, impacting survival negatively.\n\n5. **ERBB2**: Overexpression or mutation leads to enhanced cellular proliferation and survival, contributing to aggressive tumor phenotypes with poorer prognosis.\n\n6. **CDKN2A**: Loss of function mutations in CDKN2A negatively impact cell cycle regulation, promoting tumorigenesis and reducing survival.\n\n7. **MRE11A**: Involved in DNA repair; its mutation or loss implies defective repair mechanisms, resulting in genomic instability and potentially poorer survival outcomes.\n\n### Biological Rationale\nThese genetic alterations interact collectively to modulate pathways of cell cycle control, repair mechanisms, and survival strategies within tumors, exerting direct influence on clinical aggressiveness and the overall survival landscape.\n\n## Sampling Bias: Limitations of Genomic Analysis\n\nIn genomic studies, bladder tumor samples often classify as primary tumors or solid tissue normal. This selection method may omit divergent molecular characteristics present in residual or small metastatic deposits.\n\n- **Primary Tumor Sampling**: May not represent the full genomic landscape because of intra-tumoral heterogeneity, affecting clarity in survival correlation studies.\n- **Solid Tissue Normal**: Utilized as a baseline often lacks precision due to potential pre-cancerous changes being unnoticed, skewing comparative genomic data and interpretations.\n\n## Synthesis of Key Survival Risk Factors\n\n### Summary\nThe interplay of tumor origin, histological subtype, and specific genetic profiles fundamentally determines the survival prognosis of bladder urothelial carcinoma. Common biases in genomic sampling, in addition to the tumor's intrinsic properties, contribute to variable treatment outcomes.\n\n### Clinically Relevant Insights\nA multifaceted understanding of these factors is essential:\n\n- **Precision Medicine**: Knowing specific genetic mutations and their biological impacts fosters tailored therapies.\n- **Risk Stratification**: Recognizing high-risk mutations such as TP53 and RB1 allows for stratified patient management, improving survival outcomes through targeted therapy.\n- **Screening and Detection**: Enhanced detection of histological characteristics and genetic profiling can aid in earlier intervention and more effective treatment planning.\n\nOverall, the integration of genomic, histological, and biological insights drives the path toward improved patient survival, underscoring the necessity for continual advancement in both detection methodologies and therapeutic strategies."
        ],
        [
         "25",
         "BLCA",
         "C67.9",
         "8130/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A47W, TCGA-XF-AAN1, TCGA-UY-A78K, TCGA-XF-A9T6, TCGA-LT-A8JT, TCGA-CF-A27C, TCGA-CF-A9FL, TCGA-XF-AAMY, TCGA-MV-A51V, TCGA-E7-A541, TCGA-2F-A9KR, TCGA-CF-A9FM, TCGA-CF-A3MF, TCGA-E7-A7DV, TCGA-CF-A3MG, TCGA-4Z-AA83, TCGA-CF-A9FH, TCGA-CF-A47X, TCGA-XF-A8HB, TCGA-S5-AA26, TCGA-XF-A9SV, TCGA-CF-A47S, TCGA-XF-AAMZ, TCGA-E7-A6MF, TCGA-E7-A4IJ, TCGA-H4-A2HO, TCGA-4Z-AA80, TCGA-CF-A47Y, TCGA-YC-A8S6, TCGA-ZF-A9R2, TCGA-CF-A3MH, TCGA-CF-A47V, TCGA-XF-A8HI, TCGA-4Z-AA7S, TCGA-CF-A3MI, TCGA-FJ-A3ZF, TCGA-CU-A0YO, TCGA-CU-A3YL, TCGA-CF-A47T, TCGA-UY-A78L, TCGA-DK-A2I1, TCGA-XF-A8HC, TCGA-XF-A9ST, TCGA-XF-A9SU, TCGA-XF-A9SI, TCGA-XF-A9SG, TCGA-GV-A6ZA",
         "Bladder NOS",
         "Bladder NOS",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "**Tumor Origin**\n\n1. **Influence on Survival:**\n   - Bladder Urothelial Carcinoma (BUC) inherently arises from the urothelium, the transitional epithelium lining the bladder. Its origin influences metastatic patterns since BUC is prone to local invasion and distant metastasis. The survival impact is predominantly negative, as the propensity for metastasis correlates with poorer prognosis.\n   \n2. **Biological Rationale:**\n   - The urothelial origin allows these tumors to develop strategies for cellular adhesion and invasion, facilitated by the loss of cell-to-cell adhesion molecules, like E-cadherin, promoting metastatic dissemination.\n\n3. **Impact on Treatment Accessibility:**\n   - Bladder NOS classification can obscure specific histological subtypes, potentially delaying appropriate subtype-specific treatment that could improve outcomes.\n\n**Histology**\n\n1. **Influence on Survival:**\n   - Papillary transitional cell carcinoma, a common histological subtype, often exhibits a more favorable prognosis compared to non-papillary variants due to its growth pattern, which is generally exophytic rather than invasive.\n\n2. **Mutation Profiles:**\n   - These tumors frequently harbor FGFR3 mutations, which are associated with low-grade tumors and better outcomes, whereas high-grade tumors might present with TP53 or RB1 mutations, indicating aggressive behavior.\n\n3. **Biological Rationale:**\n   - FGFR3 mutations lead to constitutive activation of growth factor signaling, which in a papillary context, tends to result in slower progression as opposed to TP53 mutation-driven cell cycle dysregulation that enhances tumor aggressiveness.\n\n**Sampling Bias**\n\n1. **Limitations:**\n   - Genomic data often exhibit biases due to reliance on Blood Derived Normals, which may not reflect tumor-specific mutational burdens. Similarly, reliance solely on Primary Tumor samples may miss heterogeneity and metastatic features crucial for comprehensive landscape assessment.\n\n2. **Influence on Survival Interpretation:**\n   - Sampling bias can lead to inaccurate assessment of clonality and tumor evolution, affecting survival predictions if pre-metastatic alterations are undetected.\n\n**Key Genes**\n\n1. **Associated Genes and Mechanisms:**\n   - **TP53:** Regulates apoptosis and genomic stability; mutations often lead to unchecked cell growth and poor prognosis.\n   - **FGFR3:** Associated with cell proliferation; mutations often indicate tumors with a less aggressive course.\n   - **RB1:** Involved in cell cycle regulation; loss is associated with more aggressive cancer far progression and worse survival.\n   - **PIK3CA:** Mutations activate the PI3K/AKT pathway, promoting cell survival and tumor development, impacting treatment response.\n   - **TSC1:** Integral to the mTOR pathway, its mutation can lead to advanced tumor growth and worse outcomes.\n   - **KDM6A:** Involved in chromatin modification; mutations can lead to transcriptional dysregulation.\n   - **ERBB2 (HER2):** Overexpression associated with aggressive disease but suggests potential for targeted therapy.\n\n2. **Biological Mechanism:**\n   - These genes are involved in critical pathways like cell cycle regulation, DNA repair, growth factor signaling, and immune evasion, integral to cancer progression and treatment response variances.\n\n**Conclusion: Synthesis of Survival Risk Factors**\n\n- Survival in Bladder Urothelial Carcinoma hinges on the interplay between tumor origin, histologic subtypes, and mutation profiles, with significant biases derived from inadequate genomic sampling. Clinically, identifying aggressive genetic alterations (e.g., TP53, RB1) alongside histology guides treatment strategies, while recognizing sampling bias can refine prognostic assessments. Ultimately, targeted therapies tailored to genetic landscapes promise to improve survival, underscoring the importance of precise genomic profiling in tailoring patient management."
        ],
        [
         "26",
         "BRCA",
         "C50.2",
         "8500/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18I",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Upper Inner Quadrant of Breast\n\n1. **Survival Impact**: Tumors located in the upper inner quadrant of the breast typically have a slightly different clinical presentation compared to other quadrants. This can influence survival as these tumors often have less access to the axillary lymph nodes, potentially resulting in different metastatic patterns and prognostic outcomes.\n\n2. **Biological Rationale**: The anatomical location affects lymphatic drainage pathways. The upper inner quadrant often directs drainage towards internal mammary nodes rather than axillary nodes, which may sometimes lead to later detection of metastases, altering staging and treatment planning.\n\n3. **Therapeutic Accessibility**: While tumor location can sometimes complicate surgical access, it doesnâ€™t inherently limit the feasibility of chemotherapy or radiation, preserving treatment effectiveness.\n\n### Histology: Infiltrating Duct Carcinoma, NOS (IDC)\n\n1. **Survival Impact**: Infiltrating Duct Carcinoma represents the most common form of breast cancer and is known for its heterogeneous nature, influencing prognosis variably depending on the grade and molecular subtype.\n\n2. **Biological Rationale**: Histologically, IDCs exhibit diverse morphological features and genetic alterations influencing tumor behavior and patient outcomes. Its progression and outcomes are often driven by prevalent somatic mutations in key oncogenes and tumor suppressor genes such as PIK3CA and TP53, respectively.\n\n3. **Mutation Interaction**: The interplay of genetic mutations within IDC contributes to diverse responses to treatment, refractory cases, and differential prognostic outcomes. Mutation-driven aggressiveness or resistance strongly correlates with histological findings.\n\n### Sampling Bias: Genomic Analysis\n\n1. **Survival Impact**: Sampling biases related to using Blood Derived Normal vs. Primary Tumor samples for genomic characterizations can influence apparent mutation frequencies and, consequently, inferred cancer prognosis and treatment paths.\n\n2. **Biological Rationale**: Primary tumor sampling may underrepresent heterogeneity, missing subclonal populations driving aggressive phenotypes, while blood-derived samples might not accurately reflect somatic mutations restricted to the tumor cells.\n\n3. **Biases**: Biases occur when mutations present in circulating tumor DNA may suggest high prevalence for resistant clones, potentially misrepresenting the tumorâ€™s bulk genomic profile.\n\n### Key Genes Associated with Survival\n\n1. **TP53**: Mutation in TP53 is associated with loss of apoptotic regulation and increased genomic instability, correlating with poorer survival outcomes.\n\n2. **PIK3CA**: Activating mutations in PIK3CA result in increased proliferative signals, often associated with more aggressive disease but targetable therapeutically.\n\n3. **HER2 (ERBB2)**: Overexpression or amplification leads to aggressive growth and has been linked with poorer outcomes but does benefit from targeted therapies like trastuzumab, which can improve survival.\n\n4. **BRCA1/2**: Germline mutations predispose individuals to higher risks of breast cancer with implications for treatment strategies and targeted therapies improving survival in mutation carriers.\n\n5. **ESR1**: Encodes the estrogen receptor; mutations or altered expression levels affect hormone therapy responsiveness and relate to varying survival outcomes.\n\n6. **CDH1**: Associated with cell adhesion; its loss or mutation contributes to increased tumor cell migration and metastasis, worsening prognosis.\n\n7. **PTEN**: Tumor suppressor gene whose loss can activate the PI3K/AKT pathway, enhancing cell survival and proliferation, leading to poorer outcomes.\n\n8. **KMT2C**: Known for regulating genes associated with DNA repair and cell cycle, mutations here can result in genomic alterations contributing to aggressive tumors.\n\n### Conclusion\n\nThe survival outcomes in breast invasive carcinoma are intricately linked to a convergence of anatomical, histological, and genetic factors. Upper inner quadrant tumors present unique challenges due to distinct metastatic pathways and detection difficulties, impacting survival potential. Histological variations in IDC, coupled with complex mutational landscapes, drive differential prognoses. Genomic sampling biases can either cloud or clarify therapeutic strategies depending on the source material. Understanding the contribution of key genetic alterations helps integrate molecular targeted therapy into treatment regimens, improving survival probabilities, and exemplifying precision oncologyâ€™s role in patient-centric care.\n\nThis synthesis underscores that improved prognostic assessments and personalized treatments rely on a comprehensive grasp of multi-dimensional interactions between tumor biology and treatment paths, thereby significantly impacting patient survival."
        ],
        [
         "27",
         "BRCA",
         "C50.2",
         "8524/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-LD-A7W6",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating lobular mixed with other types of carcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin: Upper Inner Quadrant of the Breast\n\n1. **Influence on Metastatic Patterns**:\n   - **Survival Impact**: Tumors originating in the upper inner quadrant of the breast may have a somewhat different pattern of lymphatic drainage, leading to distinct metastatic sites. Typically, these tumors might metastasize laterally to supraclavicular nodes due to the anatomy.\n   - **Biological Rationale**: The unique lymphatic drainage of the breast quadrants can influence the route of metastatic spread. While upper outer quadrant tumors more commonly spread axillary, upper inner quadrant ones might have varied paths, potentially affecting treatment strategies.\n   - **Treatment Accessibility**: Tumors in the inner quadrants may necessitate more complex surgical resections due to proximity to critical structures, potentially impacting resection completeness and thus survival.\n\n2. **Histology: Infiltrating Lobular Carcinoma Mixed with Other Types**\n\n   - **Survival Impact**: Infiltrating lobular carcinomas (ILCs) have a distinctive growth pattern, typically presenting as diffuse and less well-circumscribed tumors, which can affect detection and treatment response, often correlating with poorer prognoses compared to ductal carcinomas.\n   - **Biological Rationale**: ILCs often result from loss of E-cadherin, leading to their characteristic discohesive growth. Mixed histologies can involve different mutation profiles, complicating prediction of treatment response.\n   - **Interactions**: Mixed histology with other carcinomas can complicate genetic and histological assessments, impacting therapeutic decisions and highlighting the biological heterogeneity that affects survival outcomes.\n\n3. **Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in Genomic Analysis**\n\n   - **Survival Impact**: Relying solely on primary tumor samples and comparing them with blood-derived normal can overlook microenvironmental factors and tumoral heterogeneity, leading to misinterpretations of oncogenic drivers.\n   - **Biological Rationale**: Tumor genomic signatures are influenced by the microenvironment and evolutionary pressures, which primary versus metastatic or multi-site sampling might not capture.\n   - **Bias**: Limited sampling sites can result in a skewed understanding of the cancerâ€™s mutational landscape, overlooking potential metastatic or subclone dynamics, potentially misleading survival assessments.\n\n4. **Key Genes Impacting Survival**\n\n   - **BRCA1/2**: These genes, critical in DNA repair, when mutated, lead to homologous recombination deficiencies, common in breast carcinoma, making them targets for specific treatments (e.g., PARP inhibitors), positively influencing targeted therapy outcomes.\n   - **PIK3CA**: Mutations in this gene activate the PI3K/AKT pathway, promoting cell growth and survival, contributing to therapeutic resistance and poorer outcomes.\n   - **TP53**: Alterations in this gene, a major tumor suppressor, often correlate with more aggressive phenotypes and resistance to treatment.\n   - **GATA3**: Mutations here can influence differentiation and hormonal response, impacting endocrine therapy outcomes.\n   - **HER2 (ERBB2)**: Amplified or overexpressed in some breast cancers, directs the use of HER2-targeted therapies, which have drastically improved survival in affected patients.\n   - **CDH1**: Loss of function (as seen in lobular carcinoma) disrupts cellular adhesion, fostering invasiveness and complicating effective treatment.\n   - **PTEN**: Loss or mutation in PTEN, a tumor suppressor that inhibits PI3K signaling, can lead to unchecked cell growth and survival, complicating treatment response.\n\n### Synthesis of Key Survival Risk Factors\n\nClinically, the survival of breast carcinoma patients in the upper inner quadrant with infiltrating lobular carcinoma mixed with other types depends heavily on tumor biology, genetic profiles, and surgical accessibility. Understanding the impact of key genes on treatment resistance or sensitivity is crucial to patient-specific therapy decisions. Limitations in genomic analysis underscore the importance of comprehensive sample collection to avoid biases that could misguide treatment strategies.\n\nThese insights affirm the value of integrating tumor biology with genomic data for prognostication and emphasize precision medicine's role in improving survival through tailored therapies. Consistent monitoring and refined sampling methodologies are essential to reflect true oncologic complexity, thereby supporting optimal clinical interventions and enhancing patient outcomes."
        ],
        [
         "28",
         "BRCA",
         "C50.3",
         "8500/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18M, TCGA-BH-A18P",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin\n\n#### Influence on Survival\n- **Lower Inner Quadrant and Metastatic Patterns**: Tumors originating in the lower inner quadrant of the breast have distinct lymphatic drainage patterns. This quadrant is close to the internal mammary nodes, potentially leading to atypical metastatic spread.\n- **Patient Survival**: Tumors in this region often show poorer survival due to the relatively late detection and complex lymphatic spread, as they might bypass the more common axillary node involvement.\n- **Treatment Accessibility**: Surgical accessibility can be more challenging due to proximity to the chest wall, potentially complicating surgical margins and increasing local recurrence risks.\n\n#### Biological Rationale\n- **Lymphatic Spread**: The unique lymphatic pathway can facilitate early metastatic dissemination beyond typical axillary nodes, complicating early detection and standard treatment protocols.\n\n### Histology\n\n#### Influence on Survival\n- **Infiltrating Duct Carcinoma, NOS**: This histological type is the most common and is associated with a broad spectrum of genetic mutations. Its variability in genetic profile can contribute to divergent survival outcomes.\n\n#### Biological Rationale\n- **Mutation Profiles**: Key mutations in genes such as TP53 or PIK3CA are prevalent and impact tumor aggressiveness, propensity for metastasis, and resistance to therapies, thereby influencing patient survival outcomes.\n\n### Sampling Bias\n\n#### Limitations in Genomic Analysis\n- **Primary Tumor vs. Solid Tissue Normal**: Genomic analyses often compare cancer tissue with adjacent normal tissue. However, 'normal' tissue in cancer patients may have precancerous changes or field effects, leading to potential biases.\n- **Survival Implication**: These biases may result in underestimating actual mutation burden and potential driver mutations, skewing data towards non-representative profiles.\n\n### Key Genes\n\n1. **TP53**\n   - **Role**: Tumor suppressor gene involved in DNA repair and apoptosis.\n   - **Impact**: Mutations lead to impaired apoptosis and increased survival of malignant cells, worsening prognosis.\n\n2. **PIK3CA**\n   - **Role**: Part of the PI3K/AKT signaling pathway regulating cell growth and survival.\n   - **Impact**: Mutations are linked to enhanced tumor cell proliferation and treatment resistance, negatively impacting survival.\n\n3. **BRCA1/BRCA2**\n   - **Role**: DNA repair through homologous recombination.\n   - **Impact**: Lack of functional copies increases genomic instability, but paradoxically, may enhance responsiveness to certain chemotherapies, impacting survival variably.\n\n4. **HER2**\n   - **Role**: Promotes cell growth and differentiation.\n   - **Impact**: Overexpression leads to aggressive tumor phenotypes but also allows for targeted therapies (e.g., trastuzumab), which can improve survival.\n\n5. **ESR1**\n   - **Role**: Encodes estrogen receptor critical for hormone-responsive tumors.\n   - **Impact**: Mutations might predict resistance to hormonal therapies, negatively affecting hormone-receptor-positive breast cancer outcomes.\n\n6. **PTEN**\n   - **Role**: Tumor suppressor that negatively regulates the PI3K/AKT pathway.\n   - **Impact**: Loss of PTEN activity results in uncontrolled cell proliferation, correlating with poorer outcomes.\n\n### Conclusion\n\nThe survival impact of breast invasive carcinoma, particularly in the lower inner quadrant, is multifaceted. It involves an interplay between anatomical origin, histological subtype, and genetic makeup, compounded by challenges in accurate genomic sampling. Clinically, effective management requires a tailored approach that considers these factors. Addressing key genetic mutations with targeted treatments can optimize survival, emphasizing the importance of personalized medicine in managing breast cancer. Understanding these elements collectively improves prognostic accuracy and therapeutic strategies, directly influencing patient survival outcomes."
        ],
        [
         "29",
         "BRCA",
         "C50.3",
         "8523/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18S",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct mixed with other types of carcinoma",
         "Breast invasive carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "Certainly, let's delve into the specifics of breast invasive carcinoma originating from the lower inner quadrant of the breast and its implications on patient survival, integrating aspects of tumor origin, histology, sampling biases, and pivotal genetic factors.\n\n### Tumor Origin\n1. **Influences on Survival:**\n   - **Metastatic Patterns:** Tumors originating in the lower inner quadrant may have different lymphatic drainage patterns compared to those in other quadrants, potentially influencing sentinel node involvement and distant metastasis. These variations can affect prognosis and survival depending on how effectively metastasis occurs.\n   - **Patient Survival Impact:** Studies suggest that lesions in the inner quadrants may be less accessible for lumpectomy, complicating surgical interventions. Additionally, these regions might have a different proximity to vital structures, influencing surgical resection completeness and consequently survival.\n   - **Treatment Accessibility:** Access for imaging and biopsy might be more challenging, potentially delaying diagnosis and treatment initiation, impacting survival adversely.\n\n2. **Biological Rationale:**\n   - The anatomical location impacts the lymphatic network involved, which in turn affects the likelihood of local versus distant dissemination.\n\n3. **Potential Biases:**\n   - Variability in detection rates due to anatomical challenges may lead to underestimation of tumor burden in early detectable stages.\n\n### Histology\n1. **Influence on Survival:**\n   - Carcinomas that are infiltrating ductal mixed with other types often have heterogeneous behaviors and treatment responses, potentially leading to less predictable outcomes.\n   \n2. **Biological Rationale:**\n   - Mixed histological types suggest varied cellular origins or differentiation statuses, affecting mutation profiles and response to targeted therapies (e.g., mixed ductal and lobular elements).\n\n3. **Potential Biases:**\n   - Histological heterogeneity poses challenges in accurate grading and staging, sometimes leading to misrepresentation of aggressiveness based on sampling site.\n\n### Sampling Bias\n1. **Limitations Impacting Genomic Analysis:**\n   - Use of primary tumor and solid tissue normals in genomic studies can introduce biases, as these samples often reflect only a segment of the tumor's heterogeneity or the host tissue's baseline genomics.\n\n2. **Biological Rationale:**\n   - Genomic interpretation might overlook subclonal variations present only in metastatic sites or later emerging tumor provinces.\n\n3. **Potential Biases:**\n   - Analyses based solely on primary specimens may not capture the entirety of genomic drift and clonal evolution that occurs during metastasis.\n\n### Key Genes\n1. **Common Survival-Associated Genes:**\n   - **TP53:** Tumor suppressor whose mutation can lead to uncontrolled proliferation and resistance to apoptosis, negatively impacting survival.\n   - **PIK3CA:** Implicated in cell growth regulation and survival; mutations can lead to activated pathways supporting tumor aggressiveness.\n   - **BRCA1/2:** Associated with DNA repair mechanisms; mutations increase genomic instability, influencing survival outcomes negatively.\n   - **HER2:** Overexpression or amplification is associated with increased proliferation; targeted therapies improve survival in HER2-positive breast cancers.\n   - **ER/PR:** Hormone receptor status provides therapeutic avenues; ER/PR positive cancers often have better outcomes with hormonal therapies.\n   - **PTEN:** Loss of function mutations may activate AKT pathway, promoting cell survival and resistance to apoptosis.\n   - **CDH1 (E-cadherin):** Loss of this cell adhesion molecule is associated with increased metastatic potential and worse survival.\n\n2. **Biological Mechanisms:**\n   - These genes are pivotal in controlling key cellular processes such as cell cycle regulation, apoptosis, and cellular adhesion, all of which significantly influence cancer progression and therapeutic responses.\n\n### Synthesis of Key Survival Risk Factors\n- **Location-Specific Challenges:** Inner quadrant origination can subtly influence patterns of metastasis and treatment accessibility, impacting overall survival rates.\n- **Histological Complexity:** Mixed histology underscores the importance of personalized treatment approaches due to varied tumorigenic pathways and responses.\n- **Genomic Insights and Biases:** Recognizing limitations in sampling is crucial for accurate prognostication and therapeutic strategy formulation.\n- **Genetic Profile Utilization:** A deep understanding of genetic landscapes facilitates the targeting of therapy and impacts survival outcomes positively through precision medicine.\n\nIn summary, a multi-faceted approach integrating anatomical, histological, sampling, and genetic perspectives is essential to understand and address the survival nuances of lower inner quadrant breast carcinomas effectively. This strategy enhances the precision of treatment modalities and ultimately aims to improve patient outcomes."
        ],
        [
         "30",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A18V",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Metastatic, Solid Tissue Normal",
         "**Tumor Origin: Impact on Survival**\n\n1. **Influence on Metastatic Patterns**: \n   - The upper outer quadrant of the breast is known for a higher density of lymphatics, leading to a propensity for lymphatic spread. This often results in earlier nodal involvement, which is a significant prognostic factor.\n   - **Survival Impact**: Negative. Quick dissemination to lymph nodes often correlates with worse prognosis due to higher chances of systemic metastasis.\n\n2. **Patient Survival and Treatment Accessibility**:\n   - Tumors in the upper outer quadrant may be detected earlier in mammographic screenings because of their location, potentially improving outcomes.\n   - **Accessibility**: Positive. Early detection generally increases treatment options and improves survival rates.\n\n**Histology: Interactions with Mutation Profiles**\n\n1. **Infiltrating Duct Carcinoma, NOS**:\n   - This is the most common histological subtype and exhibits a wide range of mutation profiles.\n   - Prominent mutations often include those in the TP53, PIK3CA, and GATA3 genes, which can dictate aggressive behavior and response to therapy.\n\n2. **Survival Outcome**:\n   - **TP53 mutations**: Often lead to chemoresistance and have a negative impact on survival due to loss of apoptosis regulation.\n   - **PIK3CA mutations**: May confer sensitivity to targeted therapies, potentially improving outcomes.\n   - **Biological Rationale**: Tumor suppressors and oncogenes interact to influence tumor growth, apoptosis, and, consequently, survival.\n\n**Sampling Bias: Limitations in Genomic Analysis**\n\n1. **Metastatic Versus Solid Tissue Normal**:\n   - Samples from metastatic sites may not reflect the primary tumorâ€™s genomic landscape, leading to biases.\n   - **Survival Impact**: Misrepresented mutation burden and clonality can misguide therapeutic decisions, negatively impacting survival.\n\n2. **Potential Biases**:\n   - Normal tissue samples may contain fewer mutations, providing a non-representative baseline.\n   - **Interpretation**: Analysts may overlook clonal heterogeneity and evolution under therapeutic pressure.\n\n**Key Genes Influencing Survival**\n\n1. **TP53**: \n   - Regulates cell cycle and apoptosis.\n   - **Impact**: Frequent mutations characterize poor prognostic subtypes due to unchecked cell proliferation.\n\n2. **PIK3CA**:\n   - Part of the PI3K/AKT pathway.\n   - **Impact**: Mutations can promote survival through growth factor signaling but also offer therapeutic targets.\n\n3. **BRCA1/2**:\n   - Involved in DNA repair.\n   - **Impact**: Mutations, while increasing risk, can lead to better responses to DNA-damaging treatments.\n\n4. **HER2**:\n   - Growth factor receptor.\n   - **Impact**: Overexpression linked to aggressiveness, but targeted therapies improve survival significantly.\n\n5. **GATA3**:\n   - Transcription factor related to luminal subtype.\n   - **Impact**: Mutations are associated with favorable outcomes due to its role in maintaining differentiated epithelial characteristics.\n\n6. **MYC**:\n   - Affects transcription and cell cycle regulation.\n   - **Impact**: Amplification often correlates with aggressive cancer phenotypes and poor survival.\n\n**Concluding Synthesis**\n\nUnderstanding survival in breast invasive carcinoma requires a confluence of factors from tumor origin to molecular genetics. The upper outer quadrantâ€™s implications on metastasis emphasize the importance of early detection. Histological and genetic variances outline potential therapeutic paths and their likely effectiveness, underscoring the need for personalized medicine. Lastly, genomic analyses must account for sampling biases to avoid skewed interpretations. Collectively, these insights illuminate the pathways through which clinicians can strategize optimal individualized treatments, ultimately enhancing patient survival outcomes."
        ],
        [
         "31",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18V, TCGA-BH-A18U",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin: Upper Outer Quadrant of Breast\n\n1. **Influence on Metastatic Patterns and Survival:**\n   - The upper outer quadrant (UOQ) of the breast is the most common site for breast cancer. Its proximity to axillary lymph nodes can facilitate lymphatic spread, impacting metastatic patterns and subsequent survival.\n   - **Positive Survival Impact:** Cancers originating in the UOQ often have better access to surgical excision with clear margins and sentinel lymph node biopsy, which is a crucial step in staging and treatment planning.\n\n2. **Treatment Accessibility:**\n   - **Neutral/Positive Impact:** The anatomical location often allows for easier surgical access and complete resection, which can positively influence treatment outcomes and survival. Radiation therapy can be adequately targeted due to its location.\n\n3. **Biological Rationale:**\n   - Proximity to significant lymphatic channels increases potential for early detection but also potential for early metastasis through lymphatic spread.\n\n### Histology: Infiltrating Duct Carcinoma, NOS\n\n1. **Mutation Interaction and Outcomes:**\n   - Infiltrating duct carcinoma (IDC), NOS is the most common histological subtype, characterized by various genetic mutations impacting cell cycle regulation and apoptosis.\n   - **Negative Survival Impact:** High-grade IDCs are often associated with more aggressive behavior and poorer prognosis.\n\n2. **Biological Rationale:**\n   - Mutations, particularly in TP53 or PIK3CA, contribute to unregulated growth and resistance to apoptosis, complicating treatment and negatively influencing survival.\n\n3. **Genomic Interpretation Bias:**\n   - Overrepresentation of certain mutations in genomic databases can lead to bias in interpreting typical profiles for IDCs, potentially misinforming treatment strategies.\n\n### Sampling Bias in Genomic Analysis\n\n1. **Limitations:**\n   - Biopsies from primary tumors may not capture the full genetic diversity of metastatic sites, leading to sampling bias. This can impact survival assessment due to incomplete representation of the tumorâ€™s genomic landscape.\n\n2. **Biological Rationale:**\n   - Tumor heterogeneity means that genomic analysis based solely on primary tumor samples may not account for divergent subclones driving metastasis and resistance.\n\n### Key Genes Impacting Survival\n\n1. **BRCA1/BRCA2:**\n   - **Function:** DNA repair via homologous recombination.\n   - **Impact:** Mutations lead to genomic instability, associated with aggressive cancers and poor survival.\n\n2. **TP53:**\n   - **Function:** Regulates cell cycle and apoptosis.\n   - **Impact:** Mutations result in uncontrolled proliferation and resistance to standard therapies, leading to poorer survival.\n\n3. **PIK3CA:**\n   - **Function:** Part of the PI3K/AKT pathway, regulating cell growth and survival.\n   - **Impact:** Common mutations can drive oncogenesis, impacting treatment efficiency.\n\n4. **HER2/ERBB2:**\n   - **Function:** Growth factor receptor involved in cell proliferation.\n   - **Impact:** Amplification or overexpression is a targetable factor, with survival impact depending on response to targeted therapies.\n\n5. **ESR1:**\n   - **Function:** Codes for estrogen receptor, influencing cell growth.\n   - **Impact:** Hormone receptor positivity typically predicts better survival due to responsiveness to endocrine therapies.\n\n6. **PTEN:**\n   - **Function:** Tumor suppressor gene involved in PI3K/AKT signaling.\n   - **Impact:** Loss of function can lead to enhanced growth signaling and poorer prognosis.\n\n### Synthesis of Key Survival Risk Factors\n\n1. **Tumor Origin and Metastasis:**\n   - Location influences lymphatic spread and treatment planning.\n\n2. **Histological and Genetic Factors:**\n   - Mutation profiles in IDC significantly alter prognosis and treatment outcomes.\n\n3. **Biological and Genomic Complexity:**\n   - Perception of risk and effective treatment planning necessitates comprehensive genomic sampling and analysis.\n\n4. **Clinically Relevant Insights:**\n   - Understanding the interaction of tumor location, histology, and mutation profiles with survival is crucial for personalized treatment strategies. Advances in targeted therapies and genetically informed models can significantly refine prognosis and therapeutic approaches, ultimately improving patient survival outcomes."
        ],
        [
         "32",
         "BRCA",
         "C50.5",
         "8500/3",
         "C50.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18G",
         "Lower outer quadrant of breast",
         "Lower outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "To analyze how breast invasive carcinoma, specifically originating in the lower outer quadrant, impacts patient survival, we'll examine several factors: tumor origin, histology, sampling biases, and key genetic mutations.\n\n### Tumor Origin: Lower Outer Quadrant Effects\n\n1. **Influence on Metastatic Patterns and Survival**\n   - **Anatomic Consideration**: Tumors originating in the lower outer quadrant often tend to metastasize to axillary lymph nodes earlier due to their proximity. This can lead to earlier detection compared to other quadrants, potentially improving survival rates.\n   - **Patient Survival**: Early lymphatic involvement might initially suggest poorer outcomes. However, earlier detection through routine imaging and surgical interventions in this accessible area may offset these risks, often translating into better overall survival compared to the medial quadrants.\n   - **Treatment Accessibility**: The lower outer quadrantâ€™s accessibility facilitates surgical interventions like lumpectomy or mastectomy, boosting survival by enabling complete tumor resection.\n\n2. **Biological Rationale**: The anatomical positioning and lymphatic network around the lower outer quadrant help in directing diagnostic and treatment efforts, often leading to earlier intervention and potentially improved survival rates.\n\n### Histology: Infiltrating Duct Carcinoma, NOS\n\n1. **Interaction with Genetic Mutations**\n   - **Common Mutations**: Often characterized by mutations like PIK3CA, TP53, and BRCA1/2. These mutations can drive progression through unchecked proliferation (PIK3CA), impaired apoptosis (TP53), and defective DNA repair (BRCA1/2).\n   - **Survival Impacts**: PIK3CA mutations are generally associated with a better prognosis due to responsiveness to targeted therapies, while TP53 mutations often correlate with poorer outcomes due to aggressive tumor behavior and resistance to chemotherapy.\n\n2. **Biological Rationale**: The infiltrating nature of ductal carcinoma with these mutations facilitates both the aggressive and indolent growth patterns, impacting different survival outcomes based on the mutation burden and therapy responsiveness.\n\n### Sampling Bias: Blood Derived Normal, Primary Tumor\n\n1. **Genomic Analysis Limitations**\n   - **Blood Derived Normal**: This control can miss somatic mutations present uniquely in the tumor due to its reliance on non-tumor DNA, potentially skewing results toward germline variations.\n   - **Primary Tumor**: Sampling only the primary tumor might overlook heterogeneity within metastatic sites, leading to incomplete mutation profiles.\n\n2. **Survival Influence**: These biases could either overestimate or underestimate the aggressiveness of the tumor, influencing treatment choices and subsequent survival probabilities if certain aggressive mutations are undetected.\n\n### Key Survival-Associated Genes\n\n1. **PIK3CA**: \n   - **Mechanism**: Activates PI3K/AKT/mTOR pathway, leading to cell growth and survival.\n   - **Survival Impact**: Offers targets for specific inhibitors that improve outcomes in mutated cases.\n\n2. **TP53**: \n   - **Mechanism**: Acts as a tumor suppressor gene by regulating apoptosis and DNA repair.\n   - **Survival Impact**: Mutations often correlate with poor prognosis due to resistance to therapy.\n\n3. **BRCA1/2**: \n   - **Mechanism**: Essential for DNA repair through homologous recombination.\n   - **Survival Impact**: Mutations increase cancer risk but might respond to PARP inhibitors, altering survival positively in targeted therapies.\n\n4. **HER2**: \n   - **Mechanism**: Receptor tyrosine kinase involved in cell growth.\n   - **Survival Impact**: Amplification correlates with aggressive disease but is targetable with therapies like trastuzumab, improving survival outcomes.\n\n5. **ESR1**: \n   - **Mechanism**: Encodes estrogen receptor, critical in hormone-driven cancers.\n   - **Survival Impact**: Expression links to prognosis, modifiable by hormone therapies.\n\n### Synthesis of Key Survival Risk Factors\n\nOverall, survival outcomes in breast carcinoma involving the lower outer quadrant are influenced by a strategic interplay of anatomic positioning, characteristic histological behavior, and mutation patterns. Despite potential sampling biases, targeted therapies aligned with genetic insights pave the way for improved prognosis. Emphasizing routine imaging and comprehensive mutation profiling can refine therapeutic strategies, presenting clinical teams with vital pathways to prolong and enhance patient survival."
        ],
        [
         "33",
         "BRCA",
         "C50.8",
         "8022/3",
         "C50.8",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-Z7-A8R6",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Pleomorphic carcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "**Tumor Origin: Breast invasive carcinoma with overlapping lesions**\n\n1. **Influence on Survival and Metastatic Patterns**:\n   - **Survival Impact**: Overlapping lesions in breast carcinoma complicate the understanding of tumor boundaries, potentially allowing for more aggressive invasion into adjacent tissues. This can hasten metastatic spread, typically reducing overall survival.\n   - **Metastatic Patterns**: Given their diffuse nature, these lesions might spread through lymphatic and vascular systems more readily, leading to metastasis in common sites such as bones, liver, lungs, and brain.\n   - **Treatment Accessibility**: Complex overlapping lesions might require multimodal treatment approaches but can evade some localized treatment options such as surgery, impacting survival negatively.\n\n2. **Histology: Role of Pleomorphic Carcinoma**\n\n   - **Survival Influence**: Histologically, pleomorphic carcinoma, a subtype characterized by high-grade cellular atypia, is aggressive, often correlating with poorer survival rates.\n   - **Mutation Profiles**: These tumors frequently harbor diverse mutations, including those in TP53 and HER2. Such mutations promote unchecked proliferation and resistance to treatments, driving poor outcomes.\n   - **Outcomes**: Because of these mutations, therapeutic options targeting specific pathways (e.g., HER2-targeted therapies) may be more effective but only if identified and treated early.\n\n3. **Sampling Bias: Limitations in Genomic Analysis**\n\n   - **Blood vs. Tumor Derived Samples**: Blood-derived normal tissue samples often miss tumor heterogeneity, reducing the accuracy of genomic profiling. This can lead to biased conclusions about genetic alterations influencing survival.\n   - **Primary Tumor Samples**: While closer reflections of the tumorâ€™s genetic makeup, they may not capture the genomic variability present within metastatic sites, again skewing survival predictions.\n\n4. **Key Survival-Associated Genes**\n\n   - **TP53**: Mutations lead to loss of apoptosis regulation, contributing to both tumor survival and chemoresistance.\n   - **BRCA1/BRCA2**: Essential in DNA repair mechanisms; mutations heighten genomic instability and increase the risk of aggressive breast cancers.\n   - **HER2**: Overexpression drives proliferation. Targeted therapies improve outcomes if identified.\n   - **PIK3CA**: Mutations can activate downstream signaling (AKT/mTOR pathways), promoting growth and survival.\n   - **ESR1**: Estrogen receptor mutations affect hormone therapy effectiveness, impacting treatment outcomes.\n   - **CDH1**: E-cadherin mutations are linked with weakened cell adhesion and increased metastasis potential.\n   - **PTEN**: Loss of this tumor suppressor gene leads to increased cell survival pathways via PI3K/AKT.\n\n**Synthesis of Key Survival Risk Factors**\n\nOverall survival in breast invasive carcinoma with overlapping lesions is governed by complex interplays of tumor origin, histology, and genomic makeup. Specifically, the invasion-prone, heterogeneous nature of overlapping lesions fosters aggressive phenotypes. Histological factors such as pleomorphic characteristics further heighten aggressiveness due to distinctive mutation profiles promoting resistance against conventional therapies. Recognizing and mitigating sampling biases, especially in genomic analysis, is critical to accurately identify and target survival-associated genetic drivers such as TP53, BRCA1/2, and HER2. Clinically, early detection and personalized treatments based on comprehensive genomic profiling are essential to improving outcomes. Understanding these dynamics paves the way for developing refined, patient-specific therapeutic strategies to optimize survival."
        ],
        [
         "34",
         "BRCA",
         "C50.8",
         "8500/3",
         "C50.8",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18Q",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin\n\nThe breast invasive carcinoma classified under ICD-10 as \"Overlapping lesions of breast\" refers to tumors located at the convergence of anatomic sub-regions of the breast, often complicating clear surgical demarcation. This positional complexity can influence metastatic patterns as these tumors are predisposed to involving multiple ductal networks, thereby facilitating regional lymphatic spread and potentially distant metastasis earlier than tumors confined to a single quadrant. \n\n- **Survival Impact**: Negative, due to increased metastatic potential.\n- **Biological Rationale**: Tumors at the ductal intersections are facilitated by rich vascular networks, increasing the likelihood of hematogenous or lymphatic dissemination.\n- **Treatment Accessibility**: The overlap in anatomical regions might complicate localized surgical interventions, potentially necessitating more aggressive systemic treatments.\n\n### Histology\n\nBreast invasive carcinoma most commonly presents as Infiltrating Duct Carcinoma, Not Otherwise Specified (NOS). This histological subtype is characterized by variability in differentiation and a broad spectrum of genetic mutations, influencing clinical outcomes.\n\n- **Influence on Survival**: Variable, largely contingent on mutation profiles present.\n- **Biological Rationale**: Infiltrating duct carcinoma, NOS often shows heterogeneity in HER2, ER, and PR receptor status, which guides targeted therapies. The mutation landscapes can include BRCA, TP53, and PIK3CA among others, driving tumor behavior.\n- **Outcomes Impact**: Certain mutations like TP53 and BRCA might confer poorer prognoses due to aggressive phenotypes, while hormone receptor positivity typically predicts responsiveness to hormonal therapies.\n\n### Sampling Bias\n\nIn genomic studies, sampling biases are prominent when profiles focus on the primary tumor without adequately representing the complex tumor microenvironment or metastatic sites.\n\n- **Survival Association**: Biases could lead to overrepresentation of specific mutations that do not fully account for metastatic capacity or recurrence.\n- **Biological Rationale**: Primary tumor and solid tissue normal samples often miss the spatial genetic heterogeneity of tumors, thereby underestimating subpopulations responsible for treatment resistance.\n- **Interpretation Limitations**: Focusing solely on primary sites can mislead therapeutic strategies by omitting data on emergent clones resistant to commonly used drugs.\n\n### Key Genes\n\n1. **TP53**: Critical in DNA repair and apoptosis. Mutations often result in loss of function, leading to unchecked cell proliferation and poor prognosis.\n2. **BRCA1/2**: Implicated in homologous recombination repair; mutations notoriously lead to genomic instability and enhanced metastatic potential.\n3. **PIK3CA**: Part of the PI3K/AKT pathway, mutations lead to proliferation and survival advantages, affecting treatment resistance.\n4. **HER2**: Overexpression typically indicates aggressive growth but is also a target for specific monoclonal antibody therapies that improve outcomes.\n5. **ER/PR**: Hormone receptor positivity generally correlates with better survival due to effective engagement with hormone-blocking therapies.\n6. **PTEN**: Tumor suppressor involved in cell cycle regulation; loss or mutation correlates with poor prognosis and therapy resistance.\n7. **CDH1**: Involved in cell adhesion; mutations often relate to increased invasiveness and metastatic potential.\n\n### Conclusion\n\nIn synthesizing these factors, the complexity of breast invasive carcinoma survival trends demands a multi-faceted approach. The anatomical origin influences metastasis and surgical strategies, while histological profiles guided by genetic mutations dictate responsiveness to targeted therapies. Sampling biases in genomic studies highlight the necessity for comprehensive profiling to inform effective treatment. Clinically, key survival risk factors include mutational status of critical genes like TP53 and BRCA, which establish prospective targeting opportunities while demanding vigilant monitoring for resistance. Insightful integration of these elements is essential for optimizing patient management and improving survival outcomes."
        ],
        [
         "35",
         "BRCA",
         "C50.9",
         "8010/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A7-A5ZV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "## Tumor Origin: Breast NOS (Excludes Skin of Breast C44.5)\n\n### Influence on Survival\n\n1. **Metastatic Patterns**: Breast invasive carcinoma typically originates in the epithelial cells of the ducts or lobules. Excluding skin of breast implications, the primary concern is the propensity for these tumors to metastasize to bones, liver, lungs, and brain, significantly impacting survival negatively.\n\n2. **Survival Predictions**: Early detection of metastases often improves survival, but the location of metastasis can drastically affect survival times, with brain metastases associated with poorer prognosis.\n\n3. **Treatment Accessibility**: Variability in histological subtypes (e.g., ER, PR, HER2) dictates available treatments, impacting patient outcomes. For instance, HER2-positive cases benefit from targeted therapies improving survival, unlike certain triple-negative types which lack such options.\n\n### Biological Rationale\n\n- Breast carcinomas acquire genetic changes that enable dissemination from the primary site, guided by receptor status affecting treatment pathways.\n\n### Genomic Interpretation Bias\n\n- Variations in subtypes and heterogeneity can skew survival analysis, as generalized treatment efficacy may not account for molecular diversity.\n\n## Histology: Carcinoma, NOS\n\n### Influence on Survival\n\n1. **Outcome Drivers**: Carcinoma, NOS (not otherwise specified) describes tumors without specific histological differentiation, requiring detailed genetic profiling to dictate therapy.\n\n2. **Mutation Profiles**: Variability in common mutations (e.g., TP53, BRCA1/2) affects tumor behavior and therapeutic responsiveness, influencing outcomes. Mutations like TP53 correlate with poor prognosis due to aggressive tumor nature.\n\n### Biological Rationale\n\n- Histological ambiguity can reflect greater tumor plasticity and resilience, complicating treatment.\n\n### Genomic Interpretation Bias\n\n- Bias arises during tumor sampling since less differentiated tumors may represent a skewed genetic landscape compared to more typical invasive breast cancers.\n\n## Sampling Bias: Limitations of Blood Derived Normal and Primary Tumor\n\n### Influence on Survival\n\n1. **Complexity in Genomic Profiles**: Blood-derived normals may not accurately reflect tumor-specific mutations, potentially overlooking actionable targets.\n\n2. **Primary Tumor Sampling**: Spatial heterogeneity within tumors can result in sampling bias affecting mutation detection and subsequent therapy decisions.\n\n### Biological Rationale\n\n- Tumor clonal diversity must be matched in profile to treatment strategy. Sampling may miss subclonal mutations critical for tailored therapies.\n\n### Genomic Interpretation Bias\n\n- Analysis may under- or over-estimate mutation prevalence, risking ineffective treatment allocations based on incomplete mutation landscapes.\n\n## Key Genes Impacting Survival\n\n### Five to Eight Critical Genes\n\n1. **TP53**: Encodes tumor suppressor; mutations lead to unchecked cell division, correlating with poorer outcomes.\n   \n2. **BRCA1/2**: Critical in DNA repair; loss-of-function mutations increase cancer risk and guide PARP inhibitor therapy.\n\n3. **PIK3CA**: Involved in growth signaling; mutations often indicate poor prognosis but guide PI3K inhibitor use.\n\n4. **HER2 (ERBB2)**: Overexpression results in aggressive growth phenotype; targeted by trastuzumab, significantly improving survival.\n\n5. **ESR1**: Encodes ER, mutations post-therapy associate with endocrine resistance, necessitating alternative therapeutic strategies.\n\n6. **GATA3**: Implicated in differentiation; associated mutations may indicate treatment resistance.\n\n7. **CDH1**: E-cadherin mutations signify lobular subtype, often linked to survival differences due to distinct growth patterns.\n\n### Biological Mechanisms\n\n- These genes regulate proliferation, apoptosis, DNA repair, and signal transduction, essential for stratifying therapies and improving survival.\n\n### Genomic Interpretation Bias\n\n- Focusing only on these genes could overshadow polygenic interactions and epigenetic factors critical in survival predictions.\n\n## Synthesis of Key Survival Risk Factors\n\n### Clinically Relevant Insights\n\n- **Early Detection & Receptor Status**: Must be prioritized for better prognoses.\n- **Genetic Profiling Precision**: Essential for selecting effective treatments.\n- **Subtype-Specific Treatments**: Key in tapping into molecular drivers of survival.\n\n### Impact on Patient Survival\n\nClinically, understanding diverse genomic and histological landscapes enhances tailored treatment strategies, ultimately improving survival rates and quality of life for breast cancer patients. Actionable insights into these factors guide therapeutic precision, reducing overtreatment and optimizing long-term outcomes."
        ],
        [
         "36",
         "BRCA",
         "C50.9",
         "8013/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SK",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Large cell neuroendocrine carcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "## Tumor Origin\n\n### Influence on Survival\nBreast invasive carcinoma, particularly Breast NOS (excluding skin of breast C44.5), originates within the glandular tissue of the breast, impacting metastatic patterns and patient survival. Given its origin, this type of carcinoma is predisposed to spread via lymphatic and hematogenous routes to common sites such as bone, liver, lung, and brain.\n\n### Biological Rationale\nThe glandular origin encourages early access to lymphatic channels, facilitating systemic dissemination. This metastatic propensity generally worsens survival outcomes, as distant metastases are a chief determinant of prognosis.\n\n### Treatment Accessibility\nOrigin impacts treatment accessibility due to variability in receptor status (ER, PR, HER2), dictating eligibility for targeted therapies that significantly influence outcomes (e.g., HER2-targeted therapies in HER2-positive tumors improving survival).\n\n## Histology\n\n### Influence on Survival\nLarge cell neuroendocrine carcinoma of the breast, while rare, is characterized by aggressive behavior and poor prognosis due to its high-grade histologic features and rapid proliferative index.\n\n### Biological Interaction with Mutations\nThis carcinoma type often harbors complex mutation profiles involving TP53, RB1, and others that drive oncogenesis through dysregulated cell cycle control, leading to rapid tumor growth and dissemination.\n\n### Outcomes\nThe aggressive histology and mutation synergy lead to reduced survival, emphasizing the need for early detection and novel therapeutic approaches. Traditional therapies may not be as effective, necessitating consideration of histotype-specific interventions.\n\n## Sampling Bias\n\n### Limitations\nUsing blood-derived normal samples or only primary tumors for genomic analyses poses challenges. Blood-derived samples might not accurately represent tumor heterogeneity, while primary tumors may not reflect metastatic sites' genomic landscape.\n\n### Influence on Survival Interpretation\nThis sampling bias can lead to an incomplete understanding of tumor biology, potentially overlooking subclonal variations that contribute to therapy resistance and metastatic competence, skewing survival predictions.\n\n## Key Genes\n\n### Influence on Survival\n1. **TP53**: Mutations lead to loss of normal p53 tumor suppressor function, allowing unchecked cell cycle progression and resistance to apoptosis. Frequently associated with poor survival.\n2. **BRCA1/BRCA2**: Germline mutations compromise DNA repair, fostering genomic instability. Olaparib and other PARP inhibitors improve survival in mutation carriers by exploiting DNA repair deficiencies.\n3. **ERBB2 (HER2)**: Amplification drives aggressive tumor behavior due to amplified growth signaling. Survival is improved with targeted therapies such as trastuzumab.\n4. **ESR1**: Alterations leading to hormone-independent activation of estrogen receptor pathways can contribute to endocrine therapy resistance.\n5. **PIK3CA**: Activating mutations in the PI3K pathway can lead to enhanced cell growth and survival, potential targets for PI3K inhibitors.\n6. **CDH1**: Loss of E-cadherin impairs cell-cell adhesion, promoting invasion and metastasis. Associated with worse survival in lobular carcinoma.\n\n### Biological Mechanisms\nThese genes play critical roles in cellular proliferation (PIK3CA, ERBB2), apoptosis regulation (TP53), immune response modulation, and hormonal pathways (ESR1), directly affecting clinical outcomes and therapeutic approaches.\n\n## Synthesis\n\n### Key Survival Risk Factors\n1. **Metastatic Patterns**: Early lymphovascular metastasis associated with breast origin types.\n2. **Histologic Aggressiveness**: Poor prognosis linked to high-grade carcinomas like large cell neuroendocrine.\n3. **Mutation Burden**: Specific mutations (TP53, BRCA1/BRCA2, ERBB2) markedly influence treatment decision-making and survival probabilities.\n4. **Sampling Bias**: Recognition of genomic sampling limitations is crucial for accurate survival estimations and personalized treatment planning.\n\n### Clinically Relevant Insights\nUnderstanding these factors enables more precise stratification of patients for targeted therapies, improved surveillance strategies, and interventions tailored to the underlying biology of each tumor subtype, ultimately enhancing patient survival outcomes."
        ],
        [
         "37",
         "BRCA",
         "C50.9",
         "8200/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SB",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Adenoid cystic carcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "## Tumor Origin\n\n### Influence on Survival:\n1. **Metastatic Patterns and Survival Impact:**\n   - **Breast Invasive Carcinoma (Breast NOS):** Unlike localized breast cancers, this entity often involves deeper tissues, which may facilitate early lymphatic and hematogenous dissemination.\n   - **Metastatic Sites:** Common distal metastasis includes bones, lungs, and liver, adversely affecting survival due to complications like organ failure.\n   - **Treatment Challenges:** Some metastases may be less accessible to therapies designed initially for local breast cancer settings, diminishing treatment efficacy.\n\n2. **Biological Rationale:**\n   - **Growth Dynamics:** Tumors originating from the breast's epithelial components often have structural pathways amenable to rapid growth and spread.\n   - **Microenvironment Influence:** This tissue origin allows tumors to evade local immune responses effectively, promoting unchecked proliferation.\n\n3. **Potential Biases:**\n   - **Diagnostic Variability:** Classifying all non-specific breast cancers under NOS might overlook nuances in oncogenesis or response to certain treatments, impacting survival evaluations.\n\n## Histology\n\n### Influence on Survival:\n1. **Adenoid Cystic Carcinoma (ACC) Specifics:**\n   - **Prognostic Differences:** While rare, ACC generally has a slower progression but may possess resistance to conventional chemotherapy, influencing long-term survival.\n   - **Mutation Interactions:** Often presents with MYB-NFIB gene fusions, affecting cell cycle regulation and apoptosis.\n\n2. **Biological Rationale:**\n   - **Genetic Mutations:** These mutations conduct chromosomal rearrangements pivotal for tumor sustenance and chemoresistance.\n   - **Histologic Features:** ACC's characteristic infiltration into nerve tissues can contribute substantially to local recurrence and pain, affecting quality of life and survival.\n\n3. **Potential Biases:**\n   - **Sampling Bias in Histological Studies:** Certain less prevalent histologic types might be underrepresented in genomic databases, skewing insights into treatment and survival.\n\n## Sampling Bias\n\n### Limitations in Genomic Analysis:\n1. **Blood-Derived Normal Samples:**\n   - **Storage and Handling:** Potential contamination issues may skew normal baseline adjustments, affecting downstream genomic interpretations.\n   - **Genetic Reflectance:** Peripheral blood might not accurately represent somatic mutations present in the primary tumor.\n\n2. **Primary Tumor Variability:**\n   - **Heterogeneity Issues:** Tumors are often sampled from easily accessible areas, missing deeper or heterogenous regions potentially harboring aggressive clones.\n   - **Impact on Survival Analysis:** Genomic analyses based on limited sampling could inadequately predict survival outcomes due to incomplete mutational insight.\n\n## Key Genes and Their Survival Association\n\n### Genes Involved:\n1. **TP53:** Commonly mutated, leading to defective apoptosis, increased survival of malignant cells.\n2. **PIK3CA:** Drives proliferative pathways, commonly associated with aggressive cancers.\n3. **BRCA1/2:** Involved in DNA repair mechanisms; mutations lead to genomic instability.\n4. **HER2:** Overexpression triggers proliferation and survival pathways, directly impacting treatment routes.\n5. **ESR1:** Estrogen receptor essential for growth and survival; mutations can lead to endocrine therapy resistance.\n6. **EGFR:** Augments proliferation; often a target for specific therapeutic interventions.\n7. **AR:** Androgen receptor pathways implicated in certain subclass tumors influencing therapy approaches.\n\n### Biological Mechanisms:\n- **Proliferation:** PIK3CA and HER2 activate pathways leading to rapid tumor cell multiplication.\n- **Apoptosis:** TP53 mutations hinder typical cell death, conferring survival advantage.\n- **DNA Repair:** BRCA1/2 mutations lead to faulty repair and subsequent mutagenesis.\n\n### Potential Biases:\n- **Underrepresentation and Sequencing Depths:** Low-frequency mutations in smaller subpopulations might be overlooked, skewing correlations with survival outcomes.\n\n## Conclusion\n\n### Key Survival Risk Factors\n- **Prognostic factors like histology (e.g., ACC) and tumor genetic background are critical in determining patient survival trajectories.\n- **Genomic biases:** Adequate caution must be exercised regarding sampling methods, considering comprehensive tissue profiling to encompass inherent variability.\n- **Clinically Relevant Insights:** Understanding the core genetic drivers and mutations pivotal to critical pathways (e.g., TP53, BRCA1/2) forms the basis of accurate prognosis and personalized treatment planning.\n\n### Clinical Translation:\nEmphasizing specific genomic and histologic characteristics can guide therapeutic decisions, particularly tailoring interventions to individual molecular profiles, thus potentially enhancing survival rates and minimizing overtreatment."
        ],
        [
         "38",
         "BRCA",
         "C50.9",
         "8211/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73X",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Tubular adenocarcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin\n**Breast NOS (not otherwise specified)** refers to malignant neoplasms originating from breast tissue but is categorically distinct from skin lesions on the breast. This differentiation is vital because it influences the metastatic potential and patterns, which subsequently impacts survival outcomes and treatment strategies. \n\n1. **Survival Influence**: Breast NOS primarily metastasizes to the axillary lymph nodes, lung, liver, bones, and occasionally the brain. Metastasis to vital organs can significantly reduce survival rates as it complicates treatment and management.\n   \n2. **Biological Rationale**: Given its origin, Breast NOS tumors possess intrinsic traits favoring dissemination, such as enhanced cell motility and protease activity that facilitate tissue invasion and circulation entry.\n\n3. **Treatment Accessibility**: Early detection is crucial, but geographical and socioeconomic factors can limit timely access to suitable therapies, such as surgery, chemotherapy, and targeted treatments, thereby affecting survival.\n\n### Histology\n**Tubular adenocarcinoma** represents a specific histological subtype characterized by well-differentiated glandular structures.\n\n1. **Survival Influence**: Generally, tubular adenocarcinomas are associated with a more favorable prognosis compared to other subtypes, owing to their indolent growth and limited metastatic potential.\n\n2. **Biological Rationale**: This histotype often has lower-grade genetic mutations and a decreased proliferation index, which minimize aggressive behavior and thereby extend patient survival.\n\n3. **Mutation Profiles**: The mutation landscape in tubular adenocarcinoma typically lacks high-risk oncogenes associated with worse outcomes, positioning this subtype in a category with enhanced survival prognosis.\n\n### Sampling Bias\nGenomic analyses often employ **Blood Derived Normal** and **Primary Tumor** samples. However, biases can be introduced:\n\n1. **Survival Influence**: These biases might skew the understanding of tumor evolution and treatment response, inadvertently impacting prognostic models.\n\n2. **Biological Rationale**: Blood-derived DNA might not capture all somatic mutations present in primary tumors. Conversely, primary tumor samples might over-represent more abundant, but less metastatic clones, missing aggressive subclones.\n\n3. **Interpretative Limitations**: Failure to capture tumor heterogeneity can lead to underestimating potential resistive pathways that manifest under treatment pressure, affecting survival prediction and therapeutic decisions.\n\n### Key Genes\nThe genetic landscape is fundamental in shaping survival outcomes in breast carcinoma. Key genes include:\n\n1. **TP53**: Often mutated, impacting genomic stability and apoptosis, typically correlating with poorer outcomes.\n   \n2. **BRCA1/BRCA2**: Involved in DNA repair. Germline mutations in these genes can compromise DNA repair mechanisms, increasing risk but also guiding targeted therapy (e.g., PARP inhibitors).\n\n3. **HER2 (ERBB2)**: Overexpression/amplification is seen in a subset of breast cancers, requiring targeted therapy, which significantly alters survival rates when appropriately treated.\n\n4. **PIK3CA**: Common mutations here can activate major growth pathways. Presence often indicates susceptibility to PI3K inhibitors, influencing treatment and survival.\n\n5. **ESR1 (Estrogen Receptor 1)** and **PGR (Progesterone Receptor)**: Positivity indicates potential responsiveness to hormonal therapy, linked with improved survival in ER-positive cancers.\n\n6. **CDH1 (E-cadherin)**: Mutations or loss can lead to increased invasion and metastasis, typically associated with worse survival in lobular carcinomas.\n\n### Synthesis of Key Survival Risk Factors\nThe integration of tumor origin, histological subtype, genetic alterations, and sampling biases collectively shapes survival. Breast invasive carcinoma prognosis hinges on early detection and precise phenotypic and genotypic characterizations, guiding therapeutic choices. Clinically, the prompt identification of aggressive phenotypes (via genomic profiling) alongside adaptive treatment strategies is pivotal. Personalized medicine, based on robust genomic insights and available therapeutics, emerges as the cornerstone for improving patient survival outcomes amidst these complex, intertwined factors."
        ],
        [
         "39",
         "BRCA",
         "C50.9",
         "8401/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A2-A04W",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Apocrine adenocarcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin and Survival Impact\n\n1. **Influence on Metastatic Patterns and Survival:**\n   - **Tumor Origin:** Breast invasive carcinoma classified as Breast NOS (excludes Skin of breast C44.5) primarily involves glandular tissue. This origin typically allows metastasis primarily via lymphatic spread initially to axillary lymph nodes, and potentially to distant sites such as lungs, bones, liver, and brain.\n   - **Patient Survival Influence:** The potential for early lymphatic spread affects survival negatively. Rapid dissemination may lead to a higher stage at diagnosis, correlating with decreased survival outcomes.\n   - **Treatment Accessibility:** Treatment strategies often involve a combination of surgery, radiation, and systemic therapies (e.g., chemotherapy, hormonal, and targeted therapies). However, localized diagnosis without metastasis facilitates more curative treatment approaches, improving survival rates.\n\n2. **Rationale and Bias Considerations:**\n   - **Biological Rationale:** Lymphatic spread is facilitated by the close anatomical proximity of lymphatics in the breast tissue, posing a challenge for early detection before nodal involvement.\n   - **Sampling Bias:** Biopsies typically emphasize primary tumor analysis, potentially overlooking micro-metastatic exploration which can underestimate metastatic potential and alter survival estimates in genomic profiling.\n\n### Histology: Apocrine Adenocarcinoma\n\n1. **Outcome Impact via Mutation Profiles:**\n   - **Histological Influence:** Apocrine adenocarcinoma, a rare subtype, displays distinct molecular characteristics and an androgen receptor-positive status, often resistant to typical endocrine therapies.\n   - **Mutation Profiles:** Common mutations include PIK3CA, TP53, and AR. Such mutations can lead to aggressive behavior impacting patient survival negatively if not appropriately targeted.\n\n2. **Biological Rationale and Interpretation Limitations:**\n   - **Rationale:** Mutation profiles signify aberrant cell growth pathways and potential endocrine therapy resistance, complicating treatment and reducing the survival prospects.\n   - **Bias in Genomic Analysis:** Lack of comprehensive histological diversity in tumor genomic databases might skew data interpretation, masking specific survival-affecting mutations related to distinct sub-histologies.\n\n### Sampling Bias in Genomic Analysis\n\n1. **Impact of Blood Derived Normal Versus Primary Tumor:**\n   - **Bias Implications:** Using blood-derived normals for comparative genomic analysis might miss tumor-specific genomic alterations, leading to inaccurate somatic mutation profiles.\n   - **Survival Impact:** Mischaracterization of mutation load or specific genomic aberrations can influence perceived aggressiveness and treatment efficacy projections, affecting survival indirectly.\n\n2. **Rationale for Genomic Underestimations:**\n   - **Biological Understanding:** Blood-derived samples lack tumor-specific mutational context, increasing false negative rates and omitting key survival-related mutations.\n\n### Key Survival-Associated Genes\n\n1. **Identified Genes and Mechanisms:**\n   - **TP53:** Pro-apoptotic gene; mutation often leads to unchecked cellular proliferation and reduced survival.\n   - **BRCA1/2:** DNA repair genes; alterations cause genome instability, mandating aggressive treatment strategies.\n   - **PIK3CA:** Alters PI3K/AKT pathway; promotes proliferation and survival, linked to aggressive disease phenotype.\n   - **ERBB2 (HER2):** Gene amplification leads to enhanced growth signaling; targeted therapeutics significantly improve survival.\n   - **ESR1 (Estrogen Receptor):** Hormonal pathway driver; pivotal for therapy selection, impacting long-term survival.\n   - **GATA3:** Influences differentiation; loss impacts cellular maturation and growth control mechanisms.\n   - **CDH1:** E-cadherin loss impacts adhesion; drives invasion and metastasis, adversely affecting survival.\n\n2. **Biological Underpinnings and Analysis Challenges:**\n   - **Functional Insights:** Each gene described plays a critical role in pathway dysregulation, directly impacting cell cycle control, apoptosis, or metastatic potential.\n   - **Bias Considerations:** Genetic heterogeneity within tumor samples and across populations can lead to erroneous survival predictions if broad conclusions are drawn from limited data sets.\n\n### Conclusion and Synthesis\n\n- **Key Survival Risk Factors:** A comprehensive understanding that incorporates tumor origin, detailed histological analysis, mutation burden, and precise genomic profiling, reveals a multifactorial survival landscape.\n- **Clinical Insights:** Identifying critical genes and pathways offers therapeutic targeting opportunities, influencing patient management choices. Genomic biases should be mitigated by diverse and representative sampling to ensure precision oncology truly reflects individualized patient prognoses and survival projections.\n- **Overall Impact:** Focusing on personalized medicine, correct genotypic and phenotypic characterizations can direct optimal treatment strategies, significantly improving survival for breast invasive carcinoma patients."
        ],
        [
         "40",
         "BRCA",
         "C50.9",
         "8480/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73W, TCGA-A2-A3KD, TCGA-C8-A12X, TCGA-D8-A27W, TCGA-D8-A1XV, TCGA-C8-A1HL, TCGA-C8-A8HQ, TCGA-D8-A1XC, TCGA-E9-A5UO, TCGA-OL-A66H, TCGA-AC-A8OR",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Mucinous adenocarcinoma",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "**Tumor Origin: Breast Invasive Carcinoma**\n\n1. **Influence on Metastatic Patterns**: \n   Breast NOS (Not Otherwise Specified) carcinomas, excluding the skin of the breast, have distinct metastatic patterns primarily targeting bones, lungs, liver, and brain. The lack of precise subtyping can lead to less targeted early interventions, impacting overall survival.\n\n2. **Impact on Patient Survival**: \n   The broad categorization as Breast NOS means these tumors may initially be managed with generalized treatments, possibly delaying more effective targeted therapies, which affects survival adversely.\n\n3. **Treatment Accessibility**: \n   While initial treatments are standardized, complexities arise in accessing next-line therapies that are subtler to specific molecular subtypes. For instance, HER2-positive or ER-positive tumors have specific targeted therapies that, if delayed in treatment consideration, can negatively influence outcomes.\n\n**Histology: Mucinous Adenocarcinoma**\n\n1. **Influence on Outcomes**:\n   Mucinous adenocarcinoma of the breast often has a better prognosis due to its lower aggressiveness; however, its response to chemotherapy can vary significantly with its mutation profile.\n\n2. **Interaction with Mutation Profiles**:\n   This subtype commonly exhibits mutations in genes like PIK3CA, which are implicated in cell survival and proliferation pathways. When mutations lead to active signaling pathways such as PI3K/AKT, the tumor may resist certain therapies, influencing survival.\n\n**Sampling Bias: Blood-Derived Normal vs. Primary Tumor**\n\n1. **Limitations in Genomic Analysis**:\n   Blood-derived normal samples as controls may not capture intratumoral heterogeneity present in primary tumors. This can bias genomic analyses towards more common mutations, potentially overlooking rarer, significant driver mutations.\n\n2. **Impact on Survival Evaluation**:\n   Biopsying primary tumors provides more accurate mutation profiles relevant for targeted therapy. However, inadequate sampling might miss important subclonal populations, underestimating tumor aggressiveness and misrepresenting the survival outlook.\n\n**Key Genes and Survival Associations**\n\n1. **TP53**:\n   Often mutated in breast carcinoma, TP53 mutations lead to loss of apoptotic control and enhance genomic instability, worsening prognosis.\n\n2. **BRCA1/2**:\n   BRCA mutations, especially BRCA1, are associated with DNA repair deficiencies, increasing tumor aggression and affecting survival negatively. However, they open therapeutic opportunities with PARP inhibitors.\n\n3. **PIK3CA**:\n   Activation of the PI3K/AKT pathway through PIK3CA mutations generally promotes survival via enhanced cell growth, forming a common target for novel inhibitors in clinical trials.\n\n4. **HER2/ERBB2**:\n   HER2 amplification results in increased cell proliferation. While traditionally linked to poor prognosis, HER2-targeted therapies significantly improve survival outcomes.\n\n5. **ESR1**:\n   Mutations in estrogen receptor gene (ESR1) can lead to endocrine resistance. These mutations neutralize the survival advantage conferred by hormonal therapies in ER-positive cancers.\n\n6. **CDH1**:\n   Associated with E-cadherin, mutations in CDH1 can lead to loss of cell-cell adhesion, facilitating metastasis predominantly to the lobular subtype, affecting survival variably.\n\n**Conclusion: Synthesis of Key Survival Risk Factors**\n\n- *Survival in breast invasive carcinoma is intricately linked to the biological behavior dictated by tumor origin, histological variability, and the mutational landscape.*\n- *Early targeted intervention, driven by precise genomic profiling, can significantly alter survival outcomes, emphasizing the necessity of overcoming sampling biases to achieve accurate tumor characterization.*\n- *Transformative therapeutic strategies, aligned with genetic insights, substantially modulate prognosis, underscoring their critical role in improving patient-centered outcomes in breast cancer survival.*"
        ],
        [
         "41",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-E2-A15A, TCGA-E2-A15E, TCGA-E2-A15K",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Metastatic",
         "### Tumor Origin\n\n1. **Influence on Survival:**\n   - Breast invasive carcinoma, classified as Breast NOS (Not Otherwise Specified), is a primary tumor that originates within the breast tissue, excluding the skin of the breast (unlike C44.5). Survival is largely influenced by the tumor's potential to metastasize to common sites such as bone, liver, lung, and brain. The ability to metastasize is correlated with lower survival rates.\n\n2. **Biological Rationale:**\n   - The origin of the tumor in breast tissue means it interacts directly with nearby lymphatic and vascular systems, facilitating the spread of cancer cells. These pathways enable metastasis, impacting overall survival negatively.\n\n3. **Potential Biases:**\n   - In research, breast cancer patient data may preferentially include non-metastatic cases or those with easily treatable tumors, skewing survival statistics. Studies may not fully account for the heterogeneity in metastatic potential based on original tumor location.\n\n### Histology\n\n1. **Influence on Survival:**\n   - Infiltrating duct carcinoma, NOS, the most prevalent histological subtype, displays variability in outcomes based on genetic mutations. Aggressive subtypes often have poorer survival due to increased potential for early metastasis.\n\n2. **Biological Rationale:**\n   - This carcinoma type is characterized by its origin in the epithelial cells of the milk ducts. The genetic mutations within these cells can drive tumor aggressiveness and treatment resistance, influencing patient prognosis.\n\n3. **Potential Biases:**\n   - Histological evaluation may overlook nuanced prestages of invasive growth, leading to underestimation of the progression risk. Moreover, reliance on biopsy-alone data presents a limited view if the sample doesn't represent tumor heterogeneity.\n\n### Sampling Bias\n\n1. **Limitations:**\n   - Genomic analyses using blood-derived normal samples can miss tumor-specific mutations present only in the tumor tissue itself, leading to incomplete mutation profiling. Sampling metastatic rather than primary tumor sites may also not reflect the full mutation burden of the initial tumor.\n\n2. **Impact on Interpretation:**\n   - This bias can distort assessments of mutation-driven prognosis factors and affect therapeutic targeting, leading to less effective treatment strategies and poorer survival outcomes.\n\n### Key Genes\n\n1. **Influence on Survival:**\n   - Some genes known to affect survival in breast invasive carcinoma include TP53, BRCA1/2, PIK3CA, HER2, ESR1, PTEN, CDH1, and GATA3.\n\n2. **Biological Mechanisms:**\n   - **TP53**: Tumor suppressor involved in DNA repair and apoptosis. Mutations often lead to unchecked cell division.\n   - **BRCA1/2**: DNA repair proteins. Mutations increase risk of breast cancer and impact survival through inherited syndromes.\n   - **PIK3CA**: Involved in cell growth signaling pathways. Mutations result in unregulated cell proliferation.\n   - **HER2**: Growth factor receptor. Overexpression leads to rapid tumor growth.\n   - **ESR1**: Estrogen receptor that, when mutated, can lead to hormone therapy resistance.\n   - **PTEN**: Tumor suppressor gene that regulates cell cycle. Loss of function results in increased cell survival.\n   - **CDH1**: Encodes for E-cadherin, affecting cell adhesion. Loss leads to increased invasiveness.\n   - **GATA3**: Transcription factor playing role in cell differentiation. Aberrations impact cancer cell proliferation and immune interaction.\n\n3. **Potential Biases:**\n   - Variability in sample collection can result in differential expression data, impacting the perceived influence of these genes on survival. Studies might not reflect the broader genomic landscape if based on selected patient cohorts.\n\n### Synthesis of Key Survival Risk Factors\n\nClinically, survival in breast invasive carcinoma depends on a multifactorial interplay of tumor origin, histological subtype, genetic mutations, and sampling techniques. Metastatic behavior and mutation profiles primarily drive prognosis, influenced by biological factors like cell proliferation, invasion capabilities, and immune response. A nuanced understanding of these elements aids in more accurate risk stratification and treatment planning. It is crucial to recognize sampling biases in genomic studies to ensure effective translation into personalized medicine approaches. Continuous efforts toward comprehensive patient genomics integration will optimize survivorship outcomes."
        ],
        [
         "42",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-AR-A24U, TCGA-AQ-A04J, TCGA-BH-A0HK, TCGA-A2-A04U, TCGA-BH-A202, TCGA-OL-A5RU, TCGA-E2-A154, TCGA-D8-A140, TCGA-AN-A0XV, TCGA-EW-A1OV, TCGA-OL-A66L, TCGA-D8-A1JU, TCGA-C8-A1HE, TCGA-A2-A04R, TCGA-AR-A0TP, TCGA-A7-A26I, TCGA-EW-A1PB, TCGA-C8-A26V, TCGA-AN-A0XR, TCGA-A8-A08X, TCGA-AR-A1AX, TCGA-BH-A0EB, TCGA-A7-A0DB, TCGA-BH-A0W7, TCGA-BH-A0B4, TCGA-EW-A1P8, TCGA-A2-A0CV, TCGA-A8-A083, TCGA-B6-A0WY, TCGA-AN-A0XP, TCGA-A8-A07R, TCGA-A2-A04Q, TCGA-EW-A1P6, TCGA-C8-A27B, TCGA-A8-A06R, TCGA-B6-A0RH, TCGA-A2-A0YG, TCGA-A2-A0SU, TCGA-BH-A0EE, TCGA-D8-A1JH, TCGA-E2-A152, TCGA-EW-A1IZ, TCGA-OL-A5D6, TCGA-A1-A0SD, TCGA-BH-A0DK, TCGA-E2-A156, TCGA-A7-A56D, TCGA-E9-A1ND, TCGA-AR-A1AR, TCGA-A2-A1G4, TCGA-AN-A0FN, TCGA-GM-A2DA, TCGA-AR-A0TX, TCGA-BH-A0BP, TCGA-D8-A27P, TCGA-BH-A0AW, TCGA-E9-A1RF, TCGA-E9-A1R0, TCGA-A7-A6VY, TCGA-A2-A0CX, TCGA-AR-A0TZ, TCGA-A2-A25F, TCGA-E2-A15D, TCGA-OL-A5D7, TCGA-AC-A5EH, TCGA-AR-A0TR, TCGA-AQ-A1H2, TCGA-GM-A2DL, TCGA-EW-A1PD, TCGA-AN-A0XN, TCGA-AO-A03P, TCGA-D8-A1XW, TCGA-A7-A26I, TCGA-D8-A1JL, TCGA-LL-A5YN, TCGA-S3-A6ZH, TCGA-EW-A1P1, TCGA-B6-A0WW, TCGA-AN-A03Y, TCGA-D8-A1X5, TCGA-AN-A0AR, TCGA-A8-A09I, TCGA-C8-A1HO, TCGA-AO-A0JI, TCGA-BH-A0BD, TCGA-C8-A274, TCGA-B6-A1KC, TCGA-E2-A1L7, TCGA-A8-A06Q, TCGA-E9-A1R4, TCGA-A2-A0D4, TCGA-AC-A62V, TCGA-AR-A24Q, TCGA-AC-A8OP, TCGA-B6-A0WV, TCGA-D8-A27R, TCGA-D8-A1XB, TCGA-A2-A259, TCGA-D8-A1XL, TCGA-E2-A1IO, TCGA-A8-A08B, TCGA-BH-A0W5, TCGA-AO-A0JD, TCGA-3C-AALJ, TCGA-AO-A03O, TCGA-A8-A07F, TCGA-A1-A0SH, TCGA-A7-A6VV, TCGA-A2-A3XW, TCGA-B6-A0WT, TCGA-D8-A1Y3, TCGA-AR-A255, TCGA-B6-A0RT, TCGA-C8-A278, TCGA-BH-A6R8, TCGA-D8-A27K, TCGA-EW-A1PH, TCGA-3C-AALK, TCGA-EW-A6S9, TCGA-C8-A12Q, TCGA-E2-A15I, TCGA-A8-A0A9, TCGA-A2-A04X, TCGA-PL-A8LY, TCGA-E9-A24A, TCGA-B6-A0RG, TCGA-A1-A0SO, TCGA-C8-A12W, TCGA-A7-A26J, TCGA-AO-A03L, TCGA-GM-A3XL, TCGA-BH-A0DX, TCGA-A8-A07Z, TCGA-B6-A0I6, TCGA-B6-A0I6, TCGA-GM-A2DB, TCGA-E9-A247, TCGA-A8-A07G, TCGA-AN-A0XW, TCGA-BH-A0B1, TCGA-D8-A143, TCGA-D8-A1XR, TCGA-E2-A155, TCGA-D8-A1JJ, TCGA-E2-A1IG, TCGA-BH-A0B0, TCGA-D8-A1JG, TCGA-B6-A0RM, TCGA-BH-A0BM, TCGA-E2-A14V, TCGA-A2-A0ET, TCGA-AN-A0FL, TCGA-A2-A0EO, TCGA-A2-A1G0, TCGA-BH-A5J0, TCGA-C8-A138, TCGA-E2-A1B1, TCGA-C8-A1HN, TCGA-E2-A1IN, TCGA-BH-A0HN, TCGA-LD-A9QF, TCGA-A8-A09B, TCGA-E2-A574, TCGA-BH-A0H9, TCGA-C8-A131, TCGA-AC-A62X, TCGA-AN-A046, TCGA-A7-A4SF, TCGA-E2-A1L6, TCGA-AR-A24S, TCGA-A2-A0YT, TCGA-E9-A1R5, TCGA-A8-A07J, TCGA-A2-A0EV, TCGA-A8-A06X, TCGA-E2-A14N, TCGA-AO-A12A, TCGA-E2-A10C, TCGA-AN-A04C, TCGA-LL-A5YP, TCGA-AN-A0AM, TCGA-E2-A1II, TCGA-AO-A0JC, TCGA-A8-A07W, TCGA-D8-A1XY, TCGA-BH-A0DQ, TCGA-AN-A0XT, TCGA-LL-A73Z, TCGA-B6-A0I8, TCGA-AQ-A0Y5, TCGA-C8-A1HI, TCGA-A7-A0CD, TCGA-A7-A0DA, TCGA-A8-A091, TCGA-D8-A1XU, TCGA-B6-A0IK, TCGA-AR-A0U0, TCGA-EW-A6SD, TCGA-OL-A5RY, TCGA-E9-A1R2, TCGA-AN-A0AK, TCGA-AR-A252, TCGA-BH-A0EI, TCGA-E9-A22A, TCGA-A2-A25B, TCGA-BH-A0BW, TCGA-C8-A12Y, TCGA-AR-A0U3, TCGA-A2-A0CQ, TCGA-AR-A24K, TCGA-BH-A0H0, TCGA-AR-A0U2, TCGA-GM-A2DK, TCGA-BH-A0GZ, TCGA-BH-A0BL, TCGA-LL-A740, TCGA-B6-A0RO, TCGA-A2-A0T2, TCGA-E2-A15S, TCGA-A2-A0T1, TCGA-D8-A1JC, TCGA-A2-A3XU, TCGA-EW-A1P7, TCGA-C8-A1HJ, TCGA-AN-A0XU, TCGA-BH-A5IZ, TCGA-AO-A0JB, TCGA-BH-A0W4, TCGA-AN-A0AT, TCGA-A8-A07I, TCGA-A2-A0YM, TCGA-C8-A134, TCGA-B6-A1KI, TCGA-A1-A0SN, TCGA-E2-A15R, TCGA-S3-AA11, TCGA-AO-A128, TCGA-E2-A15T, TCGA-A8-A095, TCGA-D8-A1Y2, TCGA-UL-AAZ6, TCGA-A2-A0CL, TCGA-A8-A08P, TCGA-C8-A12M, TCGA-AR-A1AS, TCGA-E9-A1QZ, TCGA-A7-A6VX, TCGA-A8-A081, TCGA-BH-A0BQ, TCGA-A8-A093, TCGA-C8-A26X, TCGA-A2-A0ER, TCGA-A2-A04Y, TCGA-A2-A0D2, TCGA-D8-A1JA, TCGA-A7-A0CE, TCGA-C8-A12K, TCGA-A7-A26J, TCGA-AN-A0FS, TCGA-OL-A5RW, TCGA-A2-A0YC, TCGA-D8-A1JM, TCGA-AN-A0AL, TCGA-LL-A7SZ, TCGA-A8-A06T, TCGA-A8-A06U, TCGA-BH-A0C0, TCGA-A2-A0SV, TCGA-E9-A22G, TCGA-AR-A0TS, TCGA-A8-A06P, TCGA-B6-A0X5, TCGA-D8-A1JP, TCGA-AN-A0FD, TCGA-GM-A2DF, TCGA-AR-A0TW, TCGA-AN-A0FZ, TCGA-AN-A0FF, TCGA-C8-A12V, TCGA-AC-A23E, TCGA-A1-A0SP, TCGA-A2-A0EQ, TCGA-A2-A1FW, TCGA-C8-A1HK, TCGA-D8-A1X6, TCGA-A2-A0EY, TCGA-A8-A09C, TCGA-EW-A6SB, TCGA-A8-A07U, TCGA-A8-A08G, TCGA-BH-A0BV, TCGA-C8-A12T, TCGA-E2-A1IF, TCGA-D8-A1XA, TCGA-E2-A15A, TCGA-E2-A1B0, TCGA-AR-A24W, TCGA-A7-A26J, TCGA-A8-A06O, TCGA-D8-A1JE, TCGA-V7-A7HQ, TCGA-C8-A1HF, TCGA-C8-A137, TCGA-E2-A15E, TCGA-A2-A0D1, TCGA-AR-A24Z, TCGA-E2-A15K, TCGA-E2-A14Y, TCGA-AN-A0XO, TCGA-LD-A7W5, TCGA-D8-A1J9, TCGA-E2-A15C, TCGA-C8-A26Z, TCGA-OL-A6VR, TCGA-D8-A27N, TCGA-A8-A08H, TCGA-A8-A097, TCGA-AO-A03V, TCGA-AR-A1AH, TCGA-A2-A1G6, TCGA-E2-A1IK, TCGA-BH-A0AV, TCGA-A2-A0YJ, TCGA-A7-A26H, TCGA-C8-A12L, TCGA-UU-A93S, TCGA-E2-A1L9, TCGA-A8-A08O, TCGA-E9-A1R3, TCGA-E2-A570, TCGA-A2-A04P, TCGA-A2-A0CS, TCGA-LL-A8F5, TCGA-BH-A0HI, TCGA-EW-A1OZ, TCGA-E2-A1B6, TCGA-BH-A0C7, TCGA-S3-AA14, TCGA-B6-A0RS, TCGA-A2-A0T0, TCGA-AN-A0G0, TCGA-OL-A66I, TCGA-A8-A09N, TCGA-C8-A135, TCGA-A2-A0CT, TCGA-AO-A0JE, TCGA-D8-A1Y1, TCGA-AO-A1KP, TCGA-A8-A092, TCGA-AR-A1AO, TCGA-D8-A27L, TCGA-BH-A0E1, TCGA-E2-A573, TCGA-AR-A0TV, TCGA-A2-A04N, TCGA-AR-A250, TCGA-BH-A0B8, TCGA-E9-A243, TCGA-BH-A0BJ, TCGA-E2-A159, TCGA-E2-A14Z, TCGA-BH-A0HB, TCGA-C8-A1HG, TCGA-E9-A1R7, TCGA-D8-A141, TCGA-AO-A0JM, TCGA-BH-A0GY, TCGA-GM-A2DN, TCGA-D8-A13Z, TCGA-A7-A13E, TCGA-AR-A251, TCGA-A8-A07P, TCGA-BH-A0B9, TCGA-D8-A1Y0, TCGA-BH-A0DH, TCGA-E9-A22D, TCGA-AR-A1AP, TCGA-D8-A1XK, TCGA-AQ-A54O, TCGA-A2-A0CU, TCGA-D8-A1X9, TCGA-A2-A0T5, TCGA-D8-A1XQ, TCGA-AR-A1AY, TCGA-A8-A09G, TCGA-OL-A6VO, TCGA-AR-A254, TCGA-A8-A09M, TCGA-A8-A08R, TCGA-E2-A14X, TCGA-E9-A1RH, TCGA-A2-A4S3, TCGA-BH-A0BR, TCGA-AN-A0FY, TCGA-B6-A0IB, TCGA-E2-A15J, TCGA-E2-A1IE, TCGA-A2-A3Y0, TCGA-D8-A1XG, TCGA-A2-A0T3, TCGA-A2-A0SX, TCGA-BH-A0B3, TCGA-A7-A0D9, TCGA-D8-A1JK, TCGA-BH-A0HF, TCGA-AC-A7VB, TCGA-EW-A1P5, TCGA-B6-A0RE, TCGA-D8-A13Y, TCGA-B6-A0I5, TCGA-AC-A6NO, TCGA-E2-A15H, TCGA-AR-A24P, TCGA-AO-A03T, TCGA-D8-A1JF, TCGA-OL-A5D8, TCGA-A2-A0YH, TCGA-BH-A0HW, TCGA-GM-A2DM, TCGA-A2-A0T7, TCGA-BH-A0DE, TCGA-GM-A2DH, TCGA-AN-A0AS, TCGA-OL-A5S0, TCGA-E2-A9RU, TCGA-E2-A56Z, TCGA-C8-A275, TCGA-BH-A0DZ, TCGA-S3-AA0Z, TCGA-E2-A1LA, TCGA-E9-A1R6, TCGA-E9-A229, TCGA-E2-A14T, TCGA-PL-A8LZ, TCGA-AN-A0FW, TCGA-LL-A6FQ, TCGA-BH-A0AY, TCGA-D8-A1XM, TCGA-AN-A0XS, TCGA-E9-A1RB, TCGA-AC-A5XU, TCGA-AR-A1AU, TCGA-A8-A09D, TCGA-E9-A1RD, TCGA-EW-A1IY, TCGA-D8-A1J8, TCGA-C8-A12Z, TCGA-AO-A03R, TCGA-C8-A12U, TCGA-A7-A13D, TCGA-BH-A18H, TCGA-B6-A0X4, TCGA-C8-A12N, TCGA-AC-A8OQ, TCGA-C8-A12P, TCGA-E9-A1N8, TCGA-BH-A0W3, TCGA-AR-A24V, TCGA-A8-A090, TCGA-BH-A0HQ, TCGA-BH-A0DS, TCGA-AO-A0J4, TCGA-AO-A0J6, TCGA-A8-A099, TCGA-A7-A0DB, TCGA-EW-A1PA, TCGA-AR-A1AQ, TCGA-C8-A132, TCGA-A7-A13D, TCGA-AN-A04A, TCGA-BH-A0RX, TCGA-A2-A1FZ, TCGA-BH-A201, TCGA-A8-A085, TCGA-GM-A2DD, TCGA-A8-A09A, TCGA-AO-A0JF, TCGA-EW-A6SA, TCGA-E2-A1AZ, TCGA-B6-A1KF, TCGA-S3-A6ZF, TCGA-AQ-A1H3, TCGA-AQ-A04H, TCGA-BH-A0HY, TCGA-AN-A049, TCGA-BH-A0BC, TCGA-A2-A0D0, TCGA-A2-A0CW, TCGA-AN-A04D, TCGA-E9-A1RA, TCGA-A1-A0SF, TCGA-BH-A0E2, TCGA-OL-A66P, TCGA-A2-A0EM, TCGA-AO-A12D, TCGA-E2-A14Q, TCGA-A8-A094, TCGA-A7-A13D, TCGA-E2-A14P, TCGA-AO-A1KR, TCGA-E9-A1RG, TCGA-BH-A0HX, TCGA-LL-A5YO, TCGA-C8-A27A, TCGA-WT-AB41, TCGA-D8-A27M, TCGA-BH-A0H6, TCGA-D8-A147, TCGA-E2-A14W, TCGA-A2-A0CP, TCGA-PL-A8LX, TCGA-C8-A26W, TCGA-B6-A0RI, TCGA-A2-A0EU, TCGA-S3-AA15, TCGA-E9-A245, TCGA-BH-A0HO, TCGA-E9-A228, TCGA-C8-A12O, TCGA-A2-A0YE, TCGA-B6-A0I2, TCGA-AN-A041, TCGA-A8-A079, TCGA-A8-A08T, TCGA-E2-A150, TCGA-S3-AA17, TCGA-A2-A0D3, TCGA-AC-A6IW, TCGA-C8-A1HM, TCGA-A8-A08L, TCGA-AN-A0FV, TCGA-AN-A0FK, TCGA-E9-A227, TCGA-A7-A6VW, TCGA-AR-A24N, TCGA-A2-A0SW, TCGA-AO-A0JA, TCGA-EW-A1J6, TCGA-A8-A07L, TCGA-AC-A23C, TCGA-A2-A0YF, TCGA-A2-A1FX, TCGA-A8-A07B, TCGA-A2-A04T, TCGA-AN-A03X, TCGA-E2-A14O, TCGA-LL-A73Y, TCGA-E2-A15O, TCGA-A2-A0CM, TCGA-EW-A1J1, TCGA-A7-A0DB, TCGA-E2-A158, TCGA-A8-A09Q, TCGA-AR-A24L, TCGA-BH-A0B7, TCGA-B6-A0RN, TCGA-E9-A22E, TCGA-E9-A1NG, TCGA-B6-A0WS, TCGA-A1-A0SQ, TCGA-3C-AALI, TCGA-B6-A0RL, TCGA-D8-A1XT, TCGA-A7-A4SE, TCGA-AR-A256, TCGA-A7-A0CJ, TCGA-AR-A1AV, TCGA-A8-A08Z, TCGA-A8-A096, TCGA-E9-A226, TCGA-E2-A153, TCGA-A2-A25E, TCGA-D8-A1JI, TCGA-A1-A0SM, TCGA-A8-A075, TCGA-C8-A273, TCGA-BH-A42V, TCGA-AR-A1AN, TCGA-OL-A5RX, TCGA-OL-A5RZ, TCGA-AR-A0TQ, TCGA-A8-A06Z, TCGA-S3-AA10, TCGA-A8-A076, TCGA-AR-A1AJ, TCGA-E9-A1RE, TCGA-A1-A0SJ, TCGA-OL-A66O, TCGA-E9-A244, TCGA-OL-A5RV, TCGA-BH-A0EA, TCGA-AO-A1KT, TCGA-E2-A14R, TCGA-A8-A06Y, TCGA-A7-A5ZW, TCGA-D8-A1JD, TCGA-B6-A409, TCGA-E9-A248, TCGA-A2-A0ST, TCGA-LL-A6FR, TCGA-AN-A0FX, TCGA-AR-A0TT, TCGA-D8-A1XZ, TCGA-E9-A22H, TCGA-A1-A0SI, TCGA-EW-A1P3, TCGA-BH-A0E0, TCGA-B6-A0X1, TCGA-EW-A1OY, TCGA-EW-A2FS, TCGA-E2-A15P, TCGA-BH-A0E7, TCGA-BH-A0HU, TCGA-AR-A0TY, TCGA-E2-A1B4, TCGA-GM-A2DC, TCGA-D8-A27H, TCGA-B6-A1KN, TCGA-E2-A1BD, TCGA-A8-A08C, TCGA-AN-A0FT, TCGA-A2-A25C, TCGA-B6-A0I9, TCGA-AQ-A54N, TCGA-A7-A13E, TCGA-A8-A082, TCGA-D8-A145, TCGA-D8-A27F, TCGA-B6-A0IJ, TCGA-A7-A13F, TCGA-BH-A0H7, TCGA-A2-A04V, TCGA-S3-AA12, TCGA-B6-A0WZ, TCGA-AR-A0U1, TCGA-C8-A130, TCGA-AN-A0FJ, TCGA-AR-A1AW, TCGA-LL-A7T0, TCGA-AO-A0J2, TCGA-AR-A24R, TCGA-BH-A0BO, TCGA-A2-A1G1, TCGA-C8-A26Y, TCGA-D8-A1JB, TCGA-E2-A10A, TCGA-D8-A1XF, TCGA-A7-A13E, TCGA-AO-A12F, TCGA-D8-A142, TCGA-A8-A07O, TCGA-AR-A0TU, TCGA-B6-A401",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin\n\n**Influence on Survival:**\n1. **Metastatic Patterns:** Breast invasive carcinoma, defined here as Breast NOS (excludes Skin of breast C44.5), primarily originates in breast tissue, making it more prone to metastasize via lymphatic or hematogenous routes to bone, lungs, liver, and brain. These metastases significantly worsen prognosis.\n2. **Treatment Accessibility:** Originating within breast tissue generally allows for earlier detection through screening methods like mammography, improving survival. However, the stage at diagnosis remains critical, with earlier stages (I-II) having better prognoses compared to more advanced stages (III-IV).\n\n**Biological Rationale:**\n- The rich vascular supply and lymphatic drainage of breast tissue facilitate both the local invasion and distant spread of carcinomas, influencing metastatic patterns crucial for survival.\n\n### Histology\n\n**Influence on Survival:**\n1. **Infiltrating Duct Carcinoma, NOS:** This subtype accounts for a majority of breast cancers. It often presents with a more aggressive clinical course compared to other subtypes like lobular carcinoma.\n2. **Mutation Profiles:** Common mutations in genes like TP53, PIK3CA, and HER2 influence this carcinoma's behavior, affecting proliferation, survival, and therapeutic responses.\n\n**Biological Rationale:**\n- Specific histological subtypes possess distinct molecular characteristics. For example, HER2 overexpression seen in some ductal carcinomas leads to enhanced growth signaling. Targeted therapies such as trastuzumab substantially improve outcomes for HER2-positive tumors.\n\n### Sampling Bias\n\n**Influence on Survival:**\n1. **Blood Derived Normal Samples:** These control samples help distinguish somatic mutations from germline variants but may miss tumor microenvironment interactions.\n2. **Primary Tumor Samples:** Biopsies can provide heterogenous data, potentially missing subclonal populations relevant to resistance and progression.\n\n**Biological Rationale:**\n- Genomic analysis reliant on primary tumor samples may not fully capture clonal evolution or the presence of hypoxic regions, which drive treatment resistance and alter survival predictions.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **TP53:** Mutations lead to loss of apoptotic control, allowing for unchecked proliferation. Predicts poorer survival.\n2. **BRCA1/BRCA2:** Germinal mutations predispose individuals to breast cancer. Their impact on DNA repair mechanisms informs survival, with implications for targeted therapies like PARP inhibitors.\n3. **HER2:** Overexpression predicts aggressive behavior but also guides therapy, improving survival with effective targeting.\n4. **PIK3CA:** Commonly mutated; influences PI3K/AKT signaling, affecting cell growth and survival. Its impact varies depending on mutation context.\n5. **ESR1:** Critical for hormone receptor-positive tumors. Its modulation through therapeutics can extend survival while resistance patterns present limitations.\n6. **PTEN:** Loss of function impacts growth pathways, with its status often correlating with prognosis and treatment outcomes.\n\n**Biological Rationale:**\n- Alterations in these genes drive oncogenesis and therapeutic responses. Understanding functional roles and interactions within pathways allows precision in predicting and improving survival outcomes.\n\n### Conclusion\n\n**Synthesis of Key Survival Risk Factors:**\n- **Stage at Diagnosis:** Determines the baseline survival metric, underscoring the importance of early detection.\n- **Histological Subtype and Mutation Profile:** Dictate tumor aggressiveness and potential for targeted treatments, directly influencing survival.\n- **Genomic Insights:** While profound, are subject to sampling biases impacting interpretation, underscoring the need for comprehensive analyses including liquid biopsies to capture dynamic tumor landscapes.\n\n**Clinically Relevant Insights:**\n- Emphasizing early detection and tailored treatment approaches guided by genetic profiling holds promise for improved survival.\n- Awareness of sampling and interpretative biases in genomic data can steer research and clinical practice towards more nuanced and accurate survival prognostications.\n"
        ],
        [
         "43",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A1FE",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Metastatic, Solid Tissue Normal",
         "To address the complexity of Breast Invasive Carcinoma, I'll systematically break down the relevant factors affecting survival, including tumor origin, histology, genetic mutations, and sampling biases, while integrating potential biases in genomic interpretations.\n\n### Tumor Origin:\n1. **Influence on Survival and Metastatic Patterns:**\n   - **Breast NOS (excludes Skin of breast C44.5):** Refers broadly to breast tumors, excluding skin tumors, which means the focus is on the traditional breast tissue origin, impacting the routes of metastasis.\n   - **Impact on Metastatic Patterns:** Tumors originating from breast tissue often metastasize to axillary lymph nodes, lung, liver, bone, and brain. These sites reflect both the spread and severity, influencing survival negatively due to complications and organ failure.\n   - **Patient Survival and Treatment Accessibility:** Survival is affected by early detection and treatment access. Tumors caught in early stages have better outcomes due to interventions like surgery, chemotherapy, and radiation.\n\n2. **Biological Rationale:** The specific tissue origin affects disease progression, as breast-specific factors such as hormonal influences play a role in tumor aggression and treatment responsiveness. Hormone receptor status (e.g., estrogen, progesterone) significantly influences survival, as hormone-responsive tumors often have better prognoses due to effective hormonal therapies.\n\n### Histology:\n1. **Infiltrating Duct Carcinoma, NOS:**\n   - **Influence on Survival:** This subtype is the most common and is characterized by forming duct-like structures; it has variable survival outcomes depending on staging and grading.\n   - **Interaction with Mutation Profiles:** Common mutations include p53, HER2, and BRCA1/2. HER2 amplification often predicts poor survival but can be mitigated by targeted therapies like trastuzumab.\n\n2. **Biological Rationale:** Ductal carcinoma's histological features interact with genetic mutations, affecting cellular proliferation and apoptosis. Aberrant pathways involving these mutations lead to aggressive tumor behavior and potential resistance to therapies without specific targeting agents.\n\n### Sampling Bias:\n1. **Limitations in Genomic Analysis Using Metastatic, Solid Tissue Normal:**\n   - **Bias in Comparisons:** Often, comparisons are drawn between metastatic tissues and tissue considered \"normal\" from a nearby site, which may not accurately represent genetic baselines due to field cancerization where surrounding tissues are genetically altered.\n   - **Impact on Genomic Interpretation:** This can lead to overestimation or underestimation of mutation significance, affecting perceived survival impacts. Attributes such as tumor mutation burden and neoantigenic loads might be misrepresented without contextual baseline corrections.\n\n### Key Genes:\n1. **Survival-Associated Genes:**\n   - **TP53:** Mutations are linked to poor prognosis due to loss of function in genes regulating cell cycle and apoptosis.\n   - **BRCA1/2:** Germline mutations elevate risk and influence survival based on DNA repair inefficiencies, often necessitating specialized treatment approaches.\n   - **HER2 (ERBB2):** Overexpression associates with aggressive disease but provides a tractable target for therapy, altering survival trajectories positively with treatment.\n   - **PIK3CA:** Implicated in survival due to its role in cell growth and survival pathways; inhibitors can positively influence outcomes.\n   - **ESR1 (estrogen receptor 1):** Mutations or expression levels affect hormonal therapy responsiveness, influencing survival outcomes based on hormonal manipulations.\n   - **CDH1:** Affects cell adhesion properties, with mutations leading to invasiveness and metastasis, negatively affecting survival if unchecked by intervention.\n   - **GATA3:** Mutations are related to differentiation and proliferation, influencing survival via interactions with hormonal pathways.\n\n2. **Biological Mechanism Impacts:**\n   - **Proliferation and Growth:** Genes like PIK3CA drive proliferation through growth signaling pathways.\n   - **Immune Response:** Alterations can create immune-evasive environments, leading to decreased survival if unchecked.\n   - **Apoptosis Regulation:** Loss of regulation from TP53 mutations results in unchecked cell survival and tumor growth.\n\n### Conclusion:\nThe survival of patients with breast invasive carcinoma is multifactorial, encompassing the tumor origin, histological characteristics, genetic mutation profiles, and inherent sampling biases in genomic analyses. Clinically, these factors guide personalized treatment interventions, underscoring the importance of early detection and targeted therapies in enhancing survival. The emergence of gene-specific therapies continues to transform the landscape, offering increased survival rates when genetic aberrations are precisely targeted. Understanding these dimensions provides a robust framework for prognostication and tailoring treatment to improve patient outcomes significantly."
        ],
        [
         "44",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A1F6, TCGA-BH-A1FU, TCGA-BH-A203, TCGA-BH-A1FJ, TCGA-BH-A1FD, TCGA-BH-A0BS, TCGA-BH-A1FE, TCGA-BH-A0BF, TCGA-BH-A0DT, TCGA-A7-A13G, TCGA-BH-A18L, TCGA-BH-A0HA, TCGA-BH-A1EN, TCGA-BH-A1F8, TCGA-BH-A18T, TCGA-BH-A1F5, TCGA-BH-A1EY, TCGA-BH-A0DI, TCGA-BH-A0BZ, TCGA-E2-A1IU, TCGA-BH-A204, TCGA-AC-A2BM, TCGA-BH-A1ES, TCGA-A7-A0CH, TCGA-BH-A1EW, TCGA-BH-A18N, TCGA-A7-A13G, TCGA-GI-A2C8, TCGA-E2-A1LB, TCGA-AC-A2BK, TCGA-GM-A2DI, TCGA-BH-A0H3, TCGA-GM-A2D9, TCGA-BH-A0DO, TCGA-BH-A0AU, TCGA-BH-A1EV, TCGA-BH-A1EU, TCGA-BH-A208, TCGA-BH-A1FM, TCGA-AC-A23H, TCGA-BH-A0DV, TCGA-E2-A1LS, TCGA-BH-A18J, TCGA-E9-A1NH, TCGA-BH-A18R, TCGA-BH-A18F, TCGA-BH-A1ET, TCGA-BH-A1FH, TCGA-E2-A1LH, TCGA-BH-A0DG, TCGA-BH-A1F0, TCGA-BH-A0BT, TCGA-E2-A1LK, TCGA-BH-A18K, TCGA-BH-A0AZ, TCGA-BH-A1FL, TCGA-E2-A1LL, TCGA-BH-A1FG, TCGA-BH-A1FN, TCGA-BH-A0DD, TCGA-BH-A1EX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin\n\n1. **Influence on Survival:**\n   - Breast NOS, specifically excluding the skin of the breast (ICD-10: Breast NOS), pertains to cancers arising from the breast tissue proper without cutaneous involvement. These tumors often follow a well-defined metastatic pattern, primarily disseminating to lymph nodes, bones, liver, and lungs. The survival rate is impacted by early metastasis, particularly when it involves vital organs like the liver and lungs.\n\n2. **Biological Rationale:**\n   - The propensity of these tumors to metastasize is partly due to the presence of lymphatic and vascular channels in breast tissue that facilitate dissemination. Additionally, tumor cell-microenvironment interactions, including those involving the extracellular matrix and growth factors, can enhance metastatic potential.\n\n3. **Treatment Accessibility:**\n   - Breast NOS cancers, especially at stages where spread is more localized, often benefit from targeted therapies (e.g., HER2 inhibitors in HER2-positive cancers), which has a significant positive impact on survival outcomes.\n\n### Histology\n\n1. **Influence on Survival:**\n   - Infiltrating duct carcinoma, NOS, the most common form of breast cancer histologically, carries variable prognostics based on its molecular subtype (e.g., luminal A, luminal B, HER2-positive, or triple-negative).\n\n2. **Biological Rationale:**\n   - Different subtypes exhibit distinct mutation profiles. For instance, luminal types often harbor hormone receptor mutations conducive to hormone therapy use, while triple-negative cancers lack these targets and thus have poorer outcomes and fewer treatment options.\n\n### Sampling Bias\n\n1. **Limitations:**\n   - Genomic analyses often focus on primary tumor samples or adjacent normal tissue. This can skew findings as metastatic lesions or microenvironmental influences (e.g., immune cell infiltration) crucial for understanding progression and treatment resistance might be missed.\n\n2. **Impact on Survival Studies:**\n   - This bias can lead to an incomplete picture, particularly in understanding the genetic evolution from primary to metastatic disease, which is vital for assessing treatment efficacy and developing new therapies.\n\n### Key Genes\n\n1. **Influence on Survival:**\n   - **TP53:** Tumor suppressor; mutations often lead to unchecked proliferation, contributing to poorer prognosis.\n   - **PIK3CA:** Alters proliferation and survival pathways; mutations are common and involved in treatment resistance.\n   - **BRCA1/2:** DNA repair genes; mutations result in high breast cancer risk but predict response to PARP inhibitors, influencing survival positively when treated appropriately.\n   - **HER2 (ERBB2):** Overexpression leads to aggressive disease but good response to targeted therapies like trastuzumab, enhancing survival rates.\n   - **ESR1:** Estrogen receptor gene; mutations confer hormone therapy resistance, affecting treatment outcomes.\n   - **PTEN:** Tumor suppressor involved in apoptosis; loss correlates with aggressive phenotypes and poorer survival.\n\n2. **Biological Mechanisms:**\n   - These genes impact cell cycle regulation, DNA damage repair, growth factor signaling, and apoptotic pathways. Their interactions shape tumor behavior, response to therapy, and ultimately, patient survival.\n\n### Conclusion\n\nBreast invasive carcinomas, particularly those categorized as Breast NOS, exhibit survival outcomes influenced by their metastatic behavior, histological subtype, and genetic landscape. Their prognosis is predominantly dictated by specific genetic aberrations and histological subtyping, which guide personalized treatment strategies. Sampling bias remains a challenge, often limiting the understanding of tumor evolution and resistance in heterogenous cancer presentations. Recognizing genes that drive proliferation, survival, and therapy response leads to refined therapeutic approaches, translating into improved patient survival, especially when these molecular insights inform evidence-based clinical decisions."
        ],
        [
         "45",
         "BRCA",
         "C50.9",
         "8503/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-B6-A0IC, TCGA-EW-A2FW, TCGA-BH-A0HL, TCGA-D8-A1JS, TCGA-D8-A1X7",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Intraductal papillary adenocarcinoma with invasion",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "## Tumor Origin: Breast NOS (Excludes Skin of breast C44.5)\n\n### Influence on Survival\n- **Positive/Negative:** The origin of the breast invasive carcinoma from breast tissue excluding the skin significantly affects survival based on its ability to metastasize to distant organs such as bone, liver, lungs, and brain. In general, breast cancers that metastasize beyond regional lymph nodes have poorer survival outcomes.\n- **Biological Rationale:** Breast NOS, classified under invasive ductal carcinoma, typically originates in the milk ducts, allowing for relatively straightforward access to lymphatic and vascular channels, promoting metastasis. This invasive nature can lead to more extensive disease with a higher likelihood of spreading, thus negatively impacting survival.\n- **Potential Biases:** Regional variations in healthcare accessibility and differences in the application of biopsy and imaging protocols can result in delayed diagnosis and treatment, further influencing survival rates across populations.\n\n## Histology: Intraductal Papillary Adenocarcinoma with Invasion\n\n### Influence on Survival\n- **Positive/Negative:** The histological classification of intraductal papillary adenocarcinoma with invasive components suggests an aggressive cancer phenotype associated with worse survival compared to non-invasive forms. However, responsiveness to targeted therapies dependent on specific mutation profiles can alter outcomes positively.\n- **Biological Rationale:** This histology features a mixture of papillary structures and invasive carcinoma, which can lead to heterogeneity in growth behavior and prognosis. Invasive growth denotes a more advanced disease stage, potentially resulting in poorer survival unless managed with effective treatment strategies.\n- **Potential Biases:** Misclassification or sampling errors can occur if pre-invasive elements dominate the sample, thus skewing pathological assessments and prognostications.\n\n## Sampling Bias: Blood Derived Normal, Primary Tumor\n\n### Influence on Survival\n- **Potential Impact:** Sampling biases can lead to incomplete genomic profiling, particularly if blood-derived normals are not representative of tumor-specific genetics or if primary tumor samples are inadequately resected.\n- **Biological Rationale:** In cancer genomic studies, utilizing blood-derived DNA as a normal comparator might not fully account for germline variations, leading to false assumptions about somatic mutations within the tumor tissue. Biopsies might not capture intratumoral heterogeneity, missing crucial mutations driving cancer progression.\n- **Potential Biases:** Limited tumor sampling can result in partial characterization of the genetic landscape, potentially missing actionable mutations which could inform targeted therapies, thereby negatively impacting survival outcomes.\n\n## Key Genes: Survival-Associated\n\n### Influence on Survival\n- **Genes Identified:**\n  1. **TP53:** This tumor suppressor gene, when mutated, loses its apoptosis regulation ability, resulting in unchecked cell proliferation and tumor progression, negatively impacting survival.\n  2. **PIK3CA:** Mutations here drive proliferation through the PI3K/AKT signaling pathway. While potentially negative due to resistance in traditional therapies, specific inhibitors can provide positive survival outcomes.\n  3. **BRCA1/2:** Critical in DNA repair; mutations here lead to genomic instability but are also targets for PARP inhibitors, improving survival in targeted patient subsets.\n  4. **HER2 (ERBB2):** Overexpression leads to aggressive growth; however, HER2-targeted therapies have significantly improved survival.\n  5. **CDH1:** Loss of this gene impacts cell adhesion, facilitating metastasis, negatively influencing survival.\n  6. **GATA3:** Mutations can impact differentiation and growth, with varying effects on prognosis depending on the broader mutation context.\n  7. **ESR1:** Estrogen receptor mutations affect hormone therapy susceptibility, directly influencing treatment efficacy and survival.\n  8. **CHEK2:** Involved in DNA damage response; mutations might increase susceptibility to cancer but can also be leveraged for therapeutic targeting.\n\n## Conclusion\n\nIn summary, survival in breast invasive carcinoma (ICD-10: Breast NOS, excluding skin) is heavily influenced by the original site of tumor development and its histological properties, impacting the metastatic capacity and treatment options available. Intratumoral heterogeneity and specific genetic profiles dictate potential therapy responsiveness, with precision medicine offering a pathway to improved survival outcomes. Identifying genetic mutations in key genes such as TP53, BRCA1/2, and HER2 provides critical insights into tumor behavior and potential therapeutic intervention points. Understanding these factors, while accounting for biases in genomic sampling and interpretation, is essential for optimizing clinical interventions and ultimately improving patient survival outcomes."
        ],
        [
         "46",
         "BRCA",
         "C50.9",
         "8507/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SG, TCGA-D8-A1XS, TCGA-EW-A1PE, TCGA-EW-A2FV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Invasive micropapillary carcinoma of breast",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin and Survival\n\n**Breast NOS Impact on Metastatic Patterns and Survival:**\n1. **Influence on Metastasis:**\n   - Breast NOS cancers, excluding skin-origin tumors, predominantly originate from ductal cells. These tumors tend to metastasize to lymph nodes, lungs, bones, liver, and brain.\n   - *Survival Impact:* Metastasis generally indicates advanced disease stages, resulting in lower survival rates. The patterns of metastasis directly affect prognosis.\n\n2. **Treatment Accessibility:**\n   - Diagnosis of Breast NOS includes a broad spectrum of subtypes, influencing treatment plans and approaches. Lack of specificity might delay tailored treatments.\n   - *Survival Impact:* Access to subtype-specific treatments, like HER2-targeted therapies, is crucial for improved survival â€” untreated or delayed treatment reduces prognosis.\n\n### Histology and Mutation Profiles\n\n**Invasive Micropapillary Carcinoma (IMPC) Interaction:**\n1. **Histological Traits:**\n   - IMPC is characterized by small clusters of cancer cells surrounded by fluid spaces, highly prone to lymphovascular invasion.\n   - *Survival Impact:* This histology often correlates with a higher rate of lymph node metastasis, leading to reduced overall survival.\n\n2. **Mutation Profiles:**\n   - Common mutations associated with IMPC include PIK3CA, TP53, and GATA3. These mutations influence cell proliferation and survival.\n   - *Survival Impact:* Alteration of pathways regulating apoptosis and cell cycle control leads to aggressive tumor behavior and impacts targeted therapeutic responses, affecting survival.\n\n### Sampling Bias in Genomic Analysis\n\n**Limitations of Blood Derived Normal, Primary Tumor:**\n1. **Bias in Normal Sample Usage:**\n   - Blood-derived normal samples might not effectively represent the genetic backgrounds of breast tissues.\n   - *Impact on Survival Predictions:* Could lead to misinterpretation of somatic vs. germline mutations, skewing risk profiles and therapeutic decisions.\n\n2. **Tumor Sample Representation:**\n   - Primary tumor samples may not encompass the heterogeneity seen in metastases.\n   - *Impact on Survival Predictions:* Fails to capture full genomic landscape, affecting treatment strategies and survival estimations.\n\n### Key Genes Influencing Survival\n\n1. **TP53:** Mutations lead to impaired DNA repair and apoptosis, fostering tumor progression.\n   - *Survival Impact:* Generally negative, as loss of function correlates with aggressive disease.\n\n2. **BRCA1/2:** Involvement in DNA damage repair.\n   - *Survival Impact:* Mutations associate with increased risk but targeted PARP inhibitors can improve outcomes.\n\n3. **PIK3CA:** Affects cellular growth pathways.\n   - *Survival Impact:* Mutations suggest targeted therapy opportunities, potentially improving outcomes.\n\n4. **HER2:** Involves cell growth and differentiation.\n   - *Survival Impact:* Overexpression correlates with poor prognosis but responsive to targeted therapies (e.g., trastuzumab).\n\n5. **GATA3:** Impacts differentiation and development of luminal cells.\n   - *Survival Impact:* Mutations could disrupt differentiation, but generally linked to better prognoses in luminal breast cancers.\n\n6. **CDH1:** Encodes E-cadherin, crucial for cell adhesion.\n   - *Survival Impact:* Loss can facilitate invasion and metastasis, negatively influencing survival.\n\n7. **MYC:** Regulator of growth and apoptosis.\n   - *Survival Impact:* Amplification leads to unchecked growth, often associated with worse outcomes.\n\n### Synthesis of Key Survival Risk Factors\n\nThe major survival determinants in breast invasive carcinoma encompass tumor origin specificity, histological subtype, genetic mutation profiles, and sampling biases impacting genomic interpretation. Tumor-specific treatments, understanding of histological aggressiveness, and accurate genetic profiling are pivotal. Clinically, ensuring precise diagnosis and tailored therapies based on genomic insights, while considering sample limitations, can markedly affect survival, underscoring the need for precision oncology in improving patient outcomes."
        ],
        [
         "47",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-PL-A8LV, TCGA-AR-A1AI, TCGA-EW-A1P4",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Primary Tumor",
         "### Tumor Origin\n\n**Influence on Survival**:  \nBreast invasive carcinoma, classified under Breast NOS (not otherwise specified), does not cover specific histological subtypes like skin-originated tumors. This makes its metastatic pattern crucial as it commonly metastasizes to the bone, liver, and brain, affecting survival negatively. Early detection and treatment accessibility vary significantly based on geographical, socioeconomic, and healthcare factors.\n\n**Biological Rationale**:  \nThe breast microenvironment supports cancer cell dissemination through complex interactions among stromal and epithelial components, leading to the establishment of secondary tumors in targeted organs.\n\n**Potential Biases**:  \nThis broad classification may overlook subtype-specific management strategies, thereby potentially underestimating survival variability across different histological subtypes.\n\n### Histology\n\n**Influence on Survival**:  \nMedullary carcinoma, NOS, typically exhibits a better prognosis than other subtypes due to its association with a prominent lymphocytic infiltration, indicative of a robust immune response.\n\n**Biological Rationale**:  \nTumors characterized as medullary in nature often show specific genetic profiles, such as overexpression of BRCA mutations, which while typically being aggressive, in the medullary context, seem to elicit a stronger immune-mediated elimination of cancer cells.\n\n**Potential Biases**:  \nHistological classification can miss nuances in individual mutational landscapes, failing to capture heterogeneity. Medullary carcinoma cases in real-world settings may be misclassified due to overlapping characteristics with other subtypes.\n\n### Sampling Bias\n\n**Influence on Genomic Analysis**:  \nThe reliance on Blood Derived Normal, Primary Tumor samples introduces biases as it may not accurately represent the mutational landscape of metastases or recurrence, which are critical to survival outcomes.\n\n**Biological Rationale**:  \nBlood-derived samples predominantly capture germline mutations or highly prevalent hematological markers, missing tumor-specific mutations that occur post-diagnosis or during metastasis. This can obscure the detection of key dynamic changes in tumor biology.\n\n**Potential Biases**:  \nGenomic analyses may overlook intra-tumor heterogeneity and temporal changes in mutation profiles, reducing the precision of survival predictions and targeted therapies.\n\n### Key Genes\n\n1. **TP53**: Mutation prevalence leads to poor survival due to loss of its role in DNA repair and apoptosis.\n2. **BRCA1/2**: Germline mutations affect DNA repair mechanisms; however, therapeutic options like PARP inhibitors provide targeted treatment, improving survival in some contexts.\n3. **PIK3CA**: Frequently mutated, contributing to oncogenic signaling pathways enhancing proliferation; inhibitors can mitigate negative impacts on survival.\n4. **ERBB2 (HER2)**: Overexpression is associated with aggressive disease; however, targeted therapies like trastuzumab improve outcomes.\n5. **PTEN**: Loss of function impacts growth regulation; its status helps in therapeutic stratification.\n6. **CDH1**: Mutation inactivates cell adhesion, promoting metastasis, negatively influencing survival.\n7. **PD-L1**: Overexpression leads to immune escape; immune checkpoint inhibitors can reverse this, offering better survival.\n\n### Synthesis of Key Survival Risk Factors\n\nThe interplay between tumor origin, histology, genetic mutations, and sampling strategies crucially determines survival outcomes in breast invasive carcinoma. Histological characterization combined with precise genetic profiling can guide targeted therapies, improving patient prognoses. However, sampling biases in genomic interpretations must be diligently addressed to ensure accurate survival predictions. Advancements in genomic technologies and personalized medicine approaches are pivotal in refining these assessments, translating into more effective, individualized patient care strategies. Increasing accessibility to innovative treatments and acknowledging tumor heterogeneity remain central to optimizing survival across patient populations."
        ],
        [
         "48",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A209, TCGA-BH-A1FC",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma",
         "Primary Tumor, Solid Tissue Normal",
         "### Tumor Origin\n\n1. **Breast NOS (excludes Skin of breast C44.5) and Metastatic Patterns**: \n   - **Influence on Survival**: The origin of the breast tumor significantly impacts metastatic patterns, influencing patient survival. Breast NOS typically refers to invasive ductal carcinoma, which is prone to metastasizing to the bones, lungs, liver, and brain.\n   - **Biological Rationale**: The high propensity of ductal carcinoma cells to infiltrate surrounding tissue and enter systemic circulation facilitates distant metastases, thereby reducing survival rates. This is attributed to their ability to evade local tissue barriers and migrate, a process often enhanced by epithelial-to-mesenchymal transition (EMT).\n   - **Treatment Accessibility**: Early-stage detection improves access to curative treatments, including surgery, chemotherapy, and radiation. However, metastasis complicates treatment, often requiring systemic therapies with more limited efficacy.\n\n2. **Histology: Medullary Carcinoma, NOS and Mutation Profiles**:\n   - **Influence on Survival**: Medullary carcinoma is associated with a more favorable prognosis compared to other invasive types, often attributed to its unique histological features and immune cell presence.\n   - **Biological Rationale**: These tumors demonstrate a syncytial growth pattern with high lymphocytic infiltration, suggesting robust immune surveillance. This histology is frequently associated with BRCA1 mutations, which predict better response to DNA-damaging chemotherapies.\n   - **Interaction with Mutation Profiles**: The mutation profile of medullary carcinoma, often marked by a high mutation burden, may enhance neoantigen presentation, improving immune response and survival outcomes.\n\n### Sampling Bias\n\n- **Limitations of Primary Tumor vs. Solid Tissue Normal**:\n  - **Influence on Genomic Interpretation**: Sampling biases can skew our understanding of the tumor's genomic landscape. Primary tumors and solid tissue normals may not capture intratumor heterogeneity or subclonal populations that drive metastasis and treatment resistance.\n  - **Biological Rationale**: Genomic analyses often miss rare cell populations within the tumor that could be critical for metastasis or treatment resistance. Solid tissue normal samples may not accurately reflect the tumor microenvironment or immune contexture.\n  - **Bias Implication**: This can lead to an underestimation of the aggressive or stem-like cell populations within the tumor, which can impact prognosis and treatment strategies.\n\n### Key Genes\n\n1. **TP53**: Often mutated in breast cancer, contributing to genomic instability and resistance to apoptosis, negatively impacting survival.\n2. **BRCA1/2**: Germline mutations in these genes lead to defective DNA repair mechanisms. While they are associated with an increased predisposition to cancer, they can also predict better responses to platinum-based therapies and PARP inhibitors, potentially prolonging survival.\n3. **PIK3CA**: Mutations in this gene promote oncogenic signaling through the PI3K/AKT/mTOR pathway, affecting cell proliferation. Targeted therapies can improve outcomes in affected patients.\n4. **HER2**: Amplification leads to aggressive tumor growth, but targeted therapies (e.g., trastuzumab) have significantly improved survival outcomes.\n5. **ER (Estrogen Receptor)**: ER-positive tumors tend to have a better prognosis with hormone therapy becoming a mainstay treatment, enhancing survival.\n6. **CDH1 (E-cadherin)**: Mutations can lead to loss of cell adhesion and increased invasiveness, reducing survival; however, these mutations are less common in ductal cancers compared to lobular variants.\n7. **PD-L1**: Expression is associated with immune evasion but can also identify patients eligible for immune checkpoint inhibitors, potentially improving survival.\n8. **GATA3**: This transcription factor is involved in maintaining the differentiated state of luminal cells and is often mutated in ER-positive cancers, influencing response to endocrine therapies.\n\n### Conclusion\n\nKey determinants of survival in breast cancer include the tumor's origin, histological subtype, and specific genetic mutations. Tumor origin influences metastatic spread and treatment options, with histology impacting immune response and predictive treatment profiles. Genetic mutations, particularly in genes like TP53, BRCA1/2, and HER2, significantly impact prognosis and therapeutic strategies.\n\nAn understanding of these factors helps tailor treatment to individual tumor biology, potentially improving outcomes. However, sampling biases must be accounted for in genomic studies to ensure comprehensive and accurate representation of tumor biology. Clinical insights derived from integrating these factors emphasize personalized treatment approaches to improve survival in breast cancer patients."
        ],
        [
         "49",
         "BRCA",
         "C50.9",
         "8520/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-AC-A6IX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast invasive carcinoma",
         "Blood Derived Normal, Metastatic",
         "### Tumor Origin\n\n**Influence on Survival:**\n- Breast invasive carcinoma, specifically Breast NOS (excluding skin of breast C44.5), can metastasize to lymph nodes, bone, liver, and lungs. These patterns are critical as they determine the stage at diagnosis and dictate treatment complexity, directly impacting survival rates negatively if metastasis is extensive.\n\n**Biological Rationale:**\n- The tumor originates from the epithelial cells of the breast ducts or lobules, characterized by invasive behavior due to disruptions in cell adhesion molecules like E-cadherin. This disruption allows tumor cells to detach and invade surrounding tissues, contributing to their metastatic potential.\n\n**Genomic Interpretation Bias:**\n- When assessing genomic data, tumors categorized under Breast NOS might mask specific histological subtypes, resulting in potential overgeneralization in survival estimations.\n\n### Histology - Lobular Carcinoma, NOS\n\n**Influence on Survival:**\n- Lobular carcinoma is often distinctive in its growth patterns, exhibiting a \"single-file\" invasion mechanism. This complicates early detection and often leads to a later stage diagnosis, potentially reducing survival time.\n\n**Interaction with Mutation Profiles:**\n- Common mutations found in lobular carcinoma include CDH1 (E-cadherin) mutations which reduce cell-cell adhesion, and alterations in genes like PIK3CA, driving oncogenic signaling pathways. These genetic mutations influence responsiveness to certain therapies, affecting outcomes markedly.\n\n**Genomic Interpretation Bias:**\n- Lack of clear subtype classification might lead to underrepresentation of lobular carcinoma in data cohorts, skewing specific survival-related prognostic insights.\n\n### Sampling Bias - Blood Derived Normal, Metastatic\n\n**Limitations in Analysis:**\n- Utilizing blood-derived normal samples versus tumor tissue can lead to misinterpretation, as peripheral blood lacks the tumor-specific mutational landscape. Furthermore, metastatic site sampling may not represent the heterogeneity of the primary tumor.\n\n**Influence on Survival Prediction:**\n- Biases might skew mutation frequency data, leading to erroneous risk stratification models, ultimately affecting clinical management strategies.\n\n### Key Genes Associated with Survival\n\n1. **TP53**: Mutations lead to loss of cell cycle control and apoptotic pathways, worsening prognosis.\n   \n2. **BRCA1/BRCA2**: Alterations in these genes hinder DNA repair, fostering genomic instability and aggressive tumor phenotypes.\n\n3. **PIK3CA**: Involved in the PI3K/AKT pathway, driving cell proliferation; mutations may predict resistance to hormone therapies, impacting survival negatively.\n\n4. **HER2/ERBB2**: Amplification results in aggressive tumor growth but also indicates responsiveness to targeted therapies like trastuzumab, which can improve survival.\n\n5. **PTEN**: Loss or mutation in PTEN leads to unchecked PI3K pathway activation, contributing to tumor aggressiveness and poor survival.\n\n6. **AKT1**: Oncogenic mutations promote survival signals, enhancing resistance to apoptosis and potentially unfavorable survival outcomes.\n\n7. **CDH1**: Mutations disrupt cell adhesion, aiding metastasis particularly in lobular carcinoma, reducing survival rates.\n\n**Biological Mechanisms:**\n- These genes contribute to survival through pathways influencing cellular proliferation, apoptosis, repair fidelity, and metastatic capability, each modulated by specific alterations in their function or expression level.\n\n### Synthesis of Key Survival Risk Factors\n\nIn conclusion, survival in breast invasive carcinoma is intricately linked to the tumor's origin, histological type, and molecular characteristics. Understanding the tumor's histological subtype such as lobular carcinoma can inform targeted therapeutic approaches. Recognizing genomic biases, such as those associated with sampling methods, is crucial for accurate risk stratification. Identifying survival-associated genes and their pathways can help customize patient care, offering therapeutic targets and prognostic indicators crucial for improving patient outcomes. The clinical integration of these insights, underpinned by a precision oncology approach, holds the potential to markedly enhance survival prospects by tailoring interventions to individual genetic landscapes."
        ]
       ],
       "shape": {
        "columns": 12,
        "rows": 715
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Case IDs</th>\n",
       "      <th>ICD_10_desc</th>\n",
       "      <th>ICD_O_3_SITE_desc</th>\n",
       "      <th>ICD_O_3_HISTOLOGY_desc</th>\n",
       "      <th>CANCER_TYPE_NAME</th>\n",
       "      <th>Normalized_Sample_Type</th>\n",
       "      <th>generated_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/1</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>None</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>### Tumor Origin: Adrenocortical Carcinoma\\n\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>**Adrenocortical Carcinoma (ACC) and Survival ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>To understand the survival impact of Bladder U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>### Tumor Origin: Trigone of the Bladder\\n\\n1....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-N6-A4VF, TCGA-N6-A4VE, TCGA-N6-A4VC, TCGA...</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>1. **Tumor Origin:**\\n   - **Influences on Sur...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.1</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PI</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>### Tumor Origin: Endometrium\\n\\n**Influence o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>712</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.2</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C54.2</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A59E</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>### Uterine Carcinosarcoma and Survival Impact...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>713</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PM</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>### Tumor Origin: Influence of Fundus Uteri on...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>714</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C55</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C55.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...</td>\n",
       "      <td>None</td>\n",
       "      <td>Uterus NOS</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>## Tumor Origin: Uterus NOS and Its Influence ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>715 rows Ã— 12 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE  \\\n",
       "0                   ACC  C74.0            8370/1        C74.0   \n",
       "1                   ACC  C74.0            8370/3        C74.0   \n",
       "2                   ACC  C74.0            8370/3        C74.0   \n",
       "3                  BLCA  C67.0            8120/3        C67.0   \n",
       "4                  BLCA  C67.0            8120/3        C67.0   \n",
       "..                  ...    ...               ...          ...   \n",
       "710                 UCS  C54.1            8950/3        C54.1   \n",
       "711                 UCS  C54.1            8980/3        C54.1   \n",
       "712                 UCS  C54.2            8950/3        C54.2   \n",
       "713                 UCS  C54.3            8980/3        C54.3   \n",
       "714                 UCS    C55            8950/3        C55.9   \n",
       "\n",
       "                  Normalized Sample Type  \\\n",
       "0    Blood Derived Normal, Primary Tumor   \n",
       "1    Blood Derived Normal, Primary Tumor   \n",
       "2     Primary Tumor, Solid Tissue Normal   \n",
       "3    Blood Derived Normal, Primary Tumor   \n",
       "4     Primary Tumor, Solid Tissue Normal   \n",
       "..                                   ...   \n",
       "710   Primary Tumor, Solid Tissue Normal   \n",
       "711  Blood Derived Normal, Primary Tumor   \n",
       "712  Blood Derived Normal, Primary Tumor   \n",
       "713  Blood Derived Normal, Primary Tumor   \n",
       "714  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                              Case IDs           ICD_10_desc  \\\n",
       "0    TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...  Adrenal gland cortex   \n",
       "1    TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...  Adrenal gland cortex   \n",
       "2    TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...  Adrenal gland cortex   \n",
       "3    TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...      Trigone, bladder   \n",
       "4    TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...      Trigone, bladder   \n",
       "..                                                 ...                   ...   \n",
       "710  TCGA-N6-A4VF, TCGA-N6-A4VE, TCGA-N6-A4VC, TCGA...           Endometrium   \n",
       "711                                       TCGA-N8-A4PI           Endometrium   \n",
       "712                                       TCGA-N5-A59E            Myometrium   \n",
       "713                                       TCGA-N8-A4PM          Fundus uteri   \n",
       "714  TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...                  None   \n",
       "\n",
       "        ICD_O_3_SITE_desc            ICD_O_3_HISTOLOGY_desc  \\\n",
       "0    Adrenal gland cortex                              None   \n",
       "1    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "2    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "3        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "4        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "..                    ...                               ...   \n",
       "710           Endometrium             Mullerian mixed tumor   \n",
       "711           Endometrium               Carcinosarcoma, NOS   \n",
       "712            Myometrium             Mullerian mixed tumor   \n",
       "713          Fundus uteri               Carcinosarcoma, NOS   \n",
       "714            Uterus NOS             Mullerian mixed tumor   \n",
       "\n",
       "                 CANCER_TYPE_NAME               Normalized_Sample_Type  \\\n",
       "0        Adrenocortical carcinoma  Blood Derived Normal, Primary Tumor   \n",
       "1        Adrenocortical carcinoma  Blood Derived Normal, Primary Tumor   \n",
       "2        Adrenocortical carcinoma   Primary Tumor, Solid Tissue Normal   \n",
       "3    Bladder Urothelial Carcinoma  Blood Derived Normal, Primary Tumor   \n",
       "4    Bladder Urothelial Carcinoma   Primary Tumor, Solid Tissue Normal   \n",
       "..                            ...                                  ...   \n",
       "710        Uterine Carcinosarcoma   Primary Tumor, Solid Tissue Normal   \n",
       "711        Uterine Carcinosarcoma  Blood Derived Normal, Primary Tumor   \n",
       "712        Uterine Carcinosarcoma  Blood Derived Normal, Primary Tumor   \n",
       "713        Uterine Carcinosarcoma  Blood Derived Normal, Primary Tumor   \n",
       "714        Uterine Carcinosarcoma  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                 generated_description  \n",
       "0    ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "1    ### Tumor Origin: Adrenocortical Carcinoma\\n\\n...  \n",
       "2    **Adrenocortical Carcinoma (ACC) and Survival ...  \n",
       "3    To understand the survival impact of Bladder U...  \n",
       "4    ### Tumor Origin: Trigone of the Bladder\\n\\n1....  \n",
       "..                                                 ...  \n",
       "710  1. **Tumor Origin:**\\n   - **Influences on Sur...  \n",
       "711  ### Tumor Origin: Endometrium\\n\\n**Influence o...  \n",
       "712  ### Uterine Carcinosarcoma and Survival Impact...  \n",
       "713  ### Tumor Origin: Influence of Fundus Uteri on...  \n",
       "714  ## Tumor Origin: Uterus NOS and Its Influence ...  \n",
       "\n",
       "[715 rows x 12 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "description_meta"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
